0001333493-20-000076.txt : 20200511 0001333493-20-000076.hdr.sgml : 20200511 20200508213138 ACCESSION NUMBER: 0001333493-20-000076 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200511 DATE AS OF CHANGE: 20200508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eHealth, Inc. CENTRAL INDEX KEY: 0001333493 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] IRS NUMBER: 770470789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33071 FILM NUMBER: 20862376 BUSINESS ADDRESS: STREET 1: 2625 AUGUSTINE DRIVE, SECOND FLOOR CITY: SANTA CLARA STATE: CA ZIP: 95054 BUSINESS PHONE: 650-584-2700 MAIL ADDRESS: STREET 1: 2625 AUGUSTINE DRIVE, SECOND FLOOR CITY: SANTA CLARA STATE: CA ZIP: 95054 10-Q 1 ehth-20200331.htm 10-Q ehth-20200331
FALSE2020Q10001333493--12-3125,614,00100013334932020-01-012020-03-31xbrli:shares00013334932020-04-30iso4217:USD00013334932020-03-3100013334932019-12-310001333493ehth:CommissionMember2020-01-012020-03-310001333493ehth:CommissionMember2019-01-012019-03-310001333493us-gaap:ProductAndServiceOtherMember2020-01-012020-03-310001333493us-gaap:ProductAndServiceOtherMember2019-01-012019-03-3100013334932019-01-012019-03-31iso4217:USDxbrli:shares0001333493us-gaap:CommonStockMember2019-12-310001333493us-gaap:AdditionalPaidInCapitalMember2019-12-310001333493us-gaap:TreasuryStockMember2019-12-310001333493us-gaap:RetainedEarningsMember2019-12-310001333493us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001333493us-gaap:RetainedEarningsMember2020-01-0100013334932020-01-010001333493us-gaap:CommonStockMember2020-01-012020-03-310001333493us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001333493us-gaap:TreasuryStockMember2020-01-012020-03-310001333493us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001333493us-gaap:RetainedEarningsMember2020-01-012020-03-310001333493us-gaap:CommonStockMember2020-03-310001333493us-gaap:AdditionalPaidInCapitalMember2020-03-310001333493us-gaap:TreasuryStockMember2020-03-310001333493us-gaap:RetainedEarningsMember2020-03-310001333493us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001333493us-gaap:CommonStockMember2018-12-310001333493us-gaap:AdditionalPaidInCapitalMember2018-12-310001333493us-gaap:TreasuryStockMember2018-12-310001333493us-gaap:RetainedEarningsMember2018-12-310001333493us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100013334932018-12-310001333493us-gaap:CommonStockMember2019-01-012019-03-310001333493us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001333493us-gaap:TreasuryStockMember2019-01-012019-03-310001333493us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001333493us-gaap:RetainedEarningsMember2019-01-012019-03-310001333493us-gaap:CommonStockMember2019-03-310001333493us-gaap:AdditionalPaidInCapitalMember2019-03-310001333493us-gaap:TreasuryStockMember2019-03-310001333493us-gaap:RetainedEarningsMember2019-03-310001333493us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-3100013334932019-03-31ehth:numberOfInsuranceCarriersehth:state0001333493ehth:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-01-010001333493ehth:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-01-010001333493ehth:MedicareAdvantageMemberehth:MedicareMember2020-01-012020-03-310001333493ehth:MedicareAdvantageMemberehth:MedicareMember2019-01-012019-03-310001333493ehth:MedicareSupplementMemberehth:MedicareMember2020-01-012020-03-310001333493ehth:MedicareSupplementMemberehth:MedicareMember2019-01-012019-03-310001333493ehth:MedicarePartDMemberehth:MedicareMember2020-01-012020-03-310001333493ehth:MedicarePartDMemberehth:MedicareMember2019-01-012019-03-310001333493ehth:MedicareMember2020-01-012020-03-310001333493ehth:MedicareMember2019-01-012019-03-310001333493ehth:IndividualandFamilyMemberehth:NonQualifiedHealthPlansMember2020-01-012020-03-310001333493ehth:IndividualandFamilyMemberehth:NonQualifiedHealthPlansMember2019-01-012019-03-310001333493ehth:IndividualandFamilyMemberehth:QualifiedHealthPlansMember2020-01-012020-03-310001333493ehth:IndividualandFamilyMemberehth:QualifiedHealthPlansMember2019-01-012019-03-310001333493ehth:IndividualandFamilyMember2020-01-012020-03-310001333493ehth:IndividualandFamilyMember2019-01-012019-03-310001333493ehth:AncillariesMemberehth:ShorttermMember2020-01-012020-03-310001333493ehth:AncillariesMemberehth:ShorttermMember2019-01-012019-03-310001333493ehth:AncillariesMemberehth:DentalMember2020-01-012020-03-310001333493ehth:AncillariesMemberehth:DentalMember2019-01-012019-03-310001333493ehth:AncillariesMemberehth:VisionMember2020-01-012020-03-310001333493ehth:AncillariesMemberehth:VisionMember2019-01-012019-03-310001333493ehth:AncillariesMemberehth:OtherMember2020-01-012020-03-310001333493ehth:AncillariesMemberehth:OtherMember2019-01-012019-03-310001333493ehth:AncillariesMember2020-01-012020-03-310001333493ehth:AncillariesMember2019-01-012019-03-310001333493ehth:SmallBusinessMember2020-01-012020-03-310001333493ehth:SmallBusinessMember2019-01-012019-03-310001333493ehth:CommissionBonusMember2020-01-012020-03-310001333493ehth:CommissionBonusMember2019-01-012019-03-31xbrli:pure0001333493us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberehth:MedicareMember2020-01-012020-03-310001333493us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberehth:MedicareMember2019-01-012019-03-310001333493ehth:MedicareAdvantageMembersrt:MaximumMemberehth:MedicareMember2020-01-012020-03-310001333493srt:MinimumMemberehth:IndividualandFamilyMember2020-01-012020-03-310001333493ehth:IndividualandFamilyMembersrt:MaximumMember2020-01-012020-03-310001333493ehth:AncillariesMembersrt:MinimumMemberehth:OtherMember2020-01-012020-03-310001333493ehth:AncillariesMemberehth:OtherMembersrt:MaximumMember2020-01-012020-03-310001333493ehth:CommissionMembersApprovedInPriorPeriodsMember2020-01-012020-03-310001333493ehth:CommissionMembersApprovedInPriorPeriodsMember2019-01-012019-03-310001333493ehth:CommissionMembersApprovedDuringCurrentPeriodMemberehth:MedicareSegmentMember2020-01-012020-03-310001333493ehth:CommissionMembersApprovedDuringCurrentPeriodMemberehth:MedicareSegmentMember2019-01-012019-03-310001333493ehth:CommissionMembersApprovedInPriorPeriodsMemberehth:MedicareSegmentMember2020-01-012020-03-310001333493ehth:CommissionMembersApprovedInPriorPeriodsMemberehth:MedicareSegmentMember2019-01-012019-03-310001333493ehth:CommissionMemberehth:MedicareSegmentMember2020-01-012020-03-310001333493ehth:CommissionMemberehth:MedicareSegmentMember2019-01-012019-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberehth:CommissionMembersApprovedDuringCurrentPeriodMember2020-01-012020-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberehth:CommissionMembersApprovedDuringCurrentPeriodMember2019-01-012019-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberehth:CommissionMembersApprovedInPriorPeriodsMember2020-01-012020-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberehth:CommissionMembersApprovedInPriorPeriodsMember2019-01-012019-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberehth:CommissionMember2020-01-012020-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberehth:CommissionMember2019-01-012019-03-310001333493ehth:MedicareSegmentMember2019-12-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMember2019-12-310001333493ehth:CommissionMembersApprovedDuringCurrentPeriodMember2020-01-012020-03-310001333493ehth:MedicareSegmentMember2020-01-012020-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMember2020-01-012020-03-310001333493ehth:MedicareSegmentMember2020-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMember2020-03-310001333493ehth:MedicareSegmentMember2018-12-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMember2018-12-310001333493ehth:CommissionMembersApprovedDuringCurrentPeriodMember2019-01-012019-03-310001333493ehth:MedicareSegmentMember2019-01-012019-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMember2019-01-012019-03-310001333493ehth:MedicareSegmentMember2019-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMember2019-03-310001333493ehth:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001333493country:CN2020-03-310001333493us-gaap:CustomerConcentrationRiskMemberehth:HumanaMemberus-gaap:AccountsReceivableMember2020-01-012020-03-310001333493us-gaap:CustomerConcentrationRiskMemberehth:HumanaMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001333493us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberehth:AetnaMember2020-01-012020-03-310001333493us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberehth:AetnaMember2019-01-012019-12-310001333493ehth:UnitedhealthcareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-01-012020-03-310001333493ehth:UnitedhealthcareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-03-310001333493us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-03-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-03-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-03-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-03-310001333493us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2020-03-310001333493us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-03-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-03-310001333493us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-03-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-03-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-03-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-03-310001333493us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-03-310001333493us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-03-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001333493us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-03-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001333493us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310001333493us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001333493us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310001333493us-gaap:MoneyMarketFundsMember2020-03-310001333493us-gaap:CommercialPaperMember2020-03-310001333493us-gaap:CommercialPaperMember2020-03-310001333493us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-03-31ehth:numberOfSecurities0001333493ehth:ContingentConsiderationMember2019-12-310001333493ehth:ContingentConsiderationMember2020-01-012020-03-310001333493ehth:ContingentConsiderationMember2020-03-310001333493ehth:GoMedigapMember2019-02-012019-02-280001333493ehth:GoMedigapMember2019-02-280001333493ehth:GoMedigapMember2020-01-012020-01-310001333493ehth:GoMedigapMember2020-01-3100013334932020-03-012020-03-310001333493us-gaap:OverAllotmentOptionMember2020-03-012020-03-310001333493ehth:PreviousRepurchaseProgramsMember2020-01-012020-03-310001333493us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001333493us-gaap:EmployeeStockOptionMember2019-01-012019-03-310001333493us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001333493us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-03-310001333493us-gaap:SellingAndMarketingExpenseMember2020-01-012020-03-310001333493us-gaap:SellingAndMarketingExpenseMember2019-01-012019-03-310001333493ehth:CustomerCareAndEnrollmentExpenseMember2020-01-012020-03-310001333493ehth:CustomerCareAndEnrollmentExpenseMember2019-01-012019-03-310001333493ehth:TechnologyAndContentExpenseMember2020-01-012020-03-310001333493ehth:TechnologyAndContentExpenseMember2019-01-012019-03-310001333493us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001333493us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-03-310001333493us-gaap:EmployeeStockOptionMember2019-01-012019-03-310001333493us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-03-31ehth:plaintiff0001333493ehth:LeViasCompliantMember2019-07-012019-07-01ehth:claim0001333493us-gaap:SubsequentEventMember2020-04-082020-04-29ehth:segment0001333493ehth:MedicareSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310001333493ehth:MedicareSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310001333493ehth:IndividualFamilyAndSmallBusinessSegmentsMemberus-gaap:OperatingSegmentsMember2019-01-012019-03-310001333493us-gaap:OperatingSegmentsMember2020-01-012020-03-310001333493us-gaap:OperatingSegmentsMember2019-01-012019-03-310001333493us-gaap:CorporateNonSegmentMember2020-01-012020-03-310001333493us-gaap:CorporateNonSegmentMember2019-01-012019-03-310001333493country:US2020-03-310001333493country:US2019-12-310001333493country:CN2019-12-310001333493us-gaap:RevenueFromContractWithCustomerMemberehth:UnitedhealthcareMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001333493us-gaap:RevenueFromContractWithCustomerMemberehth:UnitedhealthcareMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-03-310001333493us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberehth:HumanaMember2020-01-012020-03-310001333493us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberehth:HumanaMember2019-01-012019-03-310001333493us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberehth:AetnaMember2020-01-012020-03-310001333493us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberehth:AetnaMember2019-01-012019-03-310001333493srt:MinimumMember2020-01-012020-03-310001333493srt:MaximumMember2020-01-012020-03-31utr:sqft0001333493ehth:GoldRiverCaliforniaMember2020-01-310001333493ehth:GoldRiverCaliforniaMember2020-03-31ehth:periods0001333493ehth:GoldRiverCaliforniaMember2020-01-010001333493us-gaap:RevolvingCreditFacilityMember2018-09-170001333493us-gaap:LetterOfCreditMember2018-09-170001333493us-gaap:RevolvingCreditFacilityMember2019-12-200001333493us-gaap:RevolvingCreditFacilityMemberehth:EligibleCommissionsReceivablesPrecedingThreeMonthsMember2020-01-012020-03-310001333493us-gaap:RevolvingCreditFacilityMemberehth:EligibleCommissionsReceivablesSucceedingThreeMonthsMember2020-01-012020-03-310001333493ehth:EligibleCommissionsReceivablesSucceedingSixMonthsMemberus-gaap:RevolvingCreditFacilityMember2020-01-012020-03-310001333493us-gaap:RevolvingCreditFacilityMember2018-09-172018-09-170001333493us-gaap:RevolvingCreditFacilityMember2019-12-202019-12-200001333493us-gaap:RevolvingCreditFacilityMemberehth:CreditAgreementAmendmentMember2019-12-310001333493us-gaap:RevolvingCreditFacilityMember2020-03-310001333493us-gaap:RevolvingCreditFacilityMember2019-12-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 001-33071
_____________________________________________
EHEALTH, INC.
(Exact name of registrant as specified in its charter)
_____________________________________________

Delaware
56-2357876
(State or other jurisdiction of incorporation or organization)(I.R.S Employer Identification No)

2625 AUGUSTINE DRIVE, SECOND FLOOR
SANTA CLARA, CA 95054
 (Address of principal executive offices)

(650) 584-2700
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.001 per shareEHTHThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The number of shares of the registrant’s common stock, par value $0.001 per share, outstanding as of April 30, 2020 was 25,614,001 shares.




EHEALTH, INC.
FORM 10-Q
TABLE OF CONTENTS

PART I FINANCIAL INFORMATIONPAGE
Item 1.
Item 2.
Item 3.
Item 4.
PART II 
OTHER INFORMATION
Item 1.
Item 1A.
Item 6.

1




PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS
EHEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
 March 31, 2020*December 31, 2019
Assets(Unaudited)
Current assets:
Cash and cash equivalents$184,167  $23,466  
Short-term marketable securities33,683    
Accounts receivable668  2,332  
Contract assets – commissions receivable – current125,252  174,526  
Prepaid expenses and other current assets9,202  7,822  
Total current assets352,972  208,146  
Contract assets – commissions receivable – non-current435,465  414,696  
Property and equipment, net12,875  10,518  
Long-term marketable securities24,409    
Operating lease right-of-use assets43,396  36,621  
Restricted cash3,353  3,354  
Other assets19,300  18,004  
Intangible assets, net9,516  10,062  
Goodwill40,233  40,233  
Total assets$941,519  $741,634  
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$8,906  $24,554  
Accrued compensation and benefits18,473  29,578  
Accrued marketing expenses4,711  12,041  
Earnout liability — current  37,273  
Lease liabilities — current4,174  4,759  
Deferred revenue2,683  2,570  
Other current liabilities3,736  2,210  
Total current liabilities42,683  112,985  
Deferred income taxes — non-current61,623  64,130  
Lease liabilities — non-current41,992  34,305  
Other non-current liabilities3,535  3,050  
Stockholders’ equity:
Common stock37  35  
Additional paid-in capital717,380  455,159  
Treasury stock, at cost(199,998) (199,998) 
Retained earnings274,157  271,852  
Accumulated other comprehensive income110  116  
Total stockholders’ equity791,686  527,164  
Total liabilities and stockholders’ equity$941,519  $741,634  
_____________
* Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.

The accompanying notes are an integral part of these condensed consolidated financial statements.
2




EHEALTH, INC. 
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands, except per share amounts, unaudited)
Three Months Ended March 31,
20202019
Revenue:  
Commission$99,669  $64,227  
Other6,739  4,546  
Total revenue106,408  68,773  
Operating costs and expenses:
Cost of revenue1,138  (77) 
Marketing and advertising37,764  23,941  
Customer care and enrollment30,535  19,944  
Technology and content15,740  9,017  
General and administrative19,653  11,278  
Amortization of intangible assets547  547  
Change in fair value of earnout liability  13,306  
Total operating costs and expenses105,377  77,956  
Income (loss) from operations1,031  (9,183) 
Other income, net373  557  
Income (loss) before benefit from income taxes1,404  (8,626) 
Benefit from income taxes(2,048) (3,467) 
Net income (loss)$3,452  $(5,159) 
 
Net income (loss) per share:   
Basic$0.14  $(0.24) 
Diluted$0.13  $(0.24) 
Weighted-average number of shares used in per share amounts:
Basic24,719  21,831  
Diluted26,179  21,831  
Comprehensive income:
Net income (loss)$3,452  $(5,159) 
Unrealized holding gain for available for sales debt securities, net of tax25    
Foreign currency translation adjustment, net of taxes(31) 29  
Comprehensive income (loss)$3,446  $(5,130) 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3




EHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, unaudited)

Three Months Ended March 31, 2020
 Common StockAdditional Paid-in
Capital
Treasury StockRetained EarningsAccumulated Other Comprehensive IncomeTotal Stockholders’ Equity
 SharesAmountSharesAmount
Balance as of December 31, 201934,752  $35  $455,159  (11,616) $(199,998) $271,852  $116  $527,164  
Cumulative effect from the adoption of ASU 2016-13  —  —  —  —  —  (1,147) —  (1,147) 
Issuance of common stock in connection with exercise of common stock options  141  —  1,091  —  —  —  —  1,091  
Repurchase of shares to satisfy employee tax withholding obligations  —  —  (4,375) (33) —  —  —  (4,375) 
Shares issued in equity offering  2,070  2  228,022  —  —  —  —  228,024  
Settlement of earnout liability  295  —  28,521  —  —  —  —  28,521  
Stock-based compensation expense  —  —  8,962  —  —  —  —  8,962  
Other comprehensive income, net of tax  —  —  —  —  —  —  (6) (6) 
Net income  —  —  —  —  —  3,452  —  3,452  
Balance as of March 31, 202037,258  $37  $717,380  (11,649) $(199,998) $274,157  $110  $791,686  

Three Months Ended March 31, 2019
 Common StockAdditional Paid-in
Capital
Treasury StockRetained EarningsAccumulated Other Comprehensive IncomeTotal Stockholders’ Equity
 SharesAmountSharesAmount
Balance as of December 31, 201830,863  $31  $298,024  (11,426) $(199,998) $204,965  $127  $303,149  
Issuance of common stock in connection with exercise of common stock options  172  —  2,367  —  —  —  —  2,367  
Repurchase of shares to satisfy employee tax withholding obligations  —  —  (1,280) (24) —  —  —  (1,280) 
Shares issued in equity offering  2,760  3  126,048  —  —  —  —  126,051  
Settlement of earnout liability  295  —  17,264  —  —  —  —  17,264  
Stock-based compensation expense  —  —  3,229  —  —  —  —  3,229  
Foreign currency translation adjustment, net of taxes  —  —  —  —  —  —  29  29  
Net loss  —  —  —  —  —  (5,159) —  (5,159) 
Balance as of March 31, 201934,090  $34  $445,652  (11,450) $(199,998) $199,806  $156  $445,650  

The accompanying notes are an integral part of these condensed consolidated financial statements.



4




EHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 
(in thousands, unaudited)
Three Months Ended March 31,
 20202019
Operating activities:
Net income (loss)$3,452  $(5,159) 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization823  655  
Amortization of internally developed software1,501  719  
Amortization of intangible assets547  547  
Stock-based compensation expense8,714  3,229  
Deferred income taxes(2,141) (3,543) 
Change in fair value of earnout liability  13,306  
Other non-cash items223  (1,194) 
Changes in operating assets and liabilities:
Accounts receivable1,664  221  
Contract assets – commissions receivable26,873  17,648  
Prepaid expenses and other assets(159) 1,111  
Accounts payable(16,279) (768) 
Accrued compensation and benefits(11,104) (9,390) 
Accrued marketing expenses(7,329) (7,147) 
Deferred revenue113  2,897  
Accrued expenses and other liabilities2,009  (383) 
Net cash provided by operating activities8,907  12,749  
Investing activities:
Capitalized internal-use software and website development costs(3,564) (1,487) 
Purchases of property and equipment and other assets(2,508) (1,509) 
Purchases of marketable securities(58,064)   
Cash used in investing activities(64,136) (2,996) 
Financing activities:
Proceeds from issuance of common stock, net of issuance costs228,024  126,051  
Net proceeds from exercise of common stock options1,091  2,367  
Repurchase of shares to satisfy employee tax withholding obligations(4,375) (1,280) 
Repayment of debt  (5,000) 
Acquisition-related contingent payments(8,751) (9,542) 
Principal payments in connection with leases(58) (25) 
Net cash provided by financing activities
215,931  112,571  
Effect of exchange rate changes on cash, cash equivalents and restricted cash(2) 62  
Net increase in cash, cash equivalents and restricted cash160,700  122,386  
Cash, cash equivalents and restricted cash at beginning of period26,820  13,089  
Cash, cash equivalents and restricted cash at end of period$187,520  $135,475  


 The accompanying notes are an integral part of these condensed consolidated financial statements.
5







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 1Summary of Business and Significant Accounting Policies

Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omni-channel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 180 health insurance carriers across all fifty states and the District of Columbia.

Basis of Presentation – The accompanying condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, and the condensed consolidated statements of comprehensive income (loss), stockholders' equity, and cash flows for the three months ended March 31, 2020 and 2019, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2019 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on March 2, 2020. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain reclassifications might be made to conform with the current presentation. However, the Company believes that the disclosures made are adequate to make the information not misleading.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2020 and December 31, 2019, and our results of operations for the periods presented. Our financial position as of March 31, 2020 and results of operations and cash flows for the three months ended March 31, 2020 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2020 and therefore should not be relied upon as an indicator of future results.

Significant Accounting Polices, Estimates and Judgements – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the commissions we expect to collect for each approved member cohort, allowance for credit loss, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.

6







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
With the exception of the change for the accounting of credit losses as a result of the adoption of Accounting Standard Updates ("ASU") No. 2016-13, Financial InstrumentsCredit Losses discussed below, there have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.

Seasonality – A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage, Medicare Supplement, and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Due to the recent reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our commission revenue is typically second-highest in our first quarter.

The majority of our major medical individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase major medical individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

Recently Adopted Accounting Pronouncement

Financial Instruments – Credit Losses (Topic 326) – In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial InstrumentsCredit Losses (Topic 326), that requires companies to present certain financial assets net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. Contract assets – commissions receivable are the Company's only financial assets that were materially impacted by this guidance.

We adopted ASU 2016-13 using a modified retrospective transition method on January 1, 2020 for all financial assets measured at amortized cost. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under the previous accounting standards. We recorded a $1.1 million decrease, net of income taxes, to the retained earnings as of January 1, 2020 for the cumulative effect of adopting ASU 2016-13. See Note 3Supplemental Financial Statement Information for further discussion on credit losses.

The impacts from the adoption are summarized as follows (in thousands):

Balance Sheet Impact:December 31, 2019Transition AdjustmentsJanuary 1, 2020
Contract assets – commissions receivable – current$174,526  $(71) $174,455  
Contract assets – commissions receivable – non-current$414,696  $(1,442) $413,254  
Other assets*$18,004  $366  $18,370  
Total assets$741,634  $(1,147) $740,487  
Retained earnings$271,852  $(1,147) $270,705  
____________
*Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.


Financial Instruments (Topic 820) – In 2018, the FASB issued ASU No. 2018-13, to change the disclosure requirements for fair value measurement with the objective of improving the effectiveness of the notes to financial statements. This new guidance removed and modified certain disclosure requirements under Topic 820. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.


7







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Intangible – Goodwill and Other (Topic 350) – In 2017, the FASB issued ASU 2017-04 to simplify the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. In addition, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

Income Taxes (Topic 740) – In December 2019, the FASB issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes, which aims to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improve consistent application of and simplify U.S. GAAP for other areas under this Topic by clarifying existing guidance. ASU 2019-12 will be effective for us beginning January 1, 2021. The amendments in this standard update have individually different adoption approaches. We do not anticipate a material impact on our consolidated financial statements and disclosure from the adoption of this standard update.



8







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Note 2Revenue

Disaggregation of Revenue – The table below disaggregates our revenue by product (in thousands):
Three Months Ended March 31,
20202019
Medicare
Medicare Advantage$68,347  $39,843  
Medicare Supplement15,170  8,597  
Medicare Part D5,661  2,336  
Total Medicare89,178  50,776  
Individual and Family (1)
Non-Qualified Health Plans1,446  2,629  
Qualified Health Plans1,210  3,508  
Total Individual and Family2,656  6,137  
Ancillary
Short-term2,216  1,316  
Dental743  790  
Vision243  462  
Other1,049  951  
Total Ancillary4,251  3,519  
Small Business2,971  2,640  
Commission Bonus613  1,155  
Total Commission Revenue99,669  64,227  
Other Revenue6,739  4,546  
Total Revenue$106,408  $68,773  
_____________

(1)We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans.

Revenue Recognition Based on Estimated Constrained LTV

We recognize revenue for plans approved during the period by applying the latest estimated constrained life time value (“LTV”) for that product. We recognize adjustment revenue for plans approved in prior periods when there is a change in estimate to expected cash collections as a result of sufficient evidence that demonstrates a trend that is different from the estimated constrained LTV at the time of approval. We recognize adjustment revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We assess the risk of significant revenue reversal based on statistical and qualitative analysis given historical information and current market conditions.

Our commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting average plan duration and forecasting the commission amounts likely to be received per member. These assumptions are based on our analysis of historical trends for different cohorts and incorporate management’s judgment in interpreting those trends to apply the constraints discussed below. For our Medicare commission revenue, which represented 89% and 79% of our total commission revenue for the three months ended March 31, 2020 and 2019, respectively, the estimated average plan duration, which is the average length of time paying
9







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
members are active on their plans, used to calculate Medicare health insurance plan LTVs historically has been approximately 3 years for Medicare Advantage plans, approximately 5 years for Medicare Part D prescription drug plans, and approximately 5 years for Medicare Supplement plans. While the average plan duration has been approximately 3 years for Medicare Advantage plans, certain members may have a duration of up to 12 years. The estimated average plan duration used to calculate the LTV for major medical individual and family health insurance plans historically has been approximately 1.5 to 2 years. For short term health insurance plan LTVs, the estimated average plan duration historically has been less than six months. For all other ancillary health insurance plan LTVs, the estimated average plan duration has historically varied from 1 to 3 years. To the extent we make changes to the assumptions we use to calculate constrained LTVs, we recognize the impact of changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained LTV recognized as revenue.

Constraints are applied to LTV for revenue recognition purposes to help ensuring that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. Judgments that can be significant in estimating LTVs are related to the constraint. To determine the constraints to be applied to LTV, we compare prior calculations of LTV to actual cash received and review the reasons for any variations. We then apply judgment in assessing whether the difference between historical cash collections and LTV is representative of differences that can be expected in future periods. We also analyze whether circumstances have changed and consider any known or potential modifications to the inputs into LTV in light of the factors that can impact the amount of cash expected to be collected in future periods including but not limited to commission rates, carrier mix, plan duration, changes in laws and regulations, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship. We evaluate the appropriateness of our constraints on a quarterly basis, and we update our assumptions when we observe a sufficient amount of evidence that would suggest that the long-term expectation underlying the assumptions has changed.

We recorded adjustment revenue of $12.7 million and $7.4 million, or $0.52 and $0.34 per basic share, or $0.49 and $0.34 per diluted share, respectively, for the three months ended March 31, 2020 and 2019, respectively.

Commission revenue by segment is presented in the table below (in thousands):

Three Months Ended March 31,
20202019
Medicare
Commission Revenue from Members Approved During the Period (1)
$81,125  $50,582  
Net Commission Revenue from Members Approved in Prior Periods (2)
8,979  1,067  
Total Medicare Segment Commission Revenue$90,104  $51,649  
Individual, Family and Small Business
Commission Revenue from Members Approved During the Period (1)
$5,796  $6,225  
Net Commission Revenue from Members Approved in Prior Periods (2)
3,769  6,353  
Total IFP/SMB Segment Commission Revenue$9,565  $12,578  
_____________

(1)These amounts include commission bonus revenue.
(2)These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustment revenue within the relevant reporting period. These amounts include revenue associated with renewing small business health insurance members. Adjustment revenue also includes reductions to revenue for certain prior periods cohorts which were immaterial for the three months ended March 31, 2020 and 2019, respectively.


10







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Since the adoption of ASC 606, we re-compute LTVs for all outstanding cohorts on a quarterly basis. We continually review and monitor changes in the data used to estimate LTV and compare the cash received for each cohort to our original estimates at the time of approval. The fluctuations of cash received for each cohort and LTV can be significant and may or may not be indicative of the need to adjust revenue for prior period cohorts. Changes in LTV may result in an increase or a decrease to revenue and a corresponding increase or decrease to contract assets – commissions receivable, accordingly. We analyze these fluctuations and, to the extent we see changes in our estimates of the cash commission collections that we believe are indicative of an increase or decrease to prior period LTVs, we adjust revenue for the affected cohorts at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. As we accumulate more historical data, we continue to enhance our LTV estimation models using statistical tools to increase the accuracy of LTV estimates with an emphasis on improving member attrition forecasting. The enhancements to the LTV estimation model provide greater statistical certainty on expected cash collections, particularly for earlier period cohorts where there is more historical data available. Our LTV estimation models for the three months ended March 31, 2020 indicate increases in LTVs and estimates of future cash collections for earlier period cohorts of certain products within our Individual, Family and Small Business segment. However, after considering various market factors and recent changes due to the impact of COVID-19 to the U.S. economy, such as increases in unemployment rate, potential delays in customer premium payments and/or health insurance carrier commission payments, potential changes to enrollment periods, and potential changes to qualified health plan subsidies, we limited the adjustment revenue recognized during the three months ended March 31, 2020 to actual cash collected in excess of previously recognized revenue for certain cohorts related to individual and family as well as ancillary plans. These prevailing market conditions did not have an impact on the amount of adjustment revenue recognized for any other products we sell.


Note 3Supplemental Financial Statement Information

Cash, Cash Equivalents and Restricted Cash

We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invested in marketable securities that are measured and recorded at fair value. See Note 4Fair Value Measurements for further discussion about our marketable securities. As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):
March 31, 2020December 31, 2019
Cash$16,364  $16,205  
Cash equivalents167,803  7,261  
Restricted cash3,353  3,354  
Total cash, cash equivalents and restricted cash$187,520  $26,820  

As of March 31, 2020 and December 31, 2019, we had $3.4 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments.

Contract Assets and Accounts Receivable

We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of March 31, 2020.

11







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Our contract assets and accounts receivable consisted of the following for the periods presented (in thousands):
 March 31, 2020December 31, 2019
Contract assets – commissions receivable – current$125,252  $174,526  
Contract assets – commissions receivable – non-current435,465  414,696  
Accounts receivable668  2,332  
Total contract assets and accounts receivable$561,385  $591,554  

We estimate the allowance for credit loss balance using relevant available information from internal and external sources, related to past events, current conditions, and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ, Standard & Poors and Moody's analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commission receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure.

Subsequent to the adoption of ASC 326, we considered the impact of recent events and global economic condition when evaluating the appropriate adjustments to our allowance as of March 31, 2020. Determining the extent of these adjustments in the three months ended March 31, 2020 was especially challenging because we do not have any historical loss information for a period of similar economic decline. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimated of credit losses was not materially impacted as of March 31, 2020. After our management's evaluation, we recorded credit loss expenses of $0.1 million during the three months ended March 31, 2020 which is included in general and administrative expense on our Condensed Consolidated Statement of Comprehensive Income. Our contract assets – commission receivable activities, net of credit losses are summarized as follows (in thousands):
Three Months Ended March 31, 2020
Medicare SegmentIFP/SMB SegmentTotal
Beginning balance$550,922  $38,300  $589,222  
Commission revenue from members approved during the period81,125  5,796  86,921  
Net commission revenue adjustments from members approved in prior period8,979  3,769  12,748  
Cash receipts(112,731) (13,811) (126,542) 
Change in credit loss allowance*(1,574) (58) (1,632) 
Ending balance$526,721  $33,996  $560,717  

Three Months Ended March 31, 2019
Medicare SegmentIFP/SMB SegmentTotal
Beginning balance$311,977  $33,881  $345,858  
Commission revenue from members approved during the period50,582  6,225  56,807  
Net commission revenue adjustments from members approved in prior period1,067  6,353  7,420  
Cash receipts(67,873) (14,001) (81,874) 
Change in credit loss allowance      
Ending balance$295,753  $32,458  $328,211  
_____________
*Amount consists of transition adjustment of $1.5 million related to the adoption of ASC 326 as of January 1, 2020 and the subsequent credit loss adjustment of $0.1 million as of March 31, 2020. See Note 1Summary of Business and Significant Accounting Policies for details regarding the adoption impact.
12







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Credit Risk

Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, contract assets – commissions receivable, and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $4.1 million as of March 31, 2020.

We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below:
 March 31, 2020December 31, 2019
Humana22 %22 %
Aetna (1)
21 %20 %
UnitedHealthCare (2)
20 %20 %
_____________
(1)Aetna also includes other carriers owned by Aetna.
(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare. 


Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets are summarized as follows (in thousands):
 March 31, 2020December 31, 2019
Prepaid maintenance contracts5,460  3,853  
Prepaid expenses1,727  2,207  
Prepaid insurance543  918  
Income tax receivable1,041  584  
Other431  260  
Prepaid expenses and other current assets9,202  7,822  


Note 4Fair Value Measurements

We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy:

Level 1Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability; and
Level 3Unobservable inputs for the asset or liability.

13







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):
March 31, 2020
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$105,798  $105,798  $  $  $105,798  
Commercial paper62,005    62,005    62,005  
Short-term marketable securities
Commercial paper23,063    23,063    23,063  
Agency bonds10,620    10,620    10,620  
Long-term marketable securities
Agency bonds24,409    24,409    24,409  
Total assets measured and recorded at fair value$225,895  $105,798  $120,097  $  $225,895  

December 31, 2019
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$7,261  $7,261  $  $  $7,261  
Liabilities
Earnout liabilitycurrent
$37,273  $  $  $37,273  $37,273  

Our cash equivalents were invested in money market funds and commercial paper with original maturity 90 days or less were classified as Level 1. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our investments as Level 1.

As of March 31, 2020, our Level 2 assets included our available for sale marketable securities, which consisted of commercial paper and agency bonds with maturity less than two years. We classify our marketable debt securities within Level 2 in the fair value hierarchy because we use quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. Our portfolio primarily consisted of financial instruments with credit rating of AA+ or equivalent by S&P Rating and Moody's Investor Services. There were no transfers between the hierarchy levels during the three months ended March 31, 2020.

The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):

As of March 31, 2020
Amortized CostFair Value
Due in 1 year$201,482  $201,486  
Due in 1 year through 5 years24,388  24,409  
Total$225,870  $225,895  

14







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Unrealized gains and losses on available-for-sale debt securities are included in accumulated other comprehensive income and summarized as follows as of March 31, 2020:

Amortized CostUnrealized GainUnrealized LossFair Value
Cash equivalents
Money market funds$105,798  $—  $—  $105,798  
Commercial paper62,005  —  —  62,005  
Short-term marketable securities
Commercial paper23,063      23,063  
Agency bonds10,616  5  (1) 10,620  
Long-term marketable securities
Agency bonds24,388  21    24,409  
Total$225,870  $26  $(1) $225,895  

As of March 31, 2020, there were four securities in net loss positions and their unrealized losses were immaterial. We did not record any credit losses regarding our available-for-sales debt securities during the three months ended March 31, 2020.

Earnout Liabilities

Our earnout liabilities in connection with our GoMedigap acquisition in 2018 have been recognized at fair value. We measure the earnout liability using internally developed assumptions; therefore, it is classified as Level 3. The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the years ended December 31, 2019 and 2018 and our stock price at the time of payment.

Earnout liability activities are summarized as follows (in thousands):
Balance as of December 31, 2019$37,273  
Change in fair value  
Settlements(37,273) 
Balance as of March 31, 2020$  

In February 2019, we made the first earnout payment to GoMedigap consisting of $9.5 million in cash and 294,608 shares of our common stock with a value of $17.3 million. In January 2020, we made the second and last payment, which consisted of $8.8 million in cash and 294,608 shares of our common stock with a value of $28.5 million.


Note 5Equity

Public Offering of Common Stock – Pursuant to the effective registration statement which was filed on December 17, 2018, and amended on January 22, 2019 and March 2, 2020, we entered into an underwriting agreement in March 2020 to issue a total of 2,070,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase 270,000 additional shares of common stock, at a price to the public of $115.00 per share. Net proceeds from the offering were approximately $228.0 million after deducting underwriting discounts, commissions and expenses of the offering. We intend to use the net proceeds of the offering for general corporate purposes, including working capital.

Stock Repurchase Programs – We had no stock repurchase activity during the three months ended March 31, 2020. In addition to 10,663,888 shares repurchased under our previous repurchase programs, we have in treasury 985,454 shares as of
15







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
March 31, 2020 that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of March 31, 2020 and December 31, 2019, we had a total of 11,649,342 shares and 11,615,558 shares, respectively, held in treasury.

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.

Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types (in thousands): 
Three Months Ended March 31,
20202019
Common stock options$306  $602  
Restricted stock units8,408  2,627  
Total stock-based compensation expense$8,714  $3,229  

Our stock-based compensation expense is summarized as follows by operating functions (in thousands): 
 Three Months Ended March 31,
 20202019
Marketing and advertising$1,730  $629  
Customer care and enrollment662  273  
Technology and content1,617  549  
General and administrative4,705  1,778  
Total stock-based compensation expense$8,714  $3,229  


Note 6 — Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income per share is computed giving effect to all potential dilutive common stock equivalent shares, including options and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted net income per share by application of the treasury stock method.
 
16







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):

Three Months Ended March 31,
20202019
Basic:
Net income (loss)$3,452  $(5,159) 
Shares used in per share calculation – basic24,719  21,831  
Net income (loss) per share – basic:$0.14  $(0.24) 
Diluted:
Net income (loss)$3,452  $(5,159) 
Shares used in per share calculation – basic24,719  21,831  
Dilutive effect of common stock1,460    
Total common stock shares used in diluted share calculation26,179  21,831  
Net income (loss) per share – diluted$0.13  $(0.24) 

For the three months ended March 31, 2019, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of 1.0 million and 1.4 million shares related to common stock options and restricted stock units, respectively. There were no antidilutive shares for the three months ended March 31, 2020.


Note 7Commitments and Contingencies

Operating Leases

Refer to Note 9Leases for commitments related to our operating leases.

Contingencies

From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We accrued approximately $1.2 million as of March 31, 2020 for amounts we believe will be payable for certain current legal proceedings, including the matters discussed below. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail.


Legal Proceedings

On April 6, 2018, a former employee, Lupita Gonzalez, filed a complaint against us in the Superior Court of the State of California for the County of Sacramento (the “Gonzalez Complaint”). The Gonzalez Complaint is brought under the California Private Attorney General Act (“PAGA”) on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The claim alleges that we violated wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime
17







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
wages; (ii) the payment of minimum wages; (iii) providing compliant meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The Gonzalez Complaint seeks penalties and costs, expenses and attorneys’ fees.

On July 1, 2019, two other current or former employees, Michael Le’Vias and Ramona Meadows, filed a related complaint against us and eHealth Ins. Serv. Co., in the Superior Court of the State of California for the County of Santa Clara (the “Le’Vias Complaint”). A substantial overlap exists between the facts and circumstances alleged in the Gonzalez Complaint and the Le’Vias Complaint. Specifically, the Le’Vias Complaint is also brought under PAGA on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The claim alleges that we violated wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime wages; (ii) the payment of minimum wages; (iii) providing compliant meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The Le’Vias Complaint seeks unpaid wages, penalties and costs, expenses and attorneys’ fees.

The parties have agreed to resolve both the Le’Vias and Gonzalez Complaints, which settlement will require court approval. In the interim, the parties have filed notices of conditional settlement in both matters, and the April 13, 2020 trial date for the Gonzalez matter has been vacated.

On April 8, 2020 and April 29, 2020, two purported class action lawsuits were filed against us, our chief executive officer, Scott N. Flanders, our chief financial officer, Derek N. Yung and our chief operating officer, David K. Francis, in the United States District Court for the Northern District of California. The cases are captioned Patel v. eHealth, Inc., et al., Case No. 5:20-cv-02395 (N.D. Cal.) and Bertrand v. eHealth, Inc. et al., Case No. 3:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that we and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn and our profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the Patel lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. We believe the lawsuits to be without merit and intend to vigorously defend ourselves against them.

Service and Licensing Obligations

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

18







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2020 are summarized as follows (in thousands): 
For the Years Ending December 31,Service and Licensing Obligations
Remainder of 2020$1,961  
20212,189  
2022692  
2023444  
2024229  
Thereafter  
Total$5,515  


Note 8Segment and Geographic Information

Operating Segments

We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments: Medicare and Individual, Family and Small Business. Please refer to Note 1Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2019 for our accounting policies of operating segments.

The following table presents summary results of our operating segments for the three months ended March 31, 2020 and 2019 (in thousands):
Three Months Ended March 31,
 20202019
Revenue:
Medicare$96,151  $54,901  
Individual, Family and Small Business10,257  13,872  
Total revenue$106,408  $68,773  
Segment profit:
Medicare segment profit$21,960  $10,826  
Individual, Family and Small Business segment profit2,603  6,024  
Total segment profit24,563  16,850  
Corporate(13,448) (8,296) 
Stock-based compensation expense(8,714) (3,229) 
Change in fair value of earnout liability  (13,306) 
Depreciation and amortization(823) (655) 
Amortization of intangible assets(547) (547) 
Other income, net373  557  
Income (loss) before benefit from income taxes$1,404  $(8,626) 

19







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
There are no internal revenue transactions between our operating segments. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3Supplemental Financial Statement Information, our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented.

Geographic Information

Our long-lived assets primarily consist of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands):

March 31, 2020December 31, 2019
United States$99,297  $64,408  
China418  471  
Total$99,715  $64,879  
 
Significant Customers

Substantially all revenue for the three months ended March 31, 2020 and 2019 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue for the three months ended March 31, 2020 and 2019 are presented in the table below: 
Three Months Ended March 31,
 20202019
UnitedHealthcare (1)
22 %17 %
Humana19 %23 %
Aetna (2)
15 %17 %

(1)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.
(2) Aetna also includes other carriers owned by Aetna.


Note 9Leases

We have operating and finance leases for our corporate offices and certain equipment. Our leases have remaining lease terms of 1 to 10 years. Our operating lease expense recognized under ASC 842 for the three months ended March 31, 2020 and 2019 were $2.1 million and $1.3 million, respectively. Our cash outflows related to operating leases were $1.6 million and $0.9 million for the three months ended March 31, 2020 and 2019, respectively. During the three months ended March 31, 2020, we had non-cash investing activities of $7.1 million relating to right-of-use assets on the Condensed Consolidated Statements of Cash Flows.

Supplemental information as of March 31, 2020 related to leases is as follows (in thousands):
Operating lease right-of-use assets$43,396  
Operating lease liabilities$46,166  
Weighted-average remaining lease term of operating leases7.9 years
Weighted-average discount rate used to recognize operating lease right-of-use-assets5.5 %

20







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
As of March 31, 2020, maturities of operating lease liabilities are as follows (in thousands):
Year ending December 31,
Reminder of 2020$5,058  
20216,950  
20226,988  
20237,863  
20247,706  
Thereafter27,603  
Total lease payments62,168  
Less imputed interest(16,002) 
Total$46,166  

Operating Lease Obligations

We lease our operating facilities and certain of our equipment, furniture and fixtures under various operating leases, the latest of which expires in January 2030. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. 

In January 2020, we entered into an amendment to the lease agreement for our Gold River, California, office of 63,206 square feet. The amended lease term commenced on January 1, 2020 and has been extended to December 31, 2027. As of March 31, 2020, future minimum payments are expected to be $13.5 million over the remaining term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease. In addition, we have an option to extend the lease for one additional period of five years at the end of the term of the lease and will receive a one-time refurbishment allowance from the landlord if the option to renew is exercised.


Note 10Debt

On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40.0 million secured asset-backed revolving credit facility with a $5.0 million letter of credit sub-facility.

On December 20, 2019, we amended our revolving credit facility agreement with RBC (the “Amendment”) and increased the borrowing amount from $40.0 to $75.0 million. The maturity date has been extended to December 20, 2022.

The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected by during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed.

Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing, the Company paid a one-time facility fee of 1.75% of the total commitments of $40 million. We also paid a one-time closing fee of
21







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
0.5% of the new commitment of $75.0 million in connection with the Amendment. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type.

The availability under the credit facility is up to the lesser of $40 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. The Amendment increased the availability up to the lesser of $75.0 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement.

Financial covenants in the original Credit Agreement required that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6 million at any time. The Amendment also changed the financial covenants to require us to maintain at least $6.0 million of Excess Availability at all times or, if greater, up to $11.3 million depending on our borrowing base as determined by eligible past and future commission receivables. In addition, the Amendment also included changes in the payment conditions to, among other things, require us to have at least $10.0 million of liquidity or, if greater, up to $18.8 million depending on our borrowing base as determined by eligible past and future commission receivables, in order for us to make certain permitted acquisitions, investments, distributions and payments of indebtedness. The Amendment also stated the seasonal amount thresholds used in connection with the cash dominion and field examination covenants in the Credit Agreement.

We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of Other assets on our Consolidated Balance Sheet of the period we entered into the Credit Agreement. The Amendment did not change the interest rate. In connection with this Amendment, we incurred closing costs totaling $0.5 million, which was capitalized and recorded as Other assets on our Consolidated Balance Sheet as of December 31, 2019. The remaining balance of unamortized issuance costs was $1.1 million as of March 31, 2020 and December 31, 2019.

As of March 31, 2020, we had no outstanding principal amount under our revolving credit facility.


Note 11Income Taxes

The Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law on March 27, 2020. The business tax provisions of the CARES Act include temporary changes to income based tax laws, including the ability to utilize net operating losses, interest expense deductions, alternative minimum tax credit refunds, charitable contributions, and depreciation of qualified improvement property. The income tax provisions of the CARES Act do not have a material impact on our Condensed Consolidated Financial Statements for the period ended March 31, 2020.

The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2020 and 2019 (in thousands, except effective tax rate):
Three Months Ended March 31,
20202019
Income (loss) before benefit from income taxes$1,404  $(8,626) 
Benefit from income taxes(2,048) (3,467) 
Effective tax rate(145.9)%40.2 %

For the three months ended March 31, 2020, we recognized a benefit from income taxes of $2.0 million, representing an effective tax rate of (145.9)%, which was lower than the statutory federal tax rate primarily due to stock-based compensation windfalls. For the three months ended March 31, 2019, we recognized a benefit from income taxes of $3.5 million, representing an effective tax rate of 40.2%, which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses and foreign income inclusions, partially offset by research and development credits.

22







EHEALTH, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of March 31, 2020, as we believe it is more likely than not that the net deferred tax assets will be realized, with the exception of certain state net operating losses that are expected to expire unutilized which have a valuation allowance.

23




ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “expect,” “anticipate,” “believe,” “estimate,” “target,” “goal,” “project,” “hope,” “intend,” “plan,” “seek,” “continue,” “may,” “could,” “should,” “might,” “forecast,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements include, among other things, statements regarding our expectations relating to approved members, new paying members and estimated membership; our estimates regarding the constrained lifetime value of commissions; our expectations relating to revenue, operating costs, cash flows and profitability; our expectations regarding our strategy and investments; our expectations regarding our Medicare business, including market opportunity, consumer demand and our competitive advantage; our expectations regarding our individual and family business, including anticipated trends and our ability to enroll individuals and families into qualified health plans; the impact of future and existing healthcare laws and regulations on our business; the expected impact of the COVID-19 on our business; our expectations regarding commission rates, payment rates, conversion rates, plan termination rates and duration, membership retention rates and membership acquisition costs; our expectations regarding health insurance agents licensing and productivity; our expectations relating to the seasonality of our business; expected competition from government-run health insurance exchanges and other sources; our expectations relating to marketing and advertising expense and expected contributions from our marketing channels; the timing of our receipt of commission and other payments; our critical accounting policies and related estimates; liquidity and capital needs; political, legislative, regulatory and legal challenges; the merits or potential impact of any lawsuits filed against us; as well as other statements regarding our future operations, financial condition, prospects and business strategies.

We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including our ability to retain existing members and enroll new members during the annual healthcare open enrollment period and Medicare annual enrollment period; changes in laws and regulations, including in connection with healthcare reform or with respect to the marketing and sale of Medicare plans; competition, including competition from government-run health insurance exchanges; the seasonality of our business and the fluctuation of our operating results; our ability to accurately estimate membership and lifetime value of commissions; changes in product offerings among carriers on our ecommerce platform and the resulting impact on our commission revenue; our ability to execute on our growth strategy in the Medicare market; the continued impact of the COVID-19 pandemic on our operations, business, financial condition and growth prospects, as well as on the general economy; exposure to security risks and our ability to safeguard the security and privacy of confidential data; our relationships with health insurance carriers; customer concentration and consolidation of the health insurance industry; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to hire, train and retain licensed health insurance agents and other employees; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; changes in the market for private health insurance; consumer satisfaction of our service; changes in member conversion rates; changes in commission rates; our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchanges; our ability to maintain and enhance our brand identity; our ability to derive desired benefits from investments in our business, including membership growth initiatives; reliance on marketing partners; the impact of our direct-to-consumer email, telephone and television marketing efforts; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; our ability to successfully make and integrate acquisitions; dependence on our operations in China; the restrictions in our debt obligations; compliance with insurance and other laws and regulations; and the performance, reliability and availability of our ecommerce platform and underlying network infrastructure and those identified under the heading “Risk Factors” in Part II, Item 1A. of this report and those discussed in our other Securities and Exchange Commission filings. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. Except as required by applicable law, we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise. The following discussion should be read in conjunction with our Annual Report on Form 10-K as filed with the Securities and Exchange Commission in March 2020, and the audited consolidated financial statements and related notes contained therein.
24




Overview 

We are a leading private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omni-channel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that include thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 180 health insurance carriers across all fifty states and the District of Columbia.


Impact from COVID-19

Our results of operations for the three months ended March 31, 2020 were not materially impacted by the COVID-19 pandemic. In response to the virus outbreak, we closed our offices in the United States and China and shifted our employees to a work-from-home model. While our offices in the United States remain closed, we reopened our office in China given the improvements in the situation in the region in China where our office is located. See Risk Factors in Part II Item 1A of this Quarterly Report on Form 10-Q for additional discussion of COVID-19.


Summary of Selected Metrics

We rely upon certain metrics to estimate and recognize commission revenue, evaluate our business performance and facilitate strategic planning. Our commission revenue is influenced by a number of factors including but not limited to:

the number of individuals on applications for Medicare-related, individual and family, small business and ancillary health insurance plans that are approved by the relevant health insurance carriers;

the number of individuals on applications for Medicare-related, individual and family, small business and ancillary health insurance plans from whom we have received an initial commission payment; and

the constrained lifetime value, or LTV, of approved members for Medicare-related, individual and family and ancillary health insurance plans we sell, as well as the estimated annual value of approved members for small business plans we sell.

We have included the number of new paying members in our selected metrics to provide more detail and visibility into new paying member contribution to the changes in membership. We count an approved member as a paying member when we have received a commission payment from the carrier for the plan. Not all approved members become paying members for various reasons. In addition, for any given period, the rate at which approved members become new paying members is impacted by the time lag between carrier approval and our receipt of the commission payment from the carrier. The difference in our metrics between the number of approved members and new paying members tends to vary, especially in the first and fourth quarters given this time lag and given that the plans we sell in the fourth quarter do not begin generating commissions until the first quarter when they become effective.

We have removed submitted applications from our selected metrics given that we do not recognize revenue based on this metric, and it is not as indicative of our commission receivable collection as other metrics we do provide.

Approved Members

Approved members represents the number of individuals on submitted applications that were approved by the relevant insurance carrier for the identified product during the current period. The applications may be submitted in either the current period or prior periods. Not all approved members ultimately become paying members.
25





The following table shows approved members by product for the periods presented:
Three Months Ended March 31, % Change
20202019
Medicare:
Medicare Advantage64,898  40,741  59 %
Medicare Supplement10,838  8,631  26 %
Medicare Part D8,966  8,527  %
Total Medicare84,702  57,899  46 %
Individual and Family:
Non-Qualified Health Plans4,820  6,071  (21)%
Qualified Health Plans4,545  5,527  (18)%
Total Individual and Family9,365  11,598  (19)%
Ancillaries:
Short-term12,138  14,932  (19)%
Dental9,710  13,056  (26)%
Vision4,501  6,415  (30)%
Other4,325  5,212  (17)%
Total Ancillaries30,674  39,615  (23)%
Small Business3,603  4,252  (15)%
Total Approved Members128,344  113,364  13 %

Total approved members grew 13% in the three months ended March 31, 2020 compared to the same period in 2019. Medicare total approved members grew 46% in the three months ended March 31, 2020 compared to the same period in 2019, primarily attributable to a 59% increase in approved Medicare Advantage plan members and a 26% increase in approved Medicare Supplement plan members. The increase in Medicare total approved members was primarily driven by an increase in enrollment volume during the Medicare Advantage open enrollment period. Individual and family plan approved members declined 19% in the three months ended March 31, 2020 compared to the same period in 2019 due to market conditions in the individual and family plan market and our devoting resources to our Medicare business. Ancillary approved members declined 23% in the three months ended March 31, 2020 compared to the same period in 2019 primarily due to decreases in dental and short-term insurance. Small business approved members declined 15% in the three months ended March 31, 2020 compared to the same period in 2019 mainly due to decreases in the volume of submitted applications and group size.
26




New Paying Members

New Paying Members consist of approved members from the period presented and any periods prior to the period presented from whom we have received an initial commission payment during the period presented. The following table shows our new paying member by product for the periods presented below:


Three Months Ended March 31, % Change
20202019
Medicare:
Medicare Advantage86,299  49,531  74 %
Medicare Supplement11,560  9,786  18 %
Medicare Part D63,705  40,796  56 %
Total Medicare161,564  100,113  61 %
Individual and Family:
Non-Qualified Health Plans9,553  14,012  (32)%
Qualified Health Plans5,957  7,390  (19)%
Total Individual and Family15,510  21,402  (28)%
Ancillaries:
Short-term12,260  20,119  (39)%
Dental10,413  14,384  (28)%
Vision5,571  8,848  (37)%
Other4,313  5,891  (27)%
Total Ancillaries32,557  49,242  (34)%
Small Business5,156  6,992  (26)%
Total New Paying Members214,787  177,749  21 %

Medicare total new paying members grew 61% in the three months ended March 31, 2020 compared to the same period in 2019. Medicare Advantage new paying members grew 74%; Medicare Part D prescription drug plans new paying members grew 56% and Medicare Supplement plan new paying members on grew 18% each compared to the same period in 2019. The increases were primarily driven by an increase in enrollment volume and approved members from the recent Medicare annual enrollment period and Medicare Advantage open enrollment period. Individual and family plan new paying members declined 28% in the three months ended March 31, 2020 compared to the same period in 2019 due to market conditions in the individual and family plan market and the shift of our focus to invest in our Medicare business. Ancillary new paying members declined 34% in the three months ended March 31, 2020 compared to the same period in 2019 primarily due to a reduction in short-term health insurance and dental insurance paying members. Small business new paying members declined 26% in the three months ended March 31, 2020 compared to the same period in 2019 primarily due to a decrease in the submitted application volume and group size.


27




Constrained LTV of Commissions Per Approved Member

The following table shows our estimated constrained LTV of commissions per approved member by product for the periods presented below:

Three Months Ended March 31, % Change
 20202019
Medicare
Medicare Advantage$1,006  $954  5%
Medicare Supplement $1,158  $999  16%
Medicare Part D $260  $258  1%
Individual and Family
Non-Qualified Health Plans $199  $178  12%
Qualified Health Plans $240  $194  24%
Ancillaries
Short-term $150  $65  131%
Dental $67  $71  (6)%
Vision $52  $63  (17)%
Small Business $160  $155  3%
__________
(1)Constrained LTV of commissions per approved member represents commissions estimated to be collected over the estimated life of an approved member’s policy after applying constraints in accordance with our revenue recognition policy. The estimate is driven by multiple factors, including but not limited to, commission rates, carrier mix, estimated average plan duration, the regulatory environment, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship. These factors may result in varying values from period to period. For additional information on constrained LTV, see Critical Accounting Policies and Estimates in our Annual Report on Form 10-K for the year ended December 31, 2019.

(2)For small business, the amount represents the estimated commissions we expect to collect from the plan over the following twelve months. The estimate is driven by multiple factors, including but not limited to, contracted commission rates, carrier mix, estimated average plan duration, the regulatory environment, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship and applied constraints. These factors may result in varying values from period to period.

The constrained LTV of commissions per approved member for Medicare Advantage plans increased by 5% during the three months ended March 31, 2020 compared to the same period in 2019 primarily due to an increase in the average projected commission payments per member. When comparing the three months ended March 31, 2020 to the same period in 2019, the constrained LTV of commissions per Medicare Supplement approved member increased by 16% primarily as a result of an increase in the average projected commission payments per member and an increase in the average plan duration.

The constrained LTV of commissions per qualified health plan and non-qualified health plan for approved members increased 24% and 12%, respectively, during the three months ended March 31, 2020 compared with the same period in 2019, respectively, mostly due to improved plan duration.

The constrained LTV of commissions per short-term approved member increased 131% during the three months ended March 31, 2020 compared to the same period in 2019 primarily as a result of selling higher priced plans and an increase in average plan duration.

28




The constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained lifetime value of commissions for approved members recognized for the periods presented below are summarized as follows:
Three Months Ended March 31,
 20202019
Medicare
Medicare Advantage%%
Medicare Supplement%%
Medicare Part D%%
Individual and Family
Non-Qualified Health Plans 15 %15 %
Qualified Health Plans%20 %
Ancillaries10 %10 %
Small Business— %— %

The constraints for qualified health plans decreased to 4% during the three months ended March 31, 2020 from 20% in the same period in the prior year due to lower volatility and improved accuracy from our LTV model.

29




Estimated Membership

Estimated membership represents the estimated number of members active as of the date indicated based on the number of members for whom we have received or applied a commission payment during the period of estimation.

The following table shows estimated membership by product for the periods presented below:
As of March 31, % Change
 20202019
Medicare (1)
Medicare Advantage404,262  280,763  44 %
Medicare Supplement97,527  76,875  27 %
Medicare Part D224,154  146,239  53 %
Total Medicare725,943  503,877  44 %
Individual and Family (2)
113,483  130,297  (13)%
Ancillaries (3)
Short-term 23,553  23,626  — %
Dental123,260  137,179  (10)%
Vision70,590  76,303  (7)%
Other36,012  37,985  (5)%
Total Ancillaries253,415  275,093  (8)%
Small Business (4)
44,113  42,972  %
Total Estimated Membership1,136,954  952,239  19 %
__________________
(1)To estimate the number of members on Medicare-related health insurance plans, we take the sum of (i) the number of members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). To the extent we determine we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation.

(2)To estimate the number of members on Individual and Family health insurance plans (“IFP”), we take the sum of (i) the number of IFP members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation after reducing that number using historical experience for assumed member cancellations over the period being estimated; and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). To the extent we determine we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation.

(3)To estimate the number of members on ancillary health insurance plans (such as short-term, dental and vision insurance), we take the sum of (i) the number of members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). To the extent we determine we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation. The one to three-month period varies by insurance product and is largely dependent upon the timeliness of commission payment and related reporting from the related carriers.

(4)To estimate the number of members on small business health insurance plans, we use the number of initial members at the time the group was approved, and we update this number for changes in membership if such changes are reported to us by the group or carrier. However, groups generally notify the carrier directly of policy cancellations and increases or decreases in group size without informing us. Health insurance carriers often do not communicate policy cancellation information or group size changes to us. We often are made aware of policy cancellations and group size changes at the time of annual renewal and update our membership statistics accordingly in the period they are reported.

Health insurance carriers bill and collect insurance premiums paid by our members. The carriers do not report to us the number of members that we have as of a given date. The majority of our members who terminate their plans do so by discontinuing their premium payments to the carrier and do not inform us of the cancellation. Also, some of our members pay
30




their premiums less frequently than monthly. Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. For instance, we reconcile information carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have under estimated membership. Conversely, carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. We do not update our estimated membership numbers reported in previous periods. Instead, we reflect updated information regarding our historical membership in the membership estimate for the current period. As a result of the delay in our receipt of information from insurance carriers, actual trends in our membership are most discernible over periods longer than from one quarter to the next. As a result of the delay we experience in receiving information about our membership, it is difficult for us to determine with any certainty the impact of current conditions on our membership retention. Various circumstances could cause the assumptions and estimates that we make in connection with estimating our membership to be inaccurate, which would cause our membership estimates to be inaccurate. A member who purchases and is active on multiple standalone insurance plans will be counted as a member more than once. For example, a member who is active on both an individual and family health insurance plan and a standalone dental plan will be counted as two continuing members.

Medicare-related plan estimated membership as of March 31, 2020 grew 44% compared to estimated membership as of March 31, 2019 due to a 44% growth in Medicare Advantage membership, 27% growth in Medicare Supplement membership, and 53% growth in Medicare Part D prescription drug plan membership. The overall growth in Medicare estimated membership was due to our marketing investment in our Medicare business. Individual and family plan estimated membership as of March 31, 2020 declined 13% compared to estimated membership as of March 31, 2019 due to market conditions in the individual and family plan market and our decision to shift our marketing investment towards our Medicare business. Ancillary membership as of March 31, 2020 declined 8% compared to estimated membership as of March 31, 2019 primarily as a result of the decline in dental and vision plan members.


31




Member Acquisition

Marketing initiatives are an important component of our strategy to increase revenue. Our marketing initiatives are focused on three primary member acquisition channels: direct, marketing partners, and online advertising. Our marketing initiatives are primarily designed to encourage consumers to complete an application for health insurance. In addition, we incur customer care and enrollment expenses in assisting applicants during the enrollment process.

The following table shows our variable marketing cost per approved member and the customer care and enrollment expense per approved member metrics for the periods presented below:
Three Months Ended March 31, % Change
20202019
Medicare variable cost per approved member
Medicare variable marketing cost per approved Medicare Advantage ("MA")-equivalent member (1)
$349  $334  %
Medicare customer care and enrollment ("CC&E") cost per approved MA-equivalent member (2)
364  344  %
Total Medicare cost per approved member$713  $678  %
Individual and family plan ("IFP") variable cost per approved member
IFP variable marketing cost per approved IFP-equivalent member (3)
$36  $24  50 %
IFP CC&E cost per approved IFP-equivalent member (4)
79  66  20 %
Total IFP cost per approved member$115  $90  28 %
__________________
(1)Variable marketing cost per approved MA-equivalent member represents direct costs incurred in member acquisition for Medicare Advantage, Medicare Supplement and Medicare Part D plans from our direct, marketing partners and online advertising channels divided by MA-equivalent approved members in a given period. MA-equivalent members is a derived metric and is equal to the sum of (i) the number of Medicare Part D approved members divided by 4, (ii) the number of Medicare Advantage approved members and (iii) the number of Medicare Supplement approved members in the given period.
(2)Medicare CC&E expense per approved MA-equivalent member is equal to the CC&E expense of our Medicare business included in our operating costs and reported in our Consolidated Statements of Comprehensive Income divided by MA-equivalent approved members in a given period. MA-equivalent approved members is a derived metric and is equal to the sum of (i) the number of Medicare Part D approved members divided by 4, (ii) the number of Medicare Advantage approved members and (iii) the number of Medicare Supplement approved members in the given period.
(3)Variable marketing cost per approved IFP-equivalent member represents direct costs incurred in member acquisition for IFP plans from our direct, marketing partners and online advertising channels divided by IFP-equivalent approved members in a given period. IFP-equivalent approved members is a derived metric and is equal to the sum of (i) the number of short-term approved members divided by 3 and (ii) the IFP approved members in the given period.
(4)IFP CC&E expense per approved IFP-equivalent member is equal to the CC&E expense of our IFP business included in our operating costs and reported in our consolidated statement of comprehensive income divided by IFP-equivalent approved members in a given period. IFP-equivalent approved members is a derived metric and is equal to the sum of (i) the number of short-term approved members divided by 3 and (ii) the IFP approved members in the given period.

Variable marketing costs per approved MA-equivalent member increased 5% in the three months ended March 31, 2020 compared to the same period in 2019 due to an increase in enrollment volume from our digital advertising channel and a decline in contribution from certain marketing partners that reduced their marketing initiatives due to COVID-19. Variable CC&E costs per approved MA-equivalent member increased 6% in the three months ended March 31, 2020 compared to the same period in 2019 as we retained a higher number of agents from the Annual Enrollment Period compared to the same period in 2019. It also reflects the costs associated with shifting our call center to a remote model in March 2020 as the result of the COVID-19 situation.

While variable marketing and CC&E costs increased by 4%, variable marketing cost per approved IFP-equivalent member increased by 50% and variable CC&E cost per approved IFP-equivalent member increased 20% in the three months ended March 31, 2020 compared to the same period in 2019 due to a decline in the number of approved members for individual and family plans and ancillary plans.


32




Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, requires us to make judgments, assumptions, and estimates that affect the amounts reported in the consolidated financial statements and the accompanying notes. These estimates and assumptions are based on current facts, historical experience, and various other factors that we believe are reasonable under the circumstances to determine reported amounts of assets, liabilities, revenue and expenses that are not readily apparent from other sources. To the extent there are material differences between our estimates and the actual results, our future consolidated results of operations may be affected. 

An accounting policy is considered to be critical if the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the effect of the estimates and assumptions on financial condition or operating performance. The accounting policies we believe to reflect our more significant estimates, judgments and assumptions and are most critical to understanding and evaluating our reported financial results are as follows: 

Revenue Recognition;
Stock-Based Compensation;
Business Combinations; 
Realizability of Long-Lived Assets; and
Accounting for Income Taxes.

There have been no changes to our significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 2, 2020, that have had a material impact on our condensed consolidated financial statements and related notes. Please refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2019, for a complete discussion of our other critical accounting policies and estimates.


33




Results of Operations

The following table sets forth our operating results and related percentages of total revenue for the periods presented below (dollars in thousands):
 Three Months Ended March 31,
 20202019
Revenue:  
Commission$99,669  94 %$64,227  93 %
Other6,739  %4,546  %
Total revenue106,408  100 %68,773  100 %
Operating costs and expenses:
Cost of revenue1,138  %(77) — %
Marketing and advertising37,764  35 %23,941  35 %
Customer care and enrollment30,535  29 %19,944  29 %
Technology and content15,740  15 %9,017  13 %
General and administrative19,653  18 %11,278  16 %
Amortization of intangible assets547  %547  %
Change in fair value of earnout liability—  — %13,306  19 %
Total operating costs and expenses105,377  99 %77,956  113 %
Income (loss) from operations1,031  %(9,183) (13)%
Other income, net373  — %557  %
Income (loss) before benefit from income taxes1,404  %(8,626) (13)%
Benefit from income taxes(2,048) (2)%(3,467) (5)%
Net income (loss)$3,452  %$(5,159) (8)%

____________

(1)Operating costs and expenses include the following amounts of stock-based compensation expense (in thousands): 
 Three Months Ended March 31,
 20202019
Marketing and advertising$1,730  $629  
Customer care and enrollment662  273  
Technology and content1,617  549  
General and administrative4,705  1,778  
Total stock-based compensation expense$8,714  $3,229  


34




Revenue

The following table presents our commission revenue, other revenue and total revenue for the periods presented (dollars in thousands):
 Three Months Ended March 31, Change
 20202019$%
Commission$99,669  $64,227  $35,442  55 %
% of total revenue94 %93 %
Other6,739  4,546  2,193  48 %
% of total revenue%%
Total revenue$106,408  $68,773  $37,635  55 %

Commission revenue increased $35.4 million, or 55%, during the three months ended March 31, 2020 compared to the same period in 2019 due to a $38.5 million increase in commission revenue from the Medicare segment, partially offset by a $3.0 million decrease in commission revenue from Individual, Family and Small Business segment. The increase in commission revenue from the Medicare segment was driven by a 46% increase in Medicare plan approved members, primarily attributable to a 59% growth in Medicare Advantage plan approved members due to the recent open enrollment and an increase in adjustment revenue. The decrease in commission revenue from Individual, Family and Small Business segment was primarily due to a 19% decline in individual and family plan approved members and a decrease in adjustment revenue. See Segment Information below for further discussion.

Adjustment revenue for our Medicare segment for the three months ended March 31, 2020 and 2019 was $9.0 million and $1.1 million, respectively. For our Individual, Family and Small Business segment adjustment revenue for the three months ended March 31, 2020 and 2019 was $3.8 million and $6.4 million, respectively. Our LTV estimation models for the three months ended March 31, 2020 indicate increases in LTVs and estimates of future cash collections for earlier period cohorts of certain products within our Individual, Family and Small Business segment. However, after considering various market factors and recent changes due to the impact of COVID-19 to the U.S. economy, such as increases in unemployment rate, potential delays in customer premium payments and/or health insurance carrier commission payments, potential changes to enrollment periods, and potential changes to qualified health plan subsidies, we limited the adjustment revenue recognized during the three months ended March 31, 2020 to actual cash collected in excess of previously recognized revenue for certain cohorts related to individual and family as well as ancillary plans. These prevailing market conditions did not have an impact on the amount of adjustment revenue recognized for any other products we sell.

Other revenue increased $2.2 million, or 48%, during the three months ended March 31, 2020 compared to the same period in 2019 due to an increase in sponsorship and online advertising revenue.


Cost of Revenue 

Included in cost of revenue are payments related to health insurance plans sold to members who were referred to our website by marketing partners with whom we have revenue-sharing arrangements. In order to enter into a revenue-sharing arrangement, marketing partners must be licensed to sell health insurance in the state where the policy is sold. Costs related to revenue-sharing arrangements are expensed as the related revenue is recognized.

Additionally, cost of revenue includes the amortization of consideration we paid to certain broker partners in connection with the transfer of their health insurance members to us as the new broker of record on the underlying plans. These transfers include primarily Medicare plan members. Consideration for all book-of-business transfers is being amortized to cost of revenue as we recognize commission revenue related to the transferred members.

35




Our cost of revenue is summarized as follows (dollars in thousands): 
 Three Months Ended March 31, Change
 20202019$%
Cost of revenue$1,138  $(77) $1,215   
% of total revenue%— %
_____________
*Percentage not meaningful.

Cost of revenue increased by $1.2 million during the three months ended March 31, 2020 compared to the same period in 2019, mostly due to an increase in accruals for marketing partners with whom we have revenue sharing arrangements.


Marketing and Advertising

Marketing and advertising expenses consist primarily of member acquisition expenses associated with our direct, marketing partner and online advertising member acquisition channels, in addition to compensation and other expenses related to marketing, business development, partner management, public relations and carrier relations personnel who support our offerings.

Our marketing and advertising expenses are summarized as follows (dollars in thousands): 
Three Months Ended March 31, Change
20202019$%
Marketing and advertising$37,764  $23,941  $13,823  58 %
% of total revenue35 %35 %

Marketing and advertising expenses increased $13.8 million, or 58%, during the three months ended March 31, 2020 compared to the same period in 2019, primarily due to increases of $10.3 million in variable advertising expenses and $1.1 million in stock-based compensation expenses. The increase in Medicare-related variable advertising expenses was due to higher headcount as we continued to invest in our marketing initiatives.

Customer Care and Enrollment

Customer care and enrollment expenses primarily consist of compensation and benefits costs for personnel engaged in assistance to applicants who call our customer care center and for enrollment personnel who assist applicants during the enrollment process.

Our customer care and enrollment expenses are summarized as follows (dollars in thousands): 
 Three Months Ended March 31, Change
 20202019$%
Customer care and enrollment$30,535  $19,944  $10,591  53 %
% of total revenue29 %29 %

Customer care and enrollment expenses increased $10.6 million, or 53%, during the three months ended March 31, 2020 compared to the same period in 2019, primarily due to increases of $6.6 million in personnel costs associated with an increase in customer care and enrollment headcount, $2.2 million in consulting expenses, and $1.0 million in facilities and other operating costs.


36




Technology and Content

Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our websites.

Our technology and content expenses are summarized as follows (dollars in thousands):
 Three Months Ended March 31, Change
 20202019$%
Technology and content$15,740  $9,017  $6,723  75 %
% of total revenue15 %13 %

Technology and content expenses increased $6.7 million, or 75%, during the three months ended March 31, 2020 compared to the same period in 2019 primarily due to increases of $3.1 million in personnel and compensation costs due to higher headcount, $1.4 million in facilities and other operating costs, $1.1 million in stock-based compensation and $0.8 million of amortization of internal-use intangible assets.


General and Administrative

General and administrative expenses include compensation and benefits costs for staff working in our executive, finance, investor relations, government affairs, legal, human resources, internal audit, facilities and internal information technology departments. These expenses also include fees paid for outside professional services, including audit, tax, legal, government affairs and information technology fees.

Our general and administrative expenses are summarized as follows (dollars in thousands): 
 Three Months Ended March 31, Change
 20202019$%
General and administrative$19,653  $11,278  $8,375  74 %
% of total revenue18 %16 %

General and administrative expenses increased $8.4 million, or 74%, during the three months ended March 31, 2020 compared to the same period in 2019, primarily due to increases of $3.1 million in personnel and compensation costs, $2.9 million in stock-based compensation expense, $0.7 million in facilities and other operating costs, $0.7 million in consulting expenses, and $0.4 million in legal and professional fees.


Change in Fair Value of Earnout Liability

During the three months ended March 31, 2019, we recorded $13.3 million of additional earnout consideration expense due to an adjustment in the estimated fair value of the earnout liability related to the acquisition of GoMedigap, which was completed on January 2018. During the three months ended March 31, 2020, there were no changes in fair value of earnout liability as the earnout consideration was settled in January 2020.


37




Amortization of Intangible Assets

Our intangible asset amortization expense is summarized as follows (dollars in thousands): 
 Three Months Ended March 31, Change
 20202019$%
Amortization of intangible assets$547  $547  $—  — %
% of total revenue%%

Amortization expense related to intangible assets was primarily related to intangible assets purchased through our acquisitions. Amortization expense remained consistent during the three months ended March 31, 2020 compared to the same period in 2019.


Other Income, Net

Our other income, net is summarized as follows (dollars in thousands): 
 Three Months Ended March 31, Change
 20202019$%
Other income, net$373  $557  $(184) (33)%
% of total revenue— %%

Other income, net, for the three months ended March 31, 2020 and 2019 primarily consisted of margin earned on commissions received from Medicare plan members transferred to us in 2010 through 2012 by a broker partner, whereby we became the broker of record on the underlying policies. In addition, other income, net included interest income earned on our invested cash, cash equivalents and marketable securities balances, offset by administrative bank fees, investment management fees and interest expense on finance leases and debt.

Other income, net decreased $0.2 million during the three months ended March 31, 2020 compared to the same period in 2019, primarily due to a decrease interest income.


Benefit from Income Taxes 

Our benefit from income taxes are summarized as follows (dollars in thousands):
 Three Months Ended March 31, Change
 20202019$%
Benefit from income taxes$(2,048) $(3,467) $1,419  (41)%
Effective tax rate(145.9)%40.2 %

During the three months ended March 31, 2020, we recognized a benefit from income taxes of $2.0 million representing an effective tax rate of (145.9)% which was lower than the statutory federal tax rate primarily due to stock-based compensation windfalls. For the three months ended March 31, 2019, we recognized a benefit from income taxes of $3.5 million, representing an effective tax rate of 40.2% which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments and lobbying and other non-deductible expenses, partially offset by research and development credits.

The CARES Act was signed into law on March 27, 2020. The business tax provisions of the CARES Act include temporary changes to income based tax laws, including the ability to utilize net operating losses, interest expense deductions,
38




alternative minimum tax credit refunds, charitable contributions, and depreciation of qualified improvement property. The income tax provisions of the CARES Act do not have a material impact on our Condensed Consolidated Financial Statements for the period ended March 31, 2020.


Segment Information

We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit (loss). Our business structure is comprised of two operating segments:

Medicare; and
Individual, Family and Small Business.

Our CODM does not separately evaluate assets by segment, and therefore assets by segment are not presented.

The Medicare segment consists primarily of commissions earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision plans, as well as our advertising program that allows Medicare-related carriers to purchase advertising on a separate website developed, hosted and maintained by us and our delivery and sale to third parties of Medicare-related health insurance leads generated by our ecommerce platforms and our marketing activities.

The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual, family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term health insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology, and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.

Marketing and advertising, customer care and enrollment, technology and content, and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment, and technology and content operating expenses are allocated to each segment based on usage. Other indirect general and administrative operating expenses are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the two operating segments and instead reported within Corporate.

Segment profit is calculated as total revenue for the applicable segment less direct and allocated marketing and advertising, customer care and enrollment, technology and content, and general and administrative operating expenses, excluding stock-based compensation, change in fair value of earnout liability, depreciation and amortization expense, other income, net, and amortization of intangible assets.


39




Our operating segment revenue and profit are summarized as follows (in thousands):
Three Months Ended March 31, Change
 20202019$%
Revenue:
Medicare$96,151  $54,901  $41,250  75 %
Individual, Family and Small Business10,257  13,872  (3,615) (26)%
Total revenue$106,408  $68,773  $37,635  55 %
Segment profit:
Medicare segment profit$21,960  $10,826  $11,134  103 %
Individual, Family and Small Business segment profit2,603  6,024  (3,421) (57)%
Total segment profit24,563  16,850  7,713  46 %
Corporate(13,448) (8,296) (5,152) 62 %
Stock-based compensation expense(8,714) (3,229) (5,485) 170 %
Change in fair value of earnout liability—  (13,306) 13,306  (100)%
Depreciation and amortization(823) (655) (168) 26 %
Amortization of intangible assets(547) (547) —  — %
Other income, net373  557  (184) (33)%
Income (loss) before benefit from income taxes$1,404  $(8,626) $10,030  (116)%

Revenue

Revenue from our Medicare segment increased $41.3 million, or 75%, during the three months ended March 31, 2020 compared to the same period in 2019 due to a $38.5 million increase in Medicare commission revenue and a $2.8 million increase in other revenue. The increase in Medicare segment commission revenue was primarily attributable to a 59% growth in Medicare Advantage plan approved members and a $7.9 million increase in adjustment revenue during the three months ended March 31, 2020 compared to the same period in 2019. The overall growth of our Medicare business was a result of our continuous investments and marketing efforts. The increase in other revenue was mostly due to an increase in advertising revenue.

Revenue from our Individual, Family and Small Business segment decreased $3.6 million, or 26%, during the three months ended March 31, 2020 compared to the same period in 2019 primarily attributable to a $3.0 million decrease in commission revenue and a $0.6 million decrease in other revenue. The decrease in commission revenue from the Individual, Family and Small Business segment was primarily due to a decrease in commission revenue adjustments of $2.6 million and a 19% decline in individual and family health insurance approved members during the three months ended March 31, 2020 compared to the same period in 2019. Due to various market factors and recent changes in the U.S. economy, we limited the adjustment revenue recognized during the three months ended March 31, 2020 to actual cash collected in excess of previously recognized revenue for certain cohorts related to individual and family as well as ancillary plans. These prevailing market conditions did not have an impact on the amount of adjustment revenue recognized for any other products we sell.


Segment Profit

Our Medicare segment profit increased $11.1 million, or 103%, during the three months ended March 31, 2020 compared to the same period in 2019. The increase was primarily due to a $41.3 million increase in Medicare segment revenue, partially offset by a $30.1 million increase in operating expenses, excluding stock-based compensation, change in earnout liability, depreciation and amortization expenses and amortization of intangible assets. The increase in operating expenses was mostly attributable to an increase in marketing costs and customer care and enrollment costs.

Our Individual, Family and Small Business segment profit decreased $3.4 million, or 57%, during the three months ended March 31, 2020 compared to the same period in 2019. The decrease in profit from the Individual, Family and Small
40




Business segment was primarily due to a $3.6 million decrease in Individual, Family and Small Business segment revenue, partially offset by a $0.2 million decrease in operating expenses, excluding stock-based compensation, change in earnout liability, depreciation and amortization expenses and amortization of intangible assets.


Liquidity and Capital Resources 

We believe our current cash and cash equivalents, credit facility and expected cash collections will be sufficient to fund our operations for at least twelve months after the filing date of this Quarterly Report on Form 10-Q. Our future capital requirements will depend on many factors, including our expected membership and retention rates and our level of investment in technology, marketing and advertising and our customer care initiatives. In addition, our cash position could be impacted by further acquisitions and investments we make to pursue our growth strategy.

While we recognize constrained LTV as revenue at the time applications are approved, our collection of the cash commissions resulting from approved applications generally occurs over a number of years. The expense associated with the approved application, however, is generally incurred at the time of enrollment. As a result, the net cash flow resulting from approved applications is generally negative in the period of revenue recognition and generally becomes positive over the lifetime of the member. In periods of membership growth, cash receipts associated with new and continuing members may be less than the cash outlays to acquire new members. We expect a reduction in cash and cash equivalents in the future resulting from our continued investments to facilitate growth in our business. To the extent that available funds are insufficient to fund our future activities or to execute our financial strategy, we may raise additional capital through bank debt, or public or private equity or debt financing to the extent such funding sources are available.

As of March 31, 2020, our cash and cash equivalents totaled $184.2 million. Cash equivalents, which are comprised of financial instruments with an original maturity of 90 days or less from the date of purchase, primarily consist of money market funds. As of December 31, 2019, our cash and cash equivalents totaled $23.5 million. The increase in cash and cash equivalents reflects $215.9 million provided by financing activities and $8.9 million provided by operating activities, partially offset by $64.1 million used in investing activities. See Note 5 — Equity in our Notes to Condensed Consolidated Financial Statements for information regarding our equity offering in March 2020. We also had $3.4 million in restricted cash as of March 31, 2020 and December 31, 2019.

As of March 31, 2020, we had 1.0 million in treasury stocks that were previously surrendered by employees to satisfy tax withholding in connection with the vesting of certain restricted stock units. As of March 31, 2020 and December 31, 2019, we had a total of 11.6 million shares, held in treasury.

The following table presents a summary of our cash flows for the three months ended March 31, 2020 (in thousands):
 Three Months Ended March 31,
 20202019
Net cash provided by operating activities$8,907  $12,749  
Cash used in investing activities(64,136) (2,996) 
Net cash provided by financing activities
215,931  112,571  

Operating Activities 

Net cash provided by operating activities primarily consists of net income (loss), adjusted for certain non-cash items, including change in fair value of earnout liability, deferred income taxes, stock-based compensation expense, depreciation and amortization, amortization of intangible assets and internally developed software, other non-cash items, and the effect of changes in working capital and other activities.
 
Collection of commissions receivable depends upon the timing of our receipt of commission payments and associated commission reports from health insurance carriers. If we were to experience a delay in receiving a commission payment from a health insurance carrier within a quarter, our operating cash flows for that quarter could be adversely impacted.
41





A significant portion of our marketing and advertising expenses is driven by the number of health insurance applications submitted on our ecommerce platforms. Since our marketing and advertising costs are expensed and generally paid as incurred, and since commission revenue is recognized upon approval of a member but commission payments are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in the volume of applications submitted during a quarter or positively impacted by a substantial decline in the volume of applications submitted during a quarter. During the Medicare annual enrollment period, we experience an increase in the number of submitted Medicare-related health insurance applications and marketing and advertising expenses compared to outside of Medicare annual enrollment periods. Similarly, during open enrollment periods for individual and family health insurance plans, we experience an increase in the number of submitted individual and family plan health insurance applications and marketing and advertising expenses compared to outside of open enrollment periods. The timing of open enrollment periods for individual and family health insurance and the Medicare annual and open enrollment period for Medicare-related health insurance can positively or negatively affect our cash flows during each quarter.

Three Months Ended March 31, 2020 — Net cash provided by operating activities was $8.9 million during the three months ended March 31, 2020, primarily driven by a net income of $3.5 million and adjustments for non-cash items of $9.7 million, partially offset by changes in net operating assets and liabilities of $4.2 million. Adjustments for non-cash items primarily consisted of $8.7 million of stock-based compensation expense, $2.0 million of amortization of intangible assets and internally-developed software, $0.8 million of depreciation and amortization and a $0.2 million increase due to other non-cash items, partially offset by a $2.1 million decrease due to the change in deferred income taxes. Cash used from changes in net operating assets and liabilities during the three months ended March 31, 2020 primarily consisted of decreases of $16.3 million in accounts payable, $11.1 million in accrued compensation and benefits, $7.3 million in accrued marketing expense, and an increase of $0.2 million in prepaid expenses and other current assets, partially offset by decreases of $26.9 million in contract assets – commissions receivable and $1.7 million in accounts receivable and an increase in $2.0 million in accrued expenses and other liabilities.

Three Months Ended March 31, 2019 — Net cash provided by operating activities was $12.7 million during the three months ended March 31, 2019, primarily consisting of adjustments for non-cash items of $13.7 million and cash provided by changes in net operating assets and liabilities of $4.2 million partially offset by a net loss of $5.2 million. Adjustments for non-cash items primarily consisted of $13.3 million of expense related to the fair value adjustment of our earnout liability, $3.2 million of stock-based compensation expense, $1.3 million of amortization of intangible assets and internally developed software, and $0.7 million of depreciation and amortization, partially offset by a $3.5 million decrease in deferred income taxes and a $1.2 million decrease in other non-cash items. Cash provided by changes in net operating assets and liabilities during the three months ended March 31, 2019 primarily consisted of a decrease of $17.6 million in contract assets – commissions receivable, an increase of $2.9 million in deferred revenue, a decrease of $0.4 million in accrued expenses and other liabilities, a decrease of $0.2 million in accounts receivable, a decrease of $$1.1 million in prepaid expenses and other current assets, a decrease of $9.4 million in accrued compensation and benefits, a decrease of $7.1 million in accrued marketing expenses, and a decrease of $0.8 million in accounts payable.

Investing Activities

Our investing activities primarily consist of purchases of computer hardware and software to enhance our website and customer care operations, leasehold improvements related to facilities expansion, capitalized internal-use software and website development costs, security deposit payments, and cash used to acquire a business.

Three Months Ended March 31, 2020 — Cash used in investing activities of $64.1 million for the three months ended March 31, 2020 was due to $58.1 million in purchases of marketable securities, $3.6 million in capitalized internal-use software and website development costs and $2.5 million used to purchase property and equipment and other assets.

Three Months Ended March 31, 2019 — Cash used in investing activities of $3.0 million for the three months ended March 31, 2019 was due to $1.5 million in capitalized internal-use software and website development costs, and $1.5 million used to purchase property and equipment and other assets.

42




Financing Activities

Three Months Ended March 31, 2020 — Net cash provided by financing activities of $215.9 million for the three months ended March 31, 2020 was primarily due to $228.0 million net proceeds from the issuance of common stock in a public equity offering and $1.1 million of net proceeds from the exercise of common stock options, partially offset by $8.8 million of acquisition-related contingent payments and $4.4 million repurchase of shares to satisfying employee tax withholding obligations.

Three Months Ended March 31, 2019 — Net cash provided by financing activities of $112.6 million for the three months ended March 31, 2019 was primarily due to $126.1 million net proceeds from the issuance of common stock in a public equity offering and $2.4 million of proceeds from the exercise of common stock options, partially offset by $9.5 million of acquisition-related contingent payments, a $5.0 million debt repayment, and $1.3 million used to net-share settle equity awards.


Credit Agreement

We entered into a credit agreement with Royal Bank of Canada, or RBC, as administrative agent and collateral agent, (the “Credit Agreement”) in September 2018. The Credit Agreement provides for a $40.0 million secured asset-backed revolving credit facility with a $5 million letter of credit sub-facility. On December 20, 2019, we amended our revolving credit facility agreement with RBC (the “Amendment”) and increased the maximum borrowing amount to $75.0 million and extended the expiration to December 20, 2022.

The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC, or the Borrowing Base. The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. We have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed. Amounts not borrowed under the Credit Agreement are subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing of the Credit Agreement, we paid a one-time facility fee of 1.75% of the total commitments of $40 million. We also paid a one-time closing fee of 0.5% of the new commitment of $75.0 million in connection with the Amendment. We are also obligated to pay other customary administration fees for a credit facility of this size and type.

As of March 31, 2020, we had no outstanding principal amount under our revolving credit facility. See Note 10Debt of Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information regarding this credit agreement and subsequent amendment.


Common Stock Issuance

Pursuant to an effective registration statement that was filed on December 17, 2018, and amended on January 22, 2019 and March 2, 2020, we entered into an underwriting agreement in March 2020 to issue a total of 2,070,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase 270,000 additional shares of common stock, at a price to the public of $115.00 per share. Net proceeds from the offering were approximately $228.0 million after deducting underwriting discounts, commissions and expenses of the offering. We intend to use the net proceeds of the offering for general corporate purposes, including working capital.




43




Contractual Obligations and Commitments 

The following table presents a summary of our future minimum payments under non-cancellable operating lease agreements and contractual service and licensing obligations as of March 31, 2020 (in thousands): 
For the Years Ending December 31,Operating Lease ObligationsService and Licensing ObligationsTotal Obligations
Reminder of 2020$5,058  $1,961  $7,019  
20216,950  2,189  9,139  
20226,988  692  7,680  
20237,863  444  8,307  
20247,706  229  7,935  
Thereafter27,603  —  27,603  
Total$62,168  $5,515  $67,683  
_______
* See Note 9 – Leases of our Notes to Condensed Consolidated Financial Statements for details of our operating lease obligations.


Service and Licensing Obligations

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. The terms of these services and licensing agreements are generally up to three years. We record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.


Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, investments in special purpose entities, undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic leases.


Recent Accounting Pronouncements

See Note 1Summary of Business and Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q for recently issued accounting standards that could have an effect on us.


44




ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 


Credit and Interest Rate Risk

Our financial instruments that are exposed to concentrations of credit risk principally consist of cash and cash equivalents, accounts receivable, contract assets – commissions receivable, and marketable securities.

As of March 31, 2020 and December 31, 2019, our cash, cash equivalents and restricted cash are summarized as follows (in thousands): 
March 31, 2020December 31, 2019
Cash (1)
$16,364  $16,205  
Cash equivalents (2)
167,803  7,261  
Total cash and cash equivalents$184,167  $23,466  
Restricted cash3,353  3,354  
Total cash, cash equivalents and restricted cash$187,520  $26,820  
_________________
 
(1)We deposit our cash and cash equivalents in accounts with major banks and financial institutions and such deposits are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. 

(2)See Note 4Fair Value Measurements in our Notes to Condensed Consolidated Financial Statements for more information on our cash equivalents.

As of March 31, 2020, our net contract assets consisted of commissions receivable balance of $560.7 million. Our contracts with carriers expose us to credit risk that a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While we are exposed to credit losses due to the non-performance of our counterparties, we consider the risk of this remote. We estimate our maximum credit risk in determining the commissions receivable amount recorded on the balance sheet. Upon the adoption of ASC 326, we recorded $1.5 million of allowance for credit losses for our commissions receivable balance as of December 31, 2019. During the three months ended March 31, 2020, we recorded an additional $0.1 million for the allowance for credit losses. See Note 1Summary of Business and Significant Accounting Policies in our Notes to Condensed Consolidated Financial Statements for additional information regarding the accounting standard adoption. Our total contract assets and accounts receivable as of March 31, 2020 and December 31, 2019 are summarized as follows (in thousands):
March 31, 2020December 31, 2019
Contract assets – commissions receivable – current$125,252  $174,526  
Contract assets – commissions receivable – non-current435,465  414,696  
Accounts receivable668  2,332  
Total contract assets and accounts receivable$561,385  $591,554  

45




Our portfolio of available-for-sale debt securities is exposed to interest rate risk. As of March 31, 2020, we invested $33.7 million and $24.4 million in short-term and long-term marketable securities, respectively. These marketable securities primarily consisted of commercial paper and agency bonds with credit rating of AA+ or equivalent by S&P Rating and Moody's Investor Services. The maturity of these securities were below two years. See Note 4 Fair Value Measurements in our Notes to Condensed Consolidated Financial Statements for further discussion on our available-for-sale debt securities.


Foreign Currency Exchange Risk

To date, substantially all of our revenue has been derived from transactions denominated in United States Dollars. We have exposure to adverse changes in exchange rates associated with operating expenses of our foreign operations, which are denominated in Chinese Yuan Renminbi. Foreign currency fluctuations have not had a material impact historically on our results of operations; however, there can be no assurance that future fluctuations will not have material adverse effects on our results of operations. We have not engaged in any foreign currency hedging or other derivative transactions to date.
46




ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Our Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on management’s evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

Inherent Limitations on Effectiveness of Controls

Our management, including our chief executive officer and chief financial officer, believes that our disclosure controls and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

47




PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to Note 7Commitments and Contingencies in our Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.

In the ordinary course of our business, we have received and may continue to receive inquiries from state and federal regulators relating to various matters. We have become, and may in the future become, involved in litigation in the ordinary course of our business. If we are found to have violated laws or regulations in any jurisdiction, we could be subject to various fines and penalties, including revocation of our license to sell insurance in those states, and our business, operating results and financial condition would be harmed. Revocation of any of our licenses or penalties in one jurisdiction could cause our license to be revoked or for us to face penalties in other jurisdictions. In addition, without a health insurance license in a jurisdiction, carriers would not pay us commissions for the products we sold in that jurisdiction, and we would not be able to sell new health insurance products in that jurisdiction. We could also be harmed to the extent that related publicity damages our reputation as a trusted source of objective information relating to health insurance and its affordability. It could also be costly to defend ourselves regardless of the outcome.


ITEM 1A. RISK FACTORS

In addition to other information in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange Commission, the following risk factors should be carefully considered in evaluating our business as they may have a significant impact on our business, operating results and financial condition. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered as a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods.

Risks Related to Our Business

The marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws and regulations, and non-compliance with or changes in laws and regulations could harm our business, operating results and financial condition.

The marketing and sale of Medicare plans are subject to numerous laws, regulations and guidelines at the federal and state level. The marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans are principally regulated by the Centers for Medicare and Medicaid Services, or CMS. The marketing and sale of Medicare Supplement plans are principally regulated on a state-by-state basis by state departments of insurance. The laws and regulations applicable to the marketing and sale of Medicare plans are numerous, ambiguous and complex, and, particularly with respect to regulations and guidance issued by CMS for Medicare Advantage and Medicare Part D prescription drug plans, change frequently. The telephone calls on which we enroll individuals into Medicare Advantage and Medicare Part D prescription drug plans are required to be recorded. Health insurance carriers audit these recordings for compliance and listen to them in connection with their investigation of complaints. In addition, Medicare eligible individuals may receive a special election period and the ability to change Medicare Advantage and Part D prescription drug plans outside the Medicare annual enrollment period in the event the sale of the plan was not in accordance with CMS rules and guidelines. Given CMS’s scrutiny of Medicare product health insurance carriers and the responsibility of the health insurance carriers for actions that we take, health insurance carriers may terminate our relationship with them or take other corrective action if our Medicare product sales, marketing and operations are not in compliance or give rise to too many complaints. The termination of or change in our relationship with health insurance carriers for this reason would reduce the products we are able to offer, could result in the loss of commissions for past and future sales and would otherwise harm our business, operating results and financial condition.

As a result of the laws, regulations and guidelines relating to the sale of Medicare plans, we have altered, and likely will have to continue to alter, our websites and sales process to comply with these laws, regulations and guidelines. For instance, many aspects of our online platforms and our marketing material and processes, as well as changes to these platforms,
48




materials and processes, including call center scripts, must be filed on a regular basis with CMS and reviewed and approved by health insurance carriers in light of CMS requirements. In addition, certain aspects of our Medicare plan marketing partner relationships have been in the past, and will be in the future, subjected to CMS and health insurance carrier review. CMS, state departments of insurance or health insurance carriers may determine to object to or not to approve aspects of our online platforms, sales function or marketing material and processes and may determine that certain existing aspects of our Medicare-related business are not in compliance. Changes to the laws, regulations and guidelines relating to the sale of Medicare plans, their interpretation or the manner in which they are enforced could impact the manner in which we conduct our Medicare business, our platforms or our sale of Medicare plans, or we could be prevented from operating aspects of our Medicare revenue generating activities altogether, which would harm our business, operating results and financial condition.
If our ability to enroll individuals during enrollment periods is impeded or if investments we make in enrollment periods do not result in the returns we expected when making those investments, our business, operating results and financial condition would be harmed.

In an attempt to attract and enroll a large number of individuals during the Medicare annual enrollment period and to a lesser extent, the Medicare Advantage open enrollment period and the health care reform open enrollment period under the Affordable Care Act, we may invest in areas of our business, including technology and content, customer care and enrollment, and marketing and advertising. We have in the past made investments in areas of our business in advance of enrollment periods that have not yielded the results we expected when making those investments. Any investment we make in any enrollment period may not result in a significant number of approved and paying members or may not be as cost-efficient as we anticipated. If it does not, or is not, our business, operating results and financial condition would be harmed. If our ability to market and sell Medicare-related health insurance and individual and family health insurance is constrained during an enrollment period for any reason, such as technology failures, interruptions in the operation or our e-commerce platforms, reduced allocation of resources, any inability to timely employ, license, train, certify and retain our employees and our outsourced call centers and their health insurance agents to sell health insurance, we could acquire fewer members, suffer a reduction in our membership, and our business, operating results and financial condition could be harmed.
If we do not successfully compete with government-run health insurance exchanges, our business may be harmed.

We compete with government-run health insurance exchanges, among others, with respect to our sale of Medicare-related and individual and family health insurance. The federal government operates a website where Medicare beneficiaries can purchase Medicare Advantage and Medicare Part D prescription drug plans or be referred to carriers to purchase Medicare Supplement plans. CMS has made improvements to the consumer experience on this website and proposals exist for it to continue to do so. Medicare beneficiaries can also obtain plan selection assistance from the federal government in connection with their purchase of a Medicare Advantage or Medicare Part D prescription drug plan. The exchanges in the individual and family health insurance market created by the Affordable Care Act may elect whether or not we are able to enroll subsidy-eligible individuals in qualified health plans through them, and determine the manner in which we may do so. The Affordable Care Act exchanges have websites where individuals and small businesses can purchase health insurance, and they also have offline customer support and enrollment capabilities. Individuals who are eligible for government subsidies in the form of premium tax credits and cost sharing reductions must apply for their subsidy and purchase qualified health plans through a government exchange. In the aggregate, government exchanges have greater resources and greater public outreach capability than we do and they or the government agencies that run them may in the future impact the process we use to enroll individuals and families in a manner that results in a reduction in revenue and our membership. In addition, individuals who utilize our platform and services to apply for subsidies and health insurance through Affordable Care Act exchanges receive marketing and communications from the exchanges after they do so. In the event our existing members purchase health insurance directly through health insurance exchanges without using us as their health insurance agent, as a result of their being eligible for a subsidy or otherwise, we may no longer receive commission payments as a result of our sale of health insurance to them. Competitive pressure from government-run health insurance exchanges has resulted, and may in the future result, in our
49




experiencing increased marketing costs, decreased traffic to our website, a reduction in our membership and revenue and may otherwise harm our business, operating results and financial condition.
Our operating results will be impacted by factors that impact our estimate of the constrained lifetime value (LTV) of commissions per approved member.

Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (ASC 606) using the full retrospective method, which required us to revise our historical financial information by applying the new standard. The adoption had a material impact on our consolidated financial statements. The most significant impact of the standard was on our commission revenue. Since the adoption of ASC 606, we re-compute LTVs for all outstanding cohorts on a quarterly basis. We continually review and monitor changes in the data used to estimate LTV and compare the cash received for each cohort to our original estimates at the time of approval. The fluctuations of cash received for each cohort and LTV can be significant and may or may not be indicative of the need to adjust revenue for prior period cohorts. Changes in LTV may result in an increase or a decrease to revenue and a corresponding increase or decrease to contract assets – commissions receivable, accordingly. We analyze these fluctuations and, to the extent we see changes in our estimates of the cash commission collections that we believe are indicative of an increase or decrease to prior period LTVs, we adjust revenue for the affected cohorts at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We continue to enhance our LTV estimation models using statistical tools to increase the accuracy of LTV estimates with an emphasis on improving member attrition forecasting. We refer the net commission revenue from members approved in prior periods as “adjustment revenue” and our revenue can fluctuate significantly from period to period as a result of adjustment revenue. Adjustment revenue can have a significant favorable or unfavorable impact on our revenue.

As we continue to evaluate our LTV estimation models, we may in the future make further changes based on a number of factors and such changes could result in significant increases or decreases in our revenue. Constrained LTVs are estimates and are based on a number of assumptions, which include, but are not limited to, estimates of the conversion rates of approved members into paying members, forecasted average plan duration and forecasted commission rates we expect to receive per approved member's plan. These assumptions are based on historical trends and require significant judgment by our management in interpreting those trends and in applying the constraints. Changes in our historical trends will result in changes to our constrained LTV estimates in future periods and therefore could adversely affect our revenue and financial results in those future periods. As a result, negative changes in the factors upon which we estimate constrained LTVs, such as reduced conversion of approved members to paying members, increased health insurance plan termination or a reduction in the lifetime commission amounts we expect to receive for selling the plan to a member or other changes could harm our business, operating results and financial condition. In addition, if we ultimately receive commission payments that are less than the amount we estimated when we recognized commission revenue, we would need to write off the remaining commission receivable balance, which would adversely impact our business, operating results, and financial condition.

The rate at which approved members become paying members is a significant factor in our estimation of constrained LTVs. To the extent we experience a similar decline in the rate at which approved members turn into our paying members, our business, operating results, and financial condition would be harmed.

The forecasted average plan duration is another important factor in our estimation of constrained LTV. We receive commissions from health insurance carriers for health insurance plans sold through us. When one of these plans is canceled, or if we otherwise do not remain the agent on the policy, we no longer receive the related commission payment. Our forecasted average plan duration and health insurance plan termination rate are calculated based on our historical data by plan type. As a result, a reduction in our forecasted average plan duration or an inability to produce accurate forecasted average plan duration may adversely impact our business, operating results and financial condition.

Commission rates are also part of the significant factors in our estimation of constrained LTVs. The commission rates we receive are impacted by a variety of factors, including the particular health insurance plans chosen by our members, the carriers offering those plans, our members’ states of residence, the laws and regulations in those jurisdictions, the average premiums of plans purchased through us and health care reform. Our commission revenue per member has in the past decreased, and could in the future decrease, as a result of reductions in contractual commission rates, a change in the mix of carriers whose products we sell during a given period, and increased health insurance plan termination rates, all of which are beyond our control and may occur on short notice. To the extent these and other factors cause our commission revenue per
50




member to decline, our revenue may decline and our business, operating results and financial condition would be harmed. Given that Medicare-related and individual and family health insurance purchasing is concentrated during enrollment periods, we may experience a shift in the mix of Medicare-related and individual and family health insurance products selected by our members over a short period of time. Any reduction in our average commission revenue per member during the enrollment periods caused by such a shift or otherwise would harm our business, operating results and financial condition.
Our business may be harmed if we lose our relationship with health insurance carriers or our relationship with health insurance carriers is modified.

We typically enter into contractual relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In many cases, health insurance carriers also may amend the terms of our agreements unilaterally on short notice. Carriers may be unwilling to allow us to sell their existing or new health insurance plans, or desire to amend our agreements with them for a variety of reasons, including for competitive or regulatory reasons, dissatisfaction with the economics of the members that we place with them or because they do not want to be associated with our brand. We may also terminate our relationship with health insurance carriers. In the event we are not successful in gaining and maintaining the ability to sell Medicare, individual and family and ancillary health insurance plans, if health insurance carriers pay us no commissions or reduced commissions in connection with the sale of these plans or if health insurance carriers change our relationship with them in other ways, we could lose a substantial number of existing and potential members and commissions, which would materially harm our business, operating results and financial condition. The termination of our relationship with a health insurance carrier by us or the health insurance carrier or the amendment of or change in our relationship with a carrier could reduce the variety, quality and affordability of health insurance plans we offer, cause a loss of commission payments, cause a reduction in constrained LTVs and adversely impact our ability to recognize revenue or have other adverse impacts, which could harm our business, operating results and financial condition. It also could adversely impact, or cause the termination of, commissions for past and future sales, which would materially harm our business, operating results and financial condition. Our business could also be harmed if in the future we fail to develop new carrier relationships and are unable to offer consumers a variety of health insurance plans in each jurisdiction.

Health insurance carriers can unilaterally amend the commission rates that they pay to us. For example, given the significant losses that carriers sustained in connection with their sale of individual and family health insurance as a result of health care reform, many health insurance carriers with which we have a relationship, including large national health insurance carriers, reduced or eliminated our commissions for selling individual and family health insurance, and in a limited number of cases, our renewal commissions. As a result, we experienced a meaningful reduction in our average commission rates for our aggregate individual and family health insurance plan membership. In addition, the reduction in contractual commission rates and these carriers’ desire to not sell individual and family health insurance reduced the number of plans that we are able to offer on our websites, which resulted in less consumer demand for the individual and family health insurance that we sell and a reduction in our membership. In the future and as a result of health care reform, the COVID-19 pandemic or for other reasons, an increasing number of health insurance carriers may decide to reduce our commissions, rely on their own internal distribution channels to sell their own plans, determine not to sell their plans or otherwise limit or prohibit us from selling their plans. In addition to reducing commission rates, health insurance carriers may determine to exit certain states or increase premiums to a significant degree, which could cause our members’ health insurance to be terminated or our members to purchase new health insurance or determine not to pay for health insurance at all. If we lose these members, our business, operating results and financial condition could be harmed.

Our Medicare plan-related revenue is concentrated in a small number of health insurance carriers. The success of our Medicare-related health insurance business depends upon our ability to enter into new and maintain existing relationships with health insurance carriers on favorable economic terms. The concentration of our Medicare plan sales in a limited number of health insurance carriers makes us vulnerable to changes in carrier commission rates and changes in the competitiveness of our carriers’ Medicare products. If our Medicare carriers reduce our commission rates, reduce the amount they pay us for advertising services, or the competitiveness of their products declines compared to original Medicare or the products of Medicare carriers with which we do not have a relationship, our business, operating results and financial condition would be harmed.

We also may temporarily or permanently lose the ability to market and sell Medicare plans for our Medicare plan carriers. The regulations applicable to the business of selling health insurance are complex and frequently change. We or the health insurance agents we employ have in the past, and may in the future, violate one or more of the many requirements
51




imposed by CMS or state laws and regulations. A carrier may terminate our relationship for that or other reasons, or CMS may penalize health insurance carriers for certain regulatory violations by suspending or terminating the carrier's ability to market and sell Medicare plans for significant periods of time. CMS also may require the carrier to terminate its membership and allow its members to move to other plans. Given the concentration of our Medicare plan sales in a small number of carriers, if we lose a relationship with a health insurance carrier to market their Medicare plans temporarily or permanently or if the health insurance carrier loses its Medicare product membership, our business, operating results and financial condition would be harmed. The agreements that we have with health insurance carriers to sell Medicare plans may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact, or cause the termination of, the commission payments that we receive for selling their Medicare plans, including commissions on plans that we have already sold, which could materially harm our business operating results and financial condition.
If we are not able to maintain and enhance our brand, our business and operating results will be harmed.

We believe that maintaining and enhancing our brand identity is critical to our relationships with existing members, marketing partners and health insurance carriers and to our ability to attract new members, marketing partners and health insurance carriers. The promotion of our brand in these and other ways may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these branding initiatives may become increasingly difficult and expensive. Our brand promotion activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our operating results could be harmed. If we do not successfully maintain and enhance our brand, our business may not grow and we could lose our relationships with health insurance carriers, marketing partners and/or members, which would harm our business, operating results and financial condition.

In addition, we have historically received media attention in connection with our public relations efforts. While we cannot be certain of the impact of media coverage on our business, if it were to be reduced or if we were to receive negative publicity, the number of consumers visiting our platforms or customer call centers could decrease, and our cost of acquiring members could increase as a result of a reduction in the number of members coming from our direct member acquisition channel, both of which could harm our business, operating results and financial condition.

The ongoing COVID-19 pandemic and public health crises, illness, epidemics or pandemics could adversely impact our business, operating results and financial condition.

The spread of COVID-19 has created a global public health crisis that has resulted in unprecedented uncertainty, volatility and disruption in governmental, commercial and consumer activity in the United States and globally. In an effort to mitigate the spread of COVID-19, and to comply with applicable government directives, we have modified our business practices, including directing employees to work from home, restricting employee travel, cancelling in-person meetings and implementing our business contingency plans and protocols to the extent necessary. While we have not experienced a significant impact on our business, operating results or financial condition as a result of COVID-19 to date, there can be no assurances that they will not be materially adversely affected in the future. The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

52




COVID-19 and public health crises, illness, epidemics or pandemics, in general, and disruption to our call center and service operations, in particular, could materially impact our business, operations and financial condition. A potential COVID-19 infection of any of our employees could adversely impact our operations, including resulting in the sudden closure of any of our offices. Our business operations may be disrupted if key personnel or significant portions of our employees are unable to work effectively, especially if such disruption occurs during or in our preparation for the Medicare annual enrollment period. The transition of our employee population to a remote work environment may exacerbate certain risks to our business, including an increased demand for information technology resources, increased risk of phishing and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our customers or other third-parties. Our business operations and recruitment efforts could be impacted if government offices, including CMS and state departments of insurance, remain adversely impacted by COVID-19 given that some of our marketing materials require CMS approval and health insurance agent licensing and licensing renewals are dependent on state department of insurance processing. In addition, our ability to hire a sufficient number of new unlicensed agents in anticipation of the Medicare annual enrollment period could be negatively impacted by closure or limited capacity of health insurance license testing facilities or delays in completing background checks and fingerprinting requirements. Our product development initiatives could also be negatively impacted by extended office closures. Furthermore, if any of our health insurance carriers, business partners or vendors increase the prices of or become unable to continue to provide their products or services as a result of COVID-19, or if health insurance carriers reduce our commission rates or the amount they pay us, our business, operating results and financial condition would be harmed. The impact of COVID-19 to our Individual, Family and Small Business segment is especially uncertain because of increases in unemployment rate, potential delays in customer premium payments and/or health insurance carrier commission payments, potential changes to the open enrollment period and special enrollment period, and potential changes to qualified health plans subsidies, among others. COVID-19 presents uncertainties and risks with respect to the demand for and pricing of health insurance plans, which could negatively impact our business, operating results and financial condition.

Changes in our management and key employees could affect our business and financial results.

Our success is dependent upon our ability to attract and retain qualified personnel for all areas of our organization. We may not be successful in attracting and retaining personnel on a timely basis, on competitive terms or at all. If we are unable to attract and retain the necessary personnel, our business would be harmed. Our executive officers and employees can terminate their employment at any time. The transition and the departure of members of our senior management could result in attrition in our senior management and key personnel and any significant change in leadership over a short period of time could harm our business, operating results and financial condition.

The loss of the services of any of our executive officers or key employees could harm our business. For example, we appoint a single designated writing agent with each insurance carrier. A small number of our employees act as writing agent and each employee that acts as writing agent does so for a number of carriers. Robert Hurley, who recently resigned as an executive officer and will remain a part-time employee for a transitionary period of an undetermined amount of time, is the writing agent on a large number of our carrier relationships. During Mr. Hurley’s transitionary period, we need to replace Mr. Hurley as writing agent with another employee who has health insurance licenses. Due to our national reach and the large number of carriers whose plans are purchased by our members, this transition may be difficult and could require a significant period of time to complete. If the transition is not successful or takes too long to complete, our agency relationship with particular insurance carriers may be terminated, our commission payments could be discontinued or delayed and, as a result, our business, operating results and financial condition would be harmed.
53




Our business may be harmed if we are not successful in executing on our strategic investments and initiatives.

As part of our strategy, we have determined to invest in initiatives to accelerate growth in our Medicare product sales, including Medicare Advantage and Medicare Supplement plans. Pursuing and investing in these and other initiatives we develop will require significant investments in marketing and advertising, technology and product offerings, and customer care and enrollment, among others, and involves risks and uncertainties described elsewhere in this Risk Factors section, including the initiatives resulting in insufficient revenue to offset any expenses associated with these new investments, inadequate return of capital on our investments, legal and regulatory compliance risks, potential changes in laws and regulations and other issues that could cause us to fail to realize the anticipated benefits of our investments and incur unanticipated liabilities. Our pursuit of these strategic initiatives may not be successful. Our cash flow from operations is expected to be negative in the year ending December 31, 2020 and was negative in each of the years ended December 31, 2019, 2018 and 2017. As a result, our investment in these initiatives could result in our needing to raise additional capital. If we are not successful in executing on our business strategy, our business, operating results and financial condition would be harmed.
Significant consolidation in the health insurance industry could alter our relationships with carriers and harm our business and financial results.

The health insurance industry in the United States has experienced a substantial amount of consolidation, resulting in a decrease in the number of health insurance carriers. Consolidation in the health insurance industry could cause a loss of or changes in our relationship with carriers and reduction in our commission or other revenue, which could harm our business, operating results and financial condition. In the future, we may be forced to offer health insurance from a reduced number of insurance carriers or to derive a greater portion of our revenue from a more concentrated number of carriers as our business and the health insurance industry evolve. Revenue derived from carriers owned by UnitedHealthcare represented approximately 22% and 17% of our total revenue for the three months ended March 31, 2020 and 2019, respectively. Revenue derived from Humana represented approximately 19% and 23% of our total revenue for the three months ended March 31, 2020 and 2019, respectively. Revenue derived from Aetna represented approximately 15% and 17% of our total revenue for the three months ended March 31, 2020 and 2019, respectively. We have several agreements that govern our sale of health insurance plans with these health insurance carriers. They may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact or cause the termination of the commission payments that we receive from these health insurance carriers, including commissions on plans that we have already sold, which could materially harm our business, operating results and financial condition. Our revenue could be adversely impacted if we are unable to maintain currently-existing levels of business with any of our significant health insurance carriers if we are unable to offset any loss of business with alternative health insurance carriers. We expect that a small number of health insurance carriers will account for a significant portion of our revenue for the foreseeable future and any impairment of our relationship with, or the material financial impairment of, these health insurance carriers could adversely affect our business.
Seasonality may cause fluctuations in our financial results.

Open enrollment periods drive the seasonality of our business. The Medicare annual enrollment period occurs from October 15 to December 7 each year and the individual and family health insurance open enrollment period typically runs from November 1 through December 15 each year. In addition, the Medicare open enrollment period, where Medicare-eligible individuals who enrolled in a Medicare Advantage plan can switch to the original Medicare program or switch to a different Medicare Advantage plan, runs from January 1st through March 31st of each year. We experience an increase in the number of submitted Medicare-related applications and approved members during the fourth quarter and, to a lesser extent, in the first quarter, and an increase in Medicare plan related expense during the third and fourth quarters in connection with the open enrollment periods. Our commission revenue is the highest in our fourth quarter and second-highest in our first quarter given the increase in submitted applications and approved members in those periods compared to the rest of the year. We have typically experienced increased customer care and enrollment experience in the third and fourth quarters as we increase the number of agents to assist consumers in the enrollment periods. A significant portion of our marketing and advertising expenses is driven by the number of health insurance applications submitted through us. Since our marketing and advertising costs are expensed and generally paid as incurred and commissions from approved members are paid to us over time, our operating cash flows could be adversely impacted by a substantial increase in marketing expense as a result of a higher volume of applications submitted during a quarter or positively impacted by a substantial decline in marketing expense as a result of lower volume of applications submitted during a quarter.

54




The seasonality of our business could change in the future due to other factors, including as a result of changes in timing of the Medicare or individual and family health plan enrollment periods and changes in the laws and regulations that govern the sale of health insurance. We may not be able to timely adjust to changes in the seasonality of our business. If the timing of the enrollment periods for Medicare-related health insurance or individual and family health insurance changes, we may not be able to timely adapt to changes in customer demand. If we are not successful in responding to changes in the seasonality of our business, our business, operating results and financial condition could be harmed.
Our financial results will be adversely impacted if our membership does not grow or if we are unable to retain our existing members.

We receive commissions from health insurance carriers for health insurance plans sold through us. When one of these plans is canceled, or if we otherwise do not remain the agent on the plan, we no longer receive the related commission payment. Our members may choose to discontinue their health insurance plans for a variety of reasons. Consumers may also purchase individual and family and Medicare-related health insurance plans directly from other sources, such as government-run health insurance exchanges, and we would not remain the agent on the policy and receive the related commission. Medicare Advantage plan enrollees may enroll in another Medicare Advantage plan or disenroll from their Medicare Advantage plan and return to original Medicare during the Medicare Advantage open enrollment period that is scheduled to occur between January 1st and March 31st of each year. If the new members that we enroll during this Medicare Advantage open enrollment period do not offset any loss of existing Medicare Advantage members or if investments we make during this new Medicare Advantage open enrollment period do not result in a significant number of approved and paying Medicare Advantage members, our business, operating results and financial condition would be harmed. In addition, the open enrollment period has caused us to experience an increased Medicare Advantage plan termination rate during each of the first quarter of 2020 and 2019. We believe this increase reflects a new seasonal pattern of consumer behavior and that seniors who optimize their plans during the first quarter are less likely to change plans again later in the year. If Medicare Advantage plan termination rate does not decline in subsequent quarters as we predict, our business, operating results and financial condition would be harmed.

Health insurance carriers have in the past and may in the future terminate health insurance plans purchased and held by our members. Any decrease in the amount of time we retain our members on the health insurance plans that they purchased through us could adversely impact the estimated constrained LTV we use for purposes of recognizing revenue, which could harm our business, operating results and financial condition. Moreover, if we are not able to successfully retain existing members and limit health insurance plan termination, our business, operating results and financial condition would be harmed. In addition, the Medicare-related commission rates that we receive may be higher in the first calendar year of a plan if the plan is the first Medicare-related plan issued to the member. The individual and family commission rates that we receive are typically higher in the first twelve months of a policy. After the first twelve months, they generally decline significantly. As a result, if we do not add a sufficient number of members to new plans, our business, operating results and financial condition would be harmed. If we experience higher health insurance plan termination rate than we estimated when we recognized commission revenue, we may not collect all of the related commissions receivable, which could result in a write-off of contract assets - commissions receivable, which would harm our business, operating results and financial condition.

Our business may be harmed if our websites, marketing materials or call center scripts are not timely approved or do not comply with legal requirements.

Health insurance carriers whose Medicare plans we sell approve our websites, much of our marketing material and our call center scripts. We must receive these approvals in order for us to be able to generate Medicare plan demand and sell Medicare plans to Medicare-eligible individuals as a health insurance agent. Many of these materials also must be filed with CMS. In the event that CMS or a health insurance carrier requires change to, disapproves, or delays approval of our websites, our marketing material or call center scripts, we could lose a significant source of Medicare plan demand and our ability to sell Medicare plans would be adversely impacted, which would harm our business, operating results and financial condition. The rules and regulations relating to the approval and submission of marketing material are ambiguous and complex and state department of insurance or CMS may determine that certain aspects of our marketing material and processes are not in compliance with legal requirements. The CMS rules and regulations also apply to marketing material of our marketing partners. If we are not successful in timely submitting these marketing materials to health insurance carriers for approval, in gaining that approval and in filing all required marketing material with CMS, we could be prevented from implementing our Medicare marketing initiatives and our Medicare plan marketing could become less effective, which would harm our business, operating results and financial condition, particularly if the delay or non-compliance occurred during the Medicare annual or open
55




enrollment periods. If a marketing partner of ours does not consent to having its website or other marketing material filed with CMS, does not make changes required by carriers or CMS or does not comply with the CMS marketing guidelines or other Medicare program related laws, rules and regulations, we may lose the ability to receive referrals of individuals interested in purchasing Medicare plans from that marketing partner or our ability to receive referrals could be delayed and our business, operating results and financial condition would be harmed.

If we or our marketing partners substantively change our websites or call center scripts after they are filed with CMS, we may need to resubmit them to health insurance carriers and have them re-filed with CMS. We are not permitted to make CMS filings ourselves. Given the review cycles our scripts, websites and other marketing material undergo, it is very difficult and time consuming to make changes to them, and our inability to timely make changes to these marketing materials, whether to comply with new rules and regulations or otherwise, could adversely impact our ability to sell Medicare plans, which could adversely impact our business, operating results and financial condition. In addition, if a change to scripts, our websites or other marketing material is required by CMS, a state department of insurance or health insurance carriers, we may be prevented from using the marketing material until the change is made and approved, which would harm our business, operating results and financial condition, particularly if it occurred during the annual enrollment period.

We have received, and may in the future receive, inquiries from CMS or state departments of insurance regarding our marketing and business practices and compliance with laws and regulations. We typically respond to these inquiries by explaining how we believe we are in compliance with relevant regulations, or may modify our practices in connection with the inquiry. CMS and certain state regulators notified us in advance of and during the 2018 Medicare annual enrollment period for 2019 enrollment of their opinion that certain marketing material that we were using relating to one of our websites was misleading and did not follow certain legal and regulatory requirements. While we have resolved the matter with the relevant regulators, we may be subject to additional inquiries and proceedings in the future related to these or other materials. Inquiries and proceedings initiated by the government could adversely impact our health insurance licenses, require us to pay fines, require us to modify marketing and business practices, result in litigation and otherwise harm our business, operating results or financial condition.
The success of our customer care center operations depends upon our ability to timely hire, train, retain and ensure the productivity of our licensed health insurance agents.

In addition to our websites, we rely upon our customer care centers and, during the Medicare annual enrollment period, outsourced call centers to sell Medicare plans. The success of our customer care center operations is largely dependent on licensed health insurance agents and other employees. In order to sell Medicare-related health insurance plans, our health insurance agent employees and employees of outsourced call centers must be licensed by the states in which they are selling plans and certified and appointed with the health insurance carrier that offers the plans in each applicable state. Because a significant number of Medicare plans are sold in the fourth quarter each year during the Medicare annual enrollment period, we contract with outsourced call centers and hire additional employees on a temporary or seasonal basis in a limited period of time to address the expected increase in the volume of health insurance transactions during this period. We depend upon our employees, state departments of insurance, government exchanges and health insurance carriers for the licensing, certification and appointment of our health insurance agents. The COVID-19 pandemic and resulting containment measures have negatively impacted the capacity of health insurance license testing facilities and have caused delays in the completion of background checks and fingerprinting requirements. As a result, these health insurance agents may experience delays in obtaining health insurance licenses and certifications and health insurance carrier appointments. We and our outsourced call centers may experience difficulties hiring a sufficient number of additional licensed agents and retaining existing licensed agents for the Medicare annual enrollment period. If we and our outsourced call centers are not successful in these regards, our ability to sell Medicare-related health insurance plans will be impaired during the Medicare annual enrollment period, which would harm our business, operating results and financial condition.

Even if we or our outsourced call centers are successful in hiring licensed health insurance agents, our success depends on the productivity of these health insurance agents. Health insurance agents may not perform to the standard we expect of them, which could result in lower than expected conversion rates and revenue and higher costs of acquisition per member. We have observed that our health insurance agent employees are more productive than the employees of outsourced call centers and that experienced health insurance agents are more productive than new health insurance agents. As a result, the success of our business depends upon our ability to retain existing health insurance agents and hiring and training a sufficient number of internal health insurance agent employees who can perform to the standard we expect of them. Failure to retain, train and
56




ensure the productivity of our health insurance agent employees and employees of outsourced call centers would harm our business, operating results and financial condition.

Our ability to sell Medicare-related health insurance plans as a health insurance agent depends upon maintenance of functioning information technology systems.

The success of our Medicare plan customer care center operations is dependent upon information technology systems. Many of our Medicare plan members utilize our customer care center in connection with their purchase of a Medicare plan. CMS rules require that our health insurance agent employees utilize CMS-approved scripts in connection with the sale of Medicare plans and that we record and maintain the recording of telephonic interactions relating to the sale of Medicare plans. We rely on telephone, call recording, customer relationship management and other systems and technology in our Medicare customer care center operations, and we are dependent upon third parties for some of them, including our telephone and call recording systems. These systems have failed temporarily in the past and may experience additional disruption due to an increase in remote work or other impacts as a result of COVID-19. The effectiveness and stability of our Medicare customer care center systems and technology are critical to our ability to sell Medicare plans, particularly during the Medicare enrollment periods, and the failure or interruption of any of these systems and technology or any inability to handle increased volume would harm our business, operating results and financial condition.

Our success in selling Medicare-related health insurance will depend upon a number of factors some of which are outside of our control.

Our success in selling Medicare-related health insurance is dependent in part on the actions of federal and state governments. The adoption of laws, regulations or policies by federal and state governments has in the past and could in the future adversely impact our Medicare business. For example, we access information from CMS in our customer care centers to increase the efficiency of our customer care agents in interacting with Medicare beneficiaries. CMS has limited access to that information, and we will have to get the information in a different way or develop different processes. CMS also has in the past determined to reduce the payments it makes to health insurance carriers in connection with the sale of Medicare Advantage plans. Any similar reduction in the future could cause the cost of Medicare Advantage plans to increase or the benefits under Medicare Advantage plans to decrease, either of which would impair our ability to sell Medicare Advantage plans. CMS also has in the past adopted rules relating to the timing and nature of the compensation of agents in connection with the sale of Medicare Advantage and Medicare Part D prescription drug plans. The effect of these rules was to reduce our compensation as a health insurance agent in connection with the sale of these plans or had other adverse consequences. In addition, under the Affordable Care Act, health insurance carriers are required to pay a fee or tax on net premium revenue for certain types of health insurance. The health insurance tax applies to Medicare Advantage, Part D prescription drug, individual and family, and small group health insurance plans. This health insurance tax was suspended by the federal government in 2017 and 2019, but it is effective in 2020 and is expected to be suspended again in 2021. As a result of the health insurance tax, consumers could experience higher premiums, higher out of pocket costs and/or reduced benefits as health insurance carriers may pass the cost of the health insurance tax to the consumers. In the event the actions of the federal government, state governments or other circumstances decrease the demand for the Medicare related health insurance that we sell, or result in a reduction in the amount paid to us or have other adverse impacts, our business, operating results and financial condition could be harmed.

Our success in the Medicare plan market as a health insurance agent depends upon a number of additional factors, including:

our ability to continue to adapt our ecommerce platforms to market Medicare plans, including our development or acquisition of marketing tools and features important in the sale of Medicare plans online and the effective modification of our user experience;
our success in marketing to Medicare-eligible individuals, including television advertising, online marketing and direct mail marketing, and in entering into and maintaining marketing partner relationships to drive Medicare-eligible individuals to our ecommerce platforms or customer care centers on a cost-effective basis;
our ability to hire and retain additional employees with experience in Medicare, including our ability to timely implement Medicare sales expertise into our customer care centers;
our ability to implement and maintain an effective information technology infrastructure for the sale of Medicare plans, including the infrastructure and systems that support our websites, call centers and call recording;
57




our ability to leverage technology in order to sell, and otherwise become more efficient at selling, Medicare-related plans over the telephone;
our ability to comply with the numerous, complex and changing laws and regulations and CMS guidelines and policies relating to the marketing and sale of Medicare plans, including continuing to conform our online and offline sales processes to those laws and regulations; and
the effectiveness with which our competitors market the availability of Medicare plans from sources other than our ecommerce platforms.

As a result of these factors, we may prove unsuccessful in marketing Medicare plans and acting as a health insurance agent in connection with their sale, which would harm our business, operating results and financial condition. In addition, if our efforts to market Medicare plans during enrollment periods were impeded due to lack of health insurance carrier or CMS approval, or for other reasons, the impact on our business, operating results and financial condition would be significantly greater given the seasonality of our Medicare-related revenue, membership acquisition and expenses and the fact that much of the sales of Medicare plans occur during this period.

We may be unsuccessful in competing effectively against current and future competitors.

The market for selling health insurance plans is highly competitive. We compete with entities and individuals that offer and sell health insurance plans utilizing traditional distribution channels as well as the Internet. Our competitors include local insurance agents across the United States who sell health insurance plans in their communities. There also are a number of companies that operate websites, provide an online shopping experience for consumers interested in purchasing health insurance and act as a health insurance agent in connection with that purchase. Some local agents also use Internet advertising and “lead aggregator” services that use the Internet to find consumers interested in purchasing health insurance and are compensated for referring those consumers to health insurance agents or carriers. Many health insurance carriers also directly market and sell their plans to consumers through call centers, Internet advertising and their own websites. Although we offer health insurance plans for many of these carriers, they also compete with us by offering their plans directly to consumers. In connection with our marketing of Medicare plans, we compete with the original Medicare program. CMS also offers plan information, comparison tools, call centers and online enrollment for Medicare Advantage and Medicare Part D prescription drug plans. CMS offers plan information and referral to health insurance carriers for Medicare Supplement plans. We compete with the Federally Facilitated Marketplace, or FFM, and state health insurance exchanges implemented as a result of health care reform in marketing individual and family health insurance products. Health care reform also has resulted in health insurance plan cost and benefit data being more readily accessible, which has facilitated additional competition.

To remain competitive against our current and future competitors, we will need to market our services effectively and continue to improve the online shopping experience and functionalities of our website and other platforms that our current and future customers may access to purchase health insurance products from us. If we cannot predict, develop and deliver the right shopping experience and functionality in a timely and cost-effective manner, or if we are not effective in cost-effectively driving a substantial number of consumers interested in purchasing health insurance to our website and customer care centers, we may not be able to compete successfully against our current or future competitors and our business, operating results and financial condition may be adversely affected.

Some of our current and potential competitors have longer operating histories, larger customer bases, greater brand recognition and significantly greater financial, technical, marketing and other resources than we do. As compared to us, our current and future competitors may be able to: 

undertake more extensive marketing campaigns for their brands and services;
devote more resources to website and systems development and other aspects of their operations to comply with applicable laws, regulations and rules;
negotiate more favorable commission rates and commission override payments; and
make more attractive offers to potential employees, marketing partners and third-party service providers. 

In addition, CMS has the ability to regulate our marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans, and government-run health insurance exchanges, including CMS with respect to the FFM, have the ability to regulate our marketing and sale of qualified health plans under health care reform. CMS and the exchanges could impact the commissions we receive in connection with the sale of these plans and impose other restrictions and limitations that
58




make it difficult for us to sell them. Competitive pressures may result in our experiencing increased marketing costs, decreased demand and loss of market share, or may otherwise harm our business, operating results and financial condition.

Changes in the market for private health insurance, including passage and implementation of a law reflecting any current proposal to create a single payor health insurance program, could harm our business and operating results.

Our business depends upon the private sector of the United States health insurance system, its relative role in financing health care delivery and health insurance carriers’ use of, and payment of commissions to, agents and brokers to market health insurance plans. The market for private health insurance in the United States is evolving and our future financial performance will depend in part on growth in this market. Changes and developments in the health insurance system in the United States could reduce demand for our services and harm our business. For example, there has been an ongoing national debate relating to the health care reimbursement system in the United States. Certain candidates for President of the United States, as well as some members of Congress have introduced proposals to expand the Medicare program, ranging from proposals generally known as Medicare-for-all that would create a new single payor national health insurance program for all United States residents, replacing virtually all other sources of public and private insurance, to more incremental approaches such as lowering the age of eligibility for the Medicare program or creating a new public health insurance plan option as a supplement to private sources of coverage. In the event that laws, regulations or rules that eliminate or reduce private sources of health insurance are adopted, the demand for our products could be adversely impacted and our business, operating results and financial condition would be harmed.

Changes and developments in the health insurance industry as a result of health care reform could harm our business.

In March 2010, the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act were signed into law. These health care reform laws contain provisions that have and will continue to change the industry in which we operate in substantial ways. The implementation of health care reform has increased, and could further increase, our competition in the individual and family health insurance market and reduce or eliminate the need for health insurance agents or demand for the health insurance for individuals and families that we sell; further decrease the number of health insurance plans that we sell as well as the number of health insurance carriers offering them; cause a further reduction in our membership and revenue; cause us to incur increased expense across our business and cause health insurance carriers to further reduce our commissions and other amounts they pay for our services or change our relationship with them in other ways, any of which could materially harm our business, operating results and financial condition. These and other impacts of health care reform caused a significant decline in our individual and family plan membership and other changes in the future could have a similar impact on our Medicare related health insurance business. In addition, various aspects of health care reform have caused and could continue to cause health insurance carriers to limit the type of health insurance plans we sell and the geographies in which we sell them, to reduce or eliminate the commissions we receive from them as a result of our sale of health insurance plans, to exit the business of selling individual and family and small business health insurance plans in particular jurisdictions or altogether, to eliminate certain categories of products or attempt to move members into new plans for which we receive lower or no commissions, any of which could materially harm our business, operating results and financial condition.
Under the Affordable Care Act, health insurance carriers offering coverage in the individual or small business health insurance market must ensure that such coverage meets certain actuarial value standards, includes certain minimum health benefits and is not subject to lifetime or, for most health insurance benefits, annual dollar amount coverage limits. Moreover, health insurance carriers cannot deny individuals health insurance for health reasons. For these and other reasons, the cost of individual and family health insurance has generally increased and many health insurance carriers suffered financial losses in their individual and family health insurance businesses. As a result, many health insurance carriers exited the individual and family health insurance business in part or altogether. The number of individual and family health insurance plans offered on our website has been reduced, including states and many zip codes where we have no individual and family health insurance plans to offer. If these conditions persist, we anticipate that demand for the individual and family health insurance that we sell will continue to decrease and this would harm our business, operating results and financial condition.
The Trump administration and Republican leadership in Congress have attempted on several occasions to repeal or amend the Affordable Care Act, but their efforts at doing so have largely failed. The Affordable Care Act contains a mandate requiring individuals to maintain health insurance plans that comply with the Affordable Care Act or face a tax penalty. As a
59




part of the tax reform law that came into effect in December 2017, the tax penalty for violating the mandate was set at zero effective in 2019, essentially repealing it. The essential repeal of the individual mandate could cause individuals to determine not to purchase or maintain individual and family health insurance and could cause carriers to increase premiums, reduce commissions or exit the business of selling individual and family health insurance, any of which would adversely impact our business, operating results and financial condition.
In addition to eliminating the penalty for violating the individual mandate, the Trump administration issued an executive order in October 2017 that directed the executive branch of the government to consider proposing regulations and revising guidance to expand access to association health plans, expand the availability of short-term health insurance and increase the usability of health reimbursement arrangements. As a result of the executive order, new regulations were adopted in July and August 2018, respectively, that would facilitate association-based health insurance plans and promote the sale of more short-term health insurance. The regulations relating to short-term health insurance plans extend the initial duration of short-term health insurance from three months to less than one year and allow for short-term health insurance plans to be renewed as long as the total duration of the plan does not exceed thirty-six months. However, states have authority to impose their own laws and regulations over short-term health insurance plans sold in their markets and certain states have adopted or are contemplating laws and regulations that would ban the sale of short-term health insurance, limit their duration and renewability, apply certain aspects of the Affordable Care Act to short-term health insurance or impose stronger disclosure requirements than the federal regulation. The expansion of the availability of short-term health insurance in many states may cause individuals and families to purchase short-term health insurance instead of individual and family health insurance, which could adversely impact our business, operating results and financial condition if any reduction in our sales of individual and family health insurance is not offset by increased revenue from sales of short-term health insurance. The regulations relating to association health plans allow small businesses, including sole proprietors and other self-employed individuals, to join industry or geographically-based associations and collectively purchase large group health insurance plans. Large group health insurance is not subject to many of the provisions of the Affordable Care Act, including the requirement that health insurance plans cover all of the essential health benefits defined under the Affordable Care Act. The goal of the new regulation is to create a new health insurance option for small businesses, sole proprietors and other self-employed individuals and to reduce the cost of insurance for these purchasers if they are association members. While the regulation could present new business opportunities for us, it also may reduce the size of the individual, family and small business health insurance markets that we are able to address, which would harm our business, operating results and financial condition.

In December 2018, a federal district court in Texas in Texas v. United States of America et al., determined that the individual mandate in the Affordable Care Act is unconstitutional, because it was not within Congress’s tax power or interstate commerce power. It also determined that the remaining provisions of the Affordable Care Act were inseverable and therefore invalid. The court, however, did not rule that the operation of the Affordable Care Act be enjoined, so the law continues to operate until determined otherwise by the court or an appellate court. The Fifth Circuit Court of Appeals agreed with the district court that the mandate is unconstitutional, but remanded the case back to the district court to address whether the unconstitutionality of the mandate should impact the rest of the law. In March 2020, the Supreme Court has agreed to review the case, including whether the individual mandate is unconstitutional, and if the mandate is unconstitutional whether the rest of the Affordable Care Act can survive. If the Affordable Care Act were finally determined to be unconstitutional and no longer operated, it is unclear what impact it or its replacement would have on our business. However, it or its replacement could adversely impact our business, operating results and financial condition.
Our business may be harmed if we do not enroll subsidy-eligible individuals through government-run health insurance exchanges efficiently.

In order to offer the qualified health plans that individuals and families must purchase to receive Affordable Care Act subsidies, agents and brokers must meet certain conditions, such as receiving permission to do so from the applicable government health insurance exchange, entering into an agreement with the health insurance exchange or a partner of the exchange, ensuring that the enrollment and subsidy application is completed through the health insurance exchange and complying with privacy, security and other standards. In the event Internet-based agents and brokers such as us use the Internet for completion of qualified health plan selection purposes, their websites are required to meet certain additional requirements. To the extent we enroll individuals and families into qualified health plans, we do so through the Federally Facilitated Marketplace, or FFM, which runs all or part of the health insurance exchange in 38 states. We may experience difficulty in satisfying the conditions and requirements to offer qualified health plans to our existing members and new potential members, and in getting them enrolled through the FFM. If we are not able to satisfy these conditions and requirements, or if we are not able to successfully adopt and maintain solutions that allow us to enroll large numbers of individuals and families in qualified
60




plans over the Internet both during and outside of open enrollment periods, we will lose existing members and new members, and may incur additional expense, which would harm our business, operating results and financial condition. In addition, if we are not able to adopt or contract with and maintain solutions to integrate with government-run health insurance exchanges or if the health insurance exchange websites and other processes are unstable or not consumer friendly, efficient and compatible with the process we have adopted for enrolling individuals and families into qualified health plans through the exchanges, we would not be successful in retaining and acquiring members, and our business, operating results and financial condition would be harmed. The FFM may at any time cease allowing us to enroll individuals in qualified health plans or change the requirements for doing so. If it does so or if the FFM platform does not function properly, our ability to retain existing members and add new members could be negatively impacted, which would harm our business, operating results and financial condition.

CMS has broad authority over the requirements that must be met in order to enroll individuals into qualified health plans through the FFM without visiting the FFM website. Beginning in the open enrollment period that occurred in the fourth quarter of 2018, CMS adopted a new enhanced direct enrollment pathway for CMS-approved partners to enroll individuals into qualified health plans and complete all steps in the eligibility and enrollment process on a single website. The enhanced direct enrollment process uses an application programming interface to transfer information relating to health plan and subsidy eligibility between the FFM and the approved partner’s website. Before enhanced direct enrollment partners are approved, extensive security and privacy reviews are conducted by an independent third-party auditor and CMS reviews the audit results to ensure the entity satisfies numerous additional privacy and security standards. We entered into an agreement to outsource certain aspects of the enrollment process for qualified health plans to a third party in light of the expense and burden associated with the additional requirements, and the entity was successful in passing the required audit to use this new process for the open enrollment period for 2020 coverage. However, if we do not develop the ability to satisfy the requirements to use the improved qualified health plan enrollment process in the future, or if we are unsuccessful in entering into or maintaining a relationship with a third party who is approved to use the process, we could be required to use an alternative “double redirect process that would require our customers to visit the FFM website in the middle of purchasing qualified health insurance plans to receive a subsidy eligibility determination. We have in the past used the “double redirect” process which resulted in a reduction in the rate at which individuals and families starting the application process for qualified health plans and subsidies became members and a reduction in our individual and family health insurance plan membership and revenue. If we are forced to use the “double redirect” process in the future, we could continue to experience loss of existing members and new potential members and a reduction in our individual and family health insurance plan membership and commission revenue, which would harm our business, operating results and financial condition. In addition, if any third party we contract with to perform certain aspects of the qualified health plan selection and enrollment process has a poor consumer experience or otherwise experiences technical or other difficulties, we could experience a reduction in our individual and family health insurance plan membership and revenue and our business, operating results and financial condition could be harmed.
The medical loss ratio requirements that are a part of health care reform may harm our business.

The Affordable Care Act contains provisions requiring health insurance carriers to maintain specified medical loss ratios. The medical loss ratio requirements for both individual and family and small business health insurance require health insurance companies to spend 80% of their premium revenue in each of their individual and small group health insurance businesses on reimbursement for clinical services and activities that improve health care quality. The medical loss ratio requirement for Medicare Advantage plans is 85%. If a health insurance carrier fails to meet medical loss ratio requirements, the health insurance carrier is required to rebate a portion of its premium revenue to its members to make up for the difference. Health insurance carriers may determine to reduce our Medicare Advantage plan, individual and family, or small group commissions as a result of the medical loss ratio requirements, which would harm our business, operating results and financial condition.

If we are not successful in cost-effectively converting visitors to our website and customer call centers into members for which we receive commissions, our business and operating results would be harmed. 

Our growth depends in large part upon growth in approved members in a given period. The rate at which consumers visiting our ecommerce platforms and customer care centers seeking to purchase health insurance are converted into approved members directly impacts our revenue. In addition, the rate at which consumers who are approved become paying members impacts the constrained LTV of our approved members, which impacts the revenue that we are able to recognize. A number of factors have influenced, and could in the future influence, these conversion rates for any given period, some of which are outside of our control. These factors include:
61





changes in consumer shopping behavior due to circumstances outside of our control, such as economic conditions, consumers’ ability or willingness to pay for health insurance, availability of unemployment benefits or proposed or enacted legislative or regulatory changes impacting our business, including health care reform;
the quality of and changes to the consumer experience on our ecommerce platforms or with our customer care centers;
regulatory requirements, including those that make the experience on our ecommerce platforms cumbersome or difficult to navigate or reduce the ability of consumers to purchase plans outside of enrollment periods;
the variety, competitiveness and affordability of the health insurance plans that we offer;
system failures or interruptions in the operation of our ecommerce platform or call center operations;
changes in the mix of consumers who are referred to us through our direct, marketing partner and online advertising member acquisition channels;
health insurance carriers offering the health insurance plans for which consumers have expressed interest, and the degree to which our technology is integrated with those carriers;
health insurance carrier guidelines applicable to applications submitted by consumers, the amount of time a carrier takes to make a decision on that application and the percentage of submitted applications approved by health insurance carriers;
the effectiveness of health insurance agents in assisting consumers; and
our ability to enroll subsidy-eligible individuals in qualified health plans through government-run health insurance exchanges and the efficacy of the process we are required to use to do so.

Our conversion rates can be impacted by changes in the mix of consumers referred to us through our member acquisition channels. We may make changes to our ecommerce platforms in response to regulatory requirements or undertake other initiatives in an attempt to improve consumer experience or for other reasons. These changes have in the past, and may in the future have the unintended consequence of adversely impacting our conversion rates. A decline in the percentage of consumers who submit health insurance applications on our ecommerce platforms or telephonically via our customer care centers and are converted into approved and paying members could cause an increase in our cost of acquiring members on a per member basis and impact our revenue in any given period. To the extent the rate at which we convert consumers visiting our ecommerce platforms or telephonically via our customer care centers into members suffers, our membership may decline, which would harm our business, operating results and financial condition.

Our future operating results are likely to fluctuate and could fall short of expectations. 

Our operating results are likely to fluctuate as a result of a variety of factors, including the factors described elsewhere in this Risk Factors section, many of which are outside of our control. Among these factors, the assumptions underlying our estimates of commission revenue as required by ASC 606, may vary significantly over time. As a result, comparing our operating results on a period-to-period basis may not be meaningful and you should not rely on our past results as an indication of our future performance, particularly in light of the fact that our business and industry are undergoing substantial change as a result of health care reform and initiatives we determined to pursue. If our revenue or operating results differ from our guidance or fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, when our revenue and operating results differed from our guidance and the expectations of investors or securities analysts, the price of our common stock was impacted.

System failures or capacity constraints could harm our business and operating results. 

The performance, reliability and availability of our ecommerce platforms and underlying network infrastructures are critical to our financial results, our brand and our relationship with members, marketing partners and health insurance carriers. Although we regularly attempt to enhance our ecommerce platforms and system infrastructure, system failures and interruptions may occur if we are unsuccessful in these efforts, if we are unable to accurately project the rate or timing of increases in our website traffic or for other reasons, some of which are completely outside our control. Although we have experienced only minor system failures and interruptions to date, we could experience significant failures and interruptions in the future, which would harm our business, operating results and financial condition. If these failures or interruptions occurred during the Medicare annual enrollment period or during the open enrollment period under health care reform, the negative impact on us would be particularly pronounced.

62




We rely in part upon third-party vendors, including data center and bandwidth providers, to operate our ecommerce platforms. We cannot predict whether additional network capacity will be available from these vendors as we need it, and our network or our suppliers’ networks might be unable to achieve or maintain a sufficiently high capacity of data transmission to allow us to process health insurance applications in a timely manner or effectively download data, especially if our website traffic increases. Any system failure that causes an interruption in or decreases the responsiveness of our services would impair our revenue-generating capabilities and harm our business and operating results and damage our reputation. In addition, any loss of data could result in loss of customers and subject us to potential liability. Our facilities and our database and systems are vulnerable to damage or interruption from human error, fire, floods, power loss, telecommunications failures, physical or electronic break-ins, computer viruses, acts of terrorism, other attempts to harm our systems and similar events. In addition, our operations are vulnerable to earthquakes, fire, severe weather conditions, including those brought about by climate change, and other natural disasters in the San Francisco Bay Area and elsewhere in Northern California as well as in other parts of the country and in China where we or our outsourced health insurance agents maintain offices.

Consumers may access our customer care centers for assistance in connection with submitting health insurance applications. We depend upon third parties, including telephone service providers and third-party software providers, to operate our customer care centers. Any failure of the systems that we rely upon in the operation of our customer care centers could negatively impact sales as well as our relationship with consumers and members, which could harm our business, operating results and financial condition.

We depend upon Internet search engines to attract a significant portion of the consumers who visit our website, and if we are unable to effectively advertise on search engines on a cost-effective basis, our business and operating results would be harmed.

We derive a significant portion of our website traffic from consumers who search for health insurance through Internet search engines, such as Google, Bing and Yahoo!. A critical factor in attracting consumers to our website is whether we are prominently displayed in response to an Internet search relating to health insurance. Search engines typically provide two types of search results, algorithmic listings and paid advertisements. We rely on both to attract consumers to our websites and otherwise generate demand for our services.

Algorithmic search result listings are determined and displayed in accordance with a set of formulas or algorithms developed by the particular Internet search engine. The algorithms determine the order of the listing of results in response to the consumer’s Internet search. From time to time, search engines revise these algorithms. In some instances, these modifications have caused our website to be listed less prominently in algorithmic search results, which has resulted in decreased traffic to our website. We may also be listed less prominently as a result of new websites or changes to existing websites that result in these websites receiving higher algorithmic rankings with the search engine. For example, government health insurance exchange websites appear prominently in algorithmic search results. Our website may become listed less prominently in algorithmic search results for other reasons, such as search engine technical difficulties, search engine technical changes and changes we make to our website. In addition, search engines have deemed the practices of some companies to be inconsistent with search engine guidelines and decided not to list their website in search result listings at all. If we are listed less prominently in, or removed altogether from, search result listings for any reason, the traffic to our websites would decline and we may not be able to replace this traffic, which would harm our business, operating results and financial condition. If we decide to attempt to replace this traffic, we may be required to increase our marketing expenditures, which would also increase our cost of member acquisition and harm our business, operating results and financial condition.

We purchase paid advertisements on search engines in order to attract consumers to our platforms. We typically pay a search engine for prominent placement of our website when particular health insurance-related terms are searched for on the search engine, regardless of the algorithmic search result listings. The prominence of the placement of our advertisement is determined by a combination of factors, including the amount we are willing to pay and algorithms designed to determine the relevance of our paid advertisement to a particular search term. As with algorithmic search result listings, search engines may revise the algorithms relevant to paid advertisements and websites other than our ecommerce platform may become more optimized for the algorithms. These changes may result in our having to pay increased amounts to maintain our paid advertisement placement in response to a particular search term. We could also have to pay increased amounts should the market share of major search engines continue to become more concentrated with a single search engine. Additionally, we bid against our competitors and others for the display of these paid search engine advertisements. Many of our competitors, including many health insurance carriers and government-run health insurance exchanges, have greater resources with which to
63




bid and better brand recognition than we do. We have experienced increased competition from health insurance carriers, government health insurance exchanges and some of our marketing partners for both algorithmic search result listings and for paid advertisements. The competition has increased the cost of paid internet search advertising and has increased our marketing and advertising expenses. The competition increases substantially during the enrollment periods for Medicare related health insurance and for individual and family health insurance. If paid search advertising costs increase or become cost prohibitive, whether as a results of competition, algorithm changes or otherwise our advertising expenses could rise significantly or we could reduce or discontinue our paid search advertisements, either of which would harm our business, operating results and financial condition.

We rely significantly on marketing partners and our business and operating results would be harmed if we are unable to maintain effective relationships with our existing marketing partners or if we do not establish successful relationships with new marketing partners.

In addition to marketing through Internet search engines, we frequently enter into contractual marketing relationships with other online and offline businesses that promote us. These marketing partners include financial and online service companies, affiliate programs and online advertisers and content providers. We also have relationships with strategic marketing partners, including hospitals and pharmacy chains that promote our Medicare platforms to their customers as well as pharmacy service providers. We compensate many of our marketing partners for their referrals on a submitted health insurance application basis and, if they are licensed to sell health insurance, may share a percentage of the commission we earn from the health insurance carrier for each member referred by the marketing partner.

Many factors influence the success of our relationship with our marketing partners, including:

the continued positive market presence, reputation and growth of the marketing partner;
the effectiveness of the marketing partner in marketing our website and services, including whether the marketing partner is successful in maintaining the prominence of its website in algorithmic search result listings and paid Internet advertisements;
the compliance of our marketing partners with applicable laws, regulations and guidelines;
the interest of the marketing partner’s customers in the health insurance plans that we offer;
the contractual terms we negotiate with the marketing partner, including the marketing fees we agree to pay a marketing partner;
the percentage of the marketing partner’s customers that submit applications or purchase health insurance policies through us;
the ability of a marketing partner to maintain efficient and uninterrupted operation of its website; and
our ability to work with the marketing partner to implement website changes, launch marketing campaigns and pursue other initiatives necessary to maintain positive consumer experiences and acceptable traffic volumes.

For instance, we partner with Internet lead aggregators who refer a significant number of consumers to our online platforms. Major search engines have in the past and may in the future determine not to list lead aggregator websites prominently in search result listings for various reasons, which would cause a significant reduction in the number of consumers referred to us through our marketing partner channel. While we have relationships with a large number of marketing partners, we depend upon referrals from a limited number of marketing partners for a significant portion of the submitted applications we receive from our marketing partner customer acquisition channel.

Given our reliance on our marketing partners, our business operating results and financial condition would be harmed if any of the following were to occur:

if we are unable to maintain successful relationships with our existing marketing partners, particularly marketing partners responsible for a significant number of our submitted applications;
if we fail to establish successful relationships with new marketing partners;
if we experience competition in our receipt of referrals from our high volume marketing partners; and
if we are required to pay increased amounts to our marketing partners.

Competition for referrals from our marketing partners has increased particularly during the enrollment periods for Medicare-related health insurance and individual and family health insurance. We may lose marketing partner referrals if our
64




competitors pay marketing partners more than we do or be forced to pay increased fees to our marketing partners, which could harm our business, operating results and financial condition. If we lose marketing partner referrals during the Medicare or individual and family health insurance enrollment periods, the adverse impact on our business would be particularly pronounced. In addition, the promulgation of laws, regulations or guidelines, or the interpretation of existing laws, regulations and guidelines, by state departments of insurance or by CMS, could cause our relationships with our marketing partners to be in non-compliance with those laws, regulations and guidelines. We also have relationships with hospital systems and pharmacy chains that utilize aspects of our platform and tools. Our relationships with these hospital systems and pharmacy chains result in the referral of a significant number of individuals to us who are interested in purchasing Medicare-related health insurance plans. If CMS or state departments of insurance were to change existing laws, regulations or guidelines, or interpret existing laws, regulations or guidelines, to prohibit these arrangements, or if hospital systems or pharmacy partners otherwise decided to no longer utilize aspects of our platform and tools, we could experience a significant decline in the number of Medicare-eligible individuals who are referred to our platforms and customer care centers, which would harm our business, operating results and financial condition.

If commission reports we receive from carriers are inaccurate or not sent to us in a timely manner, our business and operating results could be harmed and we may not recognize trends in our membership. 

We rely on health insurance carriers to timely and accurately report the amount of commissions earned by us, and we calculate our commission rates per member, prepare our financial reports, projections and budgets and direct our marketing and other operating efforts based on the reports we receive from health insurance carriers. There have been instances where we have determined that policy cancellation data reported to us by a health insurance carrier has not been accurate. The extent to which health insurance carriers are inaccurate in their reporting of policy cancellations could cause us to change our cancellation estimates, which could adversely impact our revenues. We apply judgment and make estimates based on historical data and current trends to independently determine whether or not carriers are accurately reporting commissions due to us. Our revenue recognition policy changed in the first quarter of 2018 as a result of our adoption of ASC 606. To the extent that health insurance carriers understate or fail to accurately report the amount of commissions due to us in a timely manner or at all, our estimates of constrained LTV may be adversely impacted, which would harm our business, operating results and financial condition. In addition, any inaccuracies in the reports would adversely impact our commission revenue for future periods which is based on historical trends, including trends relating to contracted commission rates and expected health insurance plan cancellation.

We depend on health insurance carriers and others for data related to our membership. For instance, with respect to health insurance plans other than small business health insurance, health insurance carriers do not directly report member cancellations to us, resulting in the need for us to determine cancellations using payment data that carriers provide. We infer cancellations from this payment data by analyzing whether payments from members have ceased for a period of time, and we may not learn of a cancellation for several months. With respect to our small business membership, many groups notify the carrier directly with respect to increases or decreases in group size and policy cancellations. Our insurance carrier partners often do not communicate this information to us, and it often takes a significant amount of time for us to learn about small business group cancellations and changes in our membership within the group itself. We often are not made aware of policy cancellations until the time of the group’s annual renewal.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. We also reconcile information health insurance carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated our membership. As a result of open enrollment periods, we may not receive information from our carriers on as timely a basis due to the significant increase in health insurance transaction volume, which could impair the accuracy of our membership estimates. Additionally, health insurance carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. For these and other reasons, including if current trends in membership cancellation are inconsistent with past cancellation trends that we use to estimate our membership or if carriers subsequently report changes to the commission payments that they previously reported to us, our actual membership could be different from our estimates, perhaps materially. If our actual membership is different from our estimates, the constrained LTV component of our revenue
65




recognition could also be inaccurate, including as a result of an inaccurate estimate of the average amount of time our members maintain their health insurance plans.

Our business is subject to security risks and, if we are subject to cyber attacks, security breaches or otherwise unable to safeguard the security and privacy of confidential data, including personal health information, our business will be harmed.

Our services involve the collection and storage of confidential and personally identifiable information of consumers and the transmission of this information to their chosen health insurance carriers and to government. For example, we collect names, addresses, Social Security and credit card numbers and protected health information such as information regarding the medical history of consumers. As a result, we are subject to various laws and regulations and contractual requirements regarding the collection, maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information. We also hold a significant amount of information relating to our current and former employees. We cannot guarantee that our facilities and systems, and those of our third party service providers, will be free of security breaches, cyber-attacks, acts of vandalism, computer viruses, malware, misplaced or lost data, programming and/or human errors or other similar events. Compliance with privacy and security laws, requirements and regulations, particularly new state legislation such as the California Consumer Privacy Act, may result in cost increases due to new constraints on our business, the development of new processes, the effects of potential non-compliance by us or third party service providers, and enforcement actions. We may be required to expend significant amounts and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures, techniques used to obtain unauthorized access or to sabotage systems change frequently. As a result, we may be unable to anticipate these techniques or to implement adequate preventative measures. Additionally, our third party service providers may cause security breaches for which we are responsible.

Any compromise or perceived compromise of our security or the security of one of our vendors could damage our reputation, cause the termination of relationships with government-run health insurance exchanges and our members, marketing partners and health insurance carriers, reduce demand for our services and subject us to significant liability and expense as well as regulatory action and lawsuits, which would harm our business, operating results and financial condition. The COVID-19 pandemic generally is increasing the attack surface available to criminals, as more companies and individuals work remotely and otherwise work online. Consequently, the risk of a cybersecurity incident has increased. We cannot provide assurances that our preventative efforts, or those of our vendors or service providers, will be successful.In addition, in the event that additional data security laws are implemented, or our health insurance carrier or other partners determine to impose requirements on us relating to data security, we may not be able to timely comply with such requirements or such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could result in our inability to sell health insurance plans in a particular jurisdiction or for a particular health insurance carrier or subject us to liability for non-compliance, any of which would damage our business, operating results and financial condition. For instance, health insurance carriers may require us to be compliant with security standards in order to accept credit card information from consumers or require us to comply with privacy and security standards to do business with us at all. Compliance with privacy and security standards is regularly assessed, and we may not always be compliant with the standards. If we are not in compliance, we may not be able to accept credit card information from consumers or conduct health insurance business, and our relationship with health insurance carriers could be adversely impacted or terminated, which would harm our business, operating results and financial condition.

There are many risks associated with our operations in China.

A portion of our operations is conducted by our subsidiary in China. Among other things, we use employees in China to maintain and update our ecommerce platform and perform certain tasks within our finance and customer care and enrollment functions. We rely on the Internet to communicate with our subsidiary in China. Our business would be harmed if our ability to communicate over the Internet with these employees failed, and we were prevented from promptly updating our software or implementing other changes to our database and systems, among other things. From time-to-time we receive inquiries from health insurance carriers relating to our operations in China and the security measures we have implemented to protect data that our employees in China may be able to access. As a part of these inquiries, we have implemented additional security measures relating to our operations in China. We may be required to implement further security measures to continue aspects of our operations in China or health insurance carriers may require us to bring aspects of our operations in China back to the United States, which could be time consuming and expensive and harm our operating results and financial condition. Health insurance
66




carriers may also terminate our relationship due to concerns surrounding protection of data that our employees in China are able to access, which would harm our business, operating results and financial condition.

Our operations in China also expose us to different and unfamiliar laws, rules and regulations, including different intellectual property laws, which are not as protective of our intellectual property as the laws in the United States. United States and Chinese trade laws may also impose restrictions on the importation of programming or technology to or from the United States. We are also subject to anti-bribery and anti-corruption laws, privacy and data security laws, labor laws, tax laws, foreign exchange controls and cash repatriation restrictions in China. On June 1, 2017, a national cyber security law came into effect in China. The law, along with its implementation regulations, applies to the establishment, operation, maintenance and usage of networks within China and the supervision and management of cyber security. Under the law, network operators are required to comply with certain tiered security obligations based on the networks’ relative impact on national security, social order, public interest and individuals’ privacy rights. There remains considerable uncertainty as to how the cyber security law will be applied, and the regulatory environment continues to evolve with new draft regulations and standards published frequently. Such laws, regulations and standards are complex, ambiguous and subject to change or interpretation, which create uncertainty regarding compliance. Pursuant to the draft regulations, we may be required to perform self-assessments, obtain third party certifications, report cyber security incidents and make filings with public security authorities. We could also be subject to security inspections and evaluations by public security authorities and be restricted to use only network products and services that meet certain standards based on the level of risk applicable to us. Compliance with these laws and regulations could cause us to incur substantial costs or require us to change our business operations in China. Violation of applicable laws and regulations could adversely affect our brand, affect our relationship with our health insurance carriers, and could result in regulatory enforcement actions and the imposition of civil or criminal penalties and fines, which would harm our business, operating results and financial condition.

Our business may be adversely impacted by changes in China’s economic or political condition. We have recently experienced greater competition for qualified personnel in China, which has raised market salaries and increased our compensation costs related to employees in China. If competition for personnel increases further, our compensation expenses could rise considerably or, if we determine to not increase compensation levels, our ability to attract and retain qualified personnel in China may be impaired, which could harm our business, operating results and financial condition. These risks could cause us to incur increased expenses and could harm our ability to effectively and successfully manage our operations in China. Moreover, any significant or prolonged deterioration in the relationship between United States and China could adversely affect our operations in China. Certain risks and uncertainties of doing business in China are solely within the control of the Chinese government, and Chinese law regulates the scope of our foreign investments and business conducted within China. The escalation of trade tensions initiated by the current administration has increased the risk associated with our operations in China. Either the United States or the Chinese government may sever our ability to communicate with our China operations or may take actions that force us to close our operations in China. We employ a large number of our technology and content employees in China, and we have other employees in China that support our business. Any sudden disruption of our operations in China would adversely impact our business. If we are required to move aspects of our operations from China to our offices in the United States as a result of political instability, changes in laws, inquiries from health insurance carriers or for other reasons, we could incur increased expenses, and our business, operating results and financial condition could be harmed.

Our sponsorship and advertising business may not be successful.

We sell advertising space to health insurance carriers on our website through our sponsorship and advertising program. Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. Health insurance carriers have generally determined not to spend on individual and family health insurance advertising through our sponsorship and advertising program as a result of the impact of health care reform on the profitability of their individual and family health insurance businesses. To the extent that economic conditions, health care reform or other factors impact the amount health insurance carriers are willing to pay for advertising on our ecommerce platform, our sponsorship and advertising program will be adversely impacted. Since much of our sponsorship revenue depends upon the number of applications we submit to health insurance carriers, a reduction in demand for the carrier’s product (such as outside open enrollment periods) would reduce our sponsorship revenue and our business, operating results and financial condition could be harmed. The success of our sponsorship and advertising program depends on a number of other factors, including the effectiveness of the sponsorship and advertising program as a cost-effective method for carriers to obtain additional members, consumer and health insurance carrier adoption of the Internet and our ecommerce platform as a medium for the purchase and sale of health insurance, our ability to attract consumers visiting our ecommerce platform and convert those consumers into
67




members, the existence of a relationship between us and a diverse group of carriers that offer a number of health insurance plans in the markets in which we attempt to sell advertising, the cost, benefit and brand recognition of the health insurance plan that is the subject of the advertising, the impact the advertising has on the sale of the health insurance plan that is the subject of the advertising and the effectiveness of the carrier’s other means of advertising. In addition, while our practice of selling advertising is described on our ecommerce platform, it could cause consumers to perceive us as not objective, which could harm our brand and result in a decline in our health insurance sales. It also could adversely impact our relationship with health insurance carriers that do not purchase our advertising or otherwise result in accusations that we are favoring certain plans over others. As a result, our business, operating results and financial condition could be harmed.

We also develop, host and maintain carrier dedicated Medicare plan websites and may undertake other marketing and advertising initiatives through our Medicare plan advertising program. Our success in doing so is dependent upon the same factors that could impact our sponsorship program. In addition, since we maintain relationships with a limited number of health insurance carriers to sell their Medicare plans, our Medicare plan-related advertising revenue is concentrated in a small number of health insurance carriers and our ability to generate Medicare plan-related advertising revenue would be harmed by the termination or non-renewal of any of these relationships as well as by a reduction in the amount a health insurance carrier is willing to pay for these services. Moreover, in light of the regulations applicable to the marketing and sale of Medicare plans, and given that these regulations are often unclear, change frequently and are subject to changing interpretations, we may in the future not be permitted to sell Medicare plan-related advertising. If we are not successful in generating Medicare plan-related advertising revenue, our business operating results and financial condition could be harmed.

We may not be able to adequately protect our intellectual property, which could harm our business and operating results.

We believe that our intellectual property is an essential asset of our business and that our technology currently gives us a competitive advantage in the distribution of Medicare-related, individual and family and small business health insurance. We rely on a combination of copyright, trademark and trade secret laws as well as confidentiality procedures and contractual provisions to establish and protect our intellectual property rights in the United States. The efforts we have taken to protect our intellectual property may not be sufficient or effective, and our trademarks may be held invalid or unenforceable. Moreover, the law relating to intellectual property is not as developed in China, and our intellectual property rights may not be as respected in China as they are in the United States. We may not be effective in policing unauthorized use of our intellectual property, trade secrets and other confidential information, and even if we do detect violations, litigation may be necessary to enforce our intellectual property rights. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive, could divert our management’s attention and may result in a court determining that our intellectual property or other rights are unenforceable. If we are not successful in cost-effectively protecting our intellectual property rights, trade secrets and confidential information, our business, operating results and financial condition could be harmed.

We may in the future be subject to intellectual property rights claims, which are extremely costly to defend, could require us to pay significant damages and could limit our ability to use certain technologies in the future.

There are a large number of patents, copyrights, trademarks and trade secrets applicable to the internet and technology industries and entities frequently enter into litigation based on allegations of infringement or other violations of intellectual property rights. We have received, and may in the future receive, notices that claim we have misappropriated, infringed or misused other parties’ intellectual property rights, and, to the extent we gain greater visibility, we face a higher risk of being the subject of intellectual property infringement claims. There may be third-party intellectual property rights, including issued or pending patents that cover significant aspects of our technologies or business methods or that cover third-party technology that we use as a part of our websites. Any intellectual property claim against us, with or without merit, could be time consuming, expensive to settle or litigate and could divert our management’s attention and other resources. These claims also could subject us to significant liability for damages and could result in our having to stop using technology found to be in violation of a third party’s rights. We might be required to seek a license for third-party intellectual property, which may not be available on reasonable terms or at all. Even if a license is available, we could be required to pay significant royalties, which would increase our operating expenses. We may also be required to develop alternative non-infringing technology, which could require significant effort and expense. If we cannot license or develop technology for any infringing aspect of our business, we would be forced to limit our services and may be unable to compete effectively. Any of these results would harm our business, operating results and financial condition.

68




Any legal liability, regulatory penalties, or negative publicity for the information on our website or that we otherwise provide could harm our business and operating results.

We provide information on our website, through our customer care centers, in our marketing materials and in other ways regarding health insurance in general and the health insurance plans we market and sell, including information relating to insurance premiums, coverage, benefits, provider networks, exclusions, limitations, availability, plan comparisons and insurance company ratings. A significant amount of both automated and manual effort is required to maintain the considerable amount of insurance plan information on our website. We also use the information provided on our website and otherwise collected by us to publish reports designed to educate consumers, facilitate public debate, and facilitate reform at the state and federal level. If the information we provide on our website, through our customer care centers, in our marketing materials or otherwise is not accurate or is construed as misleading, or if we do not properly assist individuals and businesses in purchasing health insurance, members, health insurance carriers and others could attempt to hold us liable for damages, our relationships with health insurance carriers could be terminated or impaired and regulators could attempt to subject us to penalties, revoke our licenses to transact health insurance business in a particular jurisdiction, and/or compromise the status of our licenses to transact health insurance business in other jurisdictions, which could result in our loss of our commission revenue. In the ordinary course of operating our business, we have received complaints that the information we provided was not accurate or was misleading. Although in the past we have resolved these complaints without significant financial cost or impact to our brand or reputation, we cannot guarantee that we will be able to do so in the future. Our sales of short-term health insurance plans that lack the same benefits as major medical health insurance plans may increase the risk that we receive complaints regarding our marketing and business practices due to the potential for consumer confusion between short-term health insurance and major medical health insurance. In addition, these types of claims could be time-consuming and expensive to defend, could divert our management’s attention and other resources, and could cause a loss of confidence in our services. As a result, whether or not we are able to successfully resolve these claims, they could harm our business, operating results and financial condition.

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We also have become, and may in the future become, involved in litigation or claims in the ordinary course of our business, including with respect to employment-related claims such as workplace discrimination or harassment. We have, and may in the future, face claims of violations of other local, state, and federal labor or employment laws, laws and regulations relating to marketing and laws and regulations relating to the sale of insurance. If we are found to have violated laws or regulations, we could lose our relationship with health insurance carriers and be subject to various fines and penalties, including revocation of our licenses to sell insurance which would cause us to lose our commission revenue, and our business, operating results and financial condition would be materially harmed. In addition, if regulators believe our websites or marketing material are not compliant with applicable laws or regulations, we could be forced to stop using our websites, marketing material or certain aspects of them, which would harm our business, operating results and financial condition.

Acquisitions could disrupt our business and harm our financial condition and operating results.

We acquired Wealth, Health and Life Advisors, LLC, more commonly known as GoMedigap, in January 2018 and we may in the future acquire other businesses, products and technologies. Our ability as an organization to successfully make and integrate acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including the following:

an acquisition may negatively impact our results of operations because it will require us to incur transaction expenses, and after the transaction, may require us to incur charges and substantial debt or liabilities, may require the amortization, write down or impairment of amounts related to deferred compensation, goodwill and other intangible assets, or may cause adverse tax consequences, substantial depreciation or deferred compensation charges, such as expenses related to the change in fair value of earnout liability;
an acquisition undertaken for strategic business purposes may negatively impact our results of operations;
we may encounter difficulties in assimilating and integrating the business, technologies, products, personnel or operations of companies that we acquire, particularly if key personnel of the acquired company departs or decide not to work for us;
an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;
we may be required to implement or improve internal controls, procedures and policies appropriate for a public company at a business that prior to the acquisition lacked these controls, procedures and policies;
69




the acquired businesses, products or technologies may not generate sufficient revenue to offset acquisition costs or to maintain our financial results;
we may have to issue securities to complete an acquisition, which would dilute our stockholders’ ownership and could adversely affect the market price of our common stock; and
acquisitions may involve the entry into geographic or business markets in which we have little or no prior experience.

We cannot assure you that we will be able to identify or consummate any future acquisition on favorable terms, or at all. If we do pursue an acquisition, it is possible that we may not realize the anticipated benefits from the acquisition or that the financial markets or investors will negatively view the acquisition. Even if we successfully complete an acquisition, it could harm our business, operating results and financial condition.

Our debt obligations contain restrictions that impact our business and expose us to risks that could materially adversely affect our liquidity and financial condition.

We are party to a credit agreement with Royal Bank of Canada and other lenders that enables us to borrow up to $75 million pursuant to a revolving credit facility. This credit agreement imposes certain covenants and restrictions on our business and our ability to obtain additional financing. As of March 31, 2020, we had no outstanding debt under our revolving credit facility.

Among other things, the credit agreement requires the lender’s consent, under certain circumstances, to:

merge or consolidate;
sell or transfer assets outside the ordinary course of business;
make certain types of investments and restricted payments;
incur additional indebtedness or guarantee indebtedness of others;
pay dividends on our capital stock;
enter into transactions with affiliates; and
grant liens on our assets, subject to certain exceptions.

Our credit agreement also contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, reporting requirements and compliance with applicable laws and regulations. Further, the credit agreement contains a financial covenant requiring the Company to maintain a minimum level of excess availability at any time. The facility contains events of default, including, among others, non-payment defaults, inaccuracy of representations and warranties, covenant defaults, cross-defaults to other indebtedness, judgment defaults, collateral defaults, bankruptcy and insolvency defaults and a change of control default.
If we experience a decline in cash flow due to any of the factors described in this “Risk Factors” section or otherwise, we could have difficulty paying interest and principal amounts due on our indebtedness and meeting the financial covenants set forth in our loan facility. If we are unable to generate sufficient cash flow or otherwise obtain the funds necessary to make required payments under the credit facility, or if we fail to comply with the requirements of our indebtedness, we could default under our credit facility. Any default that is not cured or waived could result in the acceleration of the obligations under the credit facility, an increase in the applicable interest rate under the credit facility, and would permit our lender to exercise rights and remedies with respect to all of the collateral that is securing the credit facility, which includes substantially all of our assets. Any such default could materially adversely affect our liquidity and financial condition.
Even if we comply with all of the applicable covenants, the restrictions on the conduct of our business could materially adversely affect our business by, among other things, limiting our ability to take advantage of financings, mergers, acquisitions and other corporate opportunities that may be beneficial to the business. Even if the credit facility were terminated, additional debt we could incur in the future may subject us to similar or additional covenants, which could place restrictions on the operation of our business.

70




If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements could be impaired, which could adversely affect our operating results, our ability to operate our business and our stock price.

We have a complex business organization. Ensuring that we have adequate internal financial and accounting controls and procedures in place to help ensure that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently and is complicated by the expansion of our business operations and changing accounting requirements. Our management, including our chief executive officer and chief financial officer, does not expect that our internal control over financial reporting will prevent all errors or all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in significant deficiencies or material weaknesses, cause us to fail to timely meet our periodic reporting obligations, or result in material misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations and annual auditor attestation reports regarding disclosure controls and the effectiveness of our internal control over financial reporting required under Section 404 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder. The existence of a material weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause us to fail to timely meet our reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in our stock price and potential lawsuits against us.

Changes in our provision for income taxes or adverse outcomes resulting from examination of our income or other tax returns or changes in tax legislation could adversely affect our results. 

Our provision for income taxes is subject to volatility and could be adversely affected by earnings differing materially from our projections, changes in the valuation of our deferred tax assets and liabilities, tax effects of stock-based compensation, outcomes as a result of tax examinations or by changes in tax laws, regulations, accounting principles, including accounting for uncertain tax positions, or interpretations thereof.

To the extent that our provision for income taxes is subject to volatility or adverse outcomes as a result of tax examinations, our operating results could be harmed. Significant judgment is required to determine the recognition and measurement attribute prescribed in U.S. generally accepted accounting principles, or GAAP, relating to accounting for income taxes. In addition, we are subject to examinations of our income tax returns by the Internal Revenue Service, or IRS, and other tax authorities. We assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There may be exposure that the outcomes from these examinations will have an adverse effect on our operating results and financial condition.

Regulation of the sale of health insurance is subject to change, and future regulations could harm our business and operating results.

The laws and regulations governing the offer, sale and purchase of health insurance are subject to change, and future changes may be adverse to our business. For example, a long-standing provision in most applicable state laws that we believe is advantageous to our business is that once health insurance premiums are set by the carrier and approved by state regulators, they are fixed and not generally subject to negotiation or discounting by insurance companies or agents. Additionally, state regulations generally prohibit carriers, agents and brokers from providing financial incentives, such as rebates, to their members in connection with the sale of health insurance. As a result, we do not currently compete with carriers or other agents and brokers on the price of the health insurance plans offered on our website. If these regulations change, we could be forced to reduce prices or provide rebates or other incentives for the health insurance plans sold through our ecommerce platform, which would harm our business, operating results and financial condition.
71





States have adopted and will continue to adopt new laws and regulations in response to health care reform legislation. It is difficult to predict how these new laws and regulations will impact our business, but in some cases such laws and regulations could amplify the adverse impacts of health care reform to our business, or states may adopt new requirements that adversely impact our business, operating results and financial condition. For example, certain states have adopted or are contemplating rules and regulations that would either ban the sale of short-term health insurance, limit its duration and renewability, or apply certain aspects of the Affordable Care Act to short-term health insurance, such as the essential health benefits or requiring that short-term health insurance cover pre-existing conditions. Rules and regulations such as these could adversely impact our sale of short-term health insurance for several reasons, including because carriers may exit the market of selling short-term health insurance due to regulatory concerns, determine it is not profitable to sell the plans or increase plan premiums to a degree that reduces consumer demand for them. Moreover, our sales outside of the health care reform open enrollment period could decline, because many individuals and families choose to purchase short-term health insurance outside of the open enrollment period given the unavailability of major medical individual and family health insurance to them. States may also require stronger disclosure and marketing rules governing the sale of short-term health insurance which may impact our conversion rates on the sale of short-term health insurance. We received a letter from the Committee on Energy and Commerce of the United States House of Representatives in March 2019 requesting information relating to our sale of short-term health insurance. The letter indicates that the committee is conducting oversight of short-term health insurance and companies that assist consumers enrollment in short-term health insurance plans in light of committee concerns, including its concern relating to the understanding of consumers who purchase short term health insurance coverage. Additionally, states and the federal government may adopt laws and regulations that further impact the types of health insurance coverage available to consumers, the product features and benefits, and the role and compensation of agents and brokers in the sale of health insurance.

If we fail to comply with the numerous insurance laws and regulations that are applicable to the sale of health insurance, our business and operating results could be harmed.

We are required to maintain a valid license in each state in which we transact health insurance business and to adhere to sales, documentation and administration practices specific to that state. We must maintain our health insurance licenses to continue selling plans and to continue to receive commissions from health insurance carriers. In addition, each employee who transacts health insurance business on our behalf must maintain a valid license in one or more states. Because we do business in all 50 states and the District of Columbia, compliance with health insurance-related laws, rules and regulations is difficult and imposes significant costs on our business. Each jurisdiction’s insurance department typically has the power, among other things, to:

grant, limit, suspend and revoke licenses to transact insurance business;
conduct inquiries into the insurance-related activities and conduct of agents and agencies;
require and regulate disclosure in connection with the sale and solicitation of health insurance;
authorize how, by which personnel and under what circumstances insurance premiums can be quoted and published and an insurance policy sold;
approve which entities can be paid commissions from carriers and the circumstances under which they may be paid;
regulate the content of insurance-related advertisements, including web pages, and other marketing practices;
approve policy forms, require specific benefits and benefit levels and regulate premium rates;
impose fines and other penalties; and
impose continuing education requirements. 

Due to the complexity, periodic modification and differing interpretations of insurance laws and regulations, we may not have always been, and we may not always be, in compliance with them. New insurance laws, regulations and guidelines also may not be compatible with the sale of health insurance over the Internet or with various aspects of our platform or manner of marketing or selling health insurance plans. In many cases, it is not clear how existing insurance laws and regulations apply to Internet-related health insurance advertisements and transactions. To the extent that new laws or regulations are adopted that conflict with the way we conduct our business, or to the extent that existing laws and regulations are interpreted adversely to us, our business, operating results and financial condition would be harmed. Failure to comply with insurance laws, regulations and guidelines or other laws and regulations applicable to our business could result in significant liability, additional department of insurance licensing requirements, required modification of our advertising and business practices, changes to our existing technology or platforms, the limitation, suspension and/or revocation of our licenses in a particular jurisdiction, termination of
72




our relationship with health insurance carriers or loss of commissions and/or our inability to sell health insurance plans, which would harm our business, operating results and financial condition. Moreover, an adverse regulatory action in one jurisdiction could result in penalties and adversely affect our license status, business or reputation in other jurisdictions due to the requirement that adverse regulatory actions in one jurisdiction be reported to other jurisdictions. Even if the allegations in any regulatory or other action against us are proven false, any surrounding negative publicity could harm consumer, marketing partner or health insurance carrier confidence in us, which could significantly damage our brand.

Government regulation of the Internet could adversely affect our business.

The laws governing general commerce on the Internet remain unsettled and it may take years to fully determine whether and how existing laws such as those governing intellectual property, privacy and taxation apply to the Internet. In addition, the growth and development of the market for electronic commerce may prompt calls for more stringent consumer protection laws that may impose additional burdens on companies conducting business over the Internet. Any new laws or regulations or new interpretations of existing laws or regulations relating to the Internet could harm our business and we could be forced to incur substantial costs in order to comply with them, which would harm our business, operating results and financial condition.

Our business could be harmed if we are unable to contact our consumers or market the availability of our products through specific channels.

We use email and telephone, among other channels, to market our services to potential members and as the primary means of communicating with our existing members. The laws and regulations governing the use of emails and telephone calls for marketing purposes continue to evolve, and changes in technology, the marketplace or consumer preferences may lead to the adoption of additional laws or regulations or changes in interpretation of existing laws or regulations. If new laws or regulations are adopted, or existing laws and regulations are interpreted or enforced, to impose additional restrictions on our ability to send email or telephone messages to our members or potential members, we may not be able to communicate with them in a cost-effective manner. In addition to legal restrictions on the use of email, Internet service providers, e-mail service providers and others attempt to block the transmission of unsolicited email, commonly known as “spam.” Many Internet and e-mail service providers have relationships with organizations whose purpose it is to detect and notify the Internet and e-mail service providers of entities that the organization believes is sending unsolicited e-mail. If an Internet or e-mail service provider identifies email from us as “spam” as a result of reports from these organizations or otherwise, we can be placed on a restricted list that will block our email to members or potential members.

We use telephones to communicate with customers and prospective customers and some of these communications may be subject to the Telephone Consumer Protection Act, or TCPA, and other telemarketing laws. The TCPA and other laws, including state laws, relating to telemarketing restrict our ability to market using the telephone in certain respects. For instance, the TCPA prohibits us from using an automatic telephone dialing system to make certain telephone calls to consumers without prior express consent. We have policies in place to comply with the TCPA and other telemarketing laws. However, despite our legal compliance, we have in the past and may in the future become subject to claims that we have violated the TCPA. The TCPA provides for statutory damages of $500 for each violation and $1,500 for each willful violation. In the event that we were found to have violated the TCPA, our business, operating results and financial condition could be harmed. In addition, telephone carriers may block or put consumer warnings on calls originating from call centers. Consumers increasingly screen their incoming emails and telephone calls, including by using screening tools and warnings, and therefore our members or potential members may not reliably receive our emails or telephone messages. If we are unable to communicate effectively by email or telephone with our members and potential members as a result of legislation, blockage, screening technologies or otherwise, our business, operating results and financial condition would be harmed.

Consumers depend upon third-party service providers to access our website and services, and our business and operating results could be harmed as a result of technical difficulties experienced by these service providers.

Consumers using our website and accessing our services depend upon Internet, online and other service providers for access to our website and services. Many of these service providers have experienced significant outages, delays and other difficulties in the past and could experience them in the future. Any significant interruption in access to our call centers or our website or increase in our website’s response time as a result of these difficulties could damage our relationship with insurance
73




carriers, marketing partners and existing and potential members and could harm our business, operating results and financial condition.

We cannot predict the impact that changing climate conditions, including legal, regulatory and social responses thereto, may have on our business.

Global climate change has added, and will continue to add, to the unpredictability, frequency and severity of natural disasters, including but not limited to hurricanes, tornadoes, freezes, droughts, other storms and fires in certain parts of the world. In response, a number of legal and regulatory measures and social initiatives have been introduced in an effort to reduce greenhouse gas and other carbon emissions that are chief contributors to global climate change. We cannot predict the impact that changing climate conditions will have on our business. The legal, regulatory and social responses to climate change could also adversely affect our results of business, operating results and financial conditions.

Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.

We have net operating loss carryforwards for federal and state income tax purposes to offset future taxable income. Our federal and state net operating loss carryforwards begin expiring in 2034 and 2021, respectively. A lack of future taxable income would adversely affect our ability to utilize these net operating loss carryforwards. In addition, utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred, may occur in connection with this offering or that could occur in the future, as required by Section 382 of the Code and similar state provisions. These ownership change limitations may limit the amount of net operating loss carryforwards and other tax attributes that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points (by value) of the outstanding stock of a company by certain stockholders. Our ability to use the remaining net operating loss carryforwards may be further limited if we experience a Section 382 ownership change as a result of future changes in our stock ownership.


Risks Related to Ownership of Our Common Stock

Our actual operating results may differ significantly from our guidance.

From time to time, we have released, and may continue to release guidance in earnings conference calls, earnings releases, or otherwise, regarding our future performance that represents our management's estimates as of the date of release. This guidance, which includes forward-looking statements, has been and will be based on projections prepared by our management. These projections are not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants, and neither our registered public accountants nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person expresses any opinion or any other form of assurance with respect to the projections.

Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. Among these factors, the assumptions underlying our estimates of commission revenue as required by ASC 606may vary significantly over time. We may state possible outcomes as high and low ranges. Any range we provide is not intended to imply that actual results could not fall outside of the suggested ranges. The principal reason that we release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors and we may decide to suspend guidance at any time. We do not accept any responsibility for any projections or reports published by any such third parties.

Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Our actual results have, and may in the future, vary from our guidance and the variations may be material. In light of the foregoing, investors are urged not to rely upon our guidance in making an investment decision regarding our common stock.

74




Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in this “Risk Factors” section could result in the actual operating results being different from our guidance, and the differences may be adverse and material.
The price of our common stock has been and may continue to be volatile, and the value of your investment could decline.

The trading price of our common stock has been volatile and is likely to continue to fluctuate substantially. For the quarter ended March 31, 2020, the closing price of our common stock fluctuated from $85.70 to $146.09 per share. The trading price of our common stock depends on a number of factors, including those described in this “Risk Factors” section, many of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid. Factors that could cause fluctuations in the trading price of our common stock include the following:

price and volume fluctuations in the overall stock market from time to time, including as a result of the COVID-19 pandemic;
volatility in the market prices and trading volumes of our competitors' shares, including high technology stocks, which have historically experienced high levels of volatility;
new laws or regulations or new interpretations of existing laws or regulations applicable to our business, including developments relating to the health care industry, particularly health care reform legislation and the implementation of health care reform;
actual or anticipated changes in our operating results or fluctuations in our operating results;
changes in operating performance and stock market valuations of other technology companies generally, and of our competitors;
failure of securities analysts to maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;
sales of shares of our common stock by us or our stockholders;
announcements by us or our competitors of new products or services;
the public reaction to our press releases, other public announcements, and filings with the SEC;
rumors and market speculation involving us or other companies in our industry;
negative publicity about us, including accurate and inaccurate third-party commentary or reports regarding us;
actual or anticipated developments in our business, our competitors' businesses, or the competitive landscape generally;
our ability to control costs, including our operating expenses;
litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;
developments or disputes concerning our intellectual property or other proprietary rights;
announced or completed acquisitions of businesses or technologies by us or our competitors;
changes in accounting standards, policies, guidelines, interpretations, or principles;
any significant change in our management; and
general economic conditions and slow or negative growth of our markets.
The effect of such factors on the trading market for our stock may be enhanced by the lack of a large and established trading market for our stock. In addition, the stock market in general, and the market for technology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Additionally, as a public company, we face the risk of shareholder lawsuits, particularly if we experience declines in the price of our common stock. In the past, following periods of volatility in the overall market and the market prices of a particular company's securities, securities class action lawsuits have often been instituted against affected companies. We have been, and may in the future be, subject to such legal actions.

75




Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

Our certificate of incorporation, bylaws, and Delaware law contain provisions which could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions:

creating a classified board of directors whose members serve staggered three-year terms;
authorizing undesignated preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our common stock;
limiting the liability of, and providing indemnification to, our directors and officers;
limiting the ability of our stockholders to call and bring business before special meetings;
requiring advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates for election to our board of directors;
controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings; and
providing our board of directors with the express power to postpone previously scheduled annual meetings and to cancel previously scheduled special meetings.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.

As a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock.

Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

76




ITEM 6. EXHIBITS

(a) Exhibits
Except as so indicated in Exhibits 32.1 and 32.2, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
Exhibit
Number
Incorporation by Reference Herein
Description of ExhibitFormDate
10.1Current Report on Form 8-K (File No. 001-33071)February 4, 2020
10.2Current Report on Form 8-K (File No. 001-33071)February 21, 2020
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104The cover page from the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2020, formatted in Inline XBRL and contained in Exhibit 101

† Filed herewith.
‡ Furnished herewith.


77




SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EHEALTH, INC.
Date:May 8, 2020/s/ Scott N. Flanders
Scott N. Flanders
Chief Executive Officer
(Principal Executive Officer)
Date:May 8, 2020/s/ Derek N. Yung
Derek N. Yung
Chief Financial Officer
(Principal Financial and Accounting Officer)


EX-31.1 2 a2020q1ex311.htm EX-31.1 CEO CERTIFICATION Document

Exhibit 31.1
CERTIFICATION
I, Scott N. Flanders, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
May 8, 2020/s/    SCOTT N. FLANDERS 
Scott N. Flanders
Chief Executive Officer


EX-31.2 3 a2020q1ex312.htm EX-31.2 CFO CERTIFICATION Document

Exhibit 31.2
CERTIFICATION
I, Derek N. Yung, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;  
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and  
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and  
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):  
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and  
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 8, 2020/s/    DEREK N. YUNG
Derek N. Yung
Chief Financial Officer



EX-32.1 4 a2020q1ex321.htm EX-32.1 CEO SECTION 906 CERTIFICATION Document

Exhibit 32.1
Certification of Chief Executive Officer, Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 
 
In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott N. Flanders, Chief Executive Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:  
(1)The Form 10-Q, to which this certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  
(2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

/s/    SCOTT N. FLANDERS
Scott N. Flanders
Chief Executive Officer
May 8, 2020

 
A signed original of this written statement required by Section 906 has been provided to eHealth, Inc. and will be retained by eHealth, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 5 a2020q1ex322.htm EX-32.2 CFO SECTION 906 CERTIFICATION Document

Exhibit 32.2
Certification of Chief Financial Officer, Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 
 
In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Derek N. Yung, Chief Financial Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The Form 10-Q, to which this certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  
(2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

/s/     DEREK N. YUNG
Derek N. Yung
Chief Financial Officer
May 8, 2020

 
A signed original of this written statement required by Section 906 has been provided to eHealth, Inc. and will be retained by eHealth, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 6 ehth-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Summary of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of Business and Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Business and Significant Accounting Policies - Adoption of ASU 2016-13 (Details) link:presentationLink link:calculationLink link:definitionLink 2106102 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2307302 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Revenue - Commission Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2111103 - Disclosure - Supplemental Financial Statement Information link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - Supplemental Financial Statement Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Supplemental Financial Statement Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Supplemental Financial Statement Information - Schedule of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - Supplemental Financial Statement Information - Schedule of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2418411 - Disclosure - Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2119104 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - Fair Value Measurements - Summary of Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2422413 - Disclosure - Fair Value Measurements - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2424415 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2425416 - Disclosure - Fair Value Measurements - Earnout Liability Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2126105 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2429418 - Disclosure - Equity - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2130106 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2331306 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2432419 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2433420 - Disclosure - Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2134107 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2335307 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2137108 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2338308 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2439422 - Disclosure - Segment and Geographic Information - Segment Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 2440423 - Disclosure - Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2142109 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2343309 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2147110 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2448428 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2149111 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2451429 - Disclosure - Income Taxes - Summary of Income Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 2452430 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ehth-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ehth-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ehth-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Level 3 Fair Value, Inputs, Level 3 [Member] Change in fair value of earnout liability Change in fair value of earnout liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Borrowings under line of credit Long-term Line of Credit Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Commission revenue from members approved during the period Commission, Members Approved During Current Period [Member] Commission, Members Approved During Current Period [Member] Commitments and Contingencies Commitments Contingencies and Guarantees [Text Block] Long-term marketable securities Fair Value Debt Securities, Available-for-sale, Noncurrent Treasury stock (in shares) Treasury Stock, Shares Concentration Risk [Line Items] Concentration Risk [Line Items] Recently Adopted Accounting Pronouncement; Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock 2022 Contractual Obligation, Due in Third Year China CHINA Diluted (in shares) Total common stock shares used in diluted share calculation (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Address, Postal Zip Code Entity Address, Postal Zip Code Carrying Value Reported Value Measurement [Member] Summary of Unrealized Gains and Losses Debt Securities, Available-for-sale [Table Text Block] GoMedigap GoMedigap [Member] GoMedigap [Member] Shares issued in equity offering Stock Issued During Period, Value, New Issues Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Property and equipment, net Property, Plant and Equipment, Net Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Total assets Total assets Assets Repurchase of shares to satisfy employee tax withholding obligations Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Entity Shell Company Entity Shell Company Operating lease liabilities Operating Lease, Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Cover [Abstract] Document Type Document Type Cash equivalents Cash Equivalents, at Carrying Value Unrealized Loss Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Subsequent Event [Member] Subsequent Event [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Repayment of debt Repayments of Long-term Debt Number of shares repurchased under share repurchase plan (in shares) Treasury Stock, Shares, Acquired General and administrative General and Administrative Expense [Member] Accounts receivable Increase (Decrease) in Accounts Receivable 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four Current liabilities: Liabilities, Current [Abstract] Credit Facility [Axis] Credit Facility [Axis] Repurchase of shares to satisfy employee tax withholding obligations Share-based Payment Arrangement, Cash Used to Settle Award Medicare Supplement Medicare Supplement [Member] Medicare Supplement [Member] Financial Instrument [Axis] Financial Instrument [Axis] Segment and Geographic Information Segment Reporting Disclosure [Text Block] Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents UnitedHealthcare Unitedhealthcare [Member] UnitedHealthcare [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Document Quarterly Report Document Quarterly Report Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt Instrument [Line Items] Debt Instrument [Line Items] Consolidation Items [Domain] Consolidation Items [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Due in 1 year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Money market funds Money Market Funds [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Eligible Commissions Receivables, Succeeding Three Months Eligible Commissions Receivables, Succeeding Three Months [Member] Eligible Commissions Receivables, Succeeding Three Months [Member] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Entity File Number Entity File Number Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Disaggregated Individual and Family [Domain] Disaggregated Individual and Family [Domain] Disaggregated Individual and Family [Axis] Schedule Of Stock-Based Compensation Expense By Award Type Schedule Of Stock-Based Compensation Expense [Table Text Block] Schedule Of Stock-Based Compensation Expense [Table Text Block] Borrowing Base Percentage [Axis] Borrowing Base Percentage [Axis] Borrowing Base Percentage [Axis] Schedule of Credit Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Non-Qualified Health Plans Non-Qualified Health Plans [Member] Non-Qualified Health Plans [Member] Treasury Stock Treasury Stock [Member] Segments [Axis] Segments [Axis] Cumulative effect from the adoption of ASU 2016-13 Cumulative Effect of New Accounting Principle in Period of Adoption Document Fiscal Period Focus Document Fiscal Period Focus Financial Instruments [Domain] Financial Instruments [Domain] Treasury stock, at cost Treasury Stock, Value Product and Service [Domain] Product and Service [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Diluted: Earnings Per Share, Diluted [Abstract] Commercial paper Commercial Paper [Member] Schedule Of Prepaid Expenses And Other Current Assets Schedule of Other Current Assets [Table Text Block] Income (loss) from operations Operating Income (Loss) Number of extension periods Lessee, Operating Lease, Option To Extend, Number Of Periods Lessee, Operating Lease, Option To Extend, Number Of Periods Disaggregated Medicare [Domain] Disaggregated Medicare [Domain] Disaggregated Medicare [Axis] Goodwill Goodwill Commission Commission [Member] Commission [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Segments [Domain] Segments [Domain] Marketing and advertising Marketing and Advertising Expense Statement [Line Items] Statement [Line Items] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Disaggregation of Revenue by Segment Disaggregation of Revenue [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Basic (in usd per share) Earnings per share, basic (in usd per share) Earnings Per Share, Basic Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Transition Adjustments Cumulative Effect, Period Of Adoption, Adjustment [Member] Cumulative Effect, Period Of Adoption, Adjustment Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Amendment Flag Amendment Flag Credit Agreement Amendment Credit Agreement Amendment [Member] Credit Agreement Amendment Unrealized Gain Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Gain, Before Tax Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Gain, Before Tax Summary of Financial Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Earnout consideration (in shares) Business Combination, Contingent Consideration, Shares Business Combination, Contingent Consideration, Shares Total Debt Securities, Available-for-sale, Amortized Cost Increase (Decrease) in Operating Capital [Abstract] Increase (Decrease) in Operating Capital [Abstract] Weighted-average number of shares used in per share amounts: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Customer [Axis] Customer [Axis] Significant Accounting Policies, Estimates and Judgements Use of Estimates, Policy [Policy Text Block] Local Phone Number Local Phone Number Schedule of Accounts Receivable Schedule Of Accounts Receivable [Table Text Block] Schedule Of Accounts Receivable [Table Text Block] Future minimum lease payments Total lease payments Lessee, Operating Lease, Liability, Payments, Due Cash Cash Liability Class [Axis] Liability Class [Axis] Accounts receivable Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Additional paid-in capital Additional Paid in Capital Debt Long-term Debt [Text Block] Equity Shareholders' Equity and Share-based Payments [Text Block] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Issuance of common stock in connection with exercise of common stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Extension term Lessee, Operating Lease, Renewal Term Number of plaintiffs Loss Contingency, Number of Plaintiffs Total current assets Assets, Current Entity Current Reporting Status Entity Current Reporting Status Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Short-term Short-term [Member] Short-term [Member] Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Net proceeds from exercise of common stock options Proceeds from Stock Options Exercised Common Stock Common Stock [Member] Current assets: Assets, Current [Abstract] Operating costs and expenses: Operating Costs and Expenses [Abstract] Earnout liability — current Business Combination, Contingent Consideration, Liability, Current Leases [Abstract] Leases [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restricted cash Restricted Cash, Noncurrent Product and Service [Axis] Product and Service [Axis] Operating lease cost Operating Lease, Cost Entity Small Business Entity Small Business Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Amortized Cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Entity Filer Category Entity Filer Category Letter of Credit Letter of Credit [Member] Total stock-based compensation expense Share-based Payment Arrangement, Expense Corporate Corporate, Non-Segment [Member] Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total liabilities and stockholders’ equity Liabilities and Equity Accrued marketing expenses Increase Decrease In Accrued Marketing Expenses The increase (decrease) during the reporting period in accrued marketing expenses. Entity Address, City or Town Entity Address, City or Town Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Borrowing Base Percentage [Domain] Borrowing Base Percentage [Domain] [Domain] for Borrowing Base Percentage [Axis] Supplemental Financial Statement Information Supplemental Balance Sheet Disclosures [Text Block] Adjusted Balance Cumulative Effect, Period Of Adoption, Adjusted Balance [Member] Cumulative Effect, Period Of Adoption, Adjusted Balance Commission revenue, percentage Major customer revenue, percentage Concentration Risk, Percentage Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Loss Contingencies [Table] Loss Contingencies [Table] Lease liabilities — non-current Operating Lease, Liability, Noncurrent Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Borrowing capacity Line of Credit Facility, Current Borrowing Capacity Thereafter Contractual Obligation, Due after Fifth Year Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Eligible Commissions Receivables, Succeeding Six Months Eligible Commissions Receivables, Succeeding Six Months [Member] Eligible Commissions Receivables, Succeeding Six Months [Member] Net proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Sale of stock, shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Number of health insurance carriers (more than) Number Of Health Insurance Carriers Number Of Health Insurance Carriers Revenue: Revenues [Abstract] Litigation Case [Domain] Litigation Case [Domain] Dilutive effect of common stock (in shares) Incremental Common Shares Attributable To Options Incremental Common Shares Attributable To Options Recurring Fair Value, Recurring [Member] Summary of Financial Liabilities Measured at Fair Value on a Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Repurchase of shares to satisfy employee tax withholding obligations (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Award Type [Axis] Award Type [Axis] Cost of revenue Cost of Revenue Other income, net Other Nonoperating Income (Expense) Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Current Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Operating cash outflow from operating leases Operating Lease, Payments Gold River, California Gold River, California [Member] Gold River, California [Member] Geographical [Axis] Geographical [Axis] Description of Business Description Of Business, Policy [Policy Text Block] Description Of Business, Policy Retained Earnings Retained Earnings [Member] Cumulative Effect, Period Of Adoption [Domain] Cumulative Effect, Period Of Adoption [Domain] Cumulative Effect, Period Of Adoption Subsequent Event Type [Domain] Subsequent Event Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Le'Vias Compliant Le'Vias Compliant [Member] Le'Vias Compliant [Member] Unrealized Loss Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Loss, Before Tax Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Loss, Before Tax Leases Lessee, Operating Leases [Text Block] 2023 Contractual Obligation, Due in Fourth Year Document Period End Date Document Period End Date Credit loss expense Contract with Customer, Asset, Credit Loss Expense (Reversal) Statement [Table] Statement [Table] Entity Registrant Name Entity Registrant Name Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Average plan duration Average Plan Duration, Term Average Plan Duration, Term Acquisition-related contingent payments Acquisition-related contingent payments Payment for Contingent Consideration Liability, Financing Activities Total Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Maximum Maximum [Member] 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three Qualified Health Plans Qualified Health Plans [Member] Qualified Health Plans [Member] Total Debt Securities, Available-for-sale Medicare Medicare [Member] Medicare [Member] Total contract assets and accounts receivable Accounts Receivable And Contract Assets, After Allowance For Credit Loss Accounts Receivable And Contract Assets, After Allowance For Credit Loss Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Due in 1 year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Retained earnings Decrease in retained earnings Retained Earnings (Accumulated Deficit) Stock-based compensation expense Allocated Share-based Compensation Expense, Net Of Restructuring Reversal Expense Allocated Share-based Compensation Expense, Net Of Restructuring Reversal Expense Customer care and enrollment Customer Care And Enrollment Expense [Member] Customer Care And Enrollment Expense [Member] Entity Tax Identification Number Entity Tax Identification Number 2021 Contractual Obligation, Due in Second Year Diluted (in usd per share) Earnings per share, diluted (in usd per share) Earnings Per Share, Diluted Long-lived assets Long-Lived Assets Product Concentration Risk Product Concentration Risk [Member] Covenant, minimum cash and cash equivalents Line Of Credit Facility, Covenant, Minimum Cash And Cash Equivalents Line Of Credit Facility, Covenant, Minimum Cash And Cash Equivalents Trading Symbol Trading Symbol Minimum Minimum [Member] Long-term marketable securities Debt Securities, Available-For-Sale, Noncurrent [Abstract] Debt Securities, Available-For-Sale, Noncurrent Other Product and Service, Other [Member] Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Schedule of Cash, Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Change in credit loss allowance Contract with Customer, Asset, Allowance for Credit Loss, Period Increase (Decrease) Foreign currency translation adjustment, net of taxes Foreign currency translation adjustment, net of taxes Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Medicare Advantage Medicare Advantage [Member] Medicare Advantage [Member] Deferred income taxes Deferred Income Tax Expense (Benefit) Range [Domain] Statistical Measurement [Domain] Short-term marketable securities Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Deposits Deposits Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Benefit from income taxes Benefit from income taxes Benefit from income taxes Income Tax Expense (Benefit) Operating leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Settlement of earnout liability Stock Issued During Period, Value, Acquisitions Maximum liquidity Line Of Credit Facility, Covenant, Maximum Liquidity Line Of Credit Facility, Covenant, Maximum Liquidity 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two Borrowing base percentage Line Of Credit Facility, Borrowing Base, Percentage Line Of Credit Facility, Borrowing Base, Percentage Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other non-current liabilities Other Liabilities, Noncurrent Other Other Assets, Miscellaneous, Current City Area Code City Area Code Commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Title of 12(b) Security Title of 12(b) Security Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense Total assets measured and recorded at fair value Assets, Fair Value Disclosure Fair Value Estimate of Fair Value Measurement [Member] Net income (loss) per share: Earnings Per Share [Abstract] Schedule of Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Concentration Risk [Table] Concentration Risk [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] Other non-cash items Other Noncash Income (Expense) Schedule of Operating Lease Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Number of securities in net loss positions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Income (loss) before benefit from income taxes Income (loss) before benefit from income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Assets Assets [Abstract] Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Number of operating segments Number of Operating Segments Weighted-average remaining lease term of operating leases Operating Lease, Weighted Average Remaining Lease Term Loss contingency accrued Loss Contingency Accrual Ancillary Ancillaries [Member] Ancillaries [Member] Prepaid insurance Prepaid Insurance Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares) Treasury Stock, Shares Outstanding, Shares Acquired, Previously Cancelled Vested Shares Withheld For Tax Purposes Treasury Stock, Shares Outstanding, Shares Acquired, Previously Cancelled Vested Shares Withheld For Tax Purposes Due in 1 year through 5 years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Measurement Basis [Axis] Measurement Basis [Axis] Issuance of common stock in connection with exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Customer [Domain] Customer [Domain] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accrued marketing expenses Accrued Marketing Expenses. Total carrying values as of the balance sheet date of liabilities incurred through that date and payable for obligations related to marketing and advertising services received from vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule Of Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Income Statement Location [Domain] Income Statement Location [Domain] Range [Axis] Statistical Measurement [Axis] Weighted-average discount rate used to recognize operating lease right-of-use-assets Operating Lease, Weighted Average Discount Rate, Percent Vision Vision [Member] Vision [Member] Beginning balance Ending balance Contract with Customer, Asset, after Allowance for Credit Loss Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Accounts payable Increase (Decrease) in Accounts Payable Balance Sheet Impact Statement of Financial Position [Abstract] Cumulative Effect, Period Of Adoption [Axis] Cumulative Effect, Period Of Adoption [Axis] Cumulative Effect, Period Of Adoption Basic: Earnings Per Share, Basic [Abstract] Cash equivalents Cash and Cash Equivalents [Abstract] Seasonality Seasonality Policy [Policy Text Block] Seasonality Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Allowance for credit loss Contract with Customer, Asset, Allowance for Credit Loss Technology and content Technology And Content Expense The total expense recognized in the period for technology and content. Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website. Entity Central Index Key Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Liabilities Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Sale of Stock [Domain] Sale of Stock [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Lease liabilities — current Operating Lease, Liability, Current Schedule of Computation of Basic and Diluted Net Income per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Change in Contract with Customer, Asset [Roll Forward] Change in Contract with Customer, Asset [Roll Forward] Change in Contract with Customer, Asset Disaggregated Ancillaries [Domain] Disaggregated Ancillaries [Domain] Disaggregated Ancillaries [Axis] Contract assets – commissions receivable Increase (Decrease) In Commissions Receivable Increase (Decrease) In Commissions Receivable Credit Facility [Domain] Credit Facility [Domain] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Accrued compensation and benefits Employee-related Liabilities, Current Reminder of 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Level 2 Fair Value, Inputs, Level 2 [Member] Income Taxes Income Tax Disclosure [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Revenue Revenue from Contract with Customer Benchmark [Member] Agency bonds US Government Agencies Debt Securities [Member] Contract assets – commissions receivable – non-current Contract with Customer, Asset, Net, Noncurrent Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Unrealized holding gain for available for sales debt securities, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Other assets Other Assets, Noncurrent Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Over-Allotment Option Over-Allotment Option [Member] Number of states in which the Company is licensed to market and sell health insurance Number of States in which Entity Operates Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Purchases of property and equipment and other assets Payments to Acquire Property, Plant, and Equipment Income tax receivable Income Taxes Receivable, Current 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Schedule of Contract Assets - Commissions Receivable Contract with Customer, Asset and Liability [Table Text Block] Stock issued for acquisition Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Other current liabilities Other Liabilities, Current Sale of Stock [Axis] Sale of Stock [Axis] Covenant, maximum cash and cash equivalents Line Of Credit Facility, Covenant, Maximum Cash And Cash Equivalents Line Of Credit Facility, Covenant, Maximum Cash And Cash Equivalents Other Other [Member] Other [Member] Commission, Members Approved In Prior Periods Net commission revenue adjustments from members approved in prior period Commission, Members Approved In Prior Periods [Member] Commission, Members Approved In Prior Periods [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] Revenue Revenue from Contract with Customer [Text Block] Humana Humana [Member] Humana [Member] Prepaid expenses Prepaid Expense, Current Schedule Of Stock-Based Compensation Expense By Operating Function Schedule Of Stock-Based Compensation Expense By Operating Function [Table Text Block] Schedule Of Stock-Based Compensation Expense By Operating Function [Table Text Block] Settlement of earnout liability (in shares) Stock Issued During Period, Shares, Acquisitions Deferred income taxes — non-current Deferred Income Tax Liabilities, Net Accounts Receivable Accounts Receivable [Member] United States UNITED STATES Fair Value Cash, Cash Equivalents And Available-For-Sale Debt Securities Cash, Cash Equivalents And Available-For-Sale Debt Securities Fair Value Measurement [Domain] Fair Value Measurement [Domain] Cash receipts Proceeds from Commissions Received Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Entity Address, Address Line One Entity Address, Address Line One Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Acquired right-of-use asset Lessee, Operating Lease, Right-Of-Use Asset Acquired Lessee, Operating Lease, Right-Of-Use Asset Acquired 2024 Contractual Obligation, Due in Fifth Year Geographical [Domain] Geographical [Domain] Commission Bonus Commission Bonus [Member] Commission Bonus [Member] Entity Address, State or Province Entity Address, State or Province Income Statement Location [Axis] Income Statement Location [Axis] Business Acquisition [Axis] Business Acquisition [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Operating Segments Operating Segments [Member] Schedule of Future Minimum Rental Payments for Contractual Obligations Contractual Obligation, Fiscal Year Maturity [Table Text Block] Summary of Contractual Maturities Investments Classified by Contractual Maturity Date [Table Text Block] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Cash used in investing activities Net Cash Provided by (Used in) Investing Activities Office space, square feet Area of Real Estate Property Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Capitalized internal-use software and website development costs Payments to Develop Software Segment profit (loss) Segment Operating Income (Loss) Segment Operating Income (Loss) Business Acquisition [Line Items] Business Acquisition [Line Items] General and administrative General and Administrative Expense Accounts payable Accounts Payable, Current Summary of Business and Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Previous share repurchase programs Previous Repurchase Programs [Member] Previous Repurchase Programs Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Total operating costs and expenses Costs and Expenses Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Facility fee percentage Line Of Credit Facility, Facility Fee Percentage Line Of Credit Facility, Facility Fee Percentage Technology and content Technology And Content Expense [Member] Technology And Content Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Summary of Earnout Liability Activity Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Net Income (Loss) Per Share Earnings Per Share [Text Block] Equity Award [Domain] Award Type [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Stock issued in equity offering (in shares) Stock Issued During Period, Shares, New Issues Restricted stock units Restricted Stock Units (RSUs) [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Small Business Small Business [Member] Small Business [Member] Unrealized Loss Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Loss, Before Tax Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Loss, Before Tax Schedule Of Components Of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Common stock Common Stock, Value, Issued Marketing and advertising Selling and Marketing Expense [Member] Individual, Family and Small Business Individual, Family, And Small Business Segments [Member] Individual, Family, And Small Business Segments [Member] Comprehensive income: Statement of Comprehensive Income [Abstract] Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Cash and cash equivalents Amortized Cost Cash and Cash Equivalents, at Carrying Value Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Noncurrent Basic (in shares) Shares used in per share calculation - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Disaggregated Individual and Family [Axis] Disaggregated Individual and Family [Axis] Disaggregated Individual and Family [Axis] Equity Components [Axis] Equity Components [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Disaggregated Medicare [Axis] Disaggregated Medicare [Axis] Disagregated Medicare [Axis] Total stockholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Concentration Risk Type [Domain] Concentration Risk Type [Domain] Deferred revenue Contract with Customer, Liability, Current Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Eligible Commissions Receivables, Preceding Three Months Eligible Commissions Receivables, Preceding Three Months [Member] Eligible Commissions Receivables, Preceding Three Months [Member] Contract assets – commissions receivable – current Contract with Customer, Asset, Net, Current Remainder of 2020 Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Disaggregated Ancillaries [Axis] Disaggregated Ancillaries [Axis] Disaggregated Ancillaries [Axis] Amortization of internally developed software Capitalized Computer Software, Amortization Customer care and enrollment Customer Care And Enrollment Expense The total expense recognized in the period related to providing customer care and enrollment services. These services include pre-sales assistance to applicants who call our customer care center and enrollment services to applicants during the underwriting process. Contingent Consideration Contingent Consideration [Member] Contingent Consideration [Member] Medicare Part D Medicare Part D [Member] Medicare Part D [Member] Schedule Of Revenue By Major Customers Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Cash equivalents Fair Value Cash and Cash Equivalents, Fair Value Disclosure Lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Security Exchange Name Security Exchange Name Aetna Aetna [Member] Aetna [Member] Schedule Of Long Lived Assets By Geographical Areas Schedule Of Long Lived Assets By Geographical Areas [Table Text Block] Schedule Of Long Lived Assets By Geographical Areas [Table Text Block] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Dental Dental [Member] Dental [Member] Medicare Medicare Segment [Member] Medicare Segment [Member] Depreciation and amortization Depreciation and amortization Depreciation Litigation Case [Axis] Litigation Case [Axis] Prepaid maintenance contracts Prepaid Maintenance Contracts Current Prepaid Maintenance Contracts (Current) Short-term marketable securities Fair Value Debt Securities, Available-for-sale, Current Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Equity Component [Domain] Equity Component [Domain] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Document Transition Report Document Transition Report New claims filed Loss Contingency, New Claims Filed, Number Common stock options Share-based Payment Arrangement, Option [Member] Debt issuance costs Debt Issuance Costs, Net Fair Value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Principal payments in connection with leases Finance Lease, Principal Payments Due in 1 year through 5 years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Unrealized Gain Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Gain, Before Tax Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Gain, Before Tax Total Contractual Obligation Summary of Adoption of ASU 2016-13 Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Individual and Family Individual and Family [Member] Individual and Family [Member] Assets Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Income Statement [Abstract] Income Statement [Abstract] Minimum liquidity Line Of Credit Facility, Covenant, Minimum Liquidity Line Of Credit Facility, Covenant, Minimum Liquidity EX-101.PRE 10 ehth-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 8,714 $ 3,229
Common stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 306 602
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 8,408 2,627
Marketing and advertising    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 1,730 629
Customer care and enrollment    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 662 273
Technology and content    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 1,617 549
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 4,705 $ 1,778
XML 12 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Unrealized Gains and Losses (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Cash equivalents    
Amortized Cost $ 184,167 [1] $ 23,466
Short-term marketable securities    
Fair Value 33,683 [1] 0
Long-term marketable securities    
Fair Value 24,409 [1] $ 0
Total 225,870  
Unrealized Gain 26  
Unrealized Loss (1)  
Fair Value 225,895  
Money market funds    
Cash equivalents    
Amortized Cost 105,798  
Fair Value 105,798  
Commercial paper    
Cash equivalents    
Amortized Cost 62,005  
Fair Value 62,005  
Commercial paper    
Short-term marketable securities    
Amortized Cost 23,063  
Unrealized Gain 0  
Unrealized Loss 0  
Fair Value 23,063  
Agency bonds    
Short-term marketable securities    
Amortized Cost 10,616  
Unrealized Gain 5  
Unrealized Loss (1)  
Fair Value 10,620  
Long-term marketable securities    
Amortized Cost 24,388  
Unrealized Gain 21  
Unrealized Loss 0  
Fair Value $ 24,409  
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 13 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Segment and Geographic Information - Segment Operating Results (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Segment Reporting Information [Line Items]    
Number of operating segments | segment 2  
Total revenue $ 106,408 $ 68,773
Stock-based compensation expense (8,714) (3,229)
Change in fair value of earnout liability 0 (13,306)
Depreciation and amortization (823) (655)
Amortization of intangible assets (547) (547)
Other income, net 373 557
Income (loss) before benefit from income taxes 1,404 (8,626)
Operating Segments    
Segment Reporting Information [Line Items]    
Total revenue 106,408 68,773
Segment profit (loss) 24,563 16,850
Operating Segments | Medicare    
Segment Reporting Information [Line Items]    
Total revenue 96,151 54,901
Segment profit (loss) 21,960 10,826
Operating Segments | Individual, Family and Small Business    
Segment Reporting Information [Line Items]    
Total revenue 10,257 13,872
Segment profit (loss) 2,603 6,024
Corporate    
Segment Reporting Information [Line Items]    
Segment profit (loss) $ (13,448) $ (8,296)
XML 14 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information
3 Months Ended
Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]  
Supplemental Financial Statement Information Supplemental Financial Statement Information
Cash, Cash Equivalents and Restricted Cash

We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invested in marketable securities that are measured and recorded at fair value. See Note 4Fair Value Measurements for further discussion about our marketable securities. As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):
March 31, 2020December 31, 2019
Cash$16,364  $16,205  
Cash equivalents167,803  7,261  
Restricted cash3,353  3,354  
Total cash, cash equivalents and restricted cash$187,520  $26,820  

As of March 31, 2020 and December 31, 2019, we had $3.4 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments.

Contract Assets and Accounts Receivable

We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of March 31, 2020.
Our contract assets and accounts receivable consisted of the following for the periods presented (in thousands):
 March 31, 2020December 31, 2019
Contract assets – commissions receivable – current$125,252  $174,526  
Contract assets – commissions receivable – non-current435,465  414,696  
Accounts receivable668  2,332  
Total contract assets and accounts receivable$561,385  $591,554  

We estimate the allowance for credit loss balance using relevant available information from internal and external sources, related to past events, current conditions, and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ, Standard & Poors and Moody's analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commission receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure.

Subsequent to the adoption of ASC 326, we considered the impact of recent events and global economic condition when evaluating the appropriate adjustments to our allowance as of March 31, 2020. Determining the extent of these adjustments in the three months ended March 31, 2020 was especially challenging because we do not have any historical loss information for a period of similar economic decline. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimated of credit losses was not materially impacted as of March 31, 2020. After our management's evaluation, we recorded credit loss expenses of $0.1 million during the three months ended March 31, 2020 which is included in general and administrative expense on our Condensed Consolidated Statement of Comprehensive Income. Our contract assets – commission receivable activities, net of credit losses are summarized as follows (in thousands):
Three Months Ended March 31, 2020
Medicare SegmentIFP/SMB SegmentTotal
Beginning balance$550,922  $38,300  $589,222  
Commission revenue from members approved during the period81,125  5,796  86,921  
Net commission revenue adjustments from members approved in prior period8,979  3,769  12,748  
Cash receipts(112,731) (13,811) (126,542) 
Change in credit loss allowance*(1,574) (58) (1,632) 
Ending balance$526,721  $33,996  $560,717  

Three Months Ended March 31, 2019
Medicare SegmentIFP/SMB SegmentTotal
Beginning balance$311,977  $33,881  $345,858  
Commission revenue from members approved during the period50,582  6,225  56,807  
Net commission revenue adjustments from members approved in prior period1,067  6,353  7,420  
Cash receipts(67,873) (14,001) (81,874) 
Change in credit loss allowance—  —  —  
Ending balance$295,753  $32,458  $328,211  
_____________
*Amount consists of transition adjustment of $1.5 million related to the adoption of ASC 326 as of January 1, 2020 and the subsequent credit loss adjustment of $0.1 million as of March 31, 2020. See Note 1Summary of Business and Significant Accounting Policies for details regarding the adoption impact.
Credit Risk

Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, contract assets – commissions receivable, and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $4.1 million as of March 31, 2020.

We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below:
 March 31, 2020December 31, 2019
Humana22 %22 %
Aetna (1)
21 %20 %
UnitedHealthCare (2)
20 %20 %
_____________
(1)Aetna also includes other carriers owned by Aetna.
(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare. 


Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets are summarized as follows (in thousands):
 March 31, 2020December 31, 2019
Prepaid maintenance contracts5,460  3,853  
Prepaid expenses1,727  2,207  
Prepaid insurance543  918  
Income tax receivable1,041  584  
Other431  260  
Prepaid expenses and other current assets9,202  7,822  
XML 15 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Business and Significant Accounting Policies - Narrative (Details)
$ in Thousands
Mar. 31, 2020
USD ($)
numberOfInsuranceCarriers
state
Jan. 01, 2020
USD ($)
Dec. 31, 2019
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Number of health insurance carriers (more than) | numberOfInsuranceCarriers 180    
Number of states in which the Company is licensed to market and sell health insurance | state 50    
Decrease in retained earnings $ 274,157 [1]   $ 271,852
Transition Adjustments      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Decrease in retained earnings   $ (1,147)  
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 16 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information (Tables)
3 Months Ended
Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]  
Schedule Of Cash, Cash Equivalents and Restricted Cash As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):
March 31, 2020December 31, 2019
Cash$16,364  $16,205  
Cash equivalents167,803  7,261  
Restricted cash3,353  3,354  
Total cash, cash equivalents and restricted cash$187,520  $26,820  
Schedule of Cash, Cash Equivalents and Restricted Cash As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):
March 31, 2020December 31, 2019
Cash$16,364  $16,205  
Cash equivalents167,803  7,261  
Restricted cash3,353  3,354  
Total cash, cash equivalents and restricted cash$187,520  $26,820  
Schedule of Accounts Receivable Our contract assets and accounts receivable consisted of the following for the periods presented (in thousands):
 March 31, 2020December 31, 2019
Contract assets – commissions receivable – current$125,252  $174,526  
Contract assets – commissions receivable – non-current435,465  414,696  
Accounts receivable668  2,332  
Total contract assets and accounts receivable$561,385  $591,554  
Schedule of Contract Assets - Commissions Receivable Our contract assets – commission receivable activities, net of credit losses are summarized as follows (in thousands):
Three Months Ended March 31, 2020
Medicare SegmentIFP/SMB SegmentTotal
Beginning balance$550,922  $38,300  $589,222  
Commission revenue from members approved during the period81,125  5,796  86,921  
Net commission revenue adjustments from members approved in prior period8,979  3,769  12,748  
Cash receipts(112,731) (13,811) (126,542) 
Change in credit loss allowance*(1,574) (58) (1,632) 
Ending balance$526,721  $33,996  $560,717  

Three Months Ended March 31, 2019
Medicare SegmentIFP/SMB SegmentTotal
Beginning balance$311,977  $33,881  $345,858  
Commission revenue from members approved during the period50,582  6,225  56,807  
Net commission revenue adjustments from members approved in prior period1,067  6,353  7,420  
Cash receipts(67,873) (14,001) (81,874) 
Change in credit loss allowance—  —  —  
Ending balance$295,753  $32,458  $328,211  
_____________
*Amount consists of transition adjustment of $1.5 million related to the adoption of ASC 326 as of January 1, 2020 and the subsequent credit loss adjustment of $0.1 million as of March 31, 2020. See Note 1Summary of Business and Significant Accounting Policies for details regarding the adoption impact.
Schedule of Credit Risk Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below:
 March 31, 2020December 31, 2019
Humana22 %22 %
Aetna (1)
21 %20 %
UnitedHealthCare (2)
20 %20 %
_____________
(1)Aetna also includes other carriers owned by Aetna.
(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.
Schedule Of Prepaid Expenses And Other Current Assets Prepaid expenses and other current assets are summarized as follows (in thousands):
 March 31, 2020December 31, 2019
Prepaid maintenance contracts5,460  3,853  
Prepaid expenses1,727  2,207  
Prepaid insurance543  918  
Income tax receivable1,041  584  
Other431  260  
Prepaid expenses and other current assets9,202  7,822  
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2018   30,863   (11,426)    
Beginning Balance at Dec. 31, 2018 $ 303,149 $ 31 $ 298,024 $ (199,998) $ 204,965 $ 127
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in connection with exercise of common stock options (in shares)   172        
Issuance of common stock in connection with exercise of common stock options 2,367   2,367      
Repurchase of shares to satisfy employee tax withholding obligations (1,280)   (1,280)      
Repurchase of shares to satisfy employee tax withholding obligations (in shares)       (24)    
Stock issued in equity offering (in shares)   2,760        
Shares issued in equity offering 126,051 $ 3 126,048      
Settlement of earnout liability (in shares)   295        
Settlement of earnout liability 17,264   17,264      
Stock-based compensation expense 3,229   3,229      
Foreign currency translation adjustment, net of taxes 29         29
Net income (loss) (5,159)       (5,159)  
Ending balance (in shares) at Mar. 31, 2019   34,090   (11,450)    
Ending Balance at Mar. 31, 2019 445,650 $ 34 445,652 $ (199,998) 199,806 156
Beginning balance (in shares) at Dec. 31, 2019   34,752   (11,616)    
Beginning Balance at Dec. 31, 2019 527,164 $ 35 455,159 $ (199,998) 271,852 116
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in connection with exercise of common stock options (in shares)   141        
Issuance of common stock in connection with exercise of common stock options 1,091   1,091      
Repurchase of shares to satisfy employee tax withholding obligations (4,375)   (4,375)      
Repurchase of shares to satisfy employee tax withholding obligations (in shares)       (33)    
Stock issued in equity offering (in shares)   2,070        
Shares issued in equity offering 228,024 $ 2 228,022      
Settlement of earnout liability (in shares)   295        
Settlement of earnout liability 28,521   28,521      
Stock-based compensation expense 8,962   8,962      
Other comprehensive income, net of tax (6)         (6)
Foreign currency translation adjustment, net of taxes (31)          
Net income (loss) 3,452       3,452  
Ending balance (in shares) at Mar. 31, 2020   37,258   (11,649)    
Ending Balance at Mar. 31, 2020 $ 791,686 [1] $ 37 $ 717,380 $ (199,998) $ 274,157 $ 110
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 18 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Contractual Obligations
Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2020 are summarized as follows (in thousands): 
For the Years Ending December 31,Service and Licensing Obligations
Remainder of 2020$1,961  
20212,189  
2022692  
2023444  
2024229  
Thereafter—  
Total$5,515  
XML 19 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Operating Leases

Refer to Note 9Leases for commitments related to our operating leases.

Contingencies

From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We accrued approximately $1.2 million as of March 31, 2020 for amounts we believe will be payable for certain current legal proceedings, including the matters discussed below. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail.


Legal Proceedings

On April 6, 2018, a former employee, Lupita Gonzalez, filed a complaint against us in the Superior Court of the State of California for the County of Sacramento (the “Gonzalez Complaint”). The Gonzalez Complaint is brought under the California Private Attorney General Act (“PAGA”) on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The claim alleges that we violated wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime
wages; (ii) the payment of minimum wages; (iii) providing compliant meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The Gonzalez Complaint seeks penalties and costs, expenses and attorneys’ fees.

On July 1, 2019, two other current or former employees, Michael Le’Vias and Ramona Meadows, filed a related complaint against us and eHealth Ins. Serv. Co., in the Superior Court of the State of California for the County of Santa Clara (the “Le’Vias Complaint”). A substantial overlap exists between the facts and circumstances alleged in the Gonzalez Complaint and the Le’Vias Complaint. Specifically, the Le’Vias Complaint is also brought under PAGA on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The claim alleges that we violated wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime wages; (ii) the payment of minimum wages; (iii) providing compliant meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The Le’Vias Complaint seeks unpaid wages, penalties and costs, expenses and attorneys’ fees.

The parties have agreed to resolve both the Le’Vias and Gonzalez Complaints, which settlement will require court approval. In the interim, the parties have filed notices of conditional settlement in both matters, and the April 13, 2020 trial date for the Gonzalez matter has been vacated.

On April 8, 2020 and April 29, 2020, two purported class action lawsuits were filed against us, our chief executive officer, Scott N. Flanders, our chief financial officer, Derek N. Yung and our chief operating officer, David K. Francis, in the United States District Court for the Northern District of California. The cases are captioned Patel v. eHealth, Inc., et al., Case No. 5:20-cv-02395 (N.D. Cal.) and Bertrand v. eHealth, Inc. et al., Case No. 3:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that we and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn and our profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the Patel lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. We believe the lawsuits to be without merit and intend to vigorously defend ourselves against them.

Service and Licensing Obligations

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.
Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2020 are summarized as follows (in thousands): 
For the Years Ending December 31,Service and Licensing Obligations
Remainder of 2020$1,961  
20212,189  
2022692  
2023444  
2024229  
Thereafter—  
Total$5,515  
XML 20 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law on March 27, 2020. The business tax provisions of the CARES Act include temporary changes to income based tax laws, including the ability to utilize net operating losses, interest expense deductions, alternative minimum tax credit refunds, charitable contributions, and depreciation of qualified improvement property. The income tax provisions of the CARES Act do not have a material impact on our Condensed Consolidated Financial Statements for the period ended March 31, 2020.

The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2020 and 2019 (in thousands, except effective tax rate):
Three Months Ended March 31,
20202019
Income (loss) before benefit from income taxes$1,404  $(8,626) 
Benefit from income taxes(2,048) (3,467) 
Effective tax rate(145.9)%40.2 %

For the three months ended March 31, 2020, we recognized a benefit from income taxes of $2.0 million, representing an effective tax rate of (145.9)%, which was lower than the statutory federal tax rate primarily due to stock-based compensation windfalls. For the three months ended March 31, 2019, we recognized a benefit from income taxes of $3.5 million, representing an effective tax rate of 40.2%, which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses and foreign income inclusions, partially offset by research and development credits.
Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of March 31, 2020, as we believe it is more likely than not that the net deferred tax assets will be realized, with the exception of certain state net operating losses that are expected to expire unutilized which have a valuation allowance.
XML 21 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information - Schedule of Accounts Receivable (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]    
Contract assets – commissions receivable – current $ 125,252 [1] $ 174,526
Contract assets – commissions receivable – non-current 435,465 [1] 414,696
Accounts receivable 668 [1] 2,332
Total contract assets and accounts receivable $ 561,385 $ 591,554
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 22 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Commission Revenue by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Disaggregation of Revenue [Line Items]    
Total revenue $ 106,408 $ 68,773
Commission    
Disaggregation of Revenue [Line Items]    
Total revenue 99,669 64,227
Commission revenue from members approved during the period    
Disaggregation of Revenue [Line Items]    
Total revenue 86,921 56,807
Net commission revenue adjustments from members approved in prior period    
Disaggregation of Revenue [Line Items]    
Total revenue 12,748 7,420
Medicare | Commission    
Disaggregation of Revenue [Line Items]    
Total revenue 90,104 51,649
Medicare | Commission revenue from members approved during the period    
Disaggregation of Revenue [Line Items]    
Total revenue 81,125 50,582
Medicare | Net commission revenue adjustments from members approved in prior period    
Disaggregation of Revenue [Line Items]    
Total revenue 8,979 1,067
Individual, Family and Small Business | Commission    
Disaggregation of Revenue [Line Items]    
Total revenue 9,565 12,578
Individual, Family and Small Business | Commission revenue from members approved during the period    
Disaggregation of Revenue [Line Items]    
Total revenue 5,796 6,225
Individual, Family and Small Business | Net commission revenue adjustments from members approved in prior period    
Disaggregation of Revenue [Line Items]    
Total revenue $ 3,769 $ 6,353
XML 23 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Summary of Financial Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Assets    
Short-term marketable securities $ 33,683 [1] $ 0
Long-term marketable securities 24,409 [1] 0
Liabilities    
Earnout liability — current 0 [1] 37,273
Level 1 | Recurring    
Assets    
Total assets measured and recorded at fair value 105,798  
Liabilities    
Earnout liability — current   0
Level 2 | Recurring    
Assets    
Total assets measured and recorded at fair value 120,097  
Liabilities    
Earnout liability — current   0
Level 3 | Recurring    
Assets    
Total assets measured and recorded at fair value 0  
Liabilities    
Earnout liability — current   37,273
Carrying Value | Recurring    
Assets    
Total assets measured and recorded at fair value 225,895  
Liabilities    
Earnout liability — current   37,273
Fair Value | Recurring    
Assets    
Total assets measured and recorded at fair value 225,895  
Liabilities    
Earnout liability — current   37,273
Commercial paper    
Assets    
Short-term marketable securities 23,063  
Commercial paper | Level 1 | Recurring    
Assets    
Short-term marketable securities 0  
Commercial paper | Level 2 | Recurring    
Assets    
Short-term marketable securities 23,063  
Commercial paper | Level 3 | Recurring    
Assets    
Short-term marketable securities 0  
Commercial paper | Carrying Value | Recurring    
Assets    
Short-term marketable securities 23,063  
Commercial paper | Fair Value | Recurring    
Assets    
Short-term marketable securities 23,063  
Agency bonds    
Assets    
Short-term marketable securities 10,620  
Long-term marketable securities 24,409  
Agency bonds | Level 1 | Recurring    
Assets    
Short-term marketable securities 0  
Long-term marketable securities 0  
Agency bonds | Level 2 | Recurring    
Assets    
Short-term marketable securities 10,620  
Long-term marketable securities 24,409  
Agency bonds | Level 3 | Recurring    
Assets    
Short-term marketable securities 0  
Long-term marketable securities 0  
Agency bonds | Carrying Value | Recurring    
Assets    
Short-term marketable securities 10,620  
Long-term marketable securities 24,409  
Agency bonds | Fair Value | Recurring    
Assets    
Short-term marketable securities 10,620  
Long-term marketable securities 24,409  
Money market funds    
Assets    
Cash equivalents 105,798  
Money market funds | Level 1 | Recurring    
Assets    
Cash equivalents 105,798 7,261
Money market funds | Level 2 | Recurring    
Assets    
Cash equivalents 0 0
Money market funds | Level 3 | Recurring    
Assets    
Cash equivalents 0 0
Money market funds | Carrying Value | Recurring    
Assets    
Cash equivalents 105,798 7,261
Money market funds | Fair Value | Recurring    
Assets    
Cash equivalents 105,798 $ 7,261
Commercial paper    
Assets    
Cash equivalents 62,005  
Commercial paper | Level 1 | Recurring    
Assets    
Cash equivalents 0  
Commercial paper | Level 2 | Recurring    
Assets    
Cash equivalents 62,005  
Commercial paper | Level 3 | Recurring    
Assets    
Cash equivalents 0  
Commercial paper | Carrying Value | Recurring    
Assets    
Cash equivalents 62,005  
Commercial paper | Fair Value | Recurring    
Assets    
Cash equivalents $ 62,005  
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 24 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]    
Long-lived assets $ 99,715 $ 64,879
United States    
Segment Reporting Information [Line Items]    
Long-lived assets 99,297 64,408
China    
Segment Reporting Information [Line Items]    
Long-lived assets $ 418 $ 471
XML 25 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Maturities of Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2020
USD ($)
Operating leases  
Reminder of 2020 $ 5,058
2021 6,950
2022 6,988
2023 7,863
2024 7,706
Thereafter 27,603
Total lease payments 62,168
Less imputed interest (16,002)
Operating lease liabilities $ 46,166
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Segment and Geographic Information
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Segment and Geographic Information Segment and Geographic Information
Operating Segments

We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments: Medicare and Individual, Family and Small Business. Please refer to Note 1Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2019 for our accounting policies of operating segments.

The following table presents summary results of our operating segments for the three months ended March 31, 2020 and 2019 (in thousands):
Three Months Ended March 31,
 20202019
Revenue:
Medicare$96,151  $54,901  
Individual, Family and Small Business10,257  13,872  
Total revenue$106,408  $68,773  
Segment profit:
Medicare segment profit$21,960  $10,826  
Individual, Family and Small Business segment profit2,603  6,024  
Total segment profit24,563  16,850  
Corporate(13,448) (8,296) 
Stock-based compensation expense(8,714) (3,229) 
Change in fair value of earnout liability—  (13,306) 
Depreciation and amortization(823) (655) 
Amortization of intangible assets(547) (547) 
Other income, net373  557  
Income (loss) before benefit from income taxes$1,404  $(8,626) 
There are no internal revenue transactions between our operating segments. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3Supplemental Financial Statement Information, our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented.

Geographic Information

Our long-lived assets primarily consist of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands):

March 31, 2020December 31, 2019
United States$99,297  $64,408  
China418  471  
Total$99,715  $64,879  
 
Significant Customers

Substantially all revenue for the three months ended March 31, 2020 and 2019 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue for the three months ended March 31, 2020 and 2019 are presented in the table below: 
Three Months Ended March 31,
 20202019
UnitedHealthcare (1)
22 %17 %
Humana19 %23 %
Aetna (2)
15 %17 %

(1)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.
(2) Aetna also includes other carriers owned by Aetna.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Business and Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Description of Business Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omni-channel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 180 health insurance carriers across all fifty states and the District of Columbia.
Basis of Presentation
Basis of Presentation – The accompanying condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, and the condensed consolidated statements of comprehensive income (loss), stockholders' equity, and cash flows for the three months ended March 31, 2020 and 2019, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2019 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on March 2, 2020. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain reclassifications might be made to conform with the current presentation. However, the Company believes that the disclosures made are adequate to make the information not misleading.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2020 and December 31, 2019, and our results of operations for the periods presented. Our financial position as of March 31, 2020 and results of operations and cash flows for the three months ended March 31, 2020 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2020 and therefore should not be relied upon as an indicator of future results.
Significant Accounting Policies, Estimates and Judgements Significant Accounting Polices, Estimates and Judgements – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the commissions we expect to collect for each approved member cohort, allowance for credit loss, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.With the exception of the change for the accounting of credit losses as a result of the adoption of Accounting Standard Updates ("ASU") No. 2016-13, Financial InstrumentsCredit Losses discussed below, there have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.
Seasonality
Seasonality – A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage, Medicare Supplement, and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Due to the recent reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our commission revenue is typically second-highest in our first quarter.

The majority of our major medical individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase major medical individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.
Recently Adopted Accounting Pronouncement; Accounting Pronouncements Not Yet Adopted
Recently Adopted Accounting Pronouncement

Financial Instruments – Credit Losses (Topic 326) – In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial InstrumentsCredit Losses (Topic 326), that requires companies to present certain financial assets net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. Contract assets – commissions receivable are the Company's only financial assets that were materially impacted by this guidance.

We adopted ASU 2016-13 using a modified retrospective transition method on January 1, 2020 for all financial assets measured at amortized cost. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under the previous accounting standards. We recorded a $1.1 million decrease, net of income taxes, to the retained earnings as of January 1, 2020 for the cumulative effect of adopting ASU 2016-13. See Note 3Supplemental Financial Statement Information for further discussion on credit losses.

The impacts from the adoption are summarized as follows (in thousands):

Balance Sheet Impact:December 31, 2019Transition AdjustmentsJanuary 1, 2020
Contract assets – commissions receivable – current$174,526  $(71) $174,455  
Contract assets – commissions receivable – non-current$414,696  $(1,442) $413,254  
Other assets*$18,004  $366  $18,370  
Total assets$741,634  $(1,147) $740,487  
Retained earnings$271,852  $(1,147) $270,705  
____________
*Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.


Financial Instruments (Topic 820) – In 2018, the FASB issued ASU No. 2018-13, to change the disclosure requirements for fair value measurement with the objective of improving the effectiveness of the notes to financial statements. This new guidance removed and modified certain disclosure requirements under Topic 820. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.
Intangible – Goodwill and Other (Topic 350) – In 2017, the FASB issued ASU 2017-04 to simplify the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. In addition, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

Income Taxes (Topic 740) – In December 2019, the FASB issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes, which aims to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improve consistent application of and simplify U.S. GAAP for other areas under this Topic by clarifying existing guidance. ASU 2019-12 will be effective for us beginning January 1, 2021. The amendments in this standard update have individually different adoption approaches. We do not anticipate a material impact on our consolidated financial statements and disclosure from the adoption of this standard update.
XML 28 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]    
Prepaid maintenance contracts $ 5,460 $ 3,853
Prepaid expenses 1,727 2,207
Prepaid insurance 543 918
Income tax receivable 1,041 584
Other 431 260
Prepaid expenses and other current assets $ 9,202 [1] $ 7,822
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 29 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]    
Restricted cash $ 3,353 [1] $ 3,354
Credit loss expense 100  
China    
Cash and Cash Equivalents [Line Items]    
Deposits $ 4,100  
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 30 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Disaggregation of Revenue [Line Items]    
Total revenue $ 106,408 $ 68,773
Earnings per share, basic (in usd per share) $ 0.14 $ (0.24)
Earnings per share, diluted (in usd per share) $ 0.13 $ (0.24)
Medicare    
Disaggregation of Revenue [Line Items]    
Total revenue $ 89,178 $ 50,776
Individual and Family    
Disaggregation of Revenue [Line Items]    
Total revenue 2,656 6,137
Ancillary    
Disaggregation of Revenue [Line Items]    
Total revenue 4,251 3,519
Commission, Members Approved In Prior Periods    
Disaggregation of Revenue [Line Items]    
Total revenue $ 12,748 $ 7,420
Earnings per share, basic (in usd per share) $ 0.52 $ 0.34
Earnings per share, diluted (in usd per share) $ 0.49 $ 0.34
Product Concentration Risk | Revenue | Medicare    
Disaggregation of Revenue [Line Items]    
Commission revenue, percentage 89.00% 79.00%
Medicare Advantage | Medicare    
Disaggregation of Revenue [Line Items]    
Average plan duration 3 years  
Total revenue $ 68,347 $ 39,843
Medicare Part D | Medicare    
Disaggregation of Revenue [Line Items]    
Average plan duration 5 years  
Total revenue $ 5,661 2,336
Medicare Supplement | Medicare    
Disaggregation of Revenue [Line Items]    
Average plan duration 5 years  
Total revenue $ 15,170 8,597
Other | Ancillary    
Disaggregation of Revenue [Line Items]    
Total revenue $ 1,049 $ 951
Minimum | Individual and Family    
Disaggregation of Revenue [Line Items]    
Average plan duration 1 year 6 months  
Minimum | Other | Ancillary    
Disaggregation of Revenue [Line Items]    
Average plan duration 1 year  
Maximum | Individual and Family    
Disaggregation of Revenue [Line Items]    
Average plan duration 2 years  
Maximum | Medicare Advantage | Medicare    
Disaggregation of Revenue [Line Items]    
Average plan duration 12 years  
Maximum | Other | Ancillary    
Disaggregation of Revenue [Line Items]    
Average plan duration 3 years  
XML 31 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Humana    
Revenue, Major Customer [Line Items]    
Major customer revenue, percentage 19.00% 23.00%
UnitedHealthcare    
Revenue, Major Customer [Line Items]    
Major customer revenue, percentage 22.00% 17.00%
Aetna    
Revenue, Major Customer [Line Items]    
Major customer revenue, percentage 15.00% 17.00%
XML 32 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Debt (Details) - USD ($)
3 Months Ended
Dec. 20, 2019
Sep. 17, 2018
Mar. 31, 2020
Dec. 31, 2019
Debt Instrument [Line Items]        
Borrowings under line of credit     $ 0  
Revolving Credit Facility        
Debt Instrument [Line Items]        
Borrowing capacity $ 75,000,000.0 $ 40,000,000.0    
Commitment fee percentage   0.50%    
Facility fee percentage 0.50% 1.75%    
Maximum borrowing capacity $ 75,000,000.0 $ 40,000,000    
Covenant, minimum cash and cash equivalents 6,000,000.0 6,000,000    
Covenant, maximum cash and cash equivalents 11,300,000      
Minimum liquidity 10,000,000.0      
Maximum liquidity $ 18,800,000      
Debt issuance costs   1,200,000 $ 1,100,000 $ 1,100,000
Revolving Credit Facility | Credit Agreement Amendment        
Debt Instrument [Line Items]        
Debt issuance costs       $ 500,000
Letter of Credit        
Debt Instrument [Line Items]        
Borrowing capacity   $ 5,000,000.0    
Eligible Commissions Receivables, Preceding Three Months | Revolving Credit Facility        
Debt Instrument [Line Items]        
Borrowing base percentage     80.00%  
Eligible Commissions Receivables, Succeeding Three Months | Revolving Credit Facility        
Debt Instrument [Line Items]        
Borrowing base percentage     80.00%  
Eligible Commissions Receivables, Succeeding Six Months | Revolving Credit Facility        
Debt Instrument [Line Items]        
Borrowing base percentage     50.00%  
EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end ZIP 34 0001333493-20-000076-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001333493-20-000076-xbrl.zip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

SZ;L97"_O^4D0V4;:U)07=9JVCBP$T$PIC*+FT*BR&=*\K=$^7; M%G0_HF_A@.U$MKZ,[X*M99CY,7#GB1#W160G_3B!A:$U16*.Q6;%DBV67@YO M68R0F(OD ;PSCCU/#3DB7CJ.13D$.'W'0?=F-,/L&T:,Z8Z>Y=GQ[CQRTX$ MA<[?Q,D#%"HELJ:Y%)V>=(899;V1,FTET1:WN#=Q/LHCH,/Q\[W0*EO M%A]#K1$WBD[(;)'Y8@TKJCB(V6GKFMBA>Q$],R.B%\$WN'*[&X. :ZP+O[T. MW&0G=4#8U))X$N*9[(E^.'TD*-0C(6WO__)'#CBUTMRX&SA MSBGE/80FE[;G4IFG#(QS:ACY<_LXYP["/J"H55I0[>S#FO'_66CB#MXT)GQ37?)^\5IX1$N)<.#()=>8" M5\@B0"W93"7::)SU38K]>UO!8'.MSZN7YV'\4F(HKR9T\.+;!;V8]>-^KK^P M:9$G/"#9.\AR49[6$\G"2MPS$;B-$#+]7Y,-]!%,Y^]7.JB23-N0U<";V0-M M4P31 5S+VY)'T9WGHJ0W+KOIR E$#*XMQ@M.I[QD3N?J]W-@$"6Y9)!"-DF@ M4TU.SC-HR1-W(^=1DD/DW^(*# M=3XQ.,%2PIBM%U;8-I[/$\"&-^E[Y'';*NJ3A![M]%5IW,U\0>N>O:1CEA#^ M."&9C:L [D.4J)W6EC,/4 <89\% <,.,R#*DHH*S6P4<^XH6.SWO.=#?2KQ] M1VE_P_1^,AU/WWVJ _2J:;R-+E@'Q2C+1.*DGSZ1'VG0UAQ=+T%"0(!NN:M/ M/>K9\-ZO4!O$Y?Z"$YS!F-"]R-#5EPKUXM^>&DT(93:0HNS:%5D6GK:LT)(#)RR M(9CD$F\R?N,>BJ_;B3V>D!:1_J,%\7D9D_QF#),:IEJ_4UW6U#S+L.=%G<=) M/D%7=N6;70+1K1(9^UZ;!>"I>&"8EO.'BV5>D)&O) ]*(0;R+[]NY7W"=[]P MW3V$WP8Z^^/UA_'T$^(RUGHO B^]M!8=L)*"KZ/%ZM -.EL*&G1"9N#;16<] MM1_8A^@"(W7-"9^V8*M!N.[SB/4EM+\1,_-?W_YM#2PM5>A35/]6I1]:&G5/_"RY6WM1R[^VAG>?%)Q(C:R.B18X"<,%M=(G=73V+N4:;'=TEZ[.-:R[=##R6/Q1NK M%:@HR1Y( &!16.Y2<-J'/5+NJZ72S@^O>\+-8KDE3$MM=)9@DG\8C6_H];S] MA0_K'SXAKZR_A[?F\72);+%>E(X@7>;!HJ[7*]['0/]QG;/(3NQF_539]*@C MGW/C7DP6HR6&T4=([\=*.$.0-@MJ$<=F8<8/BIVT4=4;; M:/+N=BD_?YY33+LK&L69L!')EB 'S N0+)&M@B@*Z-SFOJ^G!9Q\^WD:CA?7 MTYO)XBHI!SRB)-,^)Z;K'[%H2T(5VANIZXC%"Y3B"OWP]O99M/?!->O@S#?- MQCQQ.>LATB;;Y(-ER=:9KZG.&2C),2N+]2DZA1%:Z'&_RQ@J+_,BU/B,&G I M*9HG+OS[3[L_8%5B5;RV/!86# E%^U*8C](S$RU]HP3HV*3G3L,UG3^Z-KRF M]KOW]Z8Q#>Z-=R.[BDJ2?2>0ZULSE%:Y1ABB^S M,;$P<%FPXH*UP+-Q,*")?.[0UY>J;8>P.&A03*?((QC%1,+:](NLIYA$9DG) MH@PZ'7B3<_J"@F+]DM'LI[^T&'DWB&LI5'$R#7GDD[A MZ.D@!A3.UM%*EBM1'I-^7\&M1QYQ0N"APZ<.PT*7B_]@ RE_-+'PK&6!8$$4 MVOC0"R,XYL=HZ.?BO@84[GWLYUN@PF4HM6N8UC5W7+A:V!T40UDKNPVIS78U M1C]GU7Y(IY[-]S_YTXN49C&7*R];HK.N.8-MHR\"8P MS,%9D^K]5Y/Q;IW0#7]6]Z0AVZ=T_UPT,.:V0&[FF[P9D^ 6HU+F5\(YI5-2 MU9U)3(?$&7#T3%AT3DB>K6W2<>Y)9,]544[DH($3N T0?W])V*[G/XW&F%=P MKT!;%-X&)E4=*B?!D#WKD16)!07Z:-T >^E.;,]644[EH4'U0H4W@[2@G>YU M'(_>+>]3?KI9W,SPKR3VZYOK=3+?_(<;LJBJ-'-5]I]&\P3C_Q^!5A#JZ#;. MF5!U@I(AM0]8!',EA%2RS@:;A,1.A_YL%&U@%AO46.U< 8%]-7E;1V3F)49, MG&M,@EDIZK8:-?-*9B8=88[<^6";).-V ?>\=>D4)AK,_MB/\;?WH]D*XC+) M-X1:*F@$*;2AC54G3P>Q$*7^YWF;"1!/8_L*=.4X'EJ,"-D+\:?IS6SQ?HG1 M6JDSMYF!R;4-N'JJ*:Z4J+\H"9Y]1<@\R M)%WO]*5G.O',O'&!)0X9/$DEF";QE6[PGKW"G,#&0YWQ373F2N54"H?$P/H: M6K*:7$#!64RF\"ASSK9)X'\GFN>M$0?)^J$"A'YO9C:ABRM).&SM@T.H:HXL M3\S+@JP@9 .)IZR;'"F[X0R5'3K(KD[8#H@"?$(SC^#&3;AL ^2]O)]HH2'8A\-"J[K_8H5F>P4 M&5@,*K&<.&;C; 3L$O&[0-;WY/T-1?HA@NV[X]S/^%\CF->\Q?$()HMU^D_A M)BM$SJP(D>E 'B\$S*S8*,D9]MSKK;R\/5WF=G[\<.97(T&$=M%::4/30;]K4#SS,XL/N4>(O> M7P]AK16^"["F#;SV(3O?3*^3^7M:)TX0?HNF6GL!X(#I?3$I#;11G'MLUG%(<(O/VRK ^R&RP 4VT+)KB:RD"63H9#)/!ZH1* MA]PF*7\GFC.T%>J'K<=UX A1[[49FJ19OUU=%L D_P7K5-,/[T?IU:1,9]>K M&[E[H+KEG#[UD3TFG!Z$?COIUP<0-OEHO-)%B,A]\B8*(U540L:K ];11/;' MIUYW^^#A>.C26<@%7E#+) *]#LA]#B%!T. P&33^*3;Z2L-^XC'K?WY-%BE4 M&_-7G-,Y?DJ&]FD/'([#0U:^Q6U6TI'+) LY3#J4'*T/0GJH66<.HGZ*VR<> M?>JXAN6'_XH?IK/ZX7>>^_E*F(,60J;()$A74TX2"]$[5HRPI*TRB]PD^:<+ MN%.-@TT*Z:UXUP^=7X'C=%)Q(./'*J;K^F.*CLG$13(V^YB:I&GN170&(Z%O M[=BV%_J1?I/*/;)?;G!5[;J*9OU]M'B_&:ZPJH:M(S;F3VMOZYI]>5U+H@EX&9 M5/OVF!)8T"(SU 8MDAB2[3;]8O\SGI$"]"G-'B^JEK#NC\V,>\9F_H*+UV59 MJ7J3%C>SY1G_$6=S&&_F:DI:O-' F>*^9MWPS((UB7%>LH2<' 3722-Z O3< MU.<+3Z)*^N<\IYS1KMG9AIR9M%:R< 7Y^C4UB4T&=(RT/J>D79? MLF8TR$[_ 3_,,(U6"4>)=C^;ZG'.09()&8$!)V,R5+]+&RE,;E(=I$CSPT2"U_O7B/LU^FD^E]ZW!S: LMZ@P/Q>3_;>]*F]O( MD>SW_2_8Q7U\V0A+W3W3$;:[P^Z.^0X\D]@ES%%#CA70$2 LO?P_"Q%,7".!/OCS/J[&'!#SY=24A$VF\6SS>' M&?J+(RI,2,)JHK/$&(0K5XZ:9F),PEA$>QVA85/<)L]T@?;Y6BR@0?K[D^YQ M^UF\>EC]YS)K1 FE+3@@5%*D$E'B^UCX5,99,"HT,MH3L Z5-]WJMCRR'A3+G80PE_#+D-LK*VMOS6'8<]3SAZ9>)I6:Z/ M/I?NM)8 51@"^"BC;1.-[<8S;!9W';$VPZX*3#?88KV>SG"6\W/X^)CCL*[: M&A1U2GG"2K]IR6BI$NPDB9K14M(@*=TD-6\OH@LP@CILM\C.7/HY 2E2I="7CJ5"*U/$*P'$ "T5O1(^=YO4DT.H+MU/K"]-BP, 2RRK5Z,+ MF*9)_T_1G"G1OYY:FW;0F^H6X\8S4$I(*1R4JD@I$*D](YY;38PRB7I%?5)- MZG0.H/M+J?P#R7X,P[5S93Y &L?2Y>[9Q(53GXQ"1 *Y(,K&$L>,(TDK'3Q3 MPO,-3W%/4L3.RY]M??,4OJ=5R:KH["T0_3Q)XV_C=.]O?O*WXYN'=Y/T^=;? MW&Q:[+J%L-D=]BB]R\E M0C^Z/^^GDR_OQ]\@+?<7KQZ^_[Z_>3<#WS C_7@0 V:I]V1H(W,]B*"I5M9Z MY262% 0%EKAFRC&!KN.+F>O'PQD@FSVKG(TI'G9K7SKGTV$20EK-0!E,IA<">B(B;%B .!,SRP)DGL&T!> MZ6[A,;:PE;O>A^NF[3:[1X?&^2A !"(DE*)<-A*/KS:QF26C!,>9(OQGBZ^N MW;36Z35L\3T&)<_&^<4R-KX6(G)-0+M2OE9I$G19PT(_)'*AJ($N%M=I27\O MBK>T@'.4]-/:$E3>Z5D]V5-(ZVVH#J!J;_;M13/\;E\EM::MJ![,#A@+S"B= M2'0A$TE9*6^M X+SJ*"W5.8N:_^O4?\#>WY#RG\,PQ5ECR6%?/8P^OWS*$KN MD@N,N(!/(JG@Q,7DB;")@I;.T[ C+?=N3?,=Q/_^,OWV/ZLK%IW-^ILBLWDB M\_>[#KN'4XG^:2_N*CJ9:P37'T<8 5KMA",Q6$FD]YQ8:PQ)PHJ2HNFCEI75 MN_YX">H=R=VK7'N9YM4YR_#PP?_?=+8^7MFR!D#76P^_SG(<&YO]WH#;%!EE M$)UDD05O.%."A2"S%%)W75UY$43/MK:3^7C^\(]Q@M5MGMWD>TB$9JR%L(;P M9$JB/\_$@S8D2\HM4"MH;G+:IB.^"O6C(Y1CQ87Z3^.[?_Z*;G]1YPNPD8R9 M8T"8B-& DS2E."HHJ@F7RAOTV),/K?KP[ 4U_(I+"TO945JZC@Q-%V"VF+C: M>#6O'AXCO_7J_#+:2Z6ROC;H[CGCB932$9PP<$ZTVDJ!+XV")\K4("UC"]J3RG)=H+5,TCF [3PI.]5T?,D^>HHPL)U([4$9 MYXA()<8-41*_.$6C7.!,")G-,"/-F:MTGL,\CN&^A5FLQLTMB*OD!1Y32ME9 MPE(I21EQ9K?XW$30:)CB,GO:9,/J!5S#.]O5--RTC8H"-$D:WWHEKF 2O][Z MV3\7[X57Q>4/@201.>)3E(3@(XDF.PG9VIB'\E*> ?N/JU)!L 9IQ-OXUNA6 M+U,7?(,Z+1L 7XWGTD/6%VVF@B9#^#";.*/@5'BK"0.F2F??0(+/BH1$C2GI M5#*WZD!W!ILYWIL9T&2.D:*!J;Q0G7!=*+M,K30)DFA4Q:GSQ(% +D+(*BC0 M$G9LK32O(/EJ?)Q>HAY7+_($12JZ.V43ZOGDO'A#,A>*,TD)),.(!.&(]PR_ M90C1>*$7NPMU-L>W;_]7A"Z@:J?/[$4S?/I, M7YFFK3BNG#>S'YRP(AJ-4Z87)?G4@"#.QI(P%IG0U%,)71)]7Z/P!_)F!M'] M&&IKGWSZ^_VMG_C59&0\D]:R0+1"+TF*B)!* RYMN/?H(3FC-WJ5[CD8\_2J MPV965&)Y6H.BVL><7! R M*6X[J;;[^F]>OPJTU7[KWL'\T:*TH5SH[$FTD-'O8PE]S-+_SE%-N8F4YFXO MW9.+OGG-3B5H[P).DYRF]^#O3FLAL_K+BAE%N[!L) 1YHTV*.D7AK#3.!.%% MR,$%::@3S(RV4?7AY?0&.\_^OCI''=KE4!S<(0@P/E(IO<80$$22/GB;D@TP MVH>P#U\?_:Q$HM^@1ZK;GBM5Y_ PU@TVH^-<&:H3BTE2)0,PHZ0HG6HX(/;1 MGFOV[,=>NC# XM(_P%V_P>QVY"Q3J11>4:$,H3QD8B6UI3^G=4ID4)O5 M"_8VHMUY@^&7;FJJN]&5MC^%#?:E'FLL+1!=3^_FHR0CRUHJPI.CRUTXJ_&# M*?U6%1..IR8[4=M0+D/^2E2W+&6V0/2K?UBV,,+;"JIH)#Z4TM>98B0JT9<- M0%-T6;CQFD8QA0M:ESN _099A'5=H; M-"C99;F/[5/6P]@/]S#2@$&.U+I4Z2E;6TH1EU(F1B8:DN*9BB:%[[H"O"QS M:2)+Q7XG>T>]7Q8D_#;]<1'2K=LI_@JS\33A=!@R3TDR4OJ-$NE$)DYFOFBK MP$OV(,WRY&GFX*TOPSP&H+U!NY.=LR-,X-_^9A$JX<-"I-*13#T.@4):$E3@ M1$FE(7!A56XR\[R ZS),IH4(#9J=['[TU5XYXR8:+HG23*+Y1H>/G2*)R4** MFEH7FI3?/8!IJ+-%[2VB/^7G/BMTN%X!!EG4(QG$2HU/HHJ[S2$1B%Y3X)92 MWN4HY-NL[U)-XDYU7(ZA>K#Z'5U _27KN!RE5J="'J=0/5P=%V_0'<;7QN&H M2&1VQ?TQ@K!R7D6C]=/-(IYO1O^3ZKC4E_\8AFMOD/]M>I,^C;_![-K?C/-T M-AFO=X.#8R%);8@W(>$PEQ2Q,6)\S203*GK).>T4]I!G[-"HK+D<_ M@E@W^N@ H_:<_.3^P\_")RJPJ6$/^BK/LT_A@&=<>PP56:1IV5$U\)R(D)D[ MX1DHWZ5$Q.M0\?-D[JM./87QYYM6\&3BAJU^MLQP^GS_QQ_+11)_<^5ORJ]\_@HP?U)T MJW?NUQ'WJ)X5=NKS;>:+46I#4$)+_">Y"8$G':PT.;&489U]=]J3]M'O@Y_? MSY EN)OF9ULX^)/>PG6Y>'7%CGZB#:E2B%%Y$-G'*"$)QQE7,0FJ&(LFY]%) MSW::1C] F)]"_^+O*C*[C6,SN]1;96G,+ F&1JT\5REGQ8WQ@1G-1YN(3N>C MAU4^_?/*['2Q+"\S(!O9.NW0+;->40Q0O"TR:UTO;@Z;TE@Q?Z)5_/((WG M/_FXV'J^7C88N)K.9M-_CR=?KOT?^#_SAU',*JG2:T#;I$DY\D(L%9%DJT&[ M'"%V.NYU_![-$2"'W]"K82E;VS:M9*E]_&@7T$>$5R5+[K%4XLCBBPS"9^(R M.F%2%Y^,44LHC=)+Z:.E_J4!Z-B;OFUS:$IQ@YS475!_G]S?05H;Z_7T]G8\ M+\S\!$^!4R:IE!'0AG5I7X^^OK6*$F$$-=3H3%670^95AI9.B-^V80TK6/6D MUQVH'S\_0RD ?00I%,;KI9)"@1HD,S@^0M 09,C*G#SD[+SEV[:+AO0V2'/= M!705_&_/DC@MHC_-.-'& <&Q,!///1"1T?%V&07/;7(;CP#YMHVGN2P54V/W M&OKU]!M,_&2^6@:\]G=?WTU2^?3CO^['W_S-(N7?VA"IU8SXJ%S)R S$1I9( MRL$X#0FGWWSRN-()PMLVE0'IKYX0>PCUTLKWH(X,C3J )$Y87C(T1=F-C\1H M)8)F@2J1^AO-(0B7;C35Z*^8(-O5U-^/$6LJ0Z*4CF69)1%:E+)!I=V'2PB9 MHR\?T!+ LUJ#R^-=+]TT^I!<,16VJPU_!^H$$F)\(L'B,"=MU"0XSHFSBCN? MLK>F6RF(8^YZZ=;0A^1M:[!]'=D?(,,,D?XTGI2%T7*\].XCS$<8P LK'"/* MR(RP LYXT@ Q-EB.H;QH5%=V#YZW;14UR=ZV 5*G[QS-Q M(6D"(;&08N!!=MGM[16L7(;:)].Z8WFL]X']YP^X3/CB6C(=S#X,)JYF"-7JMOJ^8&;G"LALK=XTP8DUDY?WH-K756V [+=Z9+'R7R.,PIU M9>F@=0].AU5=*9R)-$Y#^!FC$!SH2$A>$*^U=R!U]IN-9U^/VGNR*,\E]C%4 MUA;YQYOQES$.6HO-DKM"S]TGB##^MJ@%]NL,OTZ(^S>4$#[@O/'U;I6?QG\\P MZ\2%U,A0%*5Y$T>'RF:=2.(VVLR2RYN]4GM:S0: OY;-]&&_1<>99^M@BWG8 M,A8D T]4<$B!9T!"MH(PDR+H*+2132HR;$-YZV%')9*;R[ZR_2Z8FC87V@'J M3 V%>@IV4/\>;+=H&[0+&^=1YN0=P2D+B'2.$6\$OCM1*)&IS)PU:?TRG 6\ MU!YH ,XAN0V38"F-]]*RL7SA(S5,<,L5*34(#A:2G SG):XR81G9R)C68PFTW^JG$>H.ZL>]A/B^EHY;8UBZM!\%CR"57U!"IG21!NDBD ML)%&K9EOL]>T"\P%&$!OCAL,!<_]G66%B"A$5N5,7#EH)Y7.Q"9E"06N0R[+ M[JY)5MPVE$MQ GN2W"!-\CFBTIAA7K+>?#!X M@B])I8#A6&=8&?7 4.(@90+!8,@,6G$VP FGUM;P@F,XE#$<0W;MA:3EU/3N MRPP66YCO\$,J7SS6A=%*E#W8I&W"*2H)XJ5R!*Q1CAL+D+OU!SA\GW.G&9PJ MQK0-DWO=O29'T'^>X)?PF__SM)XL3_^\XG'0O:@VCH,B=]HGD64IKBPD]R:* M8*7@6@OAA1GMP=>;J].[V&Q?I UO'?K9).HSER"=XD)2H:U/5*!Q:F6M3<&. M#F+MS>'G^]M;/WN8YL>?7<$$">AS//F8R[?A_;BGVE"$^X@.9_0V)"5= "NC MPT\FF8CC1'"C$Y^OMU8UNA =NEP;+8[J1^0=V%SF\VRUC"D')H4''C++(82< M1B_@7PW/Y4/P=_"___7_4$L#!!0 ( /"KJ% !#V_P,]8 *3D" 5 M96AT:"TR,#(P,#,S,5]L86(N>&UL[+U[<]PZEB?X_WP*;$W$=E6$4)<$01*L M?DS(LEWC#5_+8[NZIO?&1@:>$ONF,M4DT[;ZTR] ,M^93 !)4NR-[:CVE90D M<,X/B1\.@//XI__Q\VD.OLNBS)>+?_Y#^.?@#T N^%+DBX=__L/?OKV'Y __ MXU_^VW_[I_\#PO_]YLM'\';)5T]R48&[0M)*"O CKQ[!WX4L?P>J6#Z!OR^+ MW_/O%,)_J5^Z6SZ_%/G#8P50@(+#3XN_J$P2Q-(8TH1RB*60D(B(PE0FB,;3,3SVHFPU_^=^_?OS*'^43A?FBK.B"FP[*_"]E_<>/2TZK&O.+ M9;__(R_7?'@NI3C<[+XJ] M5HV4F9$R3(R4__U<9[]<(7Y/\E;'LO8@7*WNI[YD[,+T4V_B?M/\((<7>*>; MJT5NOE#O%F*L[^ZFJZM%'U[BOKX6RXK.1_A:;+O9$7EN_O!1_]1V8QKJ(-.Z MGY:Z=T25/RNY$+)AR[VF02[^^0_ZI]FJA ^4/L_>T[SX5SI?R8\Y9?D\KW)9 M_BIIN2JDN%]\D7Q5%'K5?$/+O/S;8LE*67RG;"X_+)Y7E?YXN>#ZK9KTW[RL MVWBYF].R?+M\HOEBAL(D34(:P#!(E5X+PQ2R..0PC$4D99HJA=BLVDR2F5S MOWU=ZU,+/;+$?W# OCK#(84LEZN";U??I_FI)56OIF;]);\LZ),LGVG[@E;; M&"H-$O]B% :UQH"]@(W$H!89_-8(_?_\TR];P*8P[//_>H,YG_0X+OF>9'-C M:BV+0VR7?'QL][BPQE71DM7 M+)HD,/L%SFORO5?H/D+#,+6KOOOXPG]R]'L MN"W6T-*"7_BBM$_\8CJ2SQ7<^\Z8K<(KC4&U?*6)U7P;-2Q_ ,M"R$)OMTY M?)Z Z@[+C_*[G$>_RB@!8P\%LC[1#T>1Z308CO1'>O0UGG M]3Y+-AVO^-'$FU69+V19WBV?6+ZHZ>ANN:@T<\E%I7\J<]U6_>?;HM#?%6E. M<;+=*_2WN(X]7GX;"6**/:G2,/!Z' M!LS8W?L90Q^UC+H7O8/+JQE+(X%2H2!30F^2>!C#+"(<*H0)CH6V6*+4Q6+9 M;7QJ9L6;95$L?VAH2[!::+STFK&HUQ!>B^NV<.RA:,?NOM@,3,$?EXL'J/%_ M A];/.ZZ\7"FR5.*]\EE>^V/2CBG-#MDA9//^$W=6_'OJ[*J6>/;\E;H!C4Q MT/EGFHL/BSOZG%=T_O61%M+<>0I-0\]R4=;L\47^QRHO\TI^E<7WG,OF7L:< MT#PLZE;JC=>,QTI0&240(95HTU4$D"(2PB1-6"JSA,O Z?/]S=@%J9=A0_TY?:I6-GQ3;' M1GK),-X':EEH,[.LP(Y._?'F6,#WR<6#RSPJOX\U H=KQFC]^IJ0F]N NU51 M:#%G09I%B&>!,21CB(74)F6** R55 &-9(91/*LVM]46QM)A%TY 6^$VYP_:'E=#'T:E.=4[]>L/.IE9./R MG);')N;9)Z^\5VLO^PP3_3VO'H_N^,K]2[[]&\'-EK4AH?6J^58V_YTEFBN2 M(!$099Q!' H):8 9%)QCCI,LD]+IN'P4J:=F M1NZHW'@.[RK=7E6"?;5OP$9Q4&N^<\QY QKMM];J']< _&F ^\TQ!FR0F])! M!7^=.]THG;LM:_*Q>IQI*_DI+XTO?W.G7-X^/Q?+[U*\79GNVX6S MZ;=U>R"*"Q0S#GEBG XC@2'ABD)MYR(DN>(RMG(Z].Q_TH(M*RO*;_%F]T:K^/@M)D E* M"8P1CR'.(@PS21(8IRG"$<_T'V*7W9!;]Y-<:QKI 5T(L*>"V_[&<1SL-BK# MH3O&8M("NR=Y#?-6=O";D1[4XO?H#^F'6Y^&OZ,$HUKP?N@K7C>27ZG M^=P8]^^7Q5_@GVCQNZSJ'7^Y$=SQVM!G1 A!6*10I0F#6.G= M#A-Q!C.&8[W7R<(P)+/OLF#+:8S)KBAC',X,/@"6-[&#@CKPPF-$!%L9;\!& M&ZB6!2RU/C=@*WF/UZC>J/5Z,>HNQ;A7G=XH'5U>^K?DMP1]*^HCIY?:^Z*^ M%BUG2#%$J4#07#]"C)""-$PQC *6L9AFB$OJLL:"-# !;?"IQ6O=/,ZOKI,"("GXSPH):6L>@[@Z$;;?&?> V^#;8#S*/#>\E-/K=W)[M M;>2-["6MCS>M%]_P8XQ/\L0DSQ? M]/JD.V<91B5!7X0.J=&['3?"%#*?M;<@[_.2T_F_25J\6XBWM)(S%*0XP$) M')M (8$C2!0/(0MY3)(D06$L;$BQJY.I$=_Z*J\1%!A)@185&%GM"*P3TFZ2 MZ@NHH>TH'XRLN<8&A"V?E&M"*27_\\/R^R_Z]89+] ^'%-+9]"@T8:/33L;)M>,1Z80_;A_; #;R-OU3:PQ.#1&[%_T/N#1 MFT!>K>C\GLWSAWH_^-8DA?GVF!?"\-Z,\S".XI3",,8)Q#)1,.,J@4F:DD $ M69:ERO&DYU*?4Z,D%"#D?*YS$5CK YX^X1K^I&P.TP,9KOA:YMEMZ M/?.Q!:CGPY^+W8Y]"F2+PXGC(.M7W8BFWD@5+[.[3[.,R$C*2$ I>0IQ%FO# MAF("0\QC&49A0)A5]H-MDU.CB;O'?$'M>&('EVX:\--VZ%G^/S]\NKU^!A_K MUK&]:!\V$S1=_V+F9KHS-W<:'&7J'2NPGEDG/O%;H?\N3+V]W9N+7# %8FX%^/BFA'J/XST)MMOIHW]T2CC9F=(3;@2 Q,UVO)02LZ M:&0W>[Y&;+ CM[;5&HWZL] \D>O36G,5853+S1.?0RO.MQGW@^MWBRJO7FZ% MT"V6GY>ZQ?G_G3_?+86<21D&,0\4)"FE>OTA)K='D$"!4B13@51&D.W1]?EN MIK;,-)*"5E1S)62$!5I:8,2U/[_N0/;R"78_> U,1KY0.1UC7T;BBH/LCL9' M.\J^K.#N8;;%TY[G1[0H7C27?)'/R\)03YU6;Q.=^C8O^7QI E3;&+8HD2BD M,8%IE@AM'<4)),@ C)(,X81D&@>GLR2W_J=&&VOQ??R>7:&W/&T:#M"!>64M M<5NN83>^O_]$XYXP]7K^Y"C"N&=1?O@.U=_,SUNGEYBG M@B#,S(%X"G&<)9 )DL"4QAF+-*DQZG1-Y]+YU&CLZ^KIB18O9C_QMT4AZ3S_ M3ST/_TKS11/G]G%9EJYQ-4Z#8<=M0T$\,+%9A'* WVKIAW$]\H&M3Z)SZG]4 MEO-!YI#BO-KP2,CQU^6O4N0/]+DU!QC),A[$""(9:A*C,H)$&!*()CS* M$+?.MG'0^-3X:2.>0X*&0[RZ*>9:% :FD(UD/JDJ#I%PR$-Q!2(C)9EP0,8M M=\09U3L30QR^,U[6AS/2[J5T./>,G[%5>R\8EX9U2H@F%T1MUWV2/^I/RAGC MC"1I@"&EVK;").60A2J$.$0XDA'#H7 *++/J=6KTU9[1YK78YLC<9!VMC+FE MI-'!S;"R ][.HNH=SH%YL)87- *O4\@T(M^L\\(97^]&[OXL*">8^C2=[#H> MU69RPN+06')[^?J*#>\IK_.C_4I_YD^KITU-@SNJOV#Z[[.44X0E%9!%D331 M*R',TIA!FB9I$LLTE,K*4=NG\ZG15"LG8&M! 6\E]2_V<'$ ['AJ*%@'IJN/ M>R4BP%KR&["&>B,\N+L$]55U)&PQ&ZK.Q,7^7ZT.A2TR774JK-OP=CE_ED7U M\EE_MZK;A7BGK8=G8UI_DM5,96$L<)I!%B0$8L$B;6 Q!1G/"$L"_6'L5)*F MJ[.I$=9:UOJ,2JX%K1W+G=W(SR-LQU!]X38P(ZW%O &UH#5R[[;(?>I SL=Q M_"(D/?N,G^]O;'?QBYJ?\!2__(YGTBFNM^+&*4>*^^I1%J8"0B$?Y:+,O\L/ M"[Y\6M\Q!2Q$*M'HHIBEVAQ2$228(HA"297>N$5QZA3,:]WSU*AE1W!02P[V M1 >-[(Z)CJR'P8YR!@%W8/ZYO;_[ &ZKJLC9JLG;52W!9UH,<\OGC%"O*8RL M.Q\W59YG30Y-+[U-C+ZL;IHV_*$[>!L3R(&@KN*=SMV2#M?B;E@UBO M9U-. HQ[1N6#S=%9E5>YX8'S9W6F\-Z>K,TQH++-(1<)'IJ!OHG0B,&(T)% MR!6* A7,%O*A;M6K,JJK2%;?[*SY9A\)-MRW_(M\UDT]FD)#2[4.J=%[(2-T MJ5Z ?'J>+U^DWA_1GW5]HU9/L-S$=[JRPA7#:DDE X_22'>,E^J9KLOKU/5, MM7Y@1\&=F.E!*IOZXCI0T5)G<5ZK'JDO;AVE1KV;] W7^?HHYW/3(EV\S (F M""4ECR%&00)Q$&!*3D84&L4AB%86QF]OYF7ZF-H$W8H)YO71Z%P ^AZN= MA=(#6@//["U0M8@[%2K[LR/SH[S6'>&#>?*71]:\ MW/,0#%+LMR\97Z>N;\\(GRWAVW<_'GF(E]]E<83:;>^,EOSVEQE[&VY,/N'^;WK:1.]_TJS,ELU HA6$<$PIQ MAC.8J83!,!4JS1 1 ;/:KQPV/#7K8"T;,,+9'RWL875YXODB,/"\LU/>:=*= MTO2*.;?7W&A3[I02NS/NY.>^B3C*1^/R]YW.S>'B;;4.G:^7F%D2(*3M_!2F M.(Y-R4$$&2(QY'IH RHDP\BM6D]G=U.;G$;:VL&W%=4H\TFC8H-)OUHS.'D=.DF&C_7%.#*NW^JDO>Q"=OG7=^VNQ M+,MML@>3X>&-5,M"?J,_9XFDD>(HT*M\P"!F(8%4!J; :10S'(@H":+-+:Z# M.TH?POGUT)5+]1L[RD'6T0)N.!=P-VW;EKO<#!>-T 5NMF M[G.'JZ5Z%=9#EE?U$^Q5*ZY>A>6E(JS7->[I[[QBI;9Q])KP[KO^9YWF(U.1 M-OTBB&*%(*9,P(QF^E>9"H9CGBCEYM=\JI>IV7M;(4$MI6/6BVY$[6CR:IP& MICUWB-P]C+L@Z-63^&1'XWH,=^EZY!G<^;!GU+IF$I/%7]N!3G>QLW=/RBUD>!XI??\&.,+_*Y\4XL[]7'Y>+AFRR>C-TR MBX,XT[20PC2) HBS4$+*0P9%**(TS9*(2^GA@WNN/Y\-V3@.MJWSYE(!H>5T M8XNSZ-IQQ55@C99OM171(&2$A)K3G\#;+JR<:>(2$'V2Q-F^1J6(2QH?$L3% MY_WHX40Q^5O^'ZN\D&(62QSRA K(J5(0QXQ#IF*J?XVSC"DJ"2,N%D5'7U,S M*;:5$UJ?^V+CB"_ :J'Q;0M9;/\.GG4+_L4LN@;"CDQZ@G=@/EE+V=0?O&DK M4YBSET;4_CC% H\^::6KNU&9Q4+O0W*Q><6/7_XJ%[*@\]N%N!5/^2(OZV+T MW^6[G\;C?9W)(.5*$H0I3#/!($Y8"$G"37&)),."1 G)(A>FL>IU:IS3"ETG M6Z%[8KLQB1WD=IS2.Y #L\LNAOL2@U;D 4Y G$#JDW+L.AZ5?)RP.*0AMY?] M".G#H@G+6H=G?5BT9>#++Y++O/:]FF&. \2"1/-1&$,FR1!J:DM8S:S%D+Z<9%5FC;45%O"([#1&MQP1_7 O_)Y'3= M(/KE,J+.1.0"49\\9-7OJ#3D@L0A"SF]ZWF,*\M2RC,1!&TT:?EV)4U%UO?Z M*SG+PC0(1!3J$0CT5BQ ')*,$9AE"6,B"W 6.FW%7 68FJV$ A0YGNNZ0FYY MVCL@D$.? =>BWX#SL40WZ\CFLJGL;)0 1HL>SX<]\>OUU-A5AG'/DCT1.CIA M]FW'-[_RQMW];E68S&T;SW,A>9"J*("Q,I?5A$6F=JJ (1(AX5$0B,?]S*N!_)9+8^\ MCL\_Z3>_W[4)BK[*XGO.Y>F<)\;7^?U\^>.=4I)7YK>_E<8?]ZNLJKF\_4$+ M4))L:FXR?,ZJ_0;:CK%<9 MNH&9[F(^J3IBPZA@QK)1 M1:],>&O>/:)XGV)]RHW-L[IH>4W7\''F4'32*4X03%6001P&*60"13 +$5YD: Z_E M!%M!'0KQG<6RFQQ[0VA@HCL!CD^YPK,H.=0M[ .MD0H8>J'F5LKP$AJ=-0W/ MOCQ><<-+\N]5.;SXL&?ZGGQ!%SRG\P\+O3VNOQCU5BP3*24L#&&2&E MEBS%'M :F!1]@')/*M,- M0Z^Y8I>U+6:_K6M.$X%(0#B,",,0 M*\H@B6(*":(X$$'(LL2IO*!%GU-CBE;DVG'GKW+Y4-#GQYSKV:"6Q5-WHEQO MV.W(HV<%O@Q2.=P"HUW PBV['#0ZSQ^$H5,SA5<]SN'KC M=Z_>_>2/YDSA"ZWD?;TM/$@T\$5J\LMYI?>/^H/;A=C_P\Z3,ZEH'*62P""N MDY0*35MQ%,!0!@@E1,F(6"47'E#&J=%][K@.S+C;(5WK!XR"9BCOZJ$\3K6R5:OY MT(SMX=_>6>2Q<3_@&VXD>CWJ&T#,<0_]AL/YZ/AOP*X\#@+_MLAU@X^2SJM' ML[]>'\K$24(3Q"%FJ2E9)"0D:81A(A.2RDP&7%FY?'3T,36J;Z3\GQLI'^8_8'?]?#--*QW^&7J.\SOVX@.D_\SKPZWGE? MM^Q[IWT7'NUG9[^S5_VXR1D@8RX()0&DL3:4,8J9_HEE^I\ B30E@J9NB5DL M.IT:$Q[O27>DOJ;"I,T ^&WRKX5U]%V^,Z)7;_.[(!IRGW^RWU?=Z'_[6BA9[:\Y>FHQF*0B98$,%0H,340@P@XZF&6X8L# 2)F"D9Z9:? M]Z"/J;'.)EOM1LYVNKBG[3U$LYM3>L)H8 IQA\\9 'K(\7O8\NCI?L^H M=BKS[[E'_9, ^Y_9$*8BR64&F5("XB ,(-%[,\AI*.(P3D0WLDM%._YA_U%- Y($H0@ACWD$ M,94"$I0$D";P3]-'*0@]U2#[&Z/;ES[/]" M)]:#G$V_QBGTNF^3&VOKR+$]#PA4J"+!"4R5J8=&8[U04I9")1B+J#3Y':C+ M@_6ZY*)?S7-1'+75C;Y=/-%_,$*8I3F(%$Z*Y (>&$!*J?TU2 ME1!"HY!C&T+HZF1J;+ G9_/=!K\UHEJR02>DW530%U!#FS<^&%GS@ T('22@ M7]\A /W;X>3O;'^4F6^CX7K:6SW[Z@55[^B_";T1^T +Q> M&=8S7R$[VVE27XR!V7="WXG7+-[:/4X3K>9Z1NC_JN5=N\=@P'JO%SKNI_37 MMGZ-L;E_I57[V]_SZC%?W"^:?$!KI68D49C%5$ 5A SB+.7:6@[ULA?1(,!8 M(!$X)2*[3IRIK60F25:^ "%XT5)>5]S+<5SL5I#QT!YCDWZIG%>KSXO^=%ZS MMEXVS&'D5SW_] *Q_AB\U9_L\9S=@NP0-5^K+;P"&K/'E*-&K M%O?R0^]252_/5OWH^-?E0K[\2HO?9?5^M1#E.FP^#:B*H@SR.(I,,9\,9I)1 M*.(L$DF*:<"=4J2=[F9J]%E+"9YJ,8$RH@&YKP&G49"4(LX M0"[K;A3Z))XS/8U**-W:'A+%A:<]O4A-RGV3@4?/+W/[4;U\6E9RD]0O%JD* M!XA:P=*K;VAWC^-ZA5II?^0/:O>61R3.NWG^D&NKYF[Y])27 MIY"M,J#6!C3J.$2V^(]9-W&--Q(#$YKW M(/C$&?F/AD,HTBBC,E*TTH"CXQ;6=#6HG9%/_JV/%QQU-0)[\5/7M^9I'.OM M^+VJU\C/1<[E9UG4^>UF!&-)$H%@I! S[JX,LH#%,$XB$J$LYIG=I?VECJ:V M"!DYZZR>3?&T9R.K\5!MJ]&9ZG-B.9_3HMS^U;$0W5G,+6WC'I ^EY]PBH=XM*&]'O\[EL:CC. M2"AE(F4($T&U#1NQ.A930"(%#JD,@I!;[:!/-3XU>FCD T9 T$AH'^QT!%SW M?+\6CJ$-17LDG.*:SJE\14#349.C13*=4V8WA.GL,]=4/OK8U%9$_[X?K MAB)C)& 4AC2.($XB!8G %$H5X"C3\S5-E7NAH[/]36T"KVORM)5X=D2^IJ3] M!D1QX[E\+HF<1HXO0]%^SZ'R7KU"BZ*+^IRL277[-X_#K;5[2AX>B M*9+X82'R[[E84?TM$>_I4SY_:1U58YJQD"4"AM+4>>3$)%XD'"8\XD2$L:)Q M8'W29=?GU!AG3VJP%;N^*6\$=W0-=AD BV.K_F$=F'Y>%U&'HZ?^D1WIG,D* MX9Z2YWH@U7EX9-G4>"=%;KKM'0LYONK!XU_YHQ2KS2;QJ*Y!6QGXFSF'VB9V M38A*% \XQ"$B$..,0T+3K/;(#C"+HB"U2DSI+\+46'ZM!+AOCSU@K0?85613 M(?O-2U-8!'S3XO0=2UYK$EOED6Q_-'X<)L32VZ^K0^RKD<0 M*Q0QAC#D$0XACC(*28H9C,-$I%G,%156L4"7.IK:^K(1U81BU(?IK;!.U1XN MPFNQ5O0$VL KPDAX.1![3[B-1-_>^+GQLP4HG2S<]?YX7&NAQ1ZCVCSO>9_; M"6W,AY)#2HEF M6"*2), <2>J4L,%#AJFQ[<9X62K05D@U4CO>\WJ,A>45\+ (CV2LES6ZN_*; M/QC9;P![J7\ C1:#V(<]@-GK_;*'&.->/?OC='0K?453'O;DI^7B?ZWH/%?Y M.M/S9_V%7+N2A8$D&DO2E-%&(_L', O=S4UEM/"PHVT MH!$7U/(Z6$?=X%K8D[U!-C!MG4?+Q_6Q&S8'L[(W^$8R+*^!T0U?+\K4.&:K"9!- MZ3OS30#5HP2T%=D/EJ1'O-NNPOS;@IEZ]&[2C?\O4M^I><>9^7G,Z; MAM_KOVE3+$H0Q51 B9""F$D*,T$8Q(C&08ACGF"K)":=O4R-'C=U51I)U_.N MEM6]\LPQJ-T!6C.HM!#"9KCMDE MTI/J=B&^RN)[SC7+W*OW^8)JHJ'S;0;GTKB2E:<_:AU7@T $&:(<1D28/,QI M!@D1,>0!(HR0E&/B=,_7IW!3(YF-I#N)RETS. \RB+:G1*\S- .3FN>H>)PR M]0]?O\=3/'X@-T$A^=0R;>Z? MF=_TG1#SO.Z#'9B_0N+*\UIV'I=?DV#2I-3_7"S%BE=;II&;HA=!@H3 =:D+ M#G$48IA%^B?""8T0CF0<<-NB%V=[F9K5U K:Y(!M)/6H>G$>U.[9WAM4 T]X M+Y2EV8=$%N>1O<"W-"GS;Z8 M>=7PZX:C[P)]9WH;O?I>M]:G2NM=>.,Z%^U[56?B.0JGN2WT_N6AOK$KW[QL MG_E,7\S?ZL#!VAUV%D0DP2)4,$B# &)!& 9R*@/(LI<4M=VY=D4V.D M77?N6FS(CF/1=K4S_L>[#[8:ME&;C3>RZ^5_;\-NZ2CP&H,YM%/!N./H[4K> M&^9#.)A?+]RKN)WWANDY9_3^.O!;%][1PE0W+]#\D)_4^/P5KR_N+'N)5#MN+1'J 9FR+6D MVVR+-Z"5=I",Y);(],ECE[HERZGL*LRPED(9!M-QV M7@O/T#O.+3*U@ ,X:W="T.LN\V1'XVXPNW0]VEMV/GSMMO*^>I3%W:HHC'52 MEK(J#[*1I(%$(N("(AQH)I!,0D()A1%-"$TB12C*_/:-E[J>&CWL)BGY7,AG MFHMU3I(2Z-T_J!4"K4:@4+.[12FHT3XVB,VS+[K8N^O MM+&R1>7\SLFZ!3]NN]8 M4I)(KAE,2#6KEA6=VY'8B3ZVH;L=B%J M1S]7XC0PSVRD VNPC(#G$_0[U#_6WY[F&P'9I9USNLMP[39 MKQL%P+Q,-N#>ZG@)"+PU MWDM*X-_*M0G*?Y4BY^:=\:&2?6Z'-VV/N@<^ MU.APXWOTN8>9LBWXV-XN)6&H6"A3&&5SV$Q/8+,PN"X!H@1+N(:T7SRR!V!X6!.7 /*2#:$"SANEL,YY3O-A:.7 MQK,1SLF[9QB%_(_5G+!U^5P4B%(RF(,642U MH1"E6)L,*8%QD&:"A5D:E_:_UH9AG#2$]:# -$"<2" M*)B1B, DBA!-1<;#Q"H2UJZ[J5A1%&@I%N!DJ,NIL8:&PFO*$I] DA+>^ J>(8V"MR0\4\O>Z3\(#EE M/[Y./>GS6I[-'GO\I-_\_B*_R\5*OMIT:S^T+71<(:Z>I">UN=K%N]&<'OAWA]0[IP!1W'LTA MXR^<4.J3Q>PZ'I6WG+ X9"JWEZ^\\]&=\?G2'/"6FW#I4+"4X$3;8)%QG!,9 M@YF(. PC)".><$0E\;KL.='9U)C(R-HDYP,[TMI$5;OC['C#YS^G0_.Q%3M<[_22S>$/+G,_2.&-,*0JI)@RH-VT,4L1, M'#I23-(4$63EV]+9R]1XHQ8*_#%?@%4I3"0&*(VLYV.27 !- L13'&H63BG$ MA G(E,DW*9,HB=(T44DZ^RX+MAP-TMW>A@-UD^=B@^<-8 ,";4?(5X,W,!.? MR@Y2RSA<0I ]"(9, ])T]*K)/_9TO93R8_]A[T0?SX5\-$%>WV43??=)5O?* MG-A$0D0$!<9[4*;:7F,9-%GA((MP1$@48LH2E_C8CKZ<&'>$.-D]44&^&S7K MG/_C++YVC- 3:@/SPCY@>Y&S-T#+:S:*6N(;<%M5122WB=RB%Q\Q?,&;L7*VING>J>WEY7)D5^G6U4RB,(@ M93#&BFGK3>-)<9S!5"8R#LTU/W,ZA3_3S]3LMZV8H)83&$']ZC^> =;R6NYZ MN(:^F_-!ROV&KAN'7J_ISG0U[EU=M[Y'%W87'K\VN]#MHLJ%25>F:>>KY*LB MKW)9-H?D4C2'Z$_/JZH]HCHT>YH4IA+3C O)8)A) 7% )20FAVV0YN_J!K8)@K>'Z]FJCHWGIV.Z_-H=M+]\"2]Y[M;$=FBY? M85BOR)W4)_K#Y%?J1<)7RL'4)[KG\S3UVHOOGE4C8VY931=?\O+W-W+!'Y]H M\7OKM$QQE'%F$E-&V&0UEPG,4*)7"21,08 0&&XD] MO<(O8FZ[F>T/R<%WM-> Z+%OM4.FW\WKA3Y'WL':(7"\C;5\SR>V]J!:[V%- MWEOQ[ZNR,AX$;>PD)2B-(FV'!GI/:_S,"&0T3"&67/\?"1 +K#PNO'J?&@_5 M9?3R)J7^1E275$;.\'>ST."@#DU)AP7%;]9%>>^W)<-O=K#V"@=VQ=PE7'A M[,<*)W8=@[Z"C3VAZPY&=FUTQ&!E3WWW@YE]&[DR\.!>U;4!'Y=S_7)IBO]4 M+QO/C(B++*,"P2QD%&(N3>HH1&#$I*190@.)W0Y!;7J=VM*P=<(WA5AVQ/X' MT CN[15C-PB6!P=]0SOT>4 ?J/H'/-B@-$@,1&?'KQ,688/%V4@)JY?=.,K4 MF+_5;8LZUGI.'V8H%DF:9B%D*N*PK@)&"5,PI5S1+$S2)+2*JCQJ>6I7]6U^W<+M>3NY3\SP_+[[_H=YIYK7\XG,[' M[8TR9<^JL9Z6YQ_PV4D64N35[4,AZQF^:;!9_'RVNYU ^>R MN>L-P+&V MX?VR^$KGC^&]?9,14&,J8H3D=BG\NU1LJD1]59,8.1T25[;YWA9J+% MBSFP>Y\OZ*(NI]A6-%LK ZC>NF]#X)8+0,%&O3K\PK%VD_.HV1V7#CD6 R^M M6WAOCM WU__[: \:Z^R+XB!1B;8RO$ZDHB-"9Z,77=OQV+*\697Y0I;EW?*) MZ7EN; F3*D+WH;E:_U3FHJW#5OM)E3,9J!!3O0\)$DDA5EA"HB2"2@0DQ2FA MB%FEK/+J?6HL:=S(EJL*\%U1ZT"].D#/-BK';R0L-AQ#XCLP\ZU%!SNRWX"M M]&!/_)O&2]3%B<,9;X<]P9"XCV3W]XR_FTGOBU^GV>[^:W=R-^ M)O:A?7]@_3\MB\I8]7?+LJJ7JUD0)C0@BL T)%R;V!A#$J5Z^0A#%,21""5! M+G&;K@(X+1XC!'/6B<[<#&1GS.T,Y"&1?+VS)[V3A&5]/+'1 !@5^C.)?7'K MTR1VEF%4D]@7H4.3V+L=/V[[L."%J>'W5C;__;#8U/:[H\^YGK<;CYU IH'D MD81")MH>EI1 D],5Q@*S$*E0X2@S^N9?\3T);PMIQE*[^W M"Y7#J-CQWC!8#\QX?<+LS'CNB/7)=0Z]C\IR[J@<\IM'"W[,]G>9/SQ64MQ^ MU\T_R'59TL8BO%]59447=4K(]4S*,,MBFH50A0VKT M;L>-(,NB,B%;Y7*>BWJ37*<$K[-8R$020A6#C#,"<8A074\9,KUIC02+9U6\]^BR>OO!G^L'C6Y/%1?I?SL/4JY"(C:2@(5%$D($[UKHYDL=][0DL':]FKT-HQ%O81M ;T +68_%.!TP& MN5,]T=WK7)^>U_OL36G'*^YFP*_TWY?%.DE^LVJE84"ID"$4@2D:GD04$FYR M#H8"82*0(M+*&?-T\U,C@[5PSFO^">0NK_?7X3'T6F\)A=,"?U[C:Q?W$RV/ MMK"?UVIW4>]XRF]!_ULI[]6[LLJ?:"7+&2<1ESR*8)KJZ:K7<&VL9RF!09 * MEJJ$TM2IML1^\U.;J5_SAT6N?^KY5X MD [9#LY@;+>V^R,W\)S6@M5)IM:BW31XO8#?VO\.XC]U&HX^5_*#'D9=O$]K M=[A>GWG*/63THX9[_OEQN6C/ V8)3D1*9 E40'$F=)K,PL03)&,I40R31*K M/?JIQJP)F'SQZ!%SW7+X6CH%GL@,23F&DYU2^(I+TJ,G1@DG/ M*;,;3WKV&0^7PIVD;,V*5'Z17.;?ZUHN^[6("(XS;5$G$&59 G$K_MMPCZ:^H%R,AY4P&,>0)-OF18PP))R'4N[-(BQ9C'CG5 M3+?M>&J4_WY5K0H)GO)%_K1Z O/:H^.YE==M!W&ZG/ 200UO>M<@W.VY'M=0W8".WWE6W MDM^ MQV5?)TWTJYH];G%MNY[U,VW*R*'VW+G]ST3)-/R<28TT?.8Z8UZ)O0" M0!,"B20I3&+$XR!()25.=VRFT:F1NY'),8^Q@<:.+%P5'OJ O$M7]W3#.\KU MFE+8M#MNVN =38Y2 ^]^=N4U]IN7S4R]F].RN73)$$5,T1@&%$40XQ1!FDD* M,QX)3(,@(\K)RNKL;6JS;R,AJ$7T*FC3#:_=1.T-M*&7\_.^SNW 8Y$;[ M9(>O0AUAL$EJ0P4RJ%0D28 M4H;#A#D50>[J;&JLL3FZ*!S/W:R0%9)S%IO*TGK;I?\Q4=-9:/Y)8AHHE822 MN)4S[0O;<:J:#HNN'1_WA=C ='SB#.T&4*7G +B=SY<_J"8>H)8%://$F6*& MFPP\/<:V6:#5:QQ;5W_CQJQ9:'X4GV;SCA]COZ%S,^1?'Z6LOL@Z<" MR\7#-UD\F7#][<[\RR$+4?WQ#2RG6MTC;+S*-A$04,YA&.(*8: (@2$20A"K@1#(: M1$X9-UT%F!I!-#([%A5R!=V./8:$2)T5)G(MQT_COM<2&/'O_OY+!>EU%W=5X^R:+)TKL\BB218 MQ$A!@2)MW+"40I))#B,4$,)9I@(I76C-HL^I,5DK,I"-S$WHR=*(#7@C,:"U M_&YD9X-^+,(P3@B&/(HIQ"A5D,6)@H$I)B4H9T2F+BY.?:,_@G?3*Z)OM[KT MC.G "\H:SE;<&LU:X#8?\P!'[PX ];EDV'0[ZBKA@,/APN#RJF]13;V>?"C+ ME11O5R8GM1\ MUBAQ]&Q3,[5T3[M\Q5!:VM&##M 8EG1K,-\MG\Q$:A*>W!:%?JXI3<5>3AG6 MX/8'+81Q#JVUNP%K_4HSL T(?=;Y]$6YWZ*?SE*,7 '4%Z7C+?E1K3FF M^+ HJZ(.9_FDO[-OET\T7\PX)01EF$!!J2'4)($TQ K&&$4DXBI.1>I"J.19<.XKK [*!BN@1%GVQSMJ]1.>62 MQH?,Z&_J;'%NY^57KO-RFT.W*\/=-F%UO(VHC_ AKZ7.!?6THH+OG5!V$LHRPE@ MAHY@V>WRU0-73NAO$Z]RZC7?2TM30Z$MG,!?U@DG/\\U4U6Y4N4L1%*;&2K2 M5F\609S@%#*$. PS26,9QDBZG?%=['%JE++-N_J\D='UKE)[)Z[!AY\ /C M5SP:MCH$[N.XUR3'>:35C#'$1"04S+K218/YA M+ Y@&BF<9&D21 EW,1+&%7]J5L@G68%\74NG]LPN'V_J?X':$ )ZHQF1SA M+11@C04P8( &C7ZS)8P_BGWG91A1@]$S0(P_.J=R3;R"%#YY(Q_UTFR.J-L* M D&6X" )$)1ZE8,X2@FD02 A5S)6$9(91E;1Z*<:GYHU78L'[<_G3P+63?W7 MPC"XN\$:@1(/WADQ&>)I:?ZQ,U MC[5TX(]S+9^C3]4^^-Q\"D;J#XT$)A1/L3N*VTI<%659T3MEJ"S[3?0\^32/1IL>YW,*I! M>5*W0WOO]$.^\0Y++J4HWVM13OM!TI1F3&B@PC@U1Q(X@%G" FVH29P**@)E M:KJ[1#M@;5+;>F?10D,4^9@"@UU3BI0I!* MD<(HRP)-/;$(8B?*.>IA:A33"-C, \>CQR/P+$\'KX%DZ .\'30&*+YW5O5> M3[V..AGW8.J)C>I][P?'"N#G\;1;FY?C<[ \_O '6*0O%*=& SF(?$Z6:,Z=>WT MF.@I)]3&3?-N65;E[6(=E+?-F8:R-"69%##&401Q@+@)X\ P"9,LE8J*2#AE MA[K8X]3(8.MMS(W$]>73.GS7D1HNHVU'$[UB.#!E;.&[V\"W%G<0_K &IT\N MN=SIJ+QBC<$AQ]B_Z)DO9V[ M02"BDEC"@*:)WEJ$&#*B1R*@62 %XB@B3G[=_J),C:'>T6*Q7%5@OLD5_G_^ M=X)"](]K-T['9)K^8V1'7^,@/S"OK94 .UK<;!W(*["GR%[IE=Z=2:\'M-?T MG/[2C)NR\VK4CM)X7M^B;Y =W;4BL,S"($HB*),40:STSHUP$D"5AAF*LE3P M,'.+J:,3-M :Z;QS!Q]@9T=A_H@,3$OV8'C$PYW2N=_P-_IJ)M-I[8Z#VTX^ MU4?H?%V\),8RB5$60Q*8 NDQBR!) @JC+$$!YVD6(R@P!PKX(P M)X"TF\;7P3/P5'9$YLJ0^*'JO9SHY17#X+LJNW0\>476S3K7W6Z*EIT,+6]> MCM+AU!MB.I\8=MH%Y;:01\\L,V@O(O><*O4ZJ\;.']H+B MR7RB_;3L::_E)7UX*.1#W?&]^B*_R\5*;B8V/32OQ%1Q[$71+2Z]'*(>V^ZY#T=T.M(2F5ZOP M4I_CVHB6"!Q9C+;O^?'-?N3')ZU+>\RJT@R),$J@)A<.<ZVAJ_/+EFE"_LVC:$4@?& U,' 'B\VYL4!:5<>03*U[=%U]E\3WGLC[BD))(SE($9:92B(.$0RKU5C%( M9,;")$VD75&Y7U*_8[[K M5W?FNO[M<)Z?;7N4^7U)L_6\OOC(*"]?FTT74YO36^^0>1VH;5QL/'UJMC#:+>C7@3/PC#Y*<7C7 M!8R_C\R1[H,XQ6Q[>1TOF",MS[J]'#_IFY'HZQ.=S]<7PC,6HD@(&D*4R@3B M+&"0!!F!:8 (91%+L; Z&3C3_M2F=9M0IY81K(5TS3JTCV#WI.X!EX%GM!LD M'IF%3BI^=4*A_59'SB-T4J7C]$&G'_,/:$KRW1/?%WRA%[>VJX MC8V=%3 8X@/329]@>\7A.(/6=XR.O0"CQ^\X8W,JML>]$<^XG^\TGYN([_?+ MXBN=RZ^2KXJ\,EU)5OU*J_:WKUJ$N6Q_?WE+*WG[9-*U_:>YCRFK-[3,MUY4 M<9@%&8J)IL-8[V22A$"J: I1**C@DD1!Z)35?0@AI\:?&TF[C?WQ!M&.05][ M:(:^C3%>.%N=;L!&7ZB6!2RUQC=@K97^=%[3IQ[$^C"FUGGS,3!:ZV?V!GJ8 M(*H!!Z77&*PAY!PWA&M I(\BP(;LRW>C^SZ?R^).]_&P+%YF/,4$BRR $<]B MB%-EXD6S",:1"@0.&:6)U:'TF?:GQMGMKJZ6$:R%=-WH[B-HN]'UQF6&NK]+0/71OD.6-42HF4@))FTIQ2 M([U_DP*R-)&I"!*MN7#:M5EU.S5":"I@U&FA6N]3ONNEVL9^.^[/[ ; AYWC^*$QM&NP^UMWW/WXGE9Z%X^ M+1=?Y8/Y6K2+*8LSBD6$((N9)B5& JB-% '3-$ :C$QSE5,"BK,]38V'-H*Z MGI*?0]+V1+P'? 8__6YEK'W<8"OF(!FG+H#1[ZGVN'P';_,S"P@V^0SI0CW4GUL%;C!FA%0#T MP*@"C"[#EBJUAG+H J:7!7GULJ;66-D4.[5OS),6V_9S:2X'ZP2 C\NY?K\T MQ2&JEUF<\3#BA,$PB@C$RC@;(11"13)&(Q9F"7*J5WBI0R>R&ZV$X7PK=7T7 M4^[(7>?'2?^QKB5469[76L-OR7X]@CHTT1T@^:X;-7?VLH2B5Z*ZU.>XG&2) MP!']V+[G4?'EN+#,+>?%2HI?:?&[K.H*,TUNL%D@19A%VL82+#'Q2"B#5#+- M/T' ! G3,)96)I=COU,SLEHYP=-:T$V>0(=B*0ZP=Q/-@& .S#>;LEUKJ<&' M!5B#NQ%\DT5P&' =BM0, _)(]6OTSF!;:>^/8ETG#8A584"N],?%IA[FO:[_N>>RM^XH]I9&<>AN?&*YKCKN%=/Q^-UWUO^6R$*D]E,_WA??%O^ M6,RR2*8J3",H"8\@SK(04H)C2&/",YJIE NKRX*./J9&\.W5=BOG#3"2:AR! MD=7UTO\8T&XZ[PFF@:G;"R$/'X"S&%SM!W#<\LB^ &=5._8'./^HW\ZRJ4WS MC?X\X4Y-8X6"+(M@* B&.&4<4AIA*-(H%@&*DS1S:\?[3 H\^M8U=WH^X:+?0^W##:O.*Q5WRS+(KE#VUO MF-O!SU)_@[3=^B#?+I]HOIC%>A^HPA!!D<09Q")DD&"$8"H1P4D8)X%=E,SE MKJ;&'!MA@9$6;,4%OS4"NY31[ ;98C/8&W0#,\>(J#GL\GI#;Z2-W1HKH+3] MU0%I3WD"[#'JW*9UMS#>SLQ*D[W-F-T;GIDD5\_/\]I7AL[?4#W,7'Y]E++: MLGCY3?ZLWFCQ?Y]%),41$3%446AB;V@*B2 $2AJG(4U"EB&G"U"7SJ=&P+NR M@_?Y0@N?ZY^^ZLG7Y!G\L-#3XZF>BHZY'UV&Q,ZN&PKH@>EZ#^-6;E +OF/X ME> W(SNHA>\S::,'9KVF9W3I?]Q$C![('*5<]&G#PWZ\6SVMYGH2?F\KU3>E M[>_5K6CJD)ROW*A0[K5^_EL>SBJ_2?,]:OJXE7Q_CA3'*FPHL7_+R M]ZV5'LX2AI2(M:VL2" AEJG)XB'T8H)QQ"1!,LJ<*B]T=3:U9:-.-U"6)KJA M:%*8WIBKOE9<5_?C#I!#3 4)%(<9#TQ%\MAX=:L (I1%,94IXR*8?9<%6XX- M\VZGPP']*_UWO1GG^IN]?)+%P&#;;3KZ G#H57A73&#DO-DYQ>C3X?LR'/WZ M?'?T-[+;]V7-CSV_+=[QOHLZ?;>][_-T7SW*8NM_N?UL%B21C!*2P@#K+0(6 M000SP2,H(\0#2K*(Q$[!;-<*-#727SO4K/TV:M>^I9%^UW72^6[KND&SO@ ; M;2B&OR5K76_>;EQO\JVWTZ'K9:W2KL>YQ4CYW*?U F_/EV[7R33VS5PO")ZX MONNG74_/\Z6I;;B3C.J;248RHT0;S_J;#H6VXJ!F6P$9BAGDB8B21*@0.68- M.-G-U/C32'F0=NVW6E#7^H.G0;5CPNNA&IC?/%!R]Q_O!*%7K_'3/8WK*]ZI M[9&'>/?3?:2NWL2[[-14B(*,2$H3R#"+M/&%]4\)QGI+K1+]/Q9DL1,E7.QQ M\PD5'_@JF3-#R^ M\DH.[T"1Q4"_4T1DY!;,O M6&6UTR+I>M0W('8AU^F2WE.^6U=]XY1S1_4WPT1G2H4U5: ,QH@*B$-J#J/# M!*8\"A).4I-KQ&FSXM#YU)ADZQ7&6PE=0V$=@+?;7A?4-:NV"LZOV?SO"DK MN,X>\#Y7U:-)(3!+L1*)$"%,8H;,526"5&(!DT#Q)!4L3A+7JTJ+;J=&7KXI M32Q!MKX]ZQFZX>_1U@*#K<2[Z4EJJ>LD);W>JCG U//]FDW/8]^T.:!QXL[- MY6T_)OIL GZ7BUO->'GQKW2^DIL?MKY_:S>\*(RB+$F@8EC341 C2$3"89C( M4,624X:M4CY[]#TU3FI%!]28 'D!:J'!KWH[K$6V2U%V]7#8$== ( _,7CW@ MZ\Q='DCU26 NW8_*8AZX'%*93Q,>WL7O-$OF>INY=7,JOT@N\^]F[UE^77$N MM7&W>/B:__Q5D^MCV83Q M&,DA>;!Q:_J/%[:S"]S(5O7 MNKIK*>X7WPJZ*+7U;^96EH8$<1[J!0DIB#.S/J7:@I!9*I!*DBRS*RKJU?O4 M%J9/L@+/Q=(,2PG,%P.8TDSF3*Y._.<8W._( M#M;" _WSCO@]QO?YH-9K@)^3 .-&^/E@Z*40$RTY< H"R&5 ME/* *J48\=P%7>Q\:J3P=7?+

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end XML 35 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Details)
$ in Thousands
1 Months Ended
Jul. 01, 2019
plaintiff
Apr. 29, 2020
claim
Mar. 31, 2020
USD ($)
Loss Contingencies [Line Items]      
Loss contingency accrued     $ 1,200
Remainder of 2020     1,961
2021     2,189
2022     692
2023     444
2024     229
Thereafter     0
Total     $ 5,515
Subsequent Event [Member]      
Loss Contingencies [Line Items]      
New claims filed | claim   2  
Le'Vias Compliant      
Loss Contingencies [Line Items]      
Number of plaintiffs | plaintiff 2    

XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 214 324 1 true 71 0 false 12 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.ehealthinsurance.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 2101101 - Disclosure - Summary of Business and Significant Accounting Policies Sheet http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPolicies Summary of Business and Significant Accounting Policies Notes 6 false false R7.htm 2106102 - Disclosure - Revenue Sheet http://www.ehealthinsurance.com/role/Revenue Revenue Notes 7 false false R8.htm 2111103 - Disclosure - Supplemental Financial Statement Information Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformation Supplemental Financial Statement Information Notes 8 false false R9.htm 2119104 - Disclosure - Fair Value Measurements Sheet http://www.ehealthinsurance.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 2126105 - Disclosure - Equity Sheet http://www.ehealthinsurance.com/role/Equity Equity Notes 10 false false R11.htm 2130106 - Disclosure - Net Income (Loss) Per Share Sheet http://www.ehealthinsurance.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 11 false false R12.htm 2134107 - Disclosure - Commitments and Contingencies Sheet http://www.ehealthinsurance.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 2137108 - Disclosure - Segment and Geographic Information Sheet http://www.ehealthinsurance.com/role/SegmentandGeographicInformation Segment and Geographic Information Notes 13 false false R14.htm 2142109 - Disclosure - Leases Sheet http://www.ehealthinsurance.com/role/Leases Leases Notes 14 false false R15.htm 2147110 - Disclosure - Debt Sheet http://www.ehealthinsurance.com/role/Debt Debt Notes 15 false false R16.htm 2149111 - Disclosure - Income Taxes Sheet http://www.ehealthinsurance.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2202201 - Disclosure - Summary of Business and Significant Accounting Policies (Policies) Sheet http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies Summary of Business and Significant Accounting Policies (Policies) Policies http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPolicies 17 false false R18.htm 2303301 - Disclosure - Summary of Business and Significant Accounting Policies (Tables) Sheet http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesTables Summary of Business and Significant Accounting Policies (Tables) Tables http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPolicies 18 false false R19.htm 2307302 - Disclosure - Revenue (Tables) Sheet http://www.ehealthinsurance.com/role/RevenueTables Revenue (Tables) Tables http://www.ehealthinsurance.com/role/Revenue 19 false false R20.htm 2312303 - Disclosure - Supplemental Financial Statement Information (Tables) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables Supplemental Financial Statement Information (Tables) Tables http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformation 20 false false R21.htm 2320304 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.ehealthinsurance.com/role/FairValueMeasurements 21 false false R22.htm 2327305 - Disclosure - Equity (Tables) Sheet http://www.ehealthinsurance.com/role/EquityTables Equity (Tables) Tables http://www.ehealthinsurance.com/role/Equity 22 false false R23.htm 2331306 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.ehealthinsurance.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.ehealthinsurance.com/role/NetIncomeLossPerShare 23 false false R24.htm 2335307 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.ehealthinsurance.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.ehealthinsurance.com/role/CommitmentsandContingencies 24 false false R25.htm 2338308 - Disclosure - Segment and Geographic Information (Tables) Sheet http://www.ehealthinsurance.com/role/SegmentandGeographicInformationTables Segment and Geographic Information (Tables) Tables http://www.ehealthinsurance.com/role/SegmentandGeographicInformation 25 false false R26.htm 2343309 - Disclosure - Leases (Tables) Sheet http://www.ehealthinsurance.com/role/LeasesTables Leases (Tables) Tables http://www.ehealthinsurance.com/role/Leases 26 false false R27.htm 2350310 - Disclosure - Income Taxes (Tables) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.ehealthinsurance.com/role/IncomeTaxes 27 false false R28.htm 2404401 - Disclosure - Summary of Business and Significant Accounting Policies - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails Summary of Business and Significant Accounting Policies - Narrative (Details) Details http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesTables 28 false false R29.htm 2405402 - Disclosure - Summary of Business and Significant Accounting Policies - Adoption of ASU 2016-13 (Details) Sheet http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details Summary of Business and Significant Accounting Policies - Adoption of ASU 2016-13 (Details) Details 29 false false R30.htm 2408403 - Disclosure - Revenue - Additional Information (Details) Sheet http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails Revenue - Additional Information (Details) Details 30 false false R31.htm 2409404 - Disclosure - Revenue - Commission Revenue by Segment (Details) Sheet http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails Revenue - Commission Revenue by Segment (Details) Details 31 false false R32.htm 2410405 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 32 false false R33.htm 2413406 - Disclosure - Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 33 false false R34.htm 2414407 - Disclosure - Supplemental Financial Statement Information - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails Supplemental Financial Statement Information - Narrative (Details) Details 34 false false R35.htm 2415408 - Disclosure - Supplemental Financial Statement Information - Schedule of Accounts Receivable (Details) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails Supplemental Financial Statement Information - Schedule of Accounts Receivable (Details) Details 35 false false R36.htm 2416409 - Disclosure - Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) Details 36 false false R37.htm 2417410 - Disclosure - Supplemental Financial Statement Information - Schedule of Credit Risk (Details) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails Supplemental Financial Statement Information - Schedule of Credit Risk (Details) Details 37 false false R38.htm 2418411 - Disclosure - Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 38 false false R39.htm 2421412 - Disclosure - Fair Value Measurements - Summary of Financial Assets (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails Fair Value Measurements - Summary of Financial Assets (Details) Details 39 false false R40.htm 2422413 - Disclosure - Fair Value Measurements - Contractual Maturities (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails Fair Value Measurements - Contractual Maturities (Details) Details 40 false false R41.htm 2423414 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails Fair Value Measurements - Unrealized Gains and Losses (Details) Details 41 false false R42.htm 2424415 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 42 false false R43.htm 2425416 - Disclosure - Fair Value Measurements - Earnout Liability Activity (Details) Sheet http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails Fair Value Measurements - Earnout Liability Activity (Details) Details 43 false false R44.htm 2428417 - Disclosure - Equity - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 44 false false R45.htm 2429418 - Disclosure - Equity - Schedule of Stock-Based Compensation Expense (Details) Sheet http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails Equity - Schedule of Stock-Based Compensation Expense (Details) Details 45 false false R46.htm 2432419 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details) Sheet http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details) Details http://www.ehealthinsurance.com/role/NetIncomeLossPerShareTables 46 false false R47.htm 2433420 - Disclosure - Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) Sheet http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) Details http://www.ehealthinsurance.com/role/NetIncomeLossPerShareTables 47 false false R48.htm 2436421 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.ehealthinsurance.com/role/CommitmentsandContingenciesTables 48 false false R49.htm 2439422 - Disclosure - Segment and Geographic Information - Segment Operating Results (Details) Sheet http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails Segment and Geographic Information - Segment Operating Results (Details) Details 49 false false R50.htm 2440423 - Disclosure - Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) Sheet http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) Details 50 false false R51.htm 2441424 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) Sheet http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) Details 51 false false R52.htm 2444425 - Disclosure - Leases - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 52 false false R53.htm 2445426 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 53 false false R54.htm 2446427 - Disclosure - Leases - Maturities of Lease Liabilities (Details) Sheet http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails Leases - Maturities of Lease Liabilities (Details) Details 54 false false R55.htm 2448428 - Disclosure - Debt (Details) Sheet http://www.ehealthinsurance.com/role/DebtDetails Debt (Details) Details http://www.ehealthinsurance.com/role/Debt 55 false false R56.htm 2451429 - Disclosure - Income Taxes - Summary of Income Tax Benefit (Details) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesSummaryofIncomeTaxBenefitDetails Income Taxes - Summary of Income Tax Benefit (Details) Details 56 false false R57.htm 2452430 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 57 false false R9999.htm Uncategorized Items - ehth-20200331.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - ehth-20200331.htm Cover 58 false false All Reports Book All Reports ehth-20200331.htm a2020q1ex311.htm a2020q1ex312.htm a2020q1ex321.htm a2020q1ex322.htm ehth-20200331.xsd ehth-20200331_cal.xml ehth-20200331_def.xml ehth-20200331_lab.xml ehth-20200331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 38 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Mar. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Equity, Class of Treasury Stock [Line Items]      
Sale of stock, shares issued (in shares) 2,070,000    
Sale of stock, price per share (in dollars per share) $ 115.00 $ 115.00  
Net proceeds from sale of stock $ 228.0    
Number of shares repurchased under share repurchase plan (in shares)   0  
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)   985,454  
Treasury stock (in shares) 11,649,342 11,649,342 11,615,558
Over-Allotment Option      
Equity, Class of Treasury Stock [Line Items]      
Sale of stock, shares issued (in shares) 270,000    
Previous share repurchase programs      
Equity, Class of Treasury Stock [Line Items]      
Number of shares repurchased under share repurchase plan (in shares)   10,663,888  
XML 39 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Contractual Maturities (Details)
$ in Thousands
Mar. 31, 2020
USD ($)
Amortized Cost  
Due in 1 year $ 201,482
Due in 1 year through 5 years 24,388
Total 225,870
Fair Value  
Due in 1 year 201,486
Due in 1 year through 5 years 24,409
Total $ 225,895
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements We classify the inputs used to measure fair value into the following hierarchy:
Level 1Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability; and
Level 3Unobservable inputs for the asset or liability.
Summary of Financial Assets Measured at Fair Value on a Recurring Basis
Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):
March 31, 2020
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$105,798  $105,798  $—  $—  $105,798  
Commercial paper62,005  —  62,005  —  62,005  
Short-term marketable securities
Commercial paper23,063  —  23,063  —  23,063  
Agency bonds10,620  —  10,620  —  10,620  
Long-term marketable securities
Agency bonds24,409  —  24,409  —  24,409  
Total assets measured and recorded at fair value$225,895  $105,798  $120,097  $—  $225,895  

December 31, 2019
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$7,261  $7,261  $—  $—  $7,261  
Liabilities
Earnout liabilitycurrent
$37,273  $—  $—  $37,273  $37,273  
Summary of Financial Liabilities Measured at Fair Value on a Recurring Basis
Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):
March 31, 2020
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$105,798  $105,798  $—  $—  $105,798  
Commercial paper62,005  —  62,005  —  62,005  
Short-term marketable securities
Commercial paper23,063  —  23,063  —  23,063  
Agency bonds10,620  —  10,620  —  10,620  
Long-term marketable securities
Agency bonds24,409  —  24,409  —  24,409  
Total assets measured and recorded at fair value$225,895  $105,798  $120,097  $—  $225,895  

December 31, 2019
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$7,261  $7,261  $—  $—  $7,261  
Liabilities
Earnout liabilitycurrent
$37,273  $—  $—  $37,273  $37,273  
Summary of Contractual Maturities
The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):

As of March 31, 2020
Amortized CostFair Value
Due in 1 year$201,482  $201,486  
Due in 1 year through 5 years24,388  24,409  
Total$225,870  $225,895  
Summary of Unrealized Gains and Losses
Unrealized gains and losses on available-for-sale debt securities are included in accumulated other comprehensive income and summarized as follows as of March 31, 2020:

Amortized CostUnrealized GainUnrealized LossFair Value
Cash equivalents
Money market funds$105,798  $—  $—  $105,798  
Commercial paper62,005  —  —  62,005  
Short-term marketable securities
Commercial paper23,063  —  —  23,063  
Agency bonds10,616   (1) 10,620  
Long-term marketable securities
Agency bonds24,388  21  —  24,409  
Total$225,870  $26  $(1) $225,895  
Summary of Earnout Liability Activity
Earnout liability activities are summarized as follows (in thousands):
Balance as of December 31, 2019$37,273  
Change in fair value—  
Settlements(37,273) 
Balance as of March 31, 2020$—  
XML 41 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating activities:    
Net income (loss) $ 3,452 $ (5,159)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 823 655
Amortization of internally developed software 1,501 719
Amortization of intangible assets 547 547
Stock-based compensation expense 8,714 3,229
Deferred income taxes (2,141) (3,543)
Change in fair value of earnout liability 0 13,306
Other non-cash items 223 (1,194)
Increase (Decrease) in Operating Capital [Abstract]    
Accounts receivable 1,664 221
Contract assets – commissions receivable 26,873 17,648
Prepaid expenses and other assets (159) 1,111
Accounts payable (16,279) (768)
Accrued compensation and benefits (11,104) (9,390)
Accrued marketing expenses (7,329) (7,147)
Deferred revenue 113 2,897
Accrued expenses and other liabilities 2,009 (383)
Net cash provided by operating activities 8,907 12,749
Investing activities:    
Capitalized internal-use software and website development costs (3,564) (1,487)
Purchases of property and equipment and other assets (2,508) (1,509)
Purchases of marketable securities (58,064) 0
Cash used in investing activities (64,136) (2,996)
Financing activities:    
Proceeds from issuance of common stock, net of issuance costs 228,024 126,051
Net proceeds from exercise of common stock options 1,091 2,367
Repurchase of shares to satisfy employee tax withholding obligations (4,375) (1,280)
Repayment of debt 0 (5,000)
Acquisition-related contingent payments (8,751) (9,542)
Principal payments in connection with leases (58) (25)
Net cash provided by financing activities 215,931 112,571
Effect of exchange rate changes on cash, cash equivalents and restricted cash (2) 62
Net increase in cash, cash equivalents and restricted cash 160,700 122,386
Cash, cash equivalents and restricted cash at beginning of period 26,820 13,089
Cash, cash equivalents and restricted cash at end of period $ 187,520 $ 135,475
XML 42 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - shares
3 Months Ended
Mar. 31, 2020
Apr. 30, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 001-33071  
Entity Registrant Name EHEALTH, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 56-2357876  
Entity Address, Address Line One 2625 AUGUSTINE DRIVE, SECOND FLOOR  
Entity Address, City or Town SANTA CLARA  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 95054  
City Area Code 650  
Local Phone Number 584-2700  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol EHTH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   25,614,001
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001333493  
Current Fiscal Year End Date --12-31  
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Segment and Geographic Information (Tables)
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents summary results of our operating segments for the three months ended March 31, 2020 and 2019 (in thousands):
Three Months Ended March 31,
 20202019
Revenue:
Medicare$96,151  $54,901  
Individual, Family and Small Business10,257  13,872  
Total revenue$106,408  $68,773  
Segment profit:
Medicare segment profit$21,960  $10,826  
Individual, Family and Small Business segment profit2,603  6,024  
Total segment profit24,563  16,850  
Corporate(13,448) (8,296) 
Stock-based compensation expense(8,714) (3,229) 
Change in fair value of earnout liability—  (13,306) 
Depreciation and amortization(823) (655) 
Amortization of intangible assets(547) (547) 
Other income, net373  557  
Income (loss) before benefit from income taxes$1,404  $(8,626) 
Schedule Of Long Lived Assets By Geographical Areas Long-lived assets by geographical area are summarized as follows (in thousands):
March 31, 2020December 31, 2019
United States$99,297  $64,408  
China418  471  
Total$99,715  $64,879  
Schedule Of Revenue By Major Customers Carriers representing 10% or more of our total revenue for the three months ended March 31, 2020 and 2019 are presented in the table below: 
Three Months Ended March 31,
 20202019
UnitedHealthcare (1)
22 %17 %
Humana19 %23 %
Aetna (2)
15 %17 %

(1)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.
(2) Aetna also includes other carriers owned by Aetna.
XML 44 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy:

Level 1Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability; and
Level 3Unobservable inputs for the asset or liability.
Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):
March 31, 2020
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$105,798  $105,798  $—  $—  $105,798  
Commercial paper62,005  —  62,005  —  62,005  
Short-term marketable securities
Commercial paper23,063  —  23,063  —  23,063  
Agency bonds10,620  —  10,620  —  10,620  
Long-term marketable securities
Agency bonds24,409  —  24,409  —  24,409  
Total assets measured and recorded at fair value$225,895  $105,798  $120,097  $—  $225,895  

December 31, 2019
Carrying ValueLevel 1Level 2Level 3Total
Assets
Cash equivalents
Money market funds$7,261  $7,261  $—  $—  $7,261  
Liabilities
Earnout liabilitycurrent
$37,273  $—  $—  $37,273  $37,273  

Our cash equivalents were invested in money market funds and commercial paper with original maturity 90 days or less were classified as Level 1. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our investments as Level 1.

As of March 31, 2020, our Level 2 assets included our available for sale marketable securities, which consisted of commercial paper and agency bonds with maturity less than two years. We classify our marketable debt securities within Level 2 in the fair value hierarchy because we use quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. Our portfolio primarily consisted of financial instruments with credit rating of AA+ or equivalent by S&P Rating and Moody's Investor Services. There were no transfers between the hierarchy levels during the three months ended March 31, 2020.

The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):

As of March 31, 2020
Amortized CostFair Value
Due in 1 year$201,482  $201,486  
Due in 1 year through 5 years24,388  24,409  
Total$225,870  $225,895  
Unrealized gains and losses on available-for-sale debt securities are included in accumulated other comprehensive income and summarized as follows as of March 31, 2020:

Amortized CostUnrealized GainUnrealized LossFair Value
Cash equivalents
Money market funds$105,798  $—  $—  $105,798  
Commercial paper62,005  —  —  62,005  
Short-term marketable securities
Commercial paper23,063  —  —  23,063  
Agency bonds10,616   (1) 10,620  
Long-term marketable securities
Agency bonds24,388  21  —  24,409  
Total$225,870  $26  $(1) $225,895  

As of March 31, 2020, there were four securities in net loss positions and their unrealized losses were immaterial. We did not record any credit losses regarding our available-for-sales debt securities during the three months ended March 31, 2020.

Earnout Liabilities

Our earnout liabilities in connection with our GoMedigap acquisition in 2018 have been recognized at fair value. We measure the earnout liability using internally developed assumptions; therefore, it is classified as Level 3. The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the years ended December 31, 2019 and 2018 and our stock price at the time of payment.

Earnout liability activities are summarized as follows (in thousands):
Balance as of December 31, 2019$37,273  
Change in fair value—  
Settlements(37,273) 
Balance as of March 31, 2020$—  

In February 2019, we made the first earnout payment to GoMedigap consisting of $9.5 million in cash and 294,608 shares of our common stock with a value of $17.3 million. In January 2020, we made the second and last payment, which consisted of $8.8 million in cash and 294,608 shares of our common stock with a value of $28.5 million.
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Business and Significant Accounting Policies - Adoption of ASU 2016-13 (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
[1]
Jan. 01, 2020
Dec. 31, 2019
Balance Sheet Impact      
Contract assets – commissions receivable – current $ 125,252   $ 174,526
Contract assets – commissions receivable – non-current 435,465   414,696
Other assets 19,300   18,004
Total assets 941,519   741,634
Retained earnings $ 274,157   $ 271,852
Transition Adjustments      
Balance Sheet Impact      
Contract assets – commissions receivable – current   $ (71)  
Contract assets – commissions receivable – non-current   (1,442)  
Other assets   366  
Total assets   (1,147)  
Retained earnings   (1,147)  
Adjusted Balance      
Balance Sheet Impact      
Contract assets – commissions receivable – current   174,455  
Contract assets – commissions receivable – non-current   413,254  
Other assets   18,370  
Total assets   740,487  
Retained earnings   $ 270,705  
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Change in Contract with Customer, Asset [Roll Forward]      
Beginning balance $ 589,222 $ 345,858  
Total revenue 106,408 68,773  
Cash receipts (126,542) (81,874)  
Change in credit loss allowance (1,632) 0  
Ending balance 560,717 328,211  
Credit loss expense 100    
Medicare      
Change in Contract with Customer, Asset [Roll Forward]      
Beginning balance 550,922 311,977  
Cash receipts (112,731) (67,873)  
Change in credit loss allowance (1,574) 0  
Ending balance 526,721 295,753  
Individual, Family and Small Business      
Change in Contract with Customer, Asset [Roll Forward]      
Beginning balance 38,300 33,881  
Cash receipts (13,811) (14,001)  
Change in credit loss allowance (58) 0  
Ending balance 33,996 32,458  
Transition Adjustments      
Change in Contract with Customer, Asset [Roll Forward]      
Allowance for credit loss     $ (1,500)
Commission revenue from members approved during the period      
Change in Contract with Customer, Asset [Roll Forward]      
Total revenue 86,921 56,807  
Commission revenue from members approved during the period | Medicare      
Change in Contract with Customer, Asset [Roll Forward]      
Total revenue 81,125 50,582  
Commission revenue from members approved during the period | Individual, Family and Small Business      
Change in Contract with Customer, Asset [Roll Forward]      
Total revenue 5,796 6,225  
Net commission revenue adjustments from members approved in prior period      
Change in Contract with Customer, Asset [Roll Forward]      
Total revenue 12,748 7,420  
Net commission revenue adjustments from members approved in prior period | Medicare      
Change in Contract with Customer, Asset [Roll Forward]      
Total revenue 8,979 1,067  
Net commission revenue adjustments from members approved in prior period | Individual, Family and Small Business      
Change in Contract with Customer, Asset [Roll Forward]      
Total revenue $ 3,769 $ 6,353  
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Disaggregation of Revenue [Line Items]    
Total revenue $ 106,408 $ 68,773
Medicare    
Disaggregation of Revenue [Line Items]    
Total revenue 89,178 50,776
Medicare | Medicare Advantage    
Disaggregation of Revenue [Line Items]    
Total revenue 68,347 39,843
Medicare | Medicare Supplement    
Disaggregation of Revenue [Line Items]    
Total revenue 15,170 8,597
Medicare | Medicare Part D    
Disaggregation of Revenue [Line Items]    
Total revenue 5,661 2,336
Individual and Family    
Disaggregation of Revenue [Line Items]    
Total revenue 2,656 6,137
Individual and Family | Non-Qualified Health Plans    
Disaggregation of Revenue [Line Items]    
Total revenue 1,446 2,629
Individual and Family | Qualified Health Plans    
Disaggregation of Revenue [Line Items]    
Total revenue 1,210 3,508
Ancillary    
Disaggregation of Revenue [Line Items]    
Total revenue 4,251 3,519
Ancillary | Short-term    
Disaggregation of Revenue [Line Items]    
Total revenue 2,216 1,316
Ancillary | Dental    
Disaggregation of Revenue [Line Items]    
Total revenue 743 790
Ancillary | Vision    
Disaggregation of Revenue [Line Items]    
Total revenue 243 462
Ancillary | Other    
Disaggregation of Revenue [Line Items]    
Total revenue 1,049 951
Small Business    
Disaggregation of Revenue [Line Items]    
Total revenue 2,971 2,640
Commission Bonus    
Disaggregation of Revenue [Line Items]    
Total revenue 613 1,155
Commission    
Disaggregation of Revenue [Line Items]    
Total revenue 99,669 64,227
Other    
Disaggregation of Revenue [Line Items]    
Total revenue $ 6,739 $ 4,546
XML 49 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Segment
Disaggregation of Revenue – The table below disaggregates our revenue by product (in thousands):
Three Months Ended March 31,
20202019
Medicare
Medicare Advantage$68,347  $39,843  
Medicare Supplement15,170  8,597  
Medicare Part D5,661  2,336  
Total Medicare89,178  50,776  
Individual and Family (1)
Non-Qualified Health Plans1,446  2,629  
Qualified Health Plans1,210  3,508  
Total Individual and Family2,656  6,137  
Ancillary
Short-term2,216  1,316  
Dental743  790  
Vision243  462  
Other1,049  951  
Total Ancillary4,251  3,519  
Small Business2,971  2,640  
Commission Bonus613  1,155  
Total Commission Revenue99,669  64,227  
Other Revenue6,739  4,546  
Total Revenue$106,408  $68,773  
_____________

(1)We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans.
Commission revenue by segment is presented in the table below (in thousands):

Three Months Ended March 31,
20202019
Medicare
Commission Revenue from Members Approved During the Period (1)
$81,125  $50,582  
Net Commission Revenue from Members Approved in Prior Periods (2)
8,979  1,067  
Total Medicare Segment Commission Revenue$90,104  $51,649  
Individual, Family and Small Business
Commission Revenue from Members Approved During the Period (1)
$5,796  $6,225  
Net Commission Revenue from Members Approved in Prior Periods (2)
3,769  6,353  
Total IFP/SMB Segment Commission Revenue$9,565  $12,578  
_____________

(1)These amounts include commission bonus revenue.
(2)These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustment revenue within the relevant reporting period. These amounts include revenue associated with renewing small business health insurance members. Adjustment revenue also includes reductions to revenue for certain prior periods cohorts which were immaterial for the three months ended March 31, 2020 and 2019, respectively.
XML 50 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share Net Income (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income per share is computed giving effect to all potential dilutive common stock equivalent shares, including options and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted net income per share by application of the treasury stock method.
 
The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):

Three Months Ended March 31,
20202019
Basic:
Net income (loss)$3,452  $(5,159) 
Shares used in per share calculation – basic24,719  21,831  
Net income (loss) per share – basic:$0.14  $(0.24) 
Diluted:
Net income (loss)$3,452  $(5,159) 
Shares used in per share calculation – basic24,719  21,831  
Dilutive effect of common stock1,460  —  
Total common stock shares used in diluted share calculation26,179  21,831  
Net income (loss) per share – diluted$0.13  $(0.24) 

For the three months ended March 31, 2019, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of 1.0 million and 1.4 million shares related to common stock options and restricted stock units, respectively. There were no antidilutive shares for the three months ended March 31, 2020.
XML 51 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Debt
3 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
Debt Debt
On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40.0 million secured asset-backed revolving credit facility with a $5.0 million letter of credit sub-facility.

On December 20, 2019, we amended our revolving credit facility agreement with RBC (the “Amendment”) and increased the borrowing amount from $40.0 to $75.0 million. The maturity date has been extended to December 20, 2022.

The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected by during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed.

Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing, the Company paid a one-time facility fee of 1.75% of the total commitments of $40 million. We also paid a one-time closing fee of
0.5% of the new commitment of $75.0 million in connection with the Amendment. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type.

The availability under the credit facility is up to the lesser of $40 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. The Amendment increased the availability up to the lesser of $75.0 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement.

Financial covenants in the original Credit Agreement required that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6 million at any time. The Amendment also changed the financial covenants to require us to maintain at least $6.0 million of Excess Availability at all times or, if greater, up to $11.3 million depending on our borrowing base as determined by eligible past and future commission receivables. In addition, the Amendment also included changes in the payment conditions to, among other things, require us to have at least $10.0 million of liquidity or, if greater, up to $18.8 million depending on our borrowing base as determined by eligible past and future commission receivables, in order for us to make certain permitted acquisitions, investments, distributions and payments of indebtedness. The Amendment also stated the seasonal amount thresholds used in connection with the cash dominion and field examination covenants in the Credit Agreement.

We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of Other assets on our Consolidated Balance Sheet of the period we entered into the Credit Agreement. The Amendment did not change the interest rate. In connection with this Amendment, we incurred closing costs totaling $0.5 million, which was capitalized and recorded as Other assets on our Consolidated Balance Sheet as of December 31, 2019. The remaining balance of unamortized issuance costs was $1.1 million as of March 31, 2020 and December 31, 2019.
As of March 31, 2020, we had no outstanding principal amount under our revolving credit facility.
XML 52 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Operating lease right-of-use assets $ 43,396 [1] $ 36,621
Operating lease liabilities $ 46,166  
Weighted-average remaining lease term of operating leases 7 years 10 months 24 days  
Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.50%  
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 53 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
Benefit from income taxes $ 2,048 $ 3,467
Effective tax rate (145.90%) 40.20%
XML 54 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Basic:    
Net income (loss) $ 3,452 $ (5,159)
Shares used in per share calculation - basic (in shares) 24,719 21,831
Earnings per share, basic (in usd per share) $ 0.14 $ (0.24)
Diluted:    
Dilutive effect of common stock (in shares) 1,460 0
Total common stock shares used in diluted share calculation (in shares) 26,179 21,831
Earnings per share, diluted (in usd per share) $ 0.13 $ (0.24)
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 31, 2020
USD ($)
shares
Feb. 28, 2019
USD ($)
shares
Mar. 31, 2020
USD ($)
numberOfSecurities
Mar. 31, 2019
USD ($)
Business Acquisition [Line Items]        
Number of securities in net loss positions | numberOfSecurities     4  
Acquisition-related contingent payments     $ 8,751 $ 9,542
GoMedigap        
Business Acquisition [Line Items]        
Acquisition-related contingent payments $ 8,800 $ 9,500    
Earnout consideration (in shares) | shares 294,608 294,608    
Stock issued for acquisition $ 28,500 $ 17,300    
XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share (Tables)
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Income per Share
The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):

Three Months Ended March 31,
20202019
Basic:
Net income (loss)$3,452  $(5,159) 
Shares used in per share calculation – basic24,719  21,831  
Net income (loss) per share – basic:$0.14  $(0.24) 
Diluted:
Net income (loss)$3,452  $(5,159) 
Shares used in per share calculation – basic24,719  21,831  
Dilutive effect of common stock1,460  —  
Total common stock shares used in diluted share calculation26,179  21,831  
Net income (loss) per share – diluted$0.13  $(0.24) 
XML 58 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Disaggregation of Revenue – The table below disaggregates our revenue by product (in thousands):
Three Months Ended March 31,
20202019
Medicare
Medicare Advantage$68,347  $39,843  
Medicare Supplement15,170  8,597  
Medicare Part D5,661  2,336  
Total Medicare89,178  50,776  
Individual and Family (1)
Non-Qualified Health Plans1,446  2,629  
Qualified Health Plans1,210  3,508  
Total Individual and Family2,656  6,137  
Ancillary
Short-term2,216  1,316  
Dental743  790  
Vision243  462  
Other1,049  951  
Total Ancillary4,251  3,519  
Small Business2,971  2,640  
Commission Bonus613  1,155  
Total Commission Revenue99,669  64,227  
Other Revenue6,739  4,546  
Total Revenue$106,408  $68,773  
_____________

(1)We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans.

Revenue Recognition Based on Estimated Constrained LTV

We recognize revenue for plans approved during the period by applying the latest estimated constrained life time value (“LTV”) for that product. We recognize adjustment revenue for plans approved in prior periods when there is a change in estimate to expected cash collections as a result of sufficient evidence that demonstrates a trend that is different from the estimated constrained LTV at the time of approval. We recognize adjustment revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We assess the risk of significant revenue reversal based on statistical and qualitative analysis given historical information and current market conditions.

Our commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting average plan duration and forecasting the commission amounts likely to be received per member. These assumptions are based on our analysis of historical trends for different cohorts and incorporate management’s judgment in interpreting those trends to apply the constraints discussed below. For our Medicare commission revenue, which represented 89% and 79% of our total commission revenue for the three months ended March 31, 2020 and 2019, respectively, the estimated average plan duration, which is the average length of time paying
members are active on their plans, used to calculate Medicare health insurance plan LTVs historically has been approximately 3 years for Medicare Advantage plans, approximately 5 years for Medicare Part D prescription drug plans, and approximately 5 years for Medicare Supplement plans. While the average plan duration has been approximately 3 years for Medicare Advantage plans, certain members may have a duration of up to 12 years. The estimated average plan duration used to calculate the LTV for major medical individual and family health insurance plans historically has been approximately 1.5 to 2 years. For short term health insurance plan LTVs, the estimated average plan duration historically has been less than six months. For all other ancillary health insurance plan LTVs, the estimated average plan duration has historically varied from 1 to 3 years. To the extent we make changes to the assumptions we use to calculate constrained LTVs, we recognize the impact of changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained LTV recognized as revenue.

Constraints are applied to LTV for revenue recognition purposes to help ensuring that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. Judgments that can be significant in estimating LTVs are related to the constraint. To determine the constraints to be applied to LTV, we compare prior calculations of LTV to actual cash received and review the reasons for any variations. We then apply judgment in assessing whether the difference between historical cash collections and LTV is representative of differences that can be expected in future periods. We also analyze whether circumstances have changed and consider any known or potential modifications to the inputs into LTV in light of the factors that can impact the amount of cash expected to be collected in future periods including but not limited to commission rates, carrier mix, plan duration, changes in laws and regulations, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship. We evaluate the appropriateness of our constraints on a quarterly basis, and we update our assumptions when we observe a sufficient amount of evidence that would suggest that the long-term expectation underlying the assumptions has changed.

We recorded adjustment revenue of $12.7 million and $7.4 million, or $0.52 and $0.34 per basic share, or $0.49 and $0.34 per diluted share, respectively, for the three months ended March 31, 2020 and 2019, respectively.

Commission revenue by segment is presented in the table below (in thousands):

Three Months Ended March 31,
20202019
Medicare
Commission Revenue from Members Approved During the Period (1)
$81,125  $50,582  
Net Commission Revenue from Members Approved in Prior Periods (2)
8,979  1,067  
Total Medicare Segment Commission Revenue$90,104  $51,649  
Individual, Family and Small Business
Commission Revenue from Members Approved During the Period (1)
$5,796  $6,225  
Net Commission Revenue from Members Approved in Prior Periods (2)
3,769  6,353  
Total IFP/SMB Segment Commission Revenue$9,565  $12,578  
_____________

(1)These amounts include commission bonus revenue.
(2)These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustment revenue within the relevant reporting period. These amounts include revenue associated with renewing small business health insurance members. Adjustment revenue also includes reductions to revenue for certain prior periods cohorts which were immaterial for the three months ended March 31, 2020 and 2019, respectively.
Since the adoption of ASC 606, we re-compute LTVs for all outstanding cohorts on a quarterly basis. We continually review and monitor changes in the data used to estimate LTV and compare the cash received for each cohort to our original estimates at the time of approval. The fluctuations of cash received for each cohort and LTV can be significant and may or may not be indicative of the need to adjust revenue for prior period cohorts. Changes in LTV may result in an increase or a decrease to revenue and a corresponding increase or decrease to contract assets – commissions receivable, accordingly. We analyze these fluctuations and, to the extent we see changes in our estimates of the cash commission collections that we believe are indicative of an increase or decrease to prior period LTVs, we adjust revenue for the affected cohorts at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. As we accumulate more historical data, we continue to enhance our LTV estimation models using statistical tools to increase the accuracy of LTV estimates with an emphasis on improving member attrition forecasting. The enhancements to the LTV estimation model provide greater statistical certainty on expected cash collections, particularly for earlier period cohorts where there is more historical data available. Our LTV estimation models for the three months ended March 31, 2020 indicate increases in LTVs and estimates of future cash collections for earlier period cohorts of certain products within our Individual, Family and Small Business segment. However, after considering various market factors and recent changes due to the impact of COVID-19 to the U.S. economy, such as increases in unemployment rate, potential delays in customer premium payments and/or health insurance carrier commission payments, potential changes to enrollment periods, and potential changes to qualified health plan subsidies, we limited the adjustment revenue recognized during the three months ended March 31, 2020 to actual cash collected in excess of previously recognized revenue for certain cohorts related to individual and family as well as ancillary plans. These prevailing market conditions did not have an impact on the amount of adjustment revenue recognized for any other products we sell.
XML 59 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenue:    
Total revenue $ 106,408 $ 68,773
Operating costs and expenses:    
Cost of revenue 1,138 (77)
Marketing and advertising 37,764 23,941
Customer care and enrollment 30,535 19,944
Technology and content 15,740 9,017
General and administrative 19,653 11,278
Amortization of intangible assets 547 547
Change in fair value of earnout liability 0 13,306
Total operating costs and expenses 105,377 77,956
Income (loss) from operations 1,031 (9,183)
Other income, net 373 557
Income (loss) before benefit from income taxes 1,404 (8,626)
Benefit from income taxes (2,048) (3,467)
Net income (loss) $ 3,452 $ (5,159)
Net income (loss) per share:    
Basic (in usd per share) $ 0.14 $ (0.24)
Diluted (in usd per share) $ 0.13 $ (0.24)
Weighted-average number of shares used in per share amounts:    
Basic (in shares) 24,719 21,831
Diluted (in shares) 26,179 21,831
Comprehensive income:    
Unrealized holding gain for available for sales debt securities, net of tax $ 25 $ 0
Foreign currency translation adjustment, net of taxes (31) 29
Comprehensive income (loss) 3,446 (5,130)
Commission    
Revenue:    
Total revenue 99,669 64,227
Other    
Revenue:    
Total revenue $ 6,739 $ 4,546
XML 60 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule Of Components Of Income Tax Expense
The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2020 and 2019 (in thousands, except effective tax rate):
Three Months Ended March 31,
20202019
Income (loss) before benefit from income taxes$1,404  $(8,626) 
Benefit from income taxes(2,048) (3,467) 
Effective tax rate(145.9)%40.2 %
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 0  
Common stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares)   1,000,000.0
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares)   1,400,000
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Earnout Liability Activity (Details) - Contingent Consideration
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance $ 37,273
Change in fair value 0
Settlements (37,273)
Ending balance $ 0
XML 64 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Equity (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Schedule Of Stock-Based Compensation Expense By Award Type Our stock-based compensation expense is summarized as follows by award types (in thousands): 
Three Months Ended March 31,
20202019
Common stock options$306  $602  
Restricted stock units8,408  2,627  
Total stock-based compensation expense$8,714  $3,229  
Schedule Of Stock-Based Compensation Expense By Operating Function
Our stock-based compensation expense is summarized as follows by operating functions (in thousands): 
 Three Months Ended March 31,
 20202019
Marketing and advertising$1,730  $629  
Customer care and enrollment662  273  
Technology and content1,617  549  
General and administrative4,705  1,778  
Total stock-based compensation expense$8,714  $3,229  
XML 65 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Business and Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Business and Significant Accounting Policies Summary of Business and Significant Accounting Policies
Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omni-channel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 180 health insurance carriers across all fifty states and the District of Columbia.

Basis of Presentation – The accompanying condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, and the condensed consolidated statements of comprehensive income (loss), stockholders' equity, and cash flows for the three months ended March 31, 2020 and 2019, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2019 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on March 2, 2020. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain reclassifications might be made to conform with the current presentation. However, the Company believes that the disclosures made are adequate to make the information not misleading.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2020 and December 31, 2019, and our results of operations for the periods presented. Our financial position as of March 31, 2020 and results of operations and cash flows for the three months ended March 31, 2020 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2020 and therefore should not be relied upon as an indicator of future results.

Significant Accounting Polices, Estimates and Judgements – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the commissions we expect to collect for each approved member cohort, allowance for credit loss, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.
With the exception of the change for the accounting of credit losses as a result of the adoption of Accounting Standard Updates ("ASU") No. 2016-13, Financial InstrumentsCredit Losses discussed below, there have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.

Seasonality – A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage, Medicare Supplement, and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Due to the recent reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our commission revenue is typically second-highest in our first quarter.

The majority of our major medical individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase major medical individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

Recently Adopted Accounting Pronouncement

Financial Instruments – Credit Losses (Topic 326) – In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial InstrumentsCredit Losses (Topic 326), that requires companies to present certain financial assets net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. Contract assets – commissions receivable are the Company's only financial assets that were materially impacted by this guidance.

We adopted ASU 2016-13 using a modified retrospective transition method on January 1, 2020 for all financial assets measured at amortized cost. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under the previous accounting standards. We recorded a $1.1 million decrease, net of income taxes, to the retained earnings as of January 1, 2020 for the cumulative effect of adopting ASU 2016-13. See Note 3Supplemental Financial Statement Information for further discussion on credit losses.

The impacts from the adoption are summarized as follows (in thousands):

Balance Sheet Impact:December 31, 2019Transition AdjustmentsJanuary 1, 2020
Contract assets – commissions receivable – current$174,526  $(71) $174,455  
Contract assets – commissions receivable – non-current$414,696  $(1,442) $413,254  
Other assets*$18,004  $366  $18,370  
Total assets$741,634  $(1,147) $740,487  
Retained earnings$271,852  $(1,147) $270,705  
____________
*Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.


Financial Instruments (Topic 820) – In 2018, the FASB issued ASU No. 2018-13, to change the disclosure requirements for fair value measurement with the objective of improving the effectiveness of the notes to financial statements. This new guidance removed and modified certain disclosure requirements under Topic 820. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.
Intangible – Goodwill and Other (Topic 350) – In 2017, the FASB issued ASU 2017-04 to simplify the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. In addition, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

Income Taxes (Topic 740) – In December 2019, the FASB issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes, which aims to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improve consistent application of and simplify U.S. GAAP for other areas under this Topic by clarifying existing guidance. ASU 2019-12 will be effective for us beginning January 1, 2021. The amendments in this standard update have individually different adoption approaches. We do not anticipate a material impact on our consolidated financial statements and disclosure from the adoption of this standard update.
XML 66 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
[1]
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 184,167 $ 23,466
Short-term marketable securities 33,683 0
Accounts receivable 668 2,332
Contract assets – commissions receivable – current 125,252 174,526
Prepaid expenses and other current assets 9,202 7,822
Total current assets 352,972 208,146
Contract assets – commissions receivable – non-current 435,465 414,696
Property and equipment, net 12,875 10,518
Long-term marketable securities 24,409 0
Operating lease right-of-use assets 43,396 36,621
Restricted cash 3,353 3,354
Other assets 19,300 18,004
Intangible assets, net 9,516 10,062
Goodwill 40,233 40,233
Total assets 941,519 741,634
Current liabilities:    
Accounts payable 8,906 24,554
Accrued compensation and benefits 18,473 29,578
Accrued marketing expenses 4,711 12,041
Earnout liability — current 0 37,273
Lease liabilities — current 4,174 4,759
Deferred revenue 2,683 2,570
Other current liabilities 3,736 2,210
Total current liabilities 42,683 112,985
Deferred income taxes — non-current 61,623 64,130
Lease liabilities — non-current 41,992 34,305
Other non-current liabilities 3,535 3,050
Stockholders’ equity:    
Common stock 37 35
Additional paid-in capital 717,380 455,159
Treasury stock, at cost (199,998) (199,998)
Retained earnings 274,157 271,852
Accumulated other comprehensive income 110 116
Total stockholders’ equity 791,686 527,164
Total liabilities and stockholders’ equity $ 941,519 $ 741,634
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
XML 67 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Tables)
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Schedule of Supplemental Balance Sheet Information
Supplemental information as of March 31, 2020 related to leases is as follows (in thousands):
Operating lease right-of-use assets$43,396  
Operating lease liabilities$46,166  
Weighted-average remaining lease term of operating leases7.9 years
Weighted-average discount rate used to recognize operating lease right-of-use-assets5.5 %
Schedule of Operating Lease Maturities
As of March 31, 2020, maturities of operating lease liabilities are as follows (in thousands):
Year ending December 31,
Reminder of 2020$5,058  
20216,950  
20226,988  
20237,863  
20247,706  
Thereafter27,603  
Total lease payments62,168  
Less imputed interest(16,002) 
Total$46,166  
XML 68 R9999.htm IDEA: XBRL DOCUMENT v3.20.1
Label Element Value
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (1,147,000)
Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (1,147,000)
XML 69 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Humana    
Concentration Risk [Line Items]    
Major customer revenue, percentage 22.00% 22.00%
Aetna    
Concentration Risk [Line Items]    
Major customer revenue, percentage 21.00% 20.00%
UnitedHealthcare    
Concentration Risk [Line Items]    
Major customer revenue, percentage 20.00% 20.00%
XML 70 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]        
Cash $ 16,364 $ 16,205    
Cash equivalents 167,803 7,261    
Restricted cash 3,353 [1] 3,354    
Total cash, cash equivalents and restricted cash $ 187,520 $ 26,820 $ 135,475 $ 13,089
[1] Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details.
JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ehth-20200331.htm": { "axisCustom": 5, "axisStandard": 25, "contextCount": 214, "dts": { "calculationLink": { "local": [ "ehth-20200331_cal.xml" ] }, "definitionLink": { "local": [ "ehth-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "ehth-20200331.htm" ] }, "labelLink": { "local": [ "ehth-20200331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ehth-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ehth-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 464, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 6 }, "keyCustom": 36, "keyStandard": 288, "memberCustom": 35, "memberStandard": 33, "nsprefix": "ehth", "nsuri": "http://www.ehealthinsurance.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.ehealthinsurance.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126105 - Disclosure - Equity", "role": "http://www.ehealthinsurance.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130106 - Disclosure - Net Income (Loss) Per Share", "role": "http://www.ehealthinsurance.com/role/NetIncomeLossPerShare", "shortName": "Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134107 - Disclosure - Commitments and Contingencies", "role": "http://www.ehealthinsurance.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137108 - Disclosure - Segment and Geographic Information", "role": "http://www.ehealthinsurance.com/role/SegmentandGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142109 - Disclosure - Leases", "role": "http://www.ehealthinsurance.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147110 - Disclosure - Debt", "role": "http://www.ehealthinsurance.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149111 - Disclosure - Income Taxes", "role": "http://www.ehealthinsurance.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "ehth:DescriptionOfBusinessPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of Business and Significant Accounting Policies (Policies)", "role": "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies", "shortName": "Summary of Business and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "ehth:DescriptionOfBusinessPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Summary of Business and Significant Accounting Policies (Tables)", "role": "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesTables", "shortName": "Summary of Business and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307302 - Disclosure - Revenue (Tables)", "role": "http://www.ehealthinsurance.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - Supplemental Financial Statement Information (Tables)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables", "shortName": "Supplemental Financial Statement Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "ehth:ScheduleOfStockBasedCompensationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Equity (Tables)", "role": "http://www.ehealthinsurance.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "ehth:ScheduleOfStockBasedCompensationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - Net Income (Loss) Per Share (Tables)", "role": "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareTables", "shortName": "Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335307 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338308 - Disclosure - Segment and Geographic Information (Tables)", "role": "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "ehth:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343309 - Disclosure - Leases (Tables)", "role": "http://www.ehealthinsurance.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "ehth:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - Income Taxes (Tables)", "role": "http://www.ehealthinsurance.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "ehth:DescriptionOfBusinessPolicyPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "INF", "first": true, "lang": null, "name": "ehth:NumberOfHealthInsuranceCarriers", "reportCount": 1, "unique": true, "unitRef": "numberofinsurancecarriers", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of Business and Significant Accounting Policies - Narrative (Details)", "role": "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Business and Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ehth:DescriptionOfBusinessPolicyPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "INF", "first": true, "lang": null, "name": "ehth:NumberOfHealthInsuranceCarriers", "reportCount": 1, "unique": true, "unitRef": "numberofinsurancecarriers", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Business and Significant Accounting Policies - Adoption of ASU 2016-13 (Details)", "role": "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "shortName": "Summary of Business and Significant Accounting Policies - Adoption of ASU 2016-13 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibbd30cd0e168431db16c1efc8be24ba6_I20200101", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "role": "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Revenue - Additional Information (Details)", "role": "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "shortName": "Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdce26130afb48c3bbd8e482d6b193c2_D20200101-20200331", "decimals": "2", "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Revenue - Commission Revenue by Segment (Details)", "role": "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "shortName": "Revenue - Commission Revenue by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i9c3367cc078c484eb50cf72b03e5e1c2_D20200101-20200331", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i799b7fb48a334612aca28cf31ba6bc79_D20200101-20200331", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails", "shortName": "Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Supplemental Financial Statement Information - Narrative (Details)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails", "shortName": "Supplemental Financial Statement Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i546c4dba054240e882ec5f3060db9fbf_I20200331", "decimals": "-5", "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Supplemental Financial Statement Information - Schedule of Accounts Receivable (Details)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails", "shortName": "Supplemental Financial Statement Information - Schedule of Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "lang": null, "name": "ehth:AccountsReceivableAndContractAssetsAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i6eb1e6090a8c4eab91c9e287abd26ccd_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails", "shortName": "Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i6eb1e6090a8c4eab91c9e287abd26ccd_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "id5e59a39ccb14b7eb4933f1705f68d32_D20200101-20200331", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417410 - Disclosure - Supplemental Financial Statement Information - Schedule of Credit Risk (Details)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails", "shortName": "Supplemental Financial Statement Information - Schedule of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "id5e59a39ccb14b7eb4933f1705f68d32_D20200101-20200331", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "ehth:PrepaidMaintenanceContractsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418411 - Disclosure - Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "ehth:PrepaidMaintenanceContractsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Fair Value Measurements - Summary of Financial Assets (Details)", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i3db35f8053254a4094aba9ed41d54c1e_I20200331", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i1014fd756ef44b9a93d9956a281a3086_I20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i1014fd756ef44b9a93d9956a281a3086_I20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Fair Value Measurements - Contractual Maturities (Details)", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails", "shortName": "Fair Value Measurements - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses (Details)", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails", "shortName": "Fair Value Measurements - Unrealized Gains and Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "lang": null, "name": "ehth:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "numberofsecurities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424415 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "numberofsecurities", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i80ada4afb2fb4c20a9a06134310c9be6_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425416 - Disclosure - Fair Value Measurements - Earnout Liability Activity (Details)", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails", "shortName": "Fair Value Measurements - Earnout Liability Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i80ada4afb2fb4c20a9a06134310c9be6_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i03c66e9e606a4bd290240b84afa2399a_D20200301-20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - Equity - Narrative (Details)", "role": "http://www.ehealthinsurance.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i03c66e9e606a4bd290240b84afa2399a_D20200301-20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ehth:ScheduleOfStockBasedCompensationExpenseByOperatingFunctionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429418 - Disclosure - Equity - Schedule of Stock-Based Compensation Expense (Details)", "role": "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails", "shortName": "Equity - Schedule of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ehth:ScheduleOfStockBasedCompensationExpenseByOperatingFunctionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432419 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details)", "role": "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails", "shortName": "Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "lang": null, "name": "ehth:IncrementalCommonSharesAttributableToOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433420 - Disclosure - Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details)", "role": "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails", "shortName": "Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - Segment and Geographic Information - Segment Operating Results (Details)", "role": "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails", "shortName": "Segment and Geographic Information - Segment Operating Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareAmortization1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440423 - Disclosure - Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details)", "role": "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails", "shortName": "Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ief5e6d82451c4d07b04e5958f54fa212_D20200101-20200331", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Major Customers (Details)", "role": "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "shortName": "Segment and Geographic Information - Schedule of Revenue by Major Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ief5e6d82451c4d07b04e5958f54fa212_D20200101-20200331", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - Leases - Narrative (Details)", "role": "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ehth:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ehth:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - Leases - Maturities of Lease Liabilities (Details)", "role": "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448428 - Disclosure - Debt (Details)", "role": "http://www.ehealthinsurance.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "ibdd5fd610d83410c99851b8cb30f974b_I20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451429 - Disclosure - Income Taxes - Summary of Income Tax Benefit (Details)", "role": "http://www.ehealthinsurance.com/role/IncomeTaxesSummaryofIncomeTaxBenefitDetails", "shortName": "Income Taxes - Summary of Income Tax Benefit (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452430 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.ehealthinsurance.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of Business and Significant Accounting Policies", "role": "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPolicies", "shortName": "Summary of Business and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106102 - Disclosure - Revenue", "role": "http://www.ehealthinsurance.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111103 - Disclosure - Supplemental Financial Statement Information", "role": "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformation", "shortName": "Supplemental Financial Statement Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119104 - Disclosure - Fair Value Measurements", "role": "http://www.ehealthinsurance.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i77e1948deac94cb18e5053cf652923ab_D20200101-20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ehth-20200331.htm", "contextRef": "i7b586368d3ca49f79e139057a349e676_I20200101", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - ehth-20200331.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - ehth-20200331.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 71, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ehth_AccountsReceivableAndContractAssetsAfterAllowanceForCreditLoss": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accounts Receivable And Contract Assets, After Allowance For Credit Loss", "label": "Accounts Receivable And Contract Assets, After Allowance For Credit Loss", "totalLabel": "Total contract assets and accounts receivable" } } }, "localname": "AccountsReceivableAndContractAssetsAfterAllowanceForCreditLoss", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "ehth_AccruedMarketingExpenses": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total carrying values as of the balance sheet date of liabilities incurred through that date and payable for obligations related to marketing and advertising services received from vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Expenses.", "terseLabel": "Accrued marketing expenses" } } }, "localname": "AccruedMarketingExpenses", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ehth_AetnaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aetna [Member]", "label": "Aetna [Member]", "terseLabel": "Aetna" } } }, "localname": "AetnaMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "ehth_AllocatedSharebasedCompensationExpenseNetOfRestructuringReversalExpense": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Allocated Share-based Compensation Expense, Net Of Restructuring Reversal Expense", "label": "Allocated Share-based Compensation Expense, Net Of Restructuring Reversal Expense", "negatedTerseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedSharebasedCompensationExpenseNetOfRestructuringReversalExpense", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "ehth_AncillariesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ancillaries [Member]", "label": "Ancillaries [Member]", "terseLabel": "Ancillary" } } }, "localname": "AncillariesMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ehth_AveragePlanDurationTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average Plan Duration, Term", "label": "Average Plan Duration, Term", "terseLabel": "Average plan duration" } } }, "localname": "AveragePlanDurationTerm", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ehth_BorrowingBasePercentageAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Borrowing Base Percentage [Axis]", "label": "Borrowing Base Percentage [Axis]", "terseLabel": "Borrowing Base Percentage [Axis]" } } }, "localname": "BorrowingBasePercentageAxis", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "ehth_BorrowingBasePercentageDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Borrowing Base Percentage [Axis]", "label": "Borrowing Base Percentage [Domain]", "terseLabel": "Borrowing Base Percentage [Domain]" } } }, "localname": "BorrowingBasePercentageDomain", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ehth_BusinessCombinationContingentConsiderationShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Shares", "label": "Business Combination, Contingent Consideration, Shares", "terseLabel": "Earnout consideration (in shares)" } } }, "localname": "BusinessCombinationContingentConsiderationShares", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecurities": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails_1": { "order": 3.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities", "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities", "totalLabel": "Fair Value" } } }, "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecurities", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost", "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost", "totalLabel": "Total" } } }, "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "ehth_ChangeInContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change in Contract with Customer, Asset", "label": "Change in Contract with Customer, Asset [Roll Forward]", "terseLabel": "Change in Contract with Customer, Asset [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerAssetRollForward", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "stringItemType" }, "ehth_CommissionBonusMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission Bonus [Member]", "label": "Commission Bonus [Member]", "terseLabel": "Commission Bonus" } } }, "localname": "CommissionBonusMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_CommissionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission [Member]", "label": "Commission [Member]", "terseLabel": "Commission" } } }, "localname": "CommissionMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_CommissionMembersApprovedDuringCurrentPeriodMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission, Members Approved During Current Period [Member]", "label": "Commission, Members Approved During Current Period [Member]", "terseLabel": "Commission revenue from members approved during the period" } } }, "localname": "CommissionMembersApprovedDuringCurrentPeriodMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "ehth_CommissionMembersApprovedInPriorPeriodsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission, Members Approved In Prior Periods [Member]", "label": "Commission, Members Approved In Prior Periods [Member]", "terseLabel": "Net commission revenue adjustments from members approved in prior period", "verboseLabel": "Commission, Members Approved In Prior Periods" } } }, "localname": "CommissionMembersApprovedInPriorPeriodsMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "ehth_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration [Member]", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "domainItemType" }, "ehth_CreditAgreementAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement Amendment", "label": "Credit Agreement Amendment [Member]", "terseLabel": "Credit Agreement Amendment" } } }, "localname": "CreditAgreementAmendmentMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ehth_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption, Adjusted Balance", "label": "Cumulative Effect, Period Of Adoption, Adjusted Balance [Member]", "terseLabel": "Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details" ], "xbrltype": "domainItemType" }, "ehth_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption, Adjustment", "label": "Cumulative Effect, Period Of Adoption, Adjustment [Member]", "terseLabel": "Transition Adjustments" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "ehth_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption", "label": "Cumulative Effect, Period Of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period Of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "stringItemType" }, "ehth_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Effect, Period Of Adoption", "label": "Cumulative Effect, Period Of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period Of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "ehth_CustomerCareAndEnrollmentExpense": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total expense recognized in the period related to providing customer care and enrollment services. These services include pre-sales assistance to applicants who call our customer care center and enrollment services to applicants during the underwriting process.", "label": "Customer Care And Enrollment Expense", "terseLabel": "Customer care and enrollment" } } }, "localname": "CustomerCareAndEnrollmentExpense", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "ehth_CustomerCareAndEnrollmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Care And Enrollment Expense [Member]", "label": "Customer Care And Enrollment Expense [Member]", "terseLabel": "Customer care and enrollment" } } }, "localname": "CustomerCareAndEnrollmentExpenseMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "ehth_DebtSecuritiesAvailableForSaleCurrentAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Gain, Before Tax", "label": "Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Gain, Before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "DebtSecuritiesAvailableForSaleCurrentAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "ehth_DebtSecuritiesAvailableForSaleCurrentAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Loss, Before Tax", "label": "Debt Securities, Available-For-Sale, Current, Accumulated Gross Unrealized Loss, Before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleCurrentAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "ehth_DebtSecuritiesAvailableForSaleNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Noncurrent", "label": "Debt Securities, Available-For-Sale, Noncurrent [Abstract]", "terseLabel": "Long-term marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleNoncurrentAbstract", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "ehth_DebtSecuritiesAvailableForSaleNoncurrentAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Gain, Before Tax", "label": "Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Gain, Before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "DebtSecuritiesAvailableForSaleNoncurrentAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "ehth_DebtSecuritiesAvailableForSaleNoncurrentAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Loss, Before Tax", "label": "Debt Securities, Available-For-Sale, Noncurrent, Accumulated Gross Unrealized Loss, Before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleNoncurrentAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "ehth_DentalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dental [Member]", "label": "Dental [Member]", "terseLabel": "Dental" } } }, "localname": "DentalMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_DescriptionOfBusinessPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description Of Business, Policy", "label": "Description Of Business, Policy [Policy Text Block]", "terseLabel": "Description of Business" } } }, "localname": "DescriptionOfBusinessPolicyPolicyTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ehth_DisaggregatedAncillariesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disaggregated Ancillaries [Axis]", "label": "Disaggregated Ancillaries [Axis]", "terseLabel": "Disaggregated Ancillaries [Axis]" } } }, "localname": "DisaggregatedAncillariesAxis", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "ehth_DisaggregatedAncillariesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disaggregated Ancillaries [Axis]", "label": "Disaggregated Ancillaries [Domain]", "terseLabel": "Disaggregated Ancillaries [Domain]" } } }, "localname": "DisaggregatedAncillariesDomain", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_DisaggregatedIndividualandFamilyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disaggregated Individual and Family [Axis]", "label": "Disaggregated Individual and Family [Axis]", "terseLabel": "Disaggregated Individual and Family [Axis]" } } }, "localname": "DisaggregatedIndividualandFamilyAxis", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "ehth_DisaggregatedIndividualandFamilyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disaggregated Individual and Family [Axis]", "label": "Disaggregated Individual and Family [Domain]", "terseLabel": "Disaggregated Individual and Family [Domain]" } } }, "localname": "DisaggregatedIndividualandFamilyDomain", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_DisaggregatedMedicareAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disagregated Medicare [Axis]", "label": "Disaggregated Medicare [Axis]", "terseLabel": "Disaggregated Medicare [Axis]" } } }, "localname": "DisaggregatedMedicareAxis", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "ehth_DisaggregatedMedicareDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disaggregated Medicare [Axis]", "label": "Disaggregated Medicare [Domain]", "terseLabel": "Disaggregated Medicare [Domain]" } } }, "localname": "DisaggregatedMedicareDomain", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_EligibleCommissionsReceivablesPrecedingThreeMonthsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eligible Commissions Receivables, Preceding Three Months [Member]", "label": "Eligible Commissions Receivables, Preceding Three Months [Member]", "terseLabel": "Eligible Commissions Receivables, Preceding Three Months" } } }, "localname": "EligibleCommissionsReceivablesPrecedingThreeMonthsMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ehth_EligibleCommissionsReceivablesSucceedingSixMonthsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eligible Commissions Receivables, Succeeding Six Months [Member]", "label": "Eligible Commissions Receivables, Succeeding Six Months [Member]", "terseLabel": "Eligible Commissions Receivables, Succeeding Six Months" } } }, "localname": "EligibleCommissionsReceivablesSucceedingSixMonthsMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ehth_EligibleCommissionsReceivablesSucceedingThreeMonthsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eligible Commissions Receivables, Succeeding Three Months [Member]", "label": "Eligible Commissions Receivables, Succeeding Three Months [Member]", "terseLabel": "Eligible Commissions Receivables, Succeeding Three Months" } } }, "localname": "EligibleCommissionsReceivablesSucceedingThreeMonthsMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ehth_GoMedigapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GoMedigap [Member]", "label": "GoMedigap [Member]", "terseLabel": "GoMedigap" } } }, "localname": "GoMedigapMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ehth_GoldRiverCaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gold River, California [Member]", "label": "Gold River, California [Member]", "terseLabel": "Gold River, California" } } }, "localname": "GoldRiverCaliforniaMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ehth_HumanaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Humana [Member]", "label": "Humana [Member]", "terseLabel": "Humana" } } }, "localname": "HumanaMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "ehth_IncreaseDecreaseInAccruedMarketingExpenses": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in accrued marketing expenses.", "label": "Increase Decrease In Accrued Marketing Expenses", "terseLabel": "Accrued marketing expenses" } } }, "localname": "IncreaseDecreaseInAccruedMarketingExpenses", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ehth_IncreaseDecreaseInCommissionsReceivable": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Commissions Receivable", "label": "Increase (Decrease) In Commissions Receivable", "terseLabel": "Contract assets \u2013 commissions receivable" } } }, "localname": "IncreaseDecreaseInCommissionsReceivable", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ehth_IncrementalCommonSharesAttributableToOptions": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental Common Shares Attributable To Options", "label": "Incremental Common Shares Attributable To Options", "terseLabel": "Dilutive effect of common stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToOptions", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "ehth_IndividualFamilyAndSmallBusinessSegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Individual, Family, And Small Business Segments [Member]", "label": "Individual, Family, And Small Business Segments [Member]", "terseLabel": "Individual, Family and Small Business" } } }, "localname": "IndividualFamilyAndSmallBusinessSegmentsMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "ehth_IndividualandFamilyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Individual and Family [Member]", "label": "Individual and Family [Member]", "terseLabel": "Individual and Family" } } }, "localname": "IndividualandFamilyMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_LeViasCompliantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Le'Vias Compliant [Member]", "label": "Le'Vias Compliant [Member]", "terseLabel": "Le'Vias Compliant" } } }, "localname": "LeViasCompliantMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ehth_LeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease, Remaining Lease Term", "label": "Lease, Remaining Lease Term", "terseLabel": "Lease term" } } }, "localname": "LeaseRemainingLeaseTerm", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "ehth_LesseeOperatingLeaseOptionToExtendNumberOfPeriods": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Option To Extend, Number Of Periods", "label": "Lessee, Operating Lease, Option To Extend, Number Of Periods", "terseLabel": "Number of extension periods" } } }, "localname": "LesseeOperatingLeaseOptionToExtendNumberOfPeriods", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ehth_LesseeOperatingLeaseRightOfUseAssetAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Right-Of-Use Asset Acquired", "label": "Lessee, Operating Lease, Right-Of-Use Asset Acquired", "terseLabel": "Acquired right-of-use asset" } } }, "localname": "LesseeOperatingLeaseRightOfUseAssetAcquired", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ehth_LineOfCreditFacilityBorrowingBasePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Borrowing Base, Percentage", "label": "Line Of Credit Facility, Borrowing Base, Percentage", "terseLabel": "Borrowing base percentage" } } }, "localname": "LineOfCreditFacilityBorrowingBasePercentage", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "ehth_LineOfCreditFacilityCovenantMaximumCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Covenant, Maximum Cash And Cash Equivalents", "label": "Line Of Credit Facility, Covenant, Maximum Cash And Cash Equivalents", "terseLabel": "Covenant, maximum cash and cash equivalents" } } }, "localname": "LineOfCreditFacilityCovenantMaximumCashAndCashEquivalents", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "ehth_LineOfCreditFacilityCovenantMaximumLiquidity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Covenant, Maximum Liquidity", "label": "Line Of Credit Facility, Covenant, Maximum Liquidity", "terseLabel": "Maximum liquidity" } } }, "localname": "LineOfCreditFacilityCovenantMaximumLiquidity", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "ehth_LineOfCreditFacilityCovenantMinimumCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Covenant, Minimum Cash And Cash Equivalents", "label": "Line Of Credit Facility, Covenant, Minimum Cash And Cash Equivalents", "terseLabel": "Covenant, minimum cash and cash equivalents" } } }, "localname": "LineOfCreditFacilityCovenantMinimumCashAndCashEquivalents", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "ehth_LineOfCreditFacilityCovenantMinimumLiquidity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Covenant, Minimum Liquidity", "label": "Line Of Credit Facility, Covenant, Minimum Liquidity", "terseLabel": "Minimum liquidity" } } }, "localname": "LineOfCreditFacilityCovenantMinimumLiquidity", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "ehth_LineOfCreditFacilityFacilityFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Facility Fee Percentage", "label": "Line Of Credit Facility, Facility Fee Percentage", "terseLabel": "Facility fee percentage" } } }, "localname": "LineOfCreditFacilityFacilityFeePercentage", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "ehth_MedicareAdvantageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Advantage [Member]", "label": "Medicare Advantage [Member]", "terseLabel": "Medicare Advantage" } } }, "localname": "MedicareAdvantageMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_MedicareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_MedicarePartDMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Part D [Member]", "label": "Medicare Part D [Member]", "terseLabel": "Medicare Part D" } } }, "localname": "MedicarePartDMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_MedicareSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Segment [Member]", "label": "Medicare Segment [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareSegmentMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "ehth_MedicareSupplementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Supplement [Member]", "label": "Medicare Supplement [Member]", "terseLabel": "Medicare Supplement" } } }, "localname": "MedicareSupplementMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_NonQualifiedHealthPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-Qualified Health Plans [Member]", "label": "Non-Qualified Health Plans [Member]", "terseLabel": "Non-Qualified Health Plans" } } }, "localname": "NonQualifiedHealthPlansMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_NumberOfHealthInsuranceCarriers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Health Insurance Carriers", "label": "Number Of Health Insurance Carriers", "terseLabel": "Number of health insurance carriers (more than)" } } }, "localname": "NumberOfHealthInsuranceCarriers", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ehth_OtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other [Member]", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_PrepaidMaintenanceContractsCurrent": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Maintenance Contracts (Current)", "label": "Prepaid Maintenance Contracts Current", "terseLabel": "Prepaid maintenance contracts" } } }, "localname": "PrepaidMaintenanceContractsCurrent", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ehth_PreviousRepurchaseProgramsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Previous Repurchase Programs", "label": "Previous Repurchase Programs [Member]", "terseLabel": "Previous share repurchase programs" } } }, "localname": "PreviousRepurchaseProgramsMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ehth_QualifiedHealthPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Qualified Health Plans [Member]", "label": "Qualified Health Plans [Member]", "terseLabel": "Qualified Health Plans" } } }, "localname": "QualifiedHealthPlansMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_ScheduleOfAccountsReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Accounts Receivable [Table Text Block]", "label": "Schedule Of Accounts Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsReceivableTableTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "ehth_ScheduleOfLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Long Lived Assets By Geographical Areas [Table Text Block]", "label": "Schedule Of Long Lived Assets By Geographical Areas [Table Text Block]", "terseLabel": "Schedule Of Long Lived Assets By Geographical Areas" } } }, "localname": "ScheduleOfLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "ehth_ScheduleOfStockBasedCompensationExpenseByOperatingFunctionTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Stock-Based Compensation Expense By Operating Function [Table Text Block]", "label": "Schedule Of Stock-Based Compensation Expense By Operating Function [Table Text Block]", "terseLabel": "Schedule Of Stock-Based Compensation Expense By Operating Function" } } }, "localname": "ScheduleOfStockBasedCompensationExpenseByOperatingFunctionTableTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ehth_ScheduleOfStockBasedCompensationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Stock-Based Compensation Expense [Table Text Block]", "label": "Schedule Of Stock-Based Compensation Expense [Table Text Block]", "terseLabel": "Schedule Of Stock-Based Compensation Expense By Award Type" } } }, "localname": "ScheduleOfStockBasedCompensationExpenseTableTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ehth_SeasonalityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Seasonality Policy [Policy Text Block]", "label": "Seasonality Policy [Policy Text Block]", "terseLabel": "Seasonality" } } }, "localname": "SeasonalityPolicyPolicyTextBlock", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ehth_SegmentOperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Segment Operating Income (Loss)", "label": "Segment Operating Income (Loss)", "terseLabel": "Segment profit (loss)" } } }, "localname": "SegmentOperatingIncomeLoss", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "ehth_ShorttermMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term [Member]", "label": "Short-term [Member]", "terseLabel": "Short-term" } } }, "localname": "ShorttermMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_SmallBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Small Business [Member]", "label": "Small Business [Member]", "terseLabel": "Small Business" } } }, "localname": "SmallBusinessMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ehth_TechnologyAndContentExpense": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total expense recognized in the period for technology and content. Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website.", "label": "Technology And Content Expense", "terseLabel": "Technology and content" } } }, "localname": "TechnologyAndContentExpense", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "ehth_TechnologyAndContentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technology And Content Expense [Member]", "label": "Technology And Content Expense [Member]", "terseLabel": "Technology and content" } } }, "localname": "TechnologyAndContentExpenseMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "ehth_TreasuryStockSharesOutstandingSharesAcquiredPreviouslyCancelledVestedSharesWithheldForTaxPurposes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Stock, Shares Outstanding, Shares Acquired, Previously Cancelled Vested Shares Withheld For Tax Purposes", "label": "Treasury Stock, Shares Outstanding, Shares Acquired, Previously Cancelled Vested Shares Withheld For Tax Purposes", "terseLabel": "Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)" } } }, "localname": "TreasuryStockSharesOutstandingSharesAcquiredPreviouslyCancelledVestedSharesWithheldForTaxPurposes", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ehth_UnitedhealthcareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "UnitedHealthcare [Member]", "label": "Unitedhealthcare [Member]", "terseLabel": "UnitedHealthcare" } } }, "localname": "UnitedhealthcareMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "ehth_VisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vision [Member]", "label": "Vision [Member]", "terseLabel": "Vision" } } }, "localname": "VisionMember", "nsuri": "http://www.ehealthinsurance.com/20200331", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r110", "r115" ], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Contractual Obligations" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r120", "r200", "r204", "r316" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r117", "r200", "r202", "r313", "r314" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r119", "r200", "r203", "r315", "r320", "r322", "r332", "r333" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r20", "r122", "r123", "r201" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails": { "order": 3.0, "parentTag": "ehth_AccountsReceivableAndContractAssetsAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r43", "r44", "r45" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r42", "r45", "r46", "r243" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Repurchase of shares to satisfy employee tax withholding obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r209", "r211", "r221", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r211", "r216", "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r72", "r158", "r160" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Amortization of intangible assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Office space, square feet" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r290", "r304" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r39" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r244" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured and recorded at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r130" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails_1": { "order": 2.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "totalLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r131" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails_1": { "order": 1.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTotalLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r128", "r146" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Total" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r134" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "terseLabel": "Due in 1 year through 5 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r132", "r134", "r301" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Due in 1 year through 5 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r133" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "terseLabel": "Due in 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r132", "r133", "r300" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Due in 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r125", "r129", "r146" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "totalLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r127", "r146" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 3.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term marketable securities", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r127", "r146" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 2.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long-term marketable securities", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]", "terseLabel": "Short-term marketable securities" } } }, "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r212", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r236", "r237" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Stock issued for acquisition" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r71", "r239" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Change in fair value of earnout liability", "terseLabel": "Change in fair value of earnout liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r235", "r238" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Earnout liability \u2014 current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "auth_ref": [ "r323", "r324" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for amortization of capitalized computer software costs.", "label": "Capitalized Computer Software, Amortization", "terseLabel": "Amortization of internally developed software" } } }, "localname": "CapitalizedComputerSoftwareAmortization1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r258", "r259" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r28", "r318", "r319" ], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r28", "r74" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 1.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Amortized Cost" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 1.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "verboseLabel": "Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r68", "r74", "r75" ], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r68", "r263" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r28" ], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r188", "r189", "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "auth_ref": [ "r167", "r176", "r179" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments, contingencies, and guarantees.", "label": "Commitments Contingencies and Guarantees [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r49", "r51", "r52" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r103", "r104", "r260", "r261" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r103", "r104", "r260", "r261", "r317" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r103", "r104", "r260", "r261", "r317" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r103", "r104", "r260", "r261" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Commission revenue, percentage", "verboseLabel": "Major customer revenue, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r100", "r103", "r104", "r105", "r260", "r262" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r103", "r104", "r260", "r261" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "auth_ref": [ "r137", "r139", "r141", "r195" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Allowance for Credit Loss", "negatedLabel": "Allowance for credit loss" } } }, "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossPeriodIncreaseDecrease": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Change in credit loss allowance" } } }, "localname": "ContractWithCustomerAssetAllowanceForCreditLossPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Schedule of Contract Assets - Commissions Receivable" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "auth_ref": [ "r140", "r196", "r199" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "terseLabel": "Credit loss expense" } } }, "localname": "ContractWithCustomerAssetCreditLossExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r193", "r195", "r201" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r193", "r195", "r201" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails": { "order": 2.0, "parentTag": "ehth_AccountsReceivableAndContractAssetsAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Net, Current", "terseLabel": "Contract assets \u2013 commissions receivable \u2013 current" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r193", "r195", "r201" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails": { "order": 1.0, "parentTag": "ehth_AccountsReceivableAndContractAssetsAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract with Customer, Asset, Net, Noncurrent", "terseLabel": "Contract assets \u2013 commissions receivable \u2013 non-current" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r193", "r194", "r201" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "totalLabel": "Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueAfterFifthYear": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation, Due after Fifth Year", "terseLabel": "Thereafter" } } }, "localname": "ContractualObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFifthYear": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation, Due in Fifth Year", "terseLabel": "2024" } } }, "localname": "ContractualObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation, Due in Fourth Year", "terseLabel": "2023" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": 5.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation, Due in Second Year", "terseLabel": "2021" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": 4.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Contractual Obligation, Due in Third Year", "terseLabel": "2022" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails": { "order": 6.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r59" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r58" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect from the adoption of ASU 2016-13" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r291", "r292", "r303" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r34", "r77", "r183", "r184", "r185", "r186", "r265", "r266", "r268", "r302" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "auth_ref": [ "r146" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 3.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Amortized Cost, Current", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "auth_ref": [ "r146" ], "calculation": { "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails": { "order": 2.0, "parentTag": "ehth_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Amortized Cost, Noncurrent", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of Unrealized Gains and Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r135", "r147" ], "lang": { "en-US": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of securities in net loss positions" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r29", "r267" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r72", "r76", "r228", "r230" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r224", "r227" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes \u2014 non-current" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits", "terseLabel": "Deposits" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r72", "r161" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedTerseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue by Segment" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r56", "r81", "r85", "r86", "r87", "r88", "r91", "r299", "r311" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)", "verboseLabel": "Earnings per share, basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r56", "r81", "r85", "r86", "r87", "r88", "r91", "r299", "r311" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)", "verboseLabel": "Earnings per share, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r263" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r78", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/IncomeTaxesNarrativeDetails", "http://www.ehealthinsurance.com/role/IncomeTaxesSummaryofIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": { "auth_ref": [ "r217" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.", "label": "Share-based Payment Arrangement, Cash Used to Settle Award", "terseLabel": "Repurchase of shares to satisfy employee tax withholding obligations" } } }, "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Common stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r244", "r245", "r246", "r253" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.", "label": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r244", "r245" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r206", "r207", "r208", "r245", "r283" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r252", "r253" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r244", "r254" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r244", "r245", "r248", "r249", "r255" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r206", "r207", "r208", "r245", "r284" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r206", "r207", "r208", "r245", "r285" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r206", "r207", "r208", "r245", "r286" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r244", "r245" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r250", "r253" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r250", "r253" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Earnout Liability Activity" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r250" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsEarnoutLiabilityActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r252", "r255" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r271", "r276" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments in connection with leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r138", "r142", "r143", "r144", "r145", "r148", "r149", "r150", "r151" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r154", "r155" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r81", "r288", "r297", "r312" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before benefit from income taxes", "totalLabel": "Income (loss) before benefit from income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/IncomeTaxesSummaryofIncomeTaxBenefitDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r111", "r231" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Benefit from income taxes", "terseLabel": "Benefit from income taxes", "verboseLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/IncomeTaxesNarrativeDetails", "http://www.ehealthinsurance.com/role/IncomeTaxesSummaryofIncomeTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r38", "r295", "r309" ], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r157", "r159" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of Contractual Maturities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of Operating Lease Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Future minimum lease payments", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails", "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Reminder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r279" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Extension term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r293", "r307" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r17", "r292", "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Borrowings under line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrued" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "New claims filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense", "terseLabel": "Marketing and advertising" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r70", "r73" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r47", "r50", "r55", "r73", "r90", "r298", "r310" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r80", "r82" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncement; Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r118" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which the Company is licensed to market and sell health insurance" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r275", "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r270" ], "calculation": { "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails", "http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r270" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities \u2014 current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r270" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities \u2014 non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r272", "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflow from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r269" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r278", "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate used to recognize operating lease right-of-use-assets" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r277", "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r110", "r115" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "auth_ref": [], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsMiscellaneousCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r240", "r241", "r242" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized holding gain for available for sales debt securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r41", "r264" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment, net of taxes", "verboseLabel": "Foreign currency translation adjustment, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r48", "r51", "r53", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r32" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Acquisition-related contingent payments", "terseLabel": "Acquisition-related contingent payments" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r62", "r63", "r126" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment and other assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r64" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Develop Software", "negatedTerseLabel": "Capitalized internal-use software and website development costs" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r26", "r27" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r6", "r153" ], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r6", "r152", "r153" ], "calculation": { "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCommissionsReceived": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received for commissions during the current period.", "label": "Proceeds from Commissions Received", "negatedTerseLabel": "Cash receipts" } } }, "localname": "ProceedsFromCommissionsReceived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r65" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r65", "r219" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Net proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r162", "r308" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r66" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r14", "r75", "r321" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r187", "r306" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "verboseLabel": "Decrease in retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details", "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r198", "r200" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/RevenueDisaggregationofRevenueDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r103" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueAdditionalInformationDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSharesExcludedfromComputationOfNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule Of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule Of Components Of Income Tax Expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Income per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleofRevenuebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r80", "r82", "r93", "r94", "r95" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Summary of Adoption of ASU 2016-13" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r11", "r75", "r289", "r305" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule Of Revenue By Major Customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r109", "r112", "r113", "r114", "r156" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r109", "r112", "r113", "r114", "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r212", "r218" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r100", "r103", "r104", "r105", "r260", "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Credit Risk" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationScheduleOfLongLivedAssetsByGeographicalAreaDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Marketing and advertising" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r210", "r213" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityScheduleofStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r192", "r223" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Repurchase of shares to satisfy employee tax withholding obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Business and Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r112", "r156", "r164", "r165", "r166", "r313" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/RevenueCommissionRevenuebySegmentDetails", "http://www.ehealthinsurance.com/role/SegmentandGeographicInformationSegmentOperatingResultsDetails", "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformationScheduleofCommissionsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r37", "r182" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Balance Sheet Impact" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesAdoptionofASU201613Details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Comprehensive income:" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r18", "r19", "r187" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Settlement of earnout liability (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r182", "r187" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued in equity offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r182", "r187", "r214" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock in connection with exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r37", "r182", "r187" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Settlement of earnout liability" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r182", "r187" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Shares issued in equity offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r37", "r182", "r187" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock in connection with exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r124" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Supplemental Financial Statement Information" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SupplementalFinancialStatementInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r36", "r188" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r36", "r188" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r19", "r182", "r187" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Number of shares repurchased under share repurchase plan (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r36", "r188", "r191" ], "calculation": { "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r206", "r294" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Agency bonds" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/FairValueMeasurementsSummaryofFinancialAssetsDetails", "http://www.ehealthinsurance.com/role/FairValueMeasurementsUnrealizedGainsandLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r96", "r97", "r98", "r99", "r106", "r107", "r108" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Significant Accounting Policies, Estimates and Judgements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/SummaryofBusinessandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r84", "r88" ], "calculation": { "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Total common stock shares used in diluted share calculation (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in per share amounts:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r83", "r88" ], "calculation": { "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Shares used in per share calculation - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.ehealthinsurance.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomeperShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(k)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756" }, "r325": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r326": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r327": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r328": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r329": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r331": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r332": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r333": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" } }, "version": "2.1" } XML 72 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Equity
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Equity Equity
Public Offering of Common Stock – Pursuant to the effective registration statement which was filed on December 17, 2018, and amended on January 22, 2019 and March 2, 2020, we entered into an underwriting agreement in March 2020 to issue a total of 2,070,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase 270,000 additional shares of common stock, at a price to the public of $115.00 per share. Net proceeds from the offering were approximately $228.0 million after deducting underwriting discounts, commissions and expenses of the offering. We intend to use the net proceeds of the offering for general corporate purposes, including working capital.

Stock Repurchase Programs – We had no stock repurchase activity during the three months ended March 31, 2020. In addition to 10,663,888 shares repurchased under our previous repurchase programs, we have in treasury 985,454 shares as of
March 31, 2020 that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of March 31, 2020 and December 31, 2019, we had a total of 11,649,342 shares and 11,615,558 shares, respectively, held in treasury.

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.

Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types (in thousands): 
Three Months Ended March 31,
20202019
Common stock options$306  $602  
Restricted stock units8,408  2,627  
Total stock-based compensation expense$8,714  $3,229  

Our stock-based compensation expense is summarized as follows by operating functions (in thousands): 
 Three Months Ended March 31,
 20202019
Marketing and advertising$1,730  $629  
Customer care and enrollment662  273  
Technology and content1,617  549  
General and administrative4,705  1,778  
Total stock-based compensation expense$8,714  $3,229  
XML 73 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Leases
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Leases Leases
We have operating and finance leases for our corporate offices and certain equipment. Our leases have remaining lease terms of 1 to 10 years. Our operating lease expense recognized under ASC 842 for the three months ended March 31, 2020 and 2019 were $2.1 million and $1.3 million, respectively. Our cash outflows related to operating leases were $1.6 million and $0.9 million for the three months ended March 31, 2020 and 2019, respectively. During the three months ended March 31, 2020, we had non-cash investing activities of $7.1 million relating to right-of-use assets on the Condensed Consolidated Statements of Cash Flows.

Supplemental information as of March 31, 2020 related to leases is as follows (in thousands):
Operating lease right-of-use assets$43,396  
Operating lease liabilities$46,166  
Weighted-average remaining lease term of operating leases7.9 years
Weighted-average discount rate used to recognize operating lease right-of-use-assets5.5 %
As of March 31, 2020, maturities of operating lease liabilities are as follows (in thousands):
Year ending December 31,
Reminder of 2020$5,058  
20216,950  
20226,988  
20237,863  
20247,706  
Thereafter27,603  
Total lease payments62,168  
Less imputed interest(16,002) 
Total$46,166  

Operating Lease Obligations

We lease our operating facilities and certain of our equipment, furniture and fixtures under various operating leases, the latest of which expires in January 2030. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. 
In January 2020, we entered into an amendment to the lease agreement for our Gold River, California, office of 63,206 square feet. The amended lease term commenced on January 1, 2020 and has been extended to December 31, 2027. As of March 31, 2020, future minimum payments are expected to be $13.5 million over the remaining term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease. In addition, we have an option to extend the lease for one additional period of five years at the end of the term of the lease and will receive a one-time refurbishment allowance from the landlord if the option to renew is exercised.
XML 74 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Business and Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Adoption of ASU 2016-13
The impacts from the adoption are summarized as follows (in thousands):

Balance Sheet Impact:December 31, 2019Transition AdjustmentsJanuary 1, 2020
Contract assets – commissions receivable – current$174,526  $(71) $174,455  
Contract assets – commissions receivable – non-current$414,696  $(1,442) $413,254  
Other assets*$18,004  $366  $18,370  
Total assets$741,634  $(1,147) $740,487  
Retained earnings$271,852  $(1,147) $270,705  
____________
*Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.
XML 75 ehth-20200331_htm.xml IDEA: XBRL DOCUMENT 0001333493 2020-01-01 2020-03-31 0001333493 2020-04-30 0001333493 2020-03-31 0001333493 2019-12-31 0001333493 ehth:CommissionMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMember 2019-01-01 2019-03-31 0001333493 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0001333493 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0001333493 2019-01-01 2019-03-31 0001333493 us-gaap:CommonStockMember 2019-12-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001333493 us-gaap:TreasuryStockMember 2019-12-31 0001333493 us-gaap:RetainedEarningsMember 2019-12-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001333493 us-gaap:RetainedEarningsMember 2020-01-01 0001333493 2020-01-01 0001333493 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001333493 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001333493 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001333493 us-gaap:CommonStockMember 2020-03-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001333493 us-gaap:TreasuryStockMember 2020-03-31 0001333493 us-gaap:RetainedEarningsMember 2020-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001333493 us-gaap:CommonStockMember 2018-12-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001333493 us-gaap:TreasuryStockMember 2018-12-31 0001333493 us-gaap:RetainedEarningsMember 2018-12-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001333493 2018-12-31 0001333493 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001333493 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001333493 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001333493 us-gaap:CommonStockMember 2019-03-31 0001333493 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001333493 us-gaap:TreasuryStockMember 2019-03-31 0001333493 us-gaap:RetainedEarningsMember 2019-03-31 0001333493 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001333493 2019-03-31 0001333493 ehth:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-01-01 0001333493 ehth:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2020-01-01 0001333493 ehth:MedicareMember ehth:MedicareAdvantageMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareMember ehth:MedicareAdvantageMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareMember ehth:MedicareSupplementMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareMember ehth:MedicareSupplementMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareMember ehth:MedicarePartDMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareMember ehth:MedicarePartDMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareMember 2019-01-01 2019-03-31 0001333493 ehth:IndividualandFamilyMember ehth:NonQualifiedHealthPlansMember 2020-01-01 2020-03-31 0001333493 ehth:IndividualandFamilyMember ehth:NonQualifiedHealthPlansMember 2019-01-01 2019-03-31 0001333493 ehth:IndividualandFamilyMember ehth:QualifiedHealthPlansMember 2020-01-01 2020-03-31 0001333493 ehth:IndividualandFamilyMember ehth:QualifiedHealthPlansMember 2019-01-01 2019-03-31 0001333493 ehth:IndividualandFamilyMember 2020-01-01 2020-03-31 0001333493 ehth:IndividualandFamilyMember 2019-01-01 2019-03-31 0001333493 ehth:AncillariesMember ehth:ShorttermMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember ehth:ShorttermMember 2019-01-01 2019-03-31 0001333493 ehth:AncillariesMember ehth:DentalMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember ehth:DentalMember 2019-01-01 2019-03-31 0001333493 ehth:AncillariesMember ehth:VisionMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember ehth:VisionMember 2019-01-01 2019-03-31 0001333493 ehth:AncillariesMember ehth:OtherMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember ehth:OtherMember 2019-01-01 2019-03-31 0001333493 ehth:AncillariesMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember 2019-01-01 2019-03-31 0001333493 ehth:SmallBusinessMember 2020-01-01 2020-03-31 0001333493 ehth:SmallBusinessMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionBonusMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionBonusMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareMember srt:MaximumMember ehth:MedicareAdvantageMember 2020-01-01 2020-03-31 0001333493 ehth:IndividualandFamilyMember srt:MinimumMember 2020-01-01 2020-03-31 0001333493 ehth:IndividualandFamilyMember srt:MaximumMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember srt:MinimumMember ehth:OtherMember 2020-01-01 2020-03-31 0001333493 ehth:AncillariesMember srt:MaximumMember ehth:OtherMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMembersApprovedInPriorPeriodsMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMembersApprovedInPriorPeriodsMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMembersApprovedDuringCurrentPeriodMember ehth:MedicareSegmentMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMembersApprovedDuringCurrentPeriodMember ehth:MedicareSegmentMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMembersApprovedInPriorPeriodsMember ehth:MedicareSegmentMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMembersApprovedInPriorPeriodsMember ehth:MedicareSegmentMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMember ehth:MedicareSegmentMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMember ehth:MedicareSegmentMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMembersApprovedDuringCurrentPeriodMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMembersApprovedDuringCurrentPeriodMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMembersApprovedInPriorPeriodsMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMembersApprovedInPriorPeriodsMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-01-01 2019-03-31 0001333493 ehth:CommissionMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2020-01-01 2020-03-31 0001333493 ehth:CommissionMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareSegmentMember 2019-12-31 0001333493 ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-12-31 0001333493 ehth:CommissionMembersApprovedDuringCurrentPeriodMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareSegmentMember 2020-01-01 2020-03-31 0001333493 ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2020-01-01 2020-03-31 0001333493 ehth:MedicareSegmentMember 2020-03-31 0001333493 ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2020-03-31 0001333493 ehth:MedicareSegmentMember 2018-12-31 0001333493 ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2018-12-31 0001333493 ehth:CommissionMembersApprovedDuringCurrentPeriodMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareSegmentMember 2019-01-01 2019-03-31 0001333493 ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-01-01 2019-03-31 0001333493 ehth:MedicareSegmentMember 2019-03-31 0001333493 ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-03-31 0001333493 ehth:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001333493 country:CN 2020-03-31 0001333493 ehth:HumanaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:HumanaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001333493 ehth:AetnaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:AetnaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001333493 ehth:UnitedhealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:UnitedhealthcareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0001333493 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0001333493 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001333493 us-gaap:MoneyMarketFundsMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:CommercialPaperMember 2020-03-31 0001333493 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0001333493 ehth:ContingentConsiderationMember 2019-12-31 0001333493 ehth:ContingentConsiderationMember 2020-01-01 2020-03-31 0001333493 ehth:ContingentConsiderationMember 2020-03-31 0001333493 ehth:GoMedigapMember 2019-02-01 2019-02-28 0001333493 ehth:GoMedigapMember 2019-02-28 0001333493 ehth:GoMedigapMember 2020-01-01 2020-01-31 0001333493 ehth:GoMedigapMember 2020-01-31 0001333493 2020-03-01 2020-03-31 0001333493 us-gaap:OverAllotmentOptionMember 2020-03-01 2020-03-31 0001333493 ehth:PreviousRepurchaseProgramsMember 2020-01-01 2020-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001333493 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-03-31 0001333493 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-03-31 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2020-01-01 2020-03-31 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2019-01-01 2019-03-31 0001333493 ehth:TechnologyAndContentExpenseMember 2020-01-01 2020-03-31 0001333493 ehth:TechnologyAndContentExpenseMember 2019-01-01 2019-03-31 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001333493 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001333493 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001333493 ehth:LeViasCompliantMember 2019-07-01 2019-07-01 0001333493 us-gaap:SubsequentEventMember 2020-04-08 2020-04-29 0001333493 us-gaap:OperatingSegmentsMember ehth:MedicareSegmentMember 2020-01-01 2020-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:MedicareSegmentMember 2019-01-01 2019-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2020-01-01 2020-03-31 0001333493 us-gaap:OperatingSegmentsMember ehth:IndividualFamilyAndSmallBusinessSegmentsMember 2019-01-01 2019-03-31 0001333493 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001333493 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001333493 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001333493 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001333493 country:US 2020-03-31 0001333493 country:US 2019-12-31 0001333493 country:CN 2019-12-31 0001333493 ehth:UnitedhealthcareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:UnitedhealthcareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:HumanaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:HumanaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 ehth:AetnaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001333493 ehth:AetnaMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001333493 srt:MinimumMember 2020-01-01 2020-03-31 0001333493 srt:MaximumMember 2020-01-01 2020-03-31 0001333493 ehth:GoldRiverCaliforniaMember 2020-01-31 0001333493 ehth:GoldRiverCaliforniaMember 2020-03-31 0001333493 ehth:GoldRiverCaliforniaMember 2020-01-01 0001333493 us-gaap:RevolvingCreditFacilityMember 2018-09-17 0001333493 us-gaap:LetterOfCreditMember 2018-09-17 0001333493 us-gaap:RevolvingCreditFacilityMember 2019-12-20 0001333493 us-gaap:RevolvingCreditFacilityMember ehth:EligibleCommissionsReceivablesPrecedingThreeMonthsMember 2020-01-01 2020-03-31 0001333493 us-gaap:RevolvingCreditFacilityMember ehth:EligibleCommissionsReceivablesSucceedingThreeMonthsMember 2020-01-01 2020-03-31 0001333493 us-gaap:RevolvingCreditFacilityMember ehth:EligibleCommissionsReceivablesSucceedingSixMonthsMember 2020-01-01 2020-03-31 0001333493 us-gaap:RevolvingCreditFacilityMember 2018-09-17 2018-09-17 0001333493 us-gaap:RevolvingCreditFacilityMember 2019-12-20 2019-12-20 0001333493 us-gaap:RevolvingCreditFacilityMember ehth:CreditAgreementAmendmentMember 2019-12-31 0001333493 us-gaap:RevolvingCreditFacilityMember 2020-03-31 0001333493 us-gaap:RevolvingCreditFacilityMember 2019-12-31 shares iso4217:USD iso4217:USD shares ehth:numberOfInsuranceCarriers ehth:state pure ehth:numberOfSecurities ehth:plaintiff ehth:claim ehth:segment utr:sqft ehth:periods false 2020 Q1 0001333493 --12-31 25614001 10-Q true 2020-03-31 false 001-33071 EHEALTH, INC. DE 56-2357876 2625 AUGUSTINE DRIVE, SECOND FLOOR SANTA CLARA CA 95054 650 584-2700 Common Stock, par value $0.001 per share EHTH NASDAQ Yes Yes Large Accelerated Filer false false false 25614001 184167000 23466000 33683000 0 668000 2332000 125252000 174526000 9202000 7822000 352972000 208146000 435465000 414696000 12875000 10518000 24409000 0 43396000 36621000 3353000 3354000 19300000 18004000 9516000 10062000 40233000 40233000 941519000 741634000 8906000 24554000 18473000 29578000 4711000 12041000 0 37273000 4174000 4759000 2683000 2570000 3736000 2210000 42683000 112985000 61623000 64130000 41992000 34305000 3535000 3050000 37000 35000 717380000 455159000 199998000 199998000 274157000 271852000 110000 116000 791686000 527164000 941519000 741634000 99669000 64227000 6739000 4546000 106408000 68773000 1138000 -77000 37764000 23941000 30535000 19944000 15740000 9017000 19653000 11278000 547000 547000 0 13306000 105377000 77956000 1031000 -9183000 373000 557000 1404000 -8626000 -2048000 -3467000 3452000 -5159000 0.14 -0.24 0.13 -0.24 24719000 21831000 26179000 21831000 3452000 -5159000 25000 0 -31000 29000 3446000 -5130000 34752000 35000 455159000 -11616000 -199998000 271852000 116000 527164000 -1147000 -1147000 141000 1091000 1091000 4375000 33000 4375000 2070000 2000 228022000 228024000 295000 28521000 28521000 8962000 8962000 -6000 -6000 3452000 3452000 37258000 37000 717380000 -11649000 -199998000 274157000 110000 791686000 30863000 31000 298024000 -11426000 -199998000 204965000 127000 303149000 172000 2367000 2367000 1280000 24000 1280000 2760000 3000 126048000 126051000 295000 17264000 17264000 3229000 3229000 29000 29000 -5159000 -5159000 34090000 34000 445652000 -11450000 -199998000 199806000 156000 445650000 3452000 -5159000 823000 655000 1501000 719000 547000 547000 8714000 3229000 -2141000 -3543000 0 13306000 -223000 1194000 -1664000 -221000 26873000 17648000 159000 -1111000 -16279000 -768000 -11104000 -9390000 -7329000 -7147000 113000 2897000 2009000 -383000 8907000 12749000 3564000 1487000 2508000 1509000 58064000 0 -64136000 -2996000 228024000 126051000 1091000 2367000 -4375000 -1280000 0 5000000 8751000 9542000 58000 25000 215931000 112571000 -2000 62000 160700000 122386000 26820000 13089000 187520000 135475000 Summary of Business and Significant Accounting Policies<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omni-channel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 180 health insurance carriers across all fifty states and the District of Columbia.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, and the condensed consolidated statements of comprehensive income (loss), stockholders' equity, and cash flows for the three months ended March 31, 2020 and 2019, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2019 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on March 2, 2020. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain reclassifications might be made to conform with the current presentation. However, the Company believes that the disclosures made are adequate to make the information not misleading. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2020 and December 31, 2019, and our results of operations for the periods presented. Our financial position as of March 31, 2020 and results of operations and cash flows for the three months ended March 31, 2020 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2020 and therefore should not be relied upon as an indicator of future results.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Polices, Estimates and Judgements – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the commissions we expect to collect for each approved member cohort, allowance for credit loss, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With the exception of the change for the accounting of credit losses as a result of the adoption of Accounting Standard Updates ("ASU") No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> discussed below, there have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Seasonality – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage, Medicare Supplement, and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Due to the recent reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our commission revenue is typically second-highest in our first quarter.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The majority of our major medical individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase major medical individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Financial Instruments – Credit Losses (Topic 326) – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Credit Losses (Topic 326), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">that requires companies to present certain financial assets net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. Contract assets – commissions receivable are the Company's only financial assets that were materially impacted by this guidance.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">We adopted ASU 2016-13 using a modified retrospective transition method on January 1, 2020 for all financial assets measured at amortized cost. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under the previous accounting standards. We recorded a $1.1 million decrease, net of income taxes, to the retained earnings as of January 1, 2020 for the cumulative effect of adopting ASU 2016-13. See </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Note 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Supplemental Financial Statement Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> for further discussion on credit losses.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">T</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">he impacts from the adoption are summarized as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.122%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.378%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Impact:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Transition Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,526 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,455 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – non-current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414,696 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,254 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,004 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">366 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,370 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">741,634 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">740,487 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,852 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270,705 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">*</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:14pt;">Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments (Topic 820) – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2018, the FASB issued ASU No. 2018-13, to change the disclosure requirements for fair value measurement with the objective of improving the effectiveness of the notes to financial statements. This new guidance removed and modified certain disclosure requirements under Topic 820. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible – Goodwill and Other (Topic 350)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">– In 2017, the FASB issued ASU 2017-04 to simplify the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. In addition, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%;">Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes (Topic 740) – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, Income Tax, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which aims to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improve consistent application of and simplify U.S. GAAP for other areas under this Topic by clarifying existing guidance. ASU 2019-12 will be effective for us beginning January 1, 2021. The amendments in this standard update have individually different adoption approaches. We do not anticipate a material impact on our consolidated financial statements and disclosure from the adoption of this standard update.</span></div> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omni-channel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 180 health insurance carriers across all fifty states and the District of Columbia.</span> 180 50 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, and the condensed consolidated statements of comprehensive income (loss), stockholders' equity, and cash flows for the three months ended March 31, 2020 and 2019, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2019 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on March 2, 2020. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain reclassifications might be made to conform with the current presentation. However, the Company believes that the disclosures made are adequate to make the information not misleading. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2020 and December 31, 2019, and our results of operations for the periods presented. Our financial position as of March 31, 2020 and results of operations and cash flows for the three months ended March 31, 2020 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2020 and therefore should not be relied upon as an indicator of future results.</span></div> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Polices, Estimates and Judgements – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the commissions we expect to collect for each approved member cohort, allowance for credit loss, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With the exception of the change for the accounting of credit losses as a result of the adoption of Accounting Standard Updates ("ASU") No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> discussed below, there have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span> <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Seasonality – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage, Medicare Supplement, and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Due to the recent reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our commission revenue is typically second-highest in our first quarter.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The majority of our major medical individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase major medical individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.</span></div> <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncement</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Financial Instruments – Credit Losses (Topic 326) – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Credit Losses (Topic 326), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">that requires companies to present certain financial assets net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. Contract assets – commissions receivable are the Company's only financial assets that were materially impacted by this guidance.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">We adopted ASU 2016-13 using a modified retrospective transition method on January 1, 2020 for all financial assets measured at amortized cost. Results for periods after January 1, 2020 are presented under ASU 2016-13 while prior period amounts continue to be reported under the previous accounting standards. We recorded a $1.1 million decrease, net of income taxes, to the retained earnings as of January 1, 2020 for the cumulative effect of adopting ASU 2016-13. See </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Note 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Supplemental Financial Statement Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> for further discussion on credit losses.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">T</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">he impacts from the adoption are summarized as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.122%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.378%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Impact:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Transition Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,526 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,455 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – non-current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414,696 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,254 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,004 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">366 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,370 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">741,634 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">740,487 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,852 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270,705 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">*</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:14pt;">Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments (Topic 820) – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2018, the FASB issued ASU No. 2018-13, to change the disclosure requirements for fair value measurement with the objective of improving the effectiveness of the notes to financial statements. This new guidance removed and modified certain disclosure requirements under Topic 820. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible – Goodwill and Other (Topic 350)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">– In 2017, the FASB issued ASU 2017-04 to simplify the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. In addition, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. We adopted this guidance in the first quarter of 2020 with no material impact on our condensed consolidated financial statements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%;">Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes (Topic 740) – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, Income Tax, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which aims to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improve consistent application of and simplify U.S. GAAP for other areas under this Topic by clarifying existing guidance. ASU 2019-12 will be effective for us beginning January 1, 2021. The amendments in this standard update have individually different adoption approaches. We do not anticipate a material impact on our consolidated financial statements and disclosure from the adoption of this standard update.</span></div> -1100000 <div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">T</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">he impacts from the adoption are summarized as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.122%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.378%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Impact:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Transition Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,526 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,455 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – non-current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414,696 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,254 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,004 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">366 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,370 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">741,634 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">740,487 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,852 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,147)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270,705 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;">*</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%;padding-left:14pt;">Adjustment to Other assets is related to the increase in deferred tax asset resulted from the adoption of the accounting guidance.</span></div> 174526000 -71000 174455000 414696000 -1442000 413254000 18004000 366000 18370000 741634000 -1147000 740487000 271852000 -1147000 270705000 Revenue<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disaggregation of Revenue – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below disaggregates our revenue by product (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.057%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:14.105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.106%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,347 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Supplement</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,170 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,597 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Part D</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,661 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,336 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,178 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,776 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Individual and Family </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-Qualified Health Plans</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,629 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Qualified Health Plans</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,210 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,508 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Individual and Family</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,656 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,137 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ancillary</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,216 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,316 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dental</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">743 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">790 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vision</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">462 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,049 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">951 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Ancillary</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,519 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Small Business</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,971 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,640 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commission Bonus</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">613 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,155 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Commission Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,669 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,227 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,739 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,546 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,773 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">_____________</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt;">We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans.</span></div><div style="text-indent:-18pt;padding-left:18pt;"><span><br/></span></div><div style="text-indent:18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition Based on Estimated Constrained LTV</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We recognize revenue for plans approved during the period by applying the latest estimated constrained life time value (“LTV”) for that product. We recognize adjustment revenue for plans approved in prior periods when there is a change in estimate to expected cash collections as a result of sufficient evidence that demonstrates a trend that is different from the estimated constrained LTV at the time of approval. We recognize adjustment revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We assess the risk of significant revenue reversal based on statistical and qualitative analysis given historical information and current market conditions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting average plan duration and forecasting the commission amounts likely to be received per member. These assumptions are based on our analysis of historical trends for different cohorts and incorporate management’s judgment in interpreting those trends to apply the constraints discussed below. For our Medicare commission revenue, which represented 89% and 79% of our total commission revenue for the three months ended March 31, 2020 and 2019, respectively, the estimated average plan duration, which is the average length of time paying </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">members are active on their plans, used to calculate Medicare health insurance plan LTVs historically has been approximately 3 years for Medicare Advantage plans, approximately 5 years for Medicare Part D prescription drug plans, and approximately 5 years for Medicare Supplement plans. While the average plan duration has been approximately 3 years for Medicare Advantage plans, certain members may have a duration of up to 12 years. The estimated average plan duration used to calculate the LTV for major medical individual and family health insurance plans historically has been approximately 1.5 to 2 years. For short term health insurance plan LTVs, the estimated average plan duration historically has been less than six months. For all other ancillary health insurance plan LTVs, the estimated average plan duration has historically varied from 1 to 3 years. To the extent we make changes to the assumptions we use to calculate constrained LTVs, we recognize the impact of changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained LTV recognized as revenue.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Constraints are applied to LTV for revenue recognition purposes to help ensuring that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. Judgments that can be significant in estimating LTVs are related to the constraint. To determine the constraints to be applied to LTV, we compare prior calculations of LTV to actual cash received and review the reasons for any variations. We then apply judgment in assessing whether the difference between historical cash collections and LTV is representative of differences that can be expected in future periods. We also analyze whether circumstances have changed and consider any known or potential modifications to the inputs into LTV in light of the factors that can impact the amount of cash expected to be collected in future periods including but not limited to commission rates, carrier mix, plan duration, changes in laws and regulations, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship. We evaluate the appropriateness of our constraints on a quarterly basis, and we update our assumptions when we observe a sufficient amount of evidence that would suggest that the long-term expectation underlying the assumptions has changed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We recorded adjustment revenue of $12.7 million and $7.4 million, or $0.52 and $0.34 per basic share, or $0.49 and $0.34 per diluted share, respectively, for the three months ended March 31, 2020 and 2019, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commission revenue by segment is presented in the table below (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Commission Revenue from Members Approved During the Period </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,582 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net Commission Revenue from Members Approved in Prior Periods</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,979 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,067 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Medicare Segment Commission Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,104 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,649 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Individual, Family and Small Business</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Commission Revenue from Members Approved During the Period</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,796 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,225 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net Commission Revenue from Members Approved in Prior Periods </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,769 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total IFP/SMB Segment Commission Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,565 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,578 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">_____________</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:0.35pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt;">These amounts include commission bonus revenue.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt;">These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustment revenue within the relevant reporting period. These amounts include revenue associated with renewing small business health insurance members. Adjustment revenue also includes reductions to revenue for certain prior periods cohorts which were immaterial for the three months ended March 31, 2020 and 2019, respectively.</span></div>Since the adoption of ASC 606, we re-compute LTVs for all outstanding cohorts on a quarterly basis. We continually review and monitor changes in the data used to estimate LTV and compare the cash received for each cohort to our original estimates at the time of approval. The fluctuations of cash received for each cohort and LTV can be significant and may or may not be indicative of the need to adjust revenue for prior period cohorts. Changes in LTV may result in an increase or a decrease to revenue and a corresponding increase or decrease to contract assets – commissions receivable, accordingly. We analyze these fluctuations and, to the extent we see changes in our estimates of the cash commission collections that we believe are indicative of an increase or decrease to prior period LTVs, we adjust revenue for the affected cohorts at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. As we accumulate more historical data, we continue to enhance our LTV estimation models using statistical tools to increase the accuracy of LTV estimates with an emphasis on improving member attrition forecasting. The enhancements to the LTV estimation model provide greater statistical certainty on expected cash collections, particularly for earlier period cohorts where there is more historical data available. Our LTV estimation models for the three months ended March 31, 2020 indicate increases in LTVs and estimates of future cash collections for earlier period cohorts of certain products within our Individual, Family and Small Business segment. However, after considering various market factors and recent changes due to the impact of COVID-19 to the U.S. economy, such as increases in unemployment rate, potential delays in customer premium payments and/or health insurance carrier commission payments, potential changes to enrollment periods, and potential changes to qualified health plan subsidies, we limited the adjustment revenue recognized during the three months ended March 31, 2020 to actual cash collected in excess of previously recognized revenue for certain cohorts related to individual and family as well as ancillary plans. These prevailing market conditions did not have an impact on the amount of adjustment revenue recognized for any other products we sell. <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disaggregation of Revenue – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below disaggregates our revenue by product (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.057%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:14.105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.106%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,347 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Supplement</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,170 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,597 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Part D</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,661 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,336 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,178 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,776 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Individual and Family </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-Qualified Health Plans</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,629 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Qualified Health Plans</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,210 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,508 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Individual and Family</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,656 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,137 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ancillary</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,216 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,316 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dental</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">743 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">790 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vision</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">462 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,049 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">951 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Ancillary</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,519 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Small Business</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,971 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,640 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commission Bonus</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">613 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,155 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Commission Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,669 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,227 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,739 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,546 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,773 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">_____________</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt;">We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commission revenue by segment is presented in the table below (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Commission Revenue from Members Approved During the Period </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,582 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net Commission Revenue from Members Approved in Prior Periods</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,979 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,067 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Medicare Segment Commission Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,104 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,649 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Individual, Family and Small Business</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Commission Revenue from Members Approved During the Period</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,796 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,225 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net Commission Revenue from Members Approved in Prior Periods </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,769 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total IFP/SMB Segment Commission Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,565 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,578 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">_____________</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:0.35pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt;">These amounts include commission bonus revenue.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt;">These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustment revenue within the relevant reporting period. These amounts include revenue associated with renewing small business health insurance members. Adjustment revenue also includes reductions to revenue for certain prior periods cohorts which were immaterial for the three months ended March 31, 2020 and 2019, respectively.</span></div> 68347000 39843000 15170000 8597000 5661000 2336000 89178000 50776000 1446000 2629000 1210000 3508000 2656000 6137000 2216000 1316000 743000 790000 243000 462000 1049000 951000 4251000 3519000 2971000 2640000 613000 1155000 99669000 64227000 6739000 4546000 106408000 68773000 0.89 0.79 P3Y P5Y P5Y P3Y P12Y P1Y6M P2Y P1Y P3Y 12700000 7400000 0.52 0.34 0.49 0.34 81125000 50582000 8979000 1067000 90104000 51649000 5796000 6225000 3769000 6353000 9565000 12578000 Supplemental Financial Statement Information<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invested in marketable securities that are measured and recorded at fair value. See </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 4</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for further discussion about our marketable securities. As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,803 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,354 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187,520 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,820 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and December 31, 2019, we had $3.4 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contract Assets and Accounts Receivable</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of March 31, 2020.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our contract assets and accounts receivable consisted of the following for the periods presented (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,252 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,526 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">435,465 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414,696 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">668 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,332 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total contract assets and accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">561,385 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">591,554 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the allowance for credit loss balance using relevant available information from internal and external sources, related to past events, current conditions, and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ, Standard &amp; Poors and Moody's analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commission receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to the adoption of ASC 326, we considered the impact of recent events and global economic condition when evaluating the appropriate adjustments to our allowance as of March 31, 2020. Determining the extent of these adjustments in the three months ended March 31, 2020 was especially challenging because we do not have any historical loss information for a period of similar economic decline. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimated of credit losses was not materially impacted as of March 31, 2020. After our management's evaluation, we recorded credit loss expenses of $0.1 million during the three months ended March 31, 2020 which is included in general and administrative expense on our Condensed Consolidated Statement of Comprehensive Income. Our contract assets – commission receivable activities, net of credit losses are summarized as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IFP/SMB Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">550,922 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589,222 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commission revenue from members approved during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,796 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,921 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net commission revenue adjustments from members approved in prior period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,979 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,769 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,748 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash receipts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,731)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,811)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,542)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in credit loss allowance*</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,574)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,632)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">526,721 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,996 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560,717 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.251%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.526%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.529%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IFP/SMB Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,977 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,881 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">345,858 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commission revenue from members approved during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,582 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,225 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,807 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net commission revenue adjustments from members approved in prior period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,067 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,420 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash receipts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,873)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,001)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,874)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in credit loss allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">295,753 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,458 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">328,211 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">_____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">*</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12.5pt;">Amount consists of transition adjustment of $1.5 million related to the adoption of ASC 326 as of January 1, 2020 and the subsequent credit loss adjustment of $0.1 million as of March 31, 2020. See </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Business and Significant Accounting Policies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> for details regarding the adoption impact.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Risk</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, contract assets – commissions receivable, and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $4.1 million as of March 31, 2020.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Humana</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Aetna</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">UnitedHealthCare </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">_____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt;">Aetna also includes other carriers owned by Aetna. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt;">UnitedHealthcare also includes other carriers owned by UnitedHealthcare. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Current</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Assets – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets are summarized as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid maintenance contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,460 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,853 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,727 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,207 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">543 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">918 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,041 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">584 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,202 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,822 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,803 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,354 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187,520 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,820 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> As of March 31, 2020 and December 31, 2019, our cash, cash equivalent and restricted cash balances were invested as follows (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,205 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,803 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,354 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187,520 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,820 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 16364000 16205000 167803000 7261000 3353000 3354000 187520000 26820000 3400000 3400000 Our contract assets and accounts receivable consisted of the following for the periods presented (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,252 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,526 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets – commissions receivable – non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">435,465 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414,696 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">668 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,332 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total contract assets and accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">561,385 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">591,554 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 125252000 174526000 435465000 414696000 668000 2332000 561385000 591554000 100000 Our contract assets – commission receivable activities, net of credit losses are summarized as follows (in thousands):<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.812%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.676%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IFP/SMB Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">550,922 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589,222 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commission revenue from members approved during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,796 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,921 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net commission revenue adjustments from members approved in prior period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,979 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,769 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,748 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash receipts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,731)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,811)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,542)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in credit loss allowance*</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,574)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,632)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">526,721 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,996 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560,717 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.251%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.526%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.529%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IFP/SMB Segment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311,977 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,881 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">345,858 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commission revenue from members approved during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,582 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,225 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,807 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net commission revenue adjustments from members approved in prior period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,067 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,353 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,420 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash receipts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,873)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,001)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,874)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in credit loss allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">295,753 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,458 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">328,211 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">_____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">*</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12.5pt;">Amount consists of transition adjustment of $1.5 million related to the adoption of ASC 326 as of January 1, 2020 and the subsequent credit loss adjustment of $0.1 million as of March 31, 2020. See </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Business and Significant Accounting Policies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> for details regarding the adoption impact.</span></div> 550922000 38300000 589222000 81125000 5796000 86921000 8979000 3769000 12748000 112731000 13811000 126542000 -1574000 -58000 -1632000 526721000 33996000 560717000 311977000 33881000 345858000 50582000 6225000 56807000 1067000 6353000 7420000 67873000 14001000 81874000 0 0 0 295753000 32458000 328211000 1500000 100000 4100000 Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below:<div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Humana</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Aetna</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">UnitedHealthCare </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">_____________</span></div><div style="text-indent:-18pt;padding-left:36pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt;">Aetna also includes other carriers owned by Aetna. </span></div>(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare. 0.22 0.22 0.21 0.20 0.20 0.20 Prepaid expenses and other current assets are summarized as follows (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:64.520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.374%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.376%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid maintenance contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,460 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,853 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,727 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,207 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">543 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">918 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,041 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">584 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,202 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,822 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 5460000 3853000 1727000 2207000 543000 918000 1041000 584000 431000 260000 9202000 7822000 Fair Value Measurements<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:89.229%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unadjusted quoted prices in active markets for identical assets or liabilities;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability; and</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable inputs for the asset or liability.</span></td></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.339%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.069%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets measured and recorded at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,097 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.339%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.069%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Earnout liability</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">current </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cash equivalents were invested in money market funds and commercial paper with original maturity 90 days or less were classified as Level 1. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our investments as Level 1. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, our Level 2 assets included our available for sale marketable securities, which consisted of commercial paper and agency bonds with maturity less than two years. We classify our marketable debt securities within Level 2 in the fair value hierarchy because we use quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. Our portfolio primarily consisted of financial instruments with credit rating of AA+ or equivalent by S&amp;P Rating and Moody's Investor Services. There were no transfers between the hierarchy levels during the three months ended March 31, 2020. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.649%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201,482 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201,486 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year through 5 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,870 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses on available-for-sale debt securities are included in accumulated other comprehensive income and summarized as follows as of March 31, 2020:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.672%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.647%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,616 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,870 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, there were four securities in net loss positions and their unrealized losses were immaterial. We did not record any credit losses regarding our available-for-sales debt securities during the three months ended March 31, 2020. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Earnout Liabilities</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our earnout liabilities in connection with our GoMedigap acquisition in 2018 have been recognized at fair value. We measure the earnout liability using internally developed assumptions; therefore, it is classified as Level 3. The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the years ended December 31, 2019 and 2018 and our stock price at the time of payment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnout liability activities are summarized as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:82.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.170%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,273)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we made the first earnout payment to GoMedigap consisting of $9.5 million in cash and 294,608 shares of our common stock with a value of $17.3 million. In January 2020, we made the second and last payment, which consisted of $8.8 million in cash and 294,608 shares of our common stock with a value of $28.5 million.</span></div> We classify the inputs used to measure fair value into the following hierarchy:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:6.771%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:89.229%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unadjusted quoted prices in active markets for identical assets or liabilities;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability; and</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable inputs for the asset or liability.</span></td></tr></table> <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.339%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.069%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets measured and recorded at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,097 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.339%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.069%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Earnout liability</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">current </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial assets and liabilities measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy for the period presented below (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.339%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.069%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets measured and recorded at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,097 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.339%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.069%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Earnout liability</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">current </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 105798000 105798000 0 0 105798000 62005000 0 62005000 0 62005000 23063000 0 23063000 0 23063000 10620000 0 10620000 0 10620000 24409000 0 24409000 0 24409000 225895000 105798000 120097000 0 225895000 7261000 7261000 0 0 7261000 37273000 0 0 37273000 37273000 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.649%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201,482 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201,486 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in 1 year through 5 years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,870 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 201482000 201486000 24388000 24409000 225870000 225895000 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses on available-for-sale debt securities are included in accumulated other comprehensive income and summarized as follows as of March 31, 2020:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.672%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.647%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,798 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,005 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,063 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,616 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,409 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,870 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 105798000 105798000 62005000 62005000 23063000 0 0 23063000 10616000 5000 1000 10620000 24388000 21000 0 24409000 225870000 26000 1000 225895000 4 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Earnout liability activities are summarized as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:82.830%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.170%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,273)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 37273000 0 37273000 0 9500000 294608 17300000 8800000 294608 28500000 Equity<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offering of Common Stock – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the effective registration statement which was filed on December 17, 2018, and amended on January 22, 2019 and March 2, 2020, we entered into an underwriting agreement in March 2020 to issue a total of 2,070,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase 270,000 additional shares of common stock, at a price to the public of $115.00 per share. Net proceeds from the offering were approximately $228.0 million after deducting underwriting discounts, commissions and expenses of the offering. We intend to use the net proceeds of the offering for general corporate purposes, including working capital. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Repurchase Programs – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We had no stock repurchase activity during the three months ended March 31, 2020. In addition to 10,663,888 shares repurchased under our previous repurchase programs, we have in treasury 985,454 shares as of </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March 31, 2020 that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of March 31, 2020 and December 31, 2019, we had a total of 11,649,342 shares and 11,615,558 shares, respectively, held in treasury.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock-based compensation expense is summarized as follows by award types (in thousands): </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"/><td style="width:79.185%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:7.037%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.540%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">602 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,627 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,714 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,229 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock-based compensation expense is summarized as follows by operating functions (in thousands): </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:78.819%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:7.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.225%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketing and advertising</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,730 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">629 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer care and enrollment</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">662 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology and content</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,617 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">549 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,705 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,778 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,714 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,229 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2070000 270000 115.00 228000000.0 0 10663888 985454 11649342 11615558 Our stock-based compensation expense is summarized as follows by award types (in thousands): <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"/><td style="width:79.185%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:7.037%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.540%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.038%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">602 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,627 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,714 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,229 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 306000 602000 8408000 2627000 8714000 3229000 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock-based compensation expense is summarized as follows by operating functions (in thousands): </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:78.819%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:7.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.225%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketing and advertising</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,730 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">629 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer care and enrollment</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">662 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology and content</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,617 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">549 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,705 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,778 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,714 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,229 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1730000 629000 662000 273000 1617000 549000 4705000 1778000 8714000 3229000 Net Income (Loss) Per Share<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net income (loss) per share is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income per share is computed giving effect to all potential dilutive common stock equivalent shares, including options and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted net income per share by application of the treasury stock method.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:76.038%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.688%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.689%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Basic:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,159)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in per share calculation – basic</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,719 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share – basic:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.14 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Diluted:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,159)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in per share calculation – basic</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,719 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of common stock</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,460 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock shares used in diluted share calculation</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,179 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:0.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share – diluted</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.13 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2019, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of 1.0 million and 1.4 million shares related to common stock options and restricted stock units, respectively. There were no antidilutive shares for the three months ended March 31, 2020.</span></div> <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:76.038%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.688%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.385%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.689%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Basic:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,159)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in per share calculation – basic</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,719 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share – basic:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.14 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Diluted:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,452 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,159)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in per share calculation – basic</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,719 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of common stock</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,460 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock shares used in diluted share calculation</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,179 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,831 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:0.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share – diluted</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.13 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 3452000 -5159000 24719000 21831000 0.14 -0.24 3452000 -5159000 24719000 21831000 1460000 0 26179000 21831000 0.13 -0.24 1000000.0 1400000 0 Commitments and Contingencies<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 9</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for commitments related to our operating leases.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We accrued approximately $1.2 million as of March 31, 2020 for amounts we believe will be payable for certain current legal proceedings, including the matters discussed below. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2018, a former employee, Lupita Gonzalez, filed a complaint against us in the Superior Court of the State of California for the County of Sacramento (the “Gonzalez Complaint”). The Gonzalez Complaint is brought under the California Private Attorney General Act (“PAGA”) on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The claim alleges that we violated wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">wages; (ii) the payment of minimum wages; (iii) providing compliant meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The Gonzalez Complaint seeks penalties and costs, expenses and attorneys’ fees.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 1, 2019, two other current or former employees, Michael Le’Vias and Ramona Meadows, filed a related complaint against us and eHealth Ins. Serv. Co., in the Superior Court of the State of California for the County of Santa Clara (the “Le’Vias Complaint”). A substantial overlap exists between the facts and circumstances alleged in the Gonzalez Complaint and the Le’Vias Complaint. Specifically, the Le’Vias Complaint is also brought under PAGA on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The claim alleges that we violated wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime wages; (ii) the payment of minimum wages; (iii) providing compliant meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The Le’Vias Complaint seeks unpaid wages, penalties and costs, expenses and attorneys’ fees.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The parties have agreed to resolve both the Le’Vias and Gonzalez Complaints, which settlement will require court approval. In the interim, the parties have filed notices of conditional settlement in both matters, and the April 13, 2020 trial date for the Gonzalez matter has been vacated.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 8, 2020 and April 29, 2020, two purported class action lawsuits were filed against us, our chief executive officer, Scott N. Flanders, our chief financial officer, Derek N. Yung and our chief operating officer, David K. Francis, in the United States District Court for the Northern District of California. The cases are captioned </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patel v. eHealth, Inc., et al</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">., Case No. 5:20-cv-02395 (N.D. Cal.) and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Bertrand v. eHealth, Inc. et al.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Case No. 3:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that we and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn and our profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patel</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. We believe the lawsuits to be without merit and intend to vigorously defend ourselves against them.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Service and Licensing Obligations</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2020 are summarized as follows (in thousands): </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.030%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service and Licensing Obligations</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,961 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,189 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">692 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">444 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">229 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,515 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1200000 2 2 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2020 are summarized as follows (in thousands): </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:77.970%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.030%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">For the Years Ending December 31,</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service and Licensing Obligations</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,961 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,189 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">692 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">444 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">229 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,515 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1961000 2189000 692000 444000 229000 0 5515000 Segment and Geographic Information<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Segments</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments: Medicare and Individual, Family and Small Business. Please refer to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Business and Significant Accounting Policies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Notes to Consolidated Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2019 for our accounting policies of operating segments.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents summary results of our operating segments for the three months ended March 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.675%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,151 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,901 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Individual, Family and Small Business</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,257 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,872 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,773 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment profit:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare segment profit</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,960 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,826 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Individual, Family and Small Business segment profit</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,024 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total segment profit</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,850 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,448)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,296)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,714)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,229)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of earnout liability</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,306)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(823)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(655)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">373 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before benefit from income taxes</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,626)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are no internal revenue transactions between our operating segments. With the exception of contract assets – commissions receivable, which is presented by segment in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> – </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Supplemental Financial Statement Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Geographic Information</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our long-lived assets primarily consist of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.397%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.935%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.938%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,297 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">China</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">418 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">471 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,715 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,879 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:58.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Customers</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Substantially all revenue for the three months ended March 31, 2020 and 2019 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue for the three months ended March 31, 2020 and 2019 are presented in the table below: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.675%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">UnitedHealthcare </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Humana</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Aetna</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.2pt;">UnitedHealthcare also includes other carriers owned by UnitedHealthcare.</span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Aetna also includes other carriers owned by Aetna.</span></div> 2 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents summary results of our operating segments for the three months ended March 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.675%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,151 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,901 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Individual, Family and Small Business</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,257 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,872 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,773 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment profit:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare segment profit</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,960 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,826 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Individual, Family and Small Business segment profit</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,024 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total segment profit</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,850 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,448)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,296)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,714)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,229)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of earnout liability</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,306)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(823)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(655)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">373 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before benefit from income taxes</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,626)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 96151000 54901000 10257000 13872000 106408000 68773000 21960000 10826000 2603000 6024000 24563000 16850000 -13448000 -8296000 8714000 3229000 0 13306000 823000 655000 547000 547000 373000 557000 1404000 -8626000 Long-lived assets by geographical area are summarized as follows (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.397%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.935%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.938%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,297 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">China</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">418 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">471 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,715 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,879 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 99297000 64408000 418000 471000 99715000 64879000 Carriers representing 10% or more of our total revenue for the three months ended March 31, 2020 and 2019 are presented in the table below: <div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:8.672%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.675%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">UnitedHealthcare </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Humana</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Aetna</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.2pt;">UnitedHealthcare also includes other carriers owned by UnitedHealthcare.</span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Aetna also includes other carriers owned by Aetna.</span></div> 0.22 0.17 0.19 0.23 0.15 0.17 Leases<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have operating and finance leases for our corporate offices and certain equipment. Our leases have remaining lease terms of 1 to 10 years. Our operating lease expense recognized under ASC 842 for the three months ended March 31, 2020 and 2019 were $2.1 million and $1.3 million, respectively. Our cash outflows related to operating leases were $1.6 million and $0.9 million for the three months ended March 31, 2020 and 2019, respectively. During the three months ended March 31, 2020, we had non-cash investing activities of $7.1 million relating to right-of-use assets on the Condensed Consolidated Statements of Cash Flows.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information as of March 31, 2020 related to leases is as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.304%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.696%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,396 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,166 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term of operating leases</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate used to recognize operating lease right-of-use-assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, maturities of operating lease liabilities are as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.157%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.843%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reminder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,058 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,950 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,988 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,863 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,706 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,168 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,002)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,166 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Lease Obligations</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We lease our operating facilities and certain of our equipment, furniture and fixtures under various operating leases, the latest of which expires in January 2030. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. </span></div>In January 2020, we entered into an amendment to the lease agreement for our Gold River, California, office of 63,206 square feet. The amended lease term commenced on January 1, 2020 and has been extended to December 31, 2027. As of March 31, 2020, future minimum payments are expected to be $13.5 million over the remaining term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease. In addition, we have an option to extend the lease for one additional period of five years at the end of the term of the lease and will receive a one-time refurbishment allowance from the landlord if the option to renew is exercised. P1Y P10Y 2100000 1300000 1600000 900000 7100000 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information as of March 31, 2020 related to leases is as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.304%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.696%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,396 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,166 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term of operating leases</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate used to recognize operating lease right-of-use-assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div> 43396000 46166000 P7Y10M24D 0.055 <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, maturities of operating lease liabilities are as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.157%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.843%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reminder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,058 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,950 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,988 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,863 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,706 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,168 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,002)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,166 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 5058000 6950000 6988000 7863000 7706000 27603000 62168000 16002000 46166000 63206 13500000 1 P5Y Debt<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40.0 million secured asset-backed revolving credit facility with a $5.0 million letter of credit sub-facility. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 20, 2019, we amended our revolving credit facility agreement with RBC (the “Amendment”) and increased the borrowing amount from $40.0 to $75.0 million. The maturity date has been extended to December 20, 2022.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected by during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At closing, the Company paid a one-time facility fee of 1.75% of the total commitments of $40 million. We also paid a one-time closing fee of </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">0.5% of the new commitment of $75.0 million in connection with the Amendment. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The availability under the credit facility is up to the lesser of $40 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. The Amendment increased the availability up to the lesser of $75.0 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial covenants in the original Credit Agreement required that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6 million at any time. The Amendment also changed the financial covenants to require us to maintain at least $6.0 million of Excess Availability at all times or, if greater, up to $11.3 million depending on our borrowing base as determined by eligible past and future commission receivables. In addition, the Amendment also included changes in the payment conditions to, among other things, require us to have at least $10.0 million of liquidity or, if greater, up to $18.8 million depending on our borrowing base as determined by eligible past and future commission receivables, in order for us to make certain permitted acquisitions, investments, distributions and payments of indebtedness. The Amendment also stated the seasonal amount thresholds used in connection with the cash dominion and field examination covenants in the Credit Agreement. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of Other assets on our Consolidated Balance Sheet of the period we entered into the Credit Agreement. The Amendment did not change the interest rate. In connection with this Amendment, we incurred closing costs totaling $0.5 million, which was capitalized and recorded as Other assets on our Consolidated Balance Sheet as of December 31, 2019. The remaining balance of unamortized issuance costs was $1.1 million as of March 31, 2020 and December 31, 2019. </span></div>As of March 31, 2020, we had no outstanding principal amount under our revolving credit facility. 40000000.0 5000000.0 40000000.0 75000000.0 0.80 0.80 0.50 0.005 0.0175 40000000 0.005 75000000.0 40000000 75000000.0 6000000 6000000.0 11300000 10000000.0 18800000 1200000 500000 1100000 1100000 0 Income Taxes <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law on March 27, 2020. The business tax provisions of the CARES Act include temporary changes to income based tax laws, including the ability to utilize net operating losses, interest expense deductions, alternative minimum tax credit refunds, charitable contributions, and depreciation of qualified improvement property. The income tax provisions of the CARES Act do not have a material impact on our Condensed Consolidated Financial Statements for the period ended March 31, 2020. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2020 and 2019 (in thousands, except effective tax rate):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.263%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:7.502%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.505%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before benefit from income taxes</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,626)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,048)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,467)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(145.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020, we recognized a benefit from income taxes of $2.0 million, representing an effective tax rate of (145.9)%, which was lower than the statutory federal tax rate primarily due to stock-based compensation windfalls. For the three months ended March 31, 2019, we recognized a benefit from income taxes of $3.5 million, representing an effective tax rate of 40.2%, which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses and foreign income inclusions, partially offset by research and development credits.</span></div>Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of March 31, 2020, as we believe it is more likely than not that the net deferred tax assets will be realized, with the exception of certain state net operating losses that are expected to expire unutilized which have a valuation allowance. <div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following table summarizes our benefit from income taxes and our effective tax rates for the three months ended March 31, 2020 and 2019 (in thousands, except effective tax rate):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.263%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:7.502%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.505%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before benefit from income taxes</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,404 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,626)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit from income taxes</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,048)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,467)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(145.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div> 1404000 -8626000 -2048000 -3467000 -1.459 0.402 -2000000.0 -1.459 -3500000 0.402 Reflects the impact from the adoption of ASC 326 on January 1, 2020. See Note 1Summary of Business and Significant Accounting Policies for details. XML 76 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Narrative (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Jan. 31, 2020
ft²
Jan. 01, 2020
periods
Lessee, Lease, Description [Line Items]        
Operating lease cost $ 2,100 $ 1,300    
Operating cash outflow from operating leases 1,600 $ 900    
Acquired right-of-use asset 7,100      
Future minimum lease payments $ 62,168      
Minimum        
Lessee, Lease, Description [Line Items]        
Lease term 1 year      
Maximum        
Lessee, Lease, Description [Line Items]        
Lease term 10 years      
Gold River, California        
Lessee, Lease, Description [Line Items]        
Office space, square feet | ft²     63,206  
Future minimum lease payments $ 13,500      
Number of extension periods | periods       1
Extension term       5 years
XML 77 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Summary of Income Tax Benefit (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
Income (loss) before benefit from income taxes $ 1,404 $ (8,626)
Benefit from income taxes $ (2,048) $ (3,467)
Effective tax rate (145.90%) 40.20%